[{"internal_id": 50113192, "Award ID": "UM1HL120877", "Award Amount": 26367043.75, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-09-26", "CFDA Number": "93.837", "Description": "ANALYSIS AND CHARACTERIZATION OF TRAUMA-INDUCED COAGULOPATHY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_UM1HL120877_7529"}, {"internal_id": 86316751, "Award ID": "UH3HL143204", "Award Amount": 2993812.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-09-20", "CFDA Number": "93.837", "Description": "TRANSFUSION OF PREMATURITY EARLY SCHOOL AGE FOLLOW-UP (TOP 5) CCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_UH3HL143204_7529"}, {"internal_id": 97470504, "Award ID": "UH3HL143192", "Award Amount": 13050056.29, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-05-15", "CFDA Number": "93.837", "Description": "1/2 SICKLE CELL DISEASE AND CARDIOVASCULAR RISK - RED CELL EXCHANGE TRIAL (SCD-CARRE TRIAL)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_UH3HL143192_7529"}, {"internal_id": 83103674, "Award ID": "UH3HL141799", "Award Amount": 2330121.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-08-14", "CFDA Number": "93.350", "Description": "MICROPHYSIOLOGICAL SYSTEMS TO MODEL VASCULAR MALFORMATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": 179153.0, "Infrastructure Obligations": null, "recipient_id": "0b710df3-c98e-f245-bbed-8bbbc32a803b-C", "generated_internal_id": "ASST_NON_UH3HL141799_7529"}, {"internal_id": 95942813, "Award ID": "UH3HL140097", "Award Amount": 4256460.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-03-15", "CFDA Number": "93.837", "Description": "1/2 POMALIDOMIDE FOR BLEEDING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_UH3HL140097_7529"}, {"internal_id": 68167921, "Award ID": "UH3HL138325", "Award Amount": 7177952.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-08-31", "CFDA Number": "93.837", "Description": "1/2 CATHETER-DIRECTED THERAPY FOR CHRONIC DVT (C-TRACT TRIAL)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_UH3HL138325_7529"}, {"internal_id": 86317362, "Award ID": "UH3HL137856", "Award Amount": 1532474.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-09-20", "CFDA Number": "93.837", "Description": "1/2 A COMPARISON OF INDIVIDUALIZED VS. WEIGHT BASED PROTOCOLS TO TREAT VASO-OCCLUSIVE EPISODES IN SICKLE CELL DISEASE (COMPARE VOE)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_UH3HL137856_7529"}, {"internal_id": 98487339, "Award ID": "UG3HL152189", "Award Amount": 825950.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-06-23", "CFDA Number": "93.837", "Description": "ENHANCING BLOOD DONATION AT SCHOOLS AND BEYOND: AN IMPLEMENTATION SCIENCE STUDY", "Place of Performance Country Code": "MWI", "Place of Performance State Code": null, "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e7be3bf-7797-e061-81dc-3347789fe417-R", "generated_internal_id": "ASST_NON_UG3HL152189_7529"}, {"internal_id": 98486471, "Award ID": "UG3HL151599", "Award Amount": 450161.02, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-06-23", "CFDA Number": "93.837", "Description": "DEVELOPMENT AND EVALUATION OF COMMUNITY-BASED APPROACHES AND DONOR CARE INTERVENTION MODELS FOR IMPROVING AVAILABILITY AND SAFETY OF BLOOD FOR THE MANAGEMENT OF SEVERE ANEMIA IN GHANA", "Place of Performance Country Code": "GHA", "Place of Performance State Code": null, "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "73985180-bc2a-cd24-7f91-87adf1d9b744-R", "generated_internal_id": "ASST_NON_UG3HL151599_7529"}, {"internal_id": 98486449, "Award ID": "UG3HL151595", "Award Amount": 687550.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-06-30", "CFDA Number": "93.837", "Description": "PATHWAYS FOR INNOVATION IN BLOOD TRANSFUSI?N SYSTEMS IN KENYA (PITS KENYA)", "Place of Performance Country Code": "KEN", "Place of Performance State Code": null, "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2d5974ba-ecee-ac9f-4ab5-6ae2851f1316-R", "generated_internal_id": "ASST_NON_UG3HL151595_7529"}, {"internal_id": 110463784, "Award ID": "UG3HL148560", "Award Amount": 720721.34, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-09-17", "CFDA Number": "93.837", "Description": "1/2 SICKEL CELL DISEASE TREATMENT WITH ARGININE THERAPY (START TRIAL)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_UG3HL148560_7529"}, {"internal_id": 69725163, "Award ID": "UG3HL143204", "Award Amount": 358866.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-09-20", "CFDA Number": "93.839", "Description": "TRANSFUSION OF PREMATURITY EARLY SCHOOL AGE FOLLOW-UP (TOP 5) CCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_UG3HL143204_7529"}, {"internal_id": 80734928, "Award ID": "UG3HL143192", "Award Amount": 770934.71, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-05-07", "CFDA Number": "93.837", "Description": "1/2 SICKLE CELL DISEASE AND CARDIOVASCULAR RISK - RED CELL EXCHANGE TRIAL (SCD-CARRE TRIAL)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_UG3HL143192_7529"}, {"internal_id": 50111010, "Award ID": "UG3HL141799", "Award Amount": 1712886.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-08-12", "CFDA Number": "93.839", "Description": "MICROPHYSIOLOGICAL SYSTEMS TO MODEL VASCULAR MALFORMATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b710df3-c98e-f245-bbed-8bbbc32a803b-C", "generated_internal_id": "ASST_NON_UG3HL141799_7529"}, {"internal_id": 78990803, "Award ID": "UG3HL140097", "Award Amount": 464431.49, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-03-05", "CFDA Number": "93.837", "Description": "1/2 POMALIDOMIDE FOR BLEEDING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_UG3HL140097_7529"}, {"internal_id": 50111007, "Award ID": "UG3HL138325", "Award Amount": 1129871.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-08-29", "CFDA Number": "93.839", "Description": "1/2 CATHETER-DIRECTED THERAPY FOR CHRONIC DVT (C-TRACT TRIAL)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_UG3HL138325_7529"}, {"internal_id": 68567407, "Award ID": "UG3HL137856", "Award Amount": 359692.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-09-06", "CFDA Number": "93.839", "Description": "1/2 A COMPARISON OF INDIVIDUALIZED VS. WEIGHT BASED PROTOCOLS TO TREAT VASO-OCCLUSIVE EPISODES IN SICKLE CELL DISEASE (COMPARE VOE)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_UG3HL137856_7529"}, {"internal_id": 50110925, "Award ID": "UG1HL138658", "Award Amount": 1126563.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-27", "CFDA Number": "93.837", "Description": "NOVEL STRATEGIES FOR ASSESSING AND OPTIMIZING THERAPY FOR MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC TRANSPLANTATION FOR AML AND MDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_UG1HL138658_7529"}, {"internal_id": 50110924, "Award ID": "UG1HL138645", "Award Amount": 1230779.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-27", "CFDA Number": "93.837", "Description": "MOUNT SINAI CORE CLINICAL CONSORTIUM FOR THE BMT CLINICAL TRIALS NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_UG1HL138645_7529"}, {"internal_id": 50110923, "Award ID": "UG1HL138641", "Award Amount": 1275124.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-27", "CFDA Number": "93.837", "Description": "CORE CLINICAL CENTERS FOR THE BLOOD AND MARROW TRANSPLANT CLINICAL TRIALS NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_UG1HL138641_7529"}, {"internal_id": 50110913, "Award ID": "UG1HL109526", "Award Amount": 978968.45, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-28", "CFDA Number": "93.837", "Description": "REDUCTION OF RELAPSE RISK THROUGH INCORPORATION OF NOVEL BIOLOGIC AGENTS FOLLOWING REDUCED INTENSITY HAPLOIDENTICAL DONOR TRANSPLANT FOR ACUTE MYELOID LEUKEMIA.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b9c1682-73ac-b326-5ec6-08be2f3cd472-C", "generated_internal_id": "ASST_NON_UG1HL109526_7529"}, {"internal_id": 50110912, "Award ID": "UG1HL109322", "Award Amount": 1358231.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-26", "CFDA Number": "93.837", "Description": "THE OHIO STATE UNIVERSITY BLOOD AND MARROW TRANSPLANT RESEARCH CONSORTIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_UG1HL109322_7529"}, {"internal_id": 50110911, "Award ID": "UG1HL109137", "Award Amount": 1155801.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-27", "CFDA Number": "93.837", "Description": "A PHASE II STUDY OF CYTOKINE INDUCED MEMORY-LIKE (CIML) NATURAL KILLER (NK) CELL ADOPTIVE THERAPY AFTER HAPLOIDENTICAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_UG1HL109137_7529"}, {"internal_id": 50110910, "Award ID": "UG1HL108987", "Award Amount": 1430446.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-26", "CFDA Number": "93.837", "Description": "CORE CLINICAL CENTERS FOR THE BLOOD AND MARROW TRANSPLANT CLINICAL TRIALS NETWORK (UG1)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dda62fdb-6501-1ff0-613d-ceb8e9bb2d48-C", "generated_internal_id": "ASST_NON_UG1HL108987_7529"}, {"internal_id": 50110909, "Award ID": "UG1HL108945", "Award Amount": 1381325.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-27", "CFDA Number": "93.837", "Description": "TARGETING HIV AND EBV ANTIGENS IN PATIENTS WITH HIV LYMPHOMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_UG1HL108945_7529"}, {"internal_id": 50110908, "Award ID": "UG1HL069330", "Award Amount": 1054164.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-26", "CFDA Number": "93.837", "Description": "UNIVERSITY OF MICHIGAN CORE CLINICAL CENTER FOR THE BMT RESEARCH NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_UG1HL069330_7529"}, {"internal_id": 50110907, "Award ID": "UG1HL069315", "Award Amount": 1396922.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-27", "CFDA Number": "93.837", "Description": "MSKCC BMT CTN RENEWAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b514fc3a-d769-87e9-75ea-7a6766afb5ee-C", "generated_internal_id": "ASST_NON_UG1HL069315_7529"}, {"internal_id": 50110906, "Award ID": "UG1HL069310", "Award Amount": 1034222.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-08-02", "CFDA Number": "93.837", "Description": "TRANSLATIONAL RESEARCH IN BLOOD AND MARROW TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_UG1HL069310_7529"}, {"internal_id": 50110905, "Award ID": "UG1HL069301", "Award Amount": 1191622.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-27", "CFDA Number": "93.837", "Description": "CORE CLINICAL CONSORTIUM FOR BLOOD AND MARROW TRANSPLANT CLINICAL TRIALS NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_UG1HL069301_7529"}, {"internal_id": 50110904, "Award ID": "UG1HL069291", "Award Amount": 1031047.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-27", "CFDA Number": "93.837", "Description": "BMT CLINICAL TRIAL NETWORK AT STANFORD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_UG1HL069291_7529"}, {"internal_id": 50110903, "Award ID": "UG1HL069290", "Award Amount": 1343738.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-26", "CFDA Number": "93.837", "Description": "ALT-803 (IL-15/IL-15R?-FC) MAINTENANCE AFTER ALLOGENEIC TRANSPLANTATION FOR AML", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_UG1HL069290_7529"}, {"internal_id": 50110902, "Award ID": "UG1HL069286", "Award Amount": 1352682.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-27", "CFDA Number": "93.837", "Description": "ABRAMSON CANCER CENTER BMT/CTN CORE CLINICAL CENTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_UG1HL069286_7529"}, {"internal_id": 50110901, "Award ID": "UG1HL069278", "Award Amount": 1496388.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-27", "CFDA Number": "93.837", "Description": "CITY OF HOPE CORE CLINICAL CENTER FOR THE BLOOD AND MARROW TRANSPLANT CLINICAL TRIALS NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e71a3a2e-7355-cc73-4dd7-2c5fef917d86-C", "generated_internal_id": "ASST_NON_UG1HL069278_7529"}, {"internal_id": 50110900, "Award ID": "UG1HL069274", "Award Amount": 1314618.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-27", "CFDA Number": "93.837", "Description": "BLOOD AND MARROW TRANSPLANT CLINICAL TRIALS NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_UG1HL069274_7529"}, {"internal_id": 50110899, "Award ID": "UG1HL069254", "Award Amount": 1314206.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-27", "CFDA Number": "93.837", "Description": "UNRELATED DONOR BMT VS. IMMUNE SUPPRESSION FOR NEWLY DIAGNOSED SEVERE APLASTIC ANEMIA IN CHILDREN AND YOUNG ADULTS: BMT CTN CORE CENTER RENEWAL FOR THE PEDIATRIC BLOOD AND MARROW TRANSPLANT CONSORTIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_UG1HL069254_7529"}, {"internal_id": 50110898, "Award ID": "UG1HL069249", "Award Amount": 1402309.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-26", "CFDA Number": "93.837", "Description": "A RANDOMIZED PHASE 2 TRIAL TO COMPARE STANDARD-OF-CARE STEROIDS VS. STEROIDS PLUS LOW-DOSE IL-2 VS. STEROIDS PLUS LOW-DOSE IL-2 AND RITUXIMAB FOR UPFRONT TREATMENT OF CHRONIC GVHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "be067fa7-a493-7bea-f9cc-e29bd2ccc74a-C", "generated_internal_id": "ASST_NON_UG1HL069249_7529"}, {"internal_id": 50110897, "Award ID": "UG1HL069246", "Award Amount": 1468181.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-27", "CFDA Number": "93.837", "Description": "BLOOD & MARROW CLINICAL TRIALS NETWORK- HUTCHINSON CENTER AS CORE CLINICAL SITE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "569197a4-81d0-b264-5640-e9db4cf71fd0-C", "generated_internal_id": "ASST_NON_UG1HL069246_7529"}, {"internal_id": 110024443, "Award ID": "U54HL156090", "Award Amount": 1000000.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-09-01", "CFDA Number": "93.310", "Description": "CENTER FOR DEVELOPMENTAL MAPPING OF HEART AND BONE TISSUES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_U54HL156090_7529"}, {"internal_id": 65894561, "Award ID": "U54HL142019", "Award Amount": 6914109.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-04-30", "CFDA Number": "93.837", "Description": "CENTER FOR THE INVESTIGATION OF FACTOR VIII INHIBITORS AND GLYCOSYLATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_U54HL142019_7529"}, {"internal_id": 65893729, "Award ID": "U54HL142012", "Award Amount": 7032244.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-04-30", "CFDA Number": "93.837", "Description": "MOLECULAR AND CELLULAR MECHANISMS OF THE FVIII IMMUNE RESPONSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_U54HL142012_7529"}, {"internal_id": 65894934, "Award ID": "U54HL141981", "Award Amount": 8116507.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-04-30", "CFDA Number": "93.837", "Description": "UNRAVELING THE IMMUNE RESPONSE TO FACTOR VIII", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_U54HL141981_7529"}, {"internal_id": 50106181, "Award ID": "U54HL141011", "Award Amount": 5547803.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-09-18", "CFDA Number": "93.310", "Description": "SICKLEGENAFRICA:SICKLE CELL DISEASE GENOMICS NETWORK OF AFRICA", "Place of Performance Country Code": "GHA", "Place of Performance State Code": null, "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "73985180-bc2a-cd24-7f91-87adf1d9b744-R", "generated_internal_id": "ASST_NON_U54HL141011_7529"}, {"internal_id": 50106172, "Award ID": "U54HL112311", "Award Amount": 12835809.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2012-04-30", "CFDA Number": "93.839", "Description": "REPROGRAMMED PLATELETS: EFFECTORS OF THROMBOSIS IN METABOLIC SYNDROMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_U54HL112311_7529"}, {"internal_id": 50106170, "Award ID": "U54HL112307", "Award Amount": 11096462.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2012-05-11", "CFDA Number": "93.839", "Description": "DTMI-CENTER FOR THROMBOTIC AND HEMOSTATIC DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_U54HL112307_7529"}, {"internal_id": 50106169, "Award ID": "U54HL112303", "Award Amount": 8764031.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2012-04-30", "CFDA Number": "93.839", "Description": "PROTEASES IN THE PATHOGENESIS AND TREATMENT OF THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_U54HL112303_7529"}, {"internal_id": 50106166, "Award ID": "U54HL096458", "Award Amount": 19952851.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2009-08-05", "CFDA Number": "93.350", "Description": "GENETIC DISORDER OF MUCOCILARY CLEARANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_U54HL096458_7529"}, {"internal_id": 98143408, "Award ID": "U24HL151541", "Award Amount": 3745332.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-06-17", "CFDA Number": "93.837", "Description": "THE BLOODSAFE DATA COORDINATING CENTER: A DATA CENTER FOR MORE SAFETRANSFUSIONS IN SUB-SAHARAN AFRICA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_U24HL151541_7529"}, {"internal_id": 110464496, "Award ID": "U24HL148563", "Award Amount": 1778210.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-09-17", "CFDA Number": "93.837", "Description": "2/2: SICKLE CELL DISEASE TREATMENT WITH ARGININE THERAPY (START) TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_U24HL148563_7529"}, {"internal_id": 80731343, "Award ID": "U24HL143217", "Award Amount": 4409642.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-05-07", "CFDA Number": "93.837", "Description": "2/2 SICKLE CELL DISEASE AND CARDIOVASCULAR RISK - RED CELL EXCHANGE TRIAL (SCD-CARRE TRIAL)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_U24HL143217_7529"}, {"internal_id": 69724900, "Award ID": "U24HL143216", "Award Amount": 4677248.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-09-20", "CFDA Number": "93.837", "Description": "TRANSFUSION OF PREMATURITY EARLY SCHOOL AGE FOLLOW-UP (TOP 5) DCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8303ed9b-9fb4-3e90-ca81-50bbcf400948-C", "generated_internal_id": "ASST_NON_U24HL143216_7529"}, {"internal_id": 78991480, "Award ID": "U24HL140090", "Award Amount": 1747078.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-03-05", "CFDA Number": "93.837", "Description": "2/2 POMALIDOMIDE FOR BLEEDING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) BLEEDING DATA COORDINATING CENTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8303ed9b-9fb4-3e90-ca81-50bbcf400948-C", "generated_internal_id": "ASST_NON_U24HL140090_7529"}, {"internal_id": 50100905, "Award ID": "U24HL138660", "Award Amount": 49875720.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-08-22", "CFDA Number": "93.395", "Description": "BLOOD AND MARROW TRANSPLANT CLINICAL TRIALS NETWORK DATA COORDINATING CENTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_U24HL138660_7529"}, {"internal_id": 68567388, "Award ID": "U24HL137907", "Award Amount": 5033135.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-09-06", "CFDA Number": "93.837", "Description": "2/2 A COMPARISON OF INDIVIDUALIZED VS. WEIGHT BASED PROTOCOLS TO TREAT VASO-OCCLUSIVE EPISODES IN SICKLE CELL DISEASE (COMPARE VOE)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_U24HL137907_7529"}, {"internal_id": 50100904, "Award ID": "U24HL137835", "Award Amount": 1712135.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-08-29", "CFDA Number": "93.837", "Description": "2/2 CATHETER-DIRECTED THERAPY FOR CHRONIC DVT (C-TRACT TRIAL)-DCC", "Place of Performance Country Code": "CAN", "Place of Performance State Code": null, "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "64b1a58e-e377-94df-b05a-f6e8981f86ec-C", "generated_internal_id": "ASST_NON_U24HL137835_7529"}, {"internal_id": 50100899, "Award ID": "U24HL135881", "Award Amount": 4260258.84, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-03-31", "CFDA Number": "93.837", "Description": "THE SICKLE PAN-AFRICAN RESEARCH CONSORTIUM (SPARCO)", "Place of Performance Country Code": "TZA", "Place of Performance State Code": null, "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f043453b-a3df-b73d-7278-b59eb9ca0ccb-C", "generated_internal_id": "ASST_NON_U24HL135881_7529"}, {"internal_id": 50100897, "Award ID": "U24HL135600", "Award Amount": 6712755.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-03-31", "CFDA Number": "93.837", "Description": "DEVELOPING A SICKLE AFRICA DATA COORDINATING CENTER (SADACC)", "Place of Performance Country Code": "ZAF", "Place of Performance State Code": null, "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": null, "generated_internal_id": "ASST_NON_U24HL135600_7529"}, {"internal_id": 50100895, "Award ID": "U24HL133948", "Award Amount": 6082577.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-08-09", "CFDA Number": "93.837", "Description": "DATA COORDINATING CENTER FOR SICKLE CELL DISEASE IMPLEMENTATION CONSORTIUM (SCDIC)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8303ed9b-9fb4-3e90-ca81-50bbcf400948-C", "generated_internal_id": "ASST_NON_U24HL133948_7529"}, {"internal_id": 97470183, "Award ID": "U19HL156247", "Award Amount": 12250287.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2020-05-13", "CFDA Number": "93.837", "Description": "NOVEL HEMATOPOIETIC STEM CELL ENGINEERING AND TRANSPLANTATION APPROACHES FOR HIV CURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_U19HL156247_7529"}, {"internal_id": 50098628, "Award ID": "U19HL129903", "Award Amount": 10954136.52, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-04-10", "CFDA Number": "93.837", "Description": "A DEFEND AND DESTROY APPROACH TO CURING HIV", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3c727a6e-aeb7-b7bb-b622-36f566d604a5-C", "generated_internal_id": "ASST_NON_U19HL129903_7529"}, {"internal_id": 50098627, "Award ID": "U19HL129902", "Award Amount": 12457790.64, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-04-10", "CFDA Number": "93.837", "Description": "NEXT GENERATION HSC GENE THERAPY FOR HIV CONTROL AND ERADICATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_U19HL129902_7529"}, {"internal_id": 50096701, "Award ID": "U10HL109322", "Award Amount": 859940.0, "Award Type": null, "Base Obligation Date": "2011-08-08", "CFDA Number": "93.839", "Description": "THE OHIO STATE BLOOD AND MARROW TRANSPLANT RESEACH CONSORTIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_U10HL109322_7529"}, {"internal_id": 50096693, "Award ID": "U10HL109137", "Award Amount": 776782.0, "Award Type": null, "Base Obligation Date": "2011-08-08", "CFDA Number": "93.839", "Description": "SARGRASTIM AND PLERIXAFOR VS. FILGRASTIM FOR ALLOGENEIC STEM CELL MOBILIZATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_U10HL109137_7529"}, {"internal_id": 50096691, "Award ID": "U10HL108987", "Award Amount": 1021593.0, "Award Type": null, "Base Obligation Date": "2011-08-08", "CFDA Number": "93.839", "Description": "BLOOD AND MARROW TRANSPLANT  CLINICAL TRIALS NETWORK (BMT CTN) - CORE CLINICAL C*", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dda62fdb-6501-1ff0-613d-ceb8e9bb2d48-C", "generated_internal_id": "ASST_NON_U10HL108987_7529"}, {"internal_id": 50096690, "Award ID": "U10HL108945", "Award Amount": 936039.0, "Award Type": null, "Base Obligation Date": "2011-08-08", "CFDA Number": "93.839", "Description": "ANTI-VIRAL AND ANTILEUKEMIC T-CELL THERAPY AS PROPHYLAXIS AFTER HSCT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_U10HL108945_7529"}, {"internal_id": 50096642, "Award ID": "U10HL069348", "Award Amount": 923214.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.837", "Description": "CASE BMT CTN: ANTIBACTERIAL PROPHYLAXIS IN POST-ENGRAFTMENT ALLOGENEIC HCT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_U10HL069348_7529"}, {"internal_id": 50096641, "Award ID": "U10HL069334", "Award Amount": 903907.0, "Award Type": null, "Base Obligation Date": "2011-08-05", "CFDA Number": "93.839", "Description": "IMPROVING THE OUTCOMES OF STEM CELL TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "07c08a07-af34-2853-20eb-9d2594ed7b35-C", "generated_internal_id": "ASST_NON_U10HL069334_7529"}, {"internal_id": 50096640, "Award ID": "U10HL069330", "Award Amount": 953287.0, "Award Type": null, "Base Obligation Date": "2011-08-08", "CFDA Number": "93.839", "Description": "UNIVERSITY OF MICHIGAN CORE CLINICAL CENTER FOR BMT RESEARCH NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_U10HL069330_7529"}, {"internal_id": 50096639, "Award ID": "U10HL069315", "Award Amount": 1118928.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.839", "Description": "MSKCC BMT CTN RENEWAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b514fc3a-d769-87e9-75ea-7a6766afb5ee-C", "generated_internal_id": "ASST_NON_U10HL069315_7529"}, {"internal_id": 50096638, "Award ID": "U10HL069310", "Award Amount": 775097.65, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.837", "Description": "TRANSLATIONAL RESEARCH IN BLOOD AND MARROW TRANSLPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_U10HL069310_7529"}, {"internal_id": 50096637, "Award ID": "U10HL069301", "Award Amount": 833020.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.837", "Description": "CORE CLINICAL CONSORTIUM FOR BLOOD AND MARROW TRANSPLANT CLINICAL TRIALS NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_U10HL069301_7529"}, {"internal_id": 50096636, "Award ID": "U10HL069294", "Award Amount": 37527254.69, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.837", "Description": "BLOOD & MARROW TRANSPLANT CLINICAL TRIALS NETWORK DATA COORDINATING CENTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_U10HL069294_7529"}, {"internal_id": 50096635, "Award ID": "U10HL069291", "Award Amount": 773852.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.839", "Description": "BMT CLINICAL TRIAL NETWORK AT STANFORD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_U10HL069291_7529"}, {"internal_id": 50096634, "Award ID": "U10HL069290", "Award Amount": 837904.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.839", "Description": "ENHANCING THE SAFETY OF ALLOGENEIC TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_U10HL069290_7529"}, {"internal_id": 50096633, "Award ID": "U10HL069286", "Award Amount": 960246.0, "Award Type": null, "Base Obligation Date": "2011-08-08", "CFDA Number": "93.839", "Description": "BONE MARROW TRANSPLANT CLINICAL NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_U10HL069286_7529"}, {"internal_id": 50096632, "Award ID": "U10HL069278", "Award Amount": 955536.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.839", "Description": "BLOOD AND MARROW TRANSPLANT CLINICAL RESEARCH NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e71a3a2e-7355-cc73-4dd7-2c5fef917d86-C", "generated_internal_id": "ASST_NON_U10HL069278_7529"}, {"internal_id": 50096631, "Award ID": "U10HL069274", "Award Amount": 890998.0, "Award Type": null, "Base Obligation Date": "2011-08-08", "CFDA Number": "93.839", "Description": "BLOOD AND MARROW TRANSPLANT CLINICAL TRIALS NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_U10HL069274_7529"}, {"internal_id": 50096630, "Award ID": "U10HL069254", "Award Amount": 811395.0, "Award Type": null, "Base Obligation Date": "2011-08-08", "CFDA Number": "93.839", "Description": "BLOOD AND MARROW TRANSPLANT CLINICAL TRIALS NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6c10cf51-1fb6-c52e-c48f-8fcef0f37eff-C", "generated_internal_id": "ASST_NON_U10HL069254_7529"}, {"internal_id": 50096629, "Award ID": "U10HL069249", "Award Amount": 1078875.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.839", "Description": "A RANDOMIZED TRIAL OF TAC/MTX/BORTEZOMIB VS TAC/MTXPLACEBO IN ALLOGENEIC HSCT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "be067fa7-a493-7bea-f9cc-e29bd2ccc74a-C", "generated_internal_id": "ASST_NON_U10HL069249_7529"}, {"internal_id": 50096628, "Award ID": "U10HL069246", "Award Amount": 1071649.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.839", "Description": "BLOOD & MARROW CLINICAL TRIALS NETWORK - HUTCHINSON CENTER CORE CLINICAL SIT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_U10HL069246_7529"}, {"internal_id": 50096627, "Award ID": "U10HL069233", "Award Amount": 695374.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-08-08", "CFDA Number": "93.837", "Description": "NEBRASKA/KANSAS BLOOD AND MARROW TRANSPLANT RESEARCH NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NE", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce6cc294-968c-0136-a2e3-f34319ce4753-C", "generated_internal_id": "ASST_NON_U10HL069233_7529"}, {"internal_id": 81395708, "Award ID": "U01HL148681", "Award Amount": 769518.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2019-06-11", "CFDA Number": "93.370", "Description": "CGMP MANUFACTURE OF FVIII-EXPRESSING PLACENTAL CELLS FOR HEMOPHILIA A", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "623a4232-bd5e-fb60-cf01-48cd08a5a593-C", "generated_internal_id": "ASST_NON_U01HL148681_7529"}, {"internal_id": 68171298, "Award ID": "U01HL143477", "Award Amount": 1050356.4, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-08-28", "CFDA Number": "93.837", "Description": "IMPLEMENTATION OF EVIDENCE BASED CARE FOR THE ACUTE TREATMENT OF SICKLE CELL DISEASE PAIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_U01HL143477_7529"}, {"internal_id": 67580412, "Award ID": "U01HL143403", "Award Amount": 4245314.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-07-20", "CFDA Number": "93.837", "Description": "TARGETING THE PLASMINOGEN ACTIVATION SYSTEM TO LIMIT PANCREATIC CANCER PROGRESSION AND ASSOCIATED THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_U01HL143403_7529"}, {"internal_id": 67579914, "Award ID": "U01HL143402", "Award Amount": 4744245.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-07-20", "CFDA Number": "93.837", "Description": "NOVEL APPROACHES TO IMPROVE PREDICTION OF CANCER-ASSOCIATED THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_U01HL143402_7529"}, {"internal_id": 67579139, "Award ID": "U01HL143365", "Award Amount": 4347623.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-07-20", "CFDA Number": "93.837", "Description": "BIOMARKERS AND MECHANISMS IN CANCER ASSOCIATED THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_U01HL143365_7529"}, {"internal_id": 67833773, "Award ID": "U01HL139483", "Award Amount": 3459673.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-08-17", "CFDA Number": "93.837", "Description": "MULTISCALE MODELING OF INFLUENZA VACCINATION STRATEGIES FOR OPTIMAL T CELL IMMUNITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_U01HL139483_7529"}, {"internal_id": 50095227, "Award ID": "U01HL136318", "Award Amount": 1820030.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-05-30", "CFDA Number": "93.837", "Description": "DARBEPOETIN TRIAL TO IMPROVE RED CELL MASS AND NEURODEVELOPMENT IN PRETERMS-CCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_U01HL136318_7529"}, {"internal_id": 50095226, "Award ID": "U01HL136306", "Award Amount": 5384319.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-05-30", "CFDA Number": "93.837", "Description": "DARBEPOETIN TRIAL TO IMPROVE RED CELL MASS AND NEUROPROTECTION IN PRETERMS - DCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8303ed9b-9fb4-3e90-ca81-50bbcf400948-C", "generated_internal_id": "ASST_NON_U01HL136306_7529"}, {"internal_id": 50095223, "Award ID": "U01HL134812", "Award Amount": 8256108.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-09-22", "CFDA Number": "93.837", "Description": "STEM CELLS FOR THERAPEUTICS DISCOVERY IN GENETIC BLOOD DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_U01HL134812_7529"}, {"internal_id": 50095218, "Award ID": "U01HL134696", "Award Amount": 8309735.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-09-15", "CFDA Number": "93.837", "Description": "IMPROVING TRANSFUSION THERAPY FOR PATIENTS WITH SICKLE CELL DISEASE WITH PLURIPOTENT STEM CELL-DERIVED RED CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_U01HL134696_7529"}, {"internal_id": 50095216, "Award ID": "U01HL134042", "Award Amount": 5066998.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-08-04", "CFDA Number": "93.837", "Description": "IMPROVING SICKLE CELL CARE IN ADOLESCENTS & ADULTS IN CHICAGO (ISAAC)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_U01HL134042_7529"}, {"internal_id": 50095215, "Award ID": "U01HL134007", "Award Amount": 4070552.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-08-04", "CFDA Number": "93.837", "Description": "SC-LINKS - LINKING THE SICKLE CELL COMMUNITY, PROVIDERS AND SYSTEMS TO IMPROVE SICKLE CELL DISEASE CARE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_U01HL134007_7529"}, {"internal_id": 50095214, "Award ID": "U01HL134004", "Award Amount": 5019397.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-08-05", "CFDA Number": "93.837", "Description": "IMPLEMENTATION OF MEDICAL HOMES FOR EVIDENCE BASED CARE OF ADOLESCENTS AND ADULTS WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aca87389-2cb6-91e2-17a4-df7e81a7314d-C", "generated_internal_id": "ASST_NON_U01HL134004_7529"}, {"internal_id": 50095213, "Award ID": "U01HL133997", "Award Amount": 5382176.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-08-05", "CFDA Number": "93.837", "Description": "NEW YORK CITY SICKLE CELL IMPLEMENTATION SCIENCE CONSORTIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_U01HL133997_7529"}, {"internal_id": 50095212, "Award ID": "U01HL133996", "Award Amount": 4550781.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-08-05", "CFDA Number": "93.837", "Description": "RE-AIMING AT HYDROXYUREA ADHERENCE FOR SICKLE CELL WITH MHEALTH (RE-HASH)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bccd984e-68ff-4e70-2020-f0129e4b9ecc-C", "generated_internal_id": "ASST_NON_U01HL133996_7529"}, {"internal_id": 50095211, "Award ID": "U01HL133994", "Award Amount": 5163199.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-08-05", "CFDA Number": "93.837", "Description": "THE IMPLEMENTATION OF COGNITIVE SCREENING AND EDUCATIONAL SUPPORT TO IMPROVE OUTCOMES OF ADOLESCENTS AND YOUNG ADULTS WITH SICKLE CELL DISEASE: FROM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_U01HL133994_7529"}, {"internal_id": 50095210, "Award ID": "U01HL133990", "Award Amount": 4065528.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-08-05", "CFDA Number": "93.837", "Description": "IMPLEMENTATION OF A SICKLE CELL ENHANCED NOVEL CARE NETWORK IN SOUTH CAROLINA (ISCENSC)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "SC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "04a78f04-ee86-46df-5fbf-c71e46ed8479-C", "generated_internal_id": "ASST_NON_U01HL133990_7529"}, {"internal_id": 50095209, "Award ID": "U01HL133964", "Award Amount": 4831553.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-08-05", "CFDA Number": "93.837", "Description": "IMPROVING SCD CARE USING WEB-BASED GUIDELINES, NURSE CARE MANAGERS AND PEER MENTORS IN PRIMARY CARE AND EMERGENCY DEPARTMENTS IN CENTRAL NORTH CAROLI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_U01HL133964_7529"}, {"internal_id": 50095208, "Award ID": "U01HL133883", "Award Amount": 6460190.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-17", "CFDA Number": "93.837", "Description": "REALIZING EFFECTIVENESS ACROSS CONTINENTS WITH HYDROXYUREA(REACH): A PHASE I/II PILOT STUDY OF HYROXYUREA FOR CHILDREN WITH SICKLE CELL ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_U01HL133883_7529"}, {"internal_id": 50095206, "Award ID": "U01HL133817", "Award Amount": 17136580.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-09-02", "CFDA Number": "93.837", "Description": "MYOCARDIAL ISCHEMIA AND TRANSFUSION (MINT) - CCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f360f59f-4329-903a-affb-d7870b1503be-C", "generated_internal_id": "ASST_NON_U01HL133817_7529"}, {"internal_id": 50095205, "Award ID": "U01HL133815", "Award Amount": 2784949.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-08-25", "CFDA Number": "93.837", "Description": "VON WILLEBRAND DISEASE MINIMIZE MENORRHAGIA (VWDMIN) TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_U01HL133815_7529"}, {"internal_id": 50095198, "Award ID": "U01HL133362", "Award Amount": 2003020.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2017-07-20", "CFDA Number": "93.837", "Description": "MULTISCALE MODELING OF CEREBRAL BLOOD FLOW AND OXYGEN TRANSPORT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_U01HL133362_7529"}, {"internal_id": 50095194, "Award ID": "U01HL132853", "Award Amount": 4120213.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-09-02", "CFDA Number": "93.837", "Description": "MYOCARDIAL ISCHEMIA AND TRANSFUSION (MINT) - DCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_U01HL132853_7529"}, {"internal_id": 50095184, "Award ID": "U01HL131053", "Award Amount": 3836363.38, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-04-18", "CFDA Number": "93.837", "Description": "MULTISCALE ANALYSIS OF TRAUMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_U01HL131053_7529"}, {"internal_id": 50095183, "Award ID": "U01HL131052", "Award Amount": 3597057.47, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-04-21", "CFDA Number": "93.837", "Description": "MULTISCALE MODELING OF BLOOD FLOW AND PLATELET MEDIATED THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3313e5e7-fa36-d54b-e36d-0e1e09cc0c30-C", "generated_internal_id": "ASST_NON_U01HL131052_7529"}, {"internal_id": 50095176, "Award ID": "U01HL130219", "Award Amount": 1844370.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-09-15", "CFDA Number": "93.837", "Description": "KIDSDOTT-DCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_U01HL130219_7529"}, {"internal_id": 50095171, "Award ID": "U01HL130048", "Award Amount": 3077262.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2016-09-15", "CFDA Number": "93.837", "Description": "KIDSDOTT-CCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_U01HL130048_7529"}, {"internal_id": 50095156, "Award ID": "U01HL128568", "Award Amount": 1744465.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.837", "Description": "HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR YOUNG ADULTS WITH SCD - DCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_U01HL128568_7529"}, {"internal_id": 50095155, "Award ID": "U01HL128566", "Award Amount": 5720467.07, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.837", "Description": "HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR YOUNG ADULTS WITH SICKLE CELL DISEASE - CLINICAL COORDINATING CENTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_U01HL128566_7529"}, {"internal_id": 50095111, "Award ID": "U01HL122894", "Award Amount": 5994580.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-08-10", "CFDA Number": "93.837", "Description": "AMERICAN TRIAL USING TRANEXAMIC ACID IN THROMBOCYTOPENIA (A-TREAT)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_U01HL122894_7529"}, {"internal_id": 50095102, "Award ID": "U01HL122272", "Award Amount": 2437537.58, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2015-08-10", "CFDA Number": "93.837", "Description": "AMERICAN TRIAL USING TRANEXAMIC ACID IN THROMBOCYTOPENIA (A-TREAT)  - DCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_U01HL122272_7529"}, {"internal_id": 50095077, "Award ID": "U01HL117721", "Award Amount": 9048246.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-08-16", "CFDA Number": "93.839", "Description": "CELLULAR AND MOLECULAR MECHANISMS OF ACUTE LUNG INJURY IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_U01HL117721_7529"}, {"internal_id": 50095076, "Award ID": "U01HL117720", "Award Amount": 7383804.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-08-16", "CFDA Number": "93.839", "Description": "TRANSLATIONAL AND CLINICAL STUDIES TARGETING Y-GLOBIN MODULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_U01HL117720_7529"}, {"internal_id": 50095075, "Award ID": "U01HL117718", "Award Amount": 9613302.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-08-16", "CFDA Number": "93.839", "Description": "MULTIMODAL BIOPHYSICAL MARKERS OF VASCULAR DISEASE IN HEMOGLOBINOPATHIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6c10cf51-1fb6-c52e-c48f-8fcef0f37eff-C", "generated_internal_id": "ASST_NON_U01HL117718_7529"}, {"internal_id": 50095074, "Award ID": "U01HL117709", "Award Amount": 8870499.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-08-16", "CFDA Number": "93.839", "Description": "CINCINNATI CENTER OF EXCELLENCE IN HEMOGLOBINOPATHIES RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_U01HL117709_7529"}, {"internal_id": 50095073, "Award ID": "U01HL117684", "Award Amount": 8101201.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-08-16", "CFDA Number": "93.839", "Description": "THE ROLE OF ENDOTHELIN-1 IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aca87389-2cb6-91e2-17a4-df7e81a7314d-C", "generated_internal_id": "ASST_NON_U01HL117684_7529"}, {"internal_id": 50095072, "Award ID": "U01HL117664", "Award Amount": 9404727.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-08-16", "CFDA Number": "93.839", "Description": "CANNABINOID-BASED THERAPY AND APPROACHES TO QUANTIFY PAIN IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_U01HL117664_7529"}, {"internal_id": 50095071, "Award ID": "U01HL117659", "Award Amount": 7551126.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-08-16", "CFDA Number": "93.839", "Description": "TARGETED ANTICOAGULANT THERAPY FOR SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_U01HL117659_7529"}, {"internal_id": 50095070, "Award ID": "U01HL117658", "Award Amount": 8128726.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-08-16", "CFDA Number": "93.839", "Description": "IMPROVING HBF INDUCTION BY INHIBITING EPIGENETIC TARGET ENZYMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_U01HL117658_7529"}, {"internal_id": 50095067, "Award ID": "U01HL116383", "Award Amount": 8107330.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-07-12", "CFDA Number": "93.839", "Description": "AGE OF BLOOD IN CHILDREN IN PEDIATRIC INTENSIVE CARE UNITS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_U01HL116383_7529"}, {"internal_id": 50095058, "Award ID": "U01HL114476", "Award Amount": 3883373.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2013-08-19", "CFDA Number": "93.839", "Description": "MULTISCALE MODELING OF SICKLE CELL ANEMIA: METHODS AND VALIDATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "378fe7f9-e157-cd75-80cc-97cbe1a426db-C", "generated_internal_id": "ASST_NON_U01HL114476_7529"}, {"internal_id": 50095051, "Award ID": "U01HL112776", "Award Amount": 1137958.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2012-07-20", "CFDA Number": "93.839", "Description": "TRANSFUSION-ASSOCIATED BRAIN IMPROVEMENT (TABI) TRIAL - CCC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_U01HL112776_7529"}, {"internal_id": 50095050, "Award ID": "U01HL112748", "Award Amount": 7361559.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2012-07-20", "CFDA Number": "93.839", "Description": "TRANSFUSION-ASSOCIATED BRAIN IMPROVEMENT (TABI) TRIAL: DATA COORDINATING CENTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8303ed9b-9fb4-3e90-ca81-50bbcf400948-C", "generated_internal_id": "ASST_NON_U01HL112748_7529"}, {"internal_id": 50095017, "Award ID": "U01HL107446", "Award Amount": 8760532.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2011-07-01", "CFDA Number": "93.839", "Description": "FUNCTIONAL GENOMICS OF PLATELET AGGREGATION USING IPS AND DERIVED MEGAKARYOCYTES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_U01HL107446_7529"}, {"internal_id": 50095016, "Award ID": "U01HL107443", "Award Amount": 8307994.0, "Award Type": null, "Base Obligation Date": "2011-07-01", "CFDA Number": "93.839", "Description": "GLOBIN GENE EXPRESSION IN SICKLE CELL GENOTYPE-SPECIFIC IPS CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_U01HL107443_7529"}, {"internal_id": 50094957, "Award ID": "U01HL099993", "Award Amount": 8333261.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2009-09-24", "CFDA Number": "93.837", "Description": "CONTROLLING HEMATOPOIETIC LINEAGE COMMITMENT FROM ESC TO PLATELETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_U01HL099993_7529"}, {"internal_id": 50033082, "Award ID": "T35HL074708", "Award Amount": 264151.95, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-30", "CFDA Number": "93.837", "Description": "TRAINING STUDENTS IN BIOMEDICAL RESEARCH IN HEMATOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_T35HL074708_7529"}, {"internal_id": 50033070, "Award ID": "T35HL007616", "Award Amount": 2580117.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-05-03", "CFDA Number": "93.837", "Description": "SHORT-TERM TRAINING GRANT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_T35HL007616_7529"}, {"internal_id": 95484154, "Award ID": "T32HL149648", "Award Amount": 883580.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-27", "CFDA Number": "93.837", "Description": "MULTIDISCIPLINARY RESEARCH TRAINING IN HEMATOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_T32HL149648_7529"}, {"internal_id": 66800195, "Award ID": "T32HL139443", "Award Amount": 1593664.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-15", "CFDA Number": "93.837", "Description": "RESEARCH TRAINING IN PEDIATRIC NON-MALIGNANT HEMATOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_T32HL139443_7529"}, {"internal_id": 67580714, "Award ID": "T32HL139425", "Award Amount": 1534066.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-25", "CFDA Number": "93.837", "Description": "COLLABORATIVE RESEARCH TRAINING IN THROMBOSIS AND INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_T32HL139425_7529"}, {"internal_id": 50032438, "Award ID": "T32HL134644", "Award Amount": 1411845.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-28", "CFDA Number": "93.837", "Description": "CURRENT TRENDS IN STEM CELL THERAPIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3c9476c3-c39d-74de-31b6-2c9a10197e11-C", "generated_internal_id": "ASST_NON_T32HL134644_7529"}, {"internal_id": 50032402, "Award ID": "T32HL120824", "Award Amount": 2370956.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-01", "CFDA Number": "93.837", "Description": "PROGRAM IN TRANSLATIONAL AND EXPERIMENTAL HEMATOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_T32HL120824_7529"}, {"internal_id": 50032399, "Award ID": "T32HL116324", "Award Amount": 5527883.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-16", "CFDA Number": "93.837", "Description": "TRAINING PROGRAM IN MOLECULAR HEMATOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_T32HL116324_7529"}, {"internal_id": 50032393, "Award ID": "T32HL116249", "Award Amount": 948128.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-15", "CFDA Number": "93.839", "Description": "HEMATOLOGY POST DOCTORAL TRAINING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f21f887-ca03-f1f2-6e30-1c1498f78b9e-C", "generated_internal_id": "ASST_NON_T32HL116249_7529"}, {"internal_id": 50032387, "Award ID": "T32HL110841", "Award Amount": 1457147.39, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-01-11", "CFDA Number": "93.837", "Description": "CHILDREN'S RESEARCH INSTITUTE HEMATOLOGY RESEARCH TRAINING GRANT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cf018231-59a5-d301-ae96-b0817a8ee227-C", "generated_internal_id": "ASST_NON_T32HL110841_7529"}, {"internal_id": 50032352, "Award ID": "T32HL092332", "Award Amount": 5367673.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-04-15", "CFDA Number": "93.837", "Description": "TRAINING IN CELL AND GENE THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_T32HL092332_7529"}, {"internal_id": 50032338, "Award ID": "T32HL086345", "Award Amount": 3512066.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-22", "CFDA Number": "93.837", "Description": "TRAINING IN DEVELOPMENTAL HEMATOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_T32HL086345_7529"}, {"internal_id": 50032337, "Award ID": "T32HL086344", "Award Amount": 4268827.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-03-27", "CFDA Number": "93.837", "Description": "BLOOD CELLS IN HEMOSTASIS AND THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_T32HL086344_7529"}, {"internal_id": 50032295, "Award ID": "T32HL069769", "Award Amount": 1798067.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-15", "CFDA Number": "93.837", "Description": "TRAINING GRANT IN TRANSFUSION MEDICINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_T32HL069769_7529"}, {"internal_id": 50032292, "Award ID": "T32HL069765", "Award Amount": 3680713.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-02", "CFDA Number": "93.839", "Description": "IMMUNOBIOLOGY OF BLOOD AND VASCULAR SYSTEMS TRAINING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4a536007-27e4-2194-a125-f4b8c55294db-C", "generated_internal_id": "ASST_NON_T32HL069765_7529"}, {"internal_id": 50032286, "Award ID": "T32HL066992", "Award Amount": 2294051.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-27", "CFDA Number": "93.839", "Description": "TRAINING FOR ACADEMIC HEMATOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_T32HL066992_7529"}, {"internal_id": 50032283, "Award ID": "T32HL066987", "Award Amount": 9412160.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-06", "CFDA Number": "93.837", "Description": "TRANSFUSION BIOLOGY AND MEDICINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_T32HL066987_7529"}, {"internal_id": 50032282, "Award ID": "T32HL007974", "Award Amount": 5447265.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-25", "CFDA Number": "93.837", "Description": "IMMUNOHEMATOLOGY/TRANSFUSION MEDICINE RESEARCH TRAINING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_T32HL007974_7529"}, {"internal_id": 50032280, "Award ID": "T32HL007971", "Award Amount": 6643133.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-06", "CFDA Number": "93.837", "Description": "TRAINING GRANT IN HEMOSTASIS AND THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_T32HL007971_7529"}, {"internal_id": 50032273, "Award ID": "T32HL007952", "Award Amount": 1368651.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-08-20", "CFDA Number": "93.837", "Description": "TRAINING PROGRAM IN HEMATOPOIETIC CELL TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_T32HL007952_7529"}, {"internal_id": 50032264, "Award ID": "T32HL007917", "Award Amount": 6690393.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-08-15", "CFDA Number": "93.837", "Description": "PROGRAM IN BLOOD COAGULATION AND VASCULAR BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_T32HL007917_7529"}, {"internal_id": 50032260, "Award ID": "T32HL007910", "Award Amount": 4923934.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-25", "CFDA Number": "93.837", "Description": "BASIC SCIENCE STUDIES ON GENE THERAPY OF BLOOD DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_T32HL007910_7529"}, {"internal_id": 50032256, "Award ID": "T32HL007899", "Award Amount": 4975663.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-08-18", "CFDA Number": "93.837", "Description": "RESEARCH TRAINING IN HEMATOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_T32HL007899_7529"}, {"internal_id": 50032232, "Award ID": "T32HL007775", "Award Amount": 1979311.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-01", "CFDA Number": "93.837", "Description": "TRANSFUSION MEDICINE RESEARCH TRAINING PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_T32HL007775_7529"}, {"internal_id": 50032217, "Award ID": "T32HL007698", "Award Amount": 5462971.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-05", "CFDA Number": "93.837", "Description": "TRANSFUSION MEDICINE RESEARCH TRAINING PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_T32HL007698_7529"}, {"internal_id": 50032205, "Award ID": "T32HL007622", "Award Amount": 5388140.49, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-09-25", "CFDA Number": "93.837", "Description": "TRAINING PROGRAM IN MOLECULAR HEMATOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_T32HL007622_7529"}, {"internal_id": 50032201, "Award ID": "T32HL007594", "Award Amount": 2514826.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-01", "CFDA Number": "93.839", "Description": "HEMOSTASIS AND THROMBOSIS PROGRAM FOR ACADEMIC TRAINEES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_T32HL007594_7529"}, {"internal_id": 50032196, "Award ID": "T32HL007574", "Award Amount": 11204880.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-27", "CFDA Number": "93.837", "Description": "PATHOPHYSIOLOGY OF HUMAN BLOOD CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_T32HL007574_7529"}, {"internal_id": 50032188, "Award ID": "T32HL007525", "Award Amount": 3818482.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-26", "CFDA Number": "93.837", "Description": "TRAINING PROGRAM IN HEMATOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_T32HL007525_7529"}, {"internal_id": 50032186, "Award ID": "T32HL007501", "Award Amount": 3321538.44, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-19", "CFDA Number": "93.837", "Description": "RESEARCH TRAINING IN BLOOD DISEASES AND RESOURCES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_T32HL007501_7529"}, {"internal_id": 50032181, "Award ID": "T32HL007439", "Award Amount": 10396044.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-30", "CFDA Number": "93.837", "Description": "HEMATOLOGY CLINICAL RESEARCH TRAINING PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_T32HL007439_7529"}, {"internal_id": 50032170, "Award ID": "T32HL007344", "Award Amount": 3933213.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-29", "CFDA Number": "93.837", "Description": "PROGRAM IN HEMATOLOGY:& CELL BIOLOGY BLOOD CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_T32HL007344_7529"}, {"internal_id": 50032155, "Award ID": "T32HL007209", "Award Amount": 1919640.52, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-08-20", "CFDA Number": "93.837", "Description": "RESEARCH TRAINING IN TRANSFUSION MEDICINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_T32HL007209_7529"}, {"internal_id": 50032146, "Award ID": "T32HL007151", "Award Amount": 3927314.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-25", "CFDA Number": "93.839", "Description": "RESEARCH IN THE PATHOGENESIS OF HEMATOLOGIC DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c07787b9-15d4-d1eb-4f0c-2e0b30320bfb-C", "generated_internal_id": "ASST_NON_T32HL007151_7529"}, {"internal_id": 50032145, "Award ID": "T32HL007150", "Award Amount": 4365392.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-06-26", "CFDA Number": "93.837", "Description": "PEDIATRIC HEMATOLOGY RESEARCH TRAINING PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_T32HL007150_7529"}, {"internal_id": 50032144, "Award ID": "T32HL007149", "Award Amount": 5345560.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-09", "CFDA Number": "93.837", "Description": "RESEARCH FELLOWSHIPS IN HEMATOLOGY/ONCOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_T32HL007149_7529"}, {"internal_id": 50032137, "Award ID": "T32HL007093", "Award Amount": 8945896.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-05", "CFDA Number": "93.837", "Description": "RESEARCH TRAINING IN HEMATOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_T32HL007093_7529"}, {"internal_id": 50032135, "Award ID": "T32HL007088", "Award Amount": 8725082.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-02-08", "CFDA Number": "93.837", "Description": "PRE-AND POSTGRADUATE TRAINING IN MOLECULAR HEMATOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_T32HL007088_7529"}, {"internal_id": 50032132, "Award ID": "T32HL007062", "Award Amount": 6332650.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-27", "CFDA Number": "93.837", "Description": "HEMATOLOGY RESEARCH TRAINING PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_T32HL007062_7529"}, {"internal_id": 50032131, "Award ID": "T32HL007057", "Award Amount": 6963814.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-29", "CFDA Number": "93.837", "Description": "TRANSFUSION MEDICINE AND RELATED AREAS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_T32HL007057_7529"}, {"internal_id": 85589603, "Award ID": "SC1HL150685", "Award Amount": 1545000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-19", "CFDA Number": "93.859", "Description": "THE ROLE OF HGFL IN THE SICKLE CELL DISEASE NEPHROPATHY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ab2545e4-42db-b0e5-c4ac-2382eeaf8c92-C", "generated_internal_id": "ASST_NON_SC1HL150685_7529"}, {"internal_id": 49980688, "Award ID": "SC1HL123911", "Award Amount": 976112.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-06-27", "CFDA Number": "93.839", "Description": "A GENOMIC APPROACH TO WARFARIN DOSE PRESCRIPTION IN ADMIXED CARIBBEAN HISPANICS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8c1ec519-5f65-cd50-5513-3bebb8a38de4-C", "generated_internal_id": "ASST_NON_SC1HL123911_7529"}, {"internal_id": 49965711, "Award ID": "SB1HL137591", "Award Amount": 50000.0, "Award Type": null, "Base Obligation Date": "2016-09-24", "CFDA Number": "93.839", "Description": "DEVELOPMENT OF AN INTELLECTUAL PROPERTY (IP) STRATEGY FOR THE COMMERCIAL ADVANCEMENT OF A DIRECT PHASE II SBIR-FUNDED HUMAN PLATELET BIOREACTOR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "92548adc-159a-6133-b616-34c17f454466-C", "generated_internal_id": "ASST_NON_SB1HL137591_7529"}, {"internal_id": 100873942, "Award ID": "SB1HL106860", "Award Amount": 410750.68, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-10", "CFDA Number": "93.837", "Description": "ENHANCING THE COMMERCIALIZATION READINESS OF A NONINVASIVE TOTAL HEMOGLOBIN MONITOR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8188e551-9fe5-136e-dbab-6b85830080b6-C", "generated_internal_id": "ASST_NON_SB1HL106860_7529"}, {"internal_id": 110024418, "Award ID": "R61HL154307", "Award Amount": 1283236.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-03", "CFDA Number": "93.837", "Description": "A VASCULARIZED MICRO-ORGAN PLATFORM FOR THE STUDY OF BRAIN-BBB-BLOOD INTERACTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b710df3-c98e-f245-bbed-8bbbc32a803b-C", "generated_internal_id": "ASST_NON_R61HL154307_7529"}, {"internal_id": 110024947, "Award ID": "R61HL154254", "Award Amount": 1302589.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-03", "CFDA Number": "93.837", "Description": "CILIA AS A BIOMARKER OF CNS VASCULAR HEALTH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R61HL154254_7529"}, {"internal_id": 110024202, "Award ID": "R61HL154250", "Award Amount": 1477401.29, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-03", "CFDA Number": "93.837", "Description": "3D MODELS OF THE BLOOD-BRAIN BARRIER FOR STUDYING TRAUMA-INDUCED CEREBRAL AND SYSTEMIC INJURIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R61HL154250_7529"}, {"internal_id": 110025172, "Award ID": "R61HL154249", "Award Amount": 1228124.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-03", "CFDA Number": "93.837", "Description": "THE ?SIM-HNVU - A HUMAN BBB PLATFORM FOR THE STUDY OF BRAIN INJURY MECHANISMS DURING SYSTEMIC INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R61HL154249_7529"}, {"internal_id": 109278267, "Award ID": "R61HL154215", "Award Amount": 786895.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-20", "CFDA Number": "93.837", "Description": "WEARABLE, GRAPHENE-BASED FLEXIBLE SENSORS FOR CHRONIC MONITORING OF VENOUS THROMBOEMBOLISM FOR HIGH-RISK PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75ab327f-73c4-0cd6-8603-65890591d8db-C", "generated_internal_id": "ASST_NON_R61HL154215_7529"}, {"internal_id": 108463096, "Award ID": "R61HL154094", "Award Amount": 693689.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-10", "CFDA Number": "93.837", "Description": "A RAPID AND INEXPENSIVE POINT-OF-CARE TEST FOR BETA-THALASSEMIA CARRIERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8f7abd33-a02f-d694-4820-eb4c70a62b2b-C", "generated_internal_id": "ASST_NON_R61HL154094_7529"}, {"internal_id": 65579316, "Award ID": "R61HL141794", "Award Amount": 738873.19, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-19", "CFDA Number": "93.837", "Description": "A SYSTEMS BIOLOGY APPROACH TO IDENTIFYING THE MECHANISMS OF SEX HORMONE INDUCED THROMBOEMBOLISM IN PRE-MENOPAUSAL WOMEN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cc5207ca-4d78-1308-62c7-b425dd44275c-C", "generated_internal_id": "ASST_NON_R61HL141794_7529"}, {"internal_id": 65578759, "Award ID": "R61HL141791", "Award Amount": 1228447.08, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-11", "CFDA Number": "93.837", "Description": "MODEL SYSTEM OF ORAL CONTRACEPTIVE-INDUCED VTE: INTEGRATING GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC DISCOVERY WITH FUNCTIONAL BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R61HL141791_7529"}, {"internal_id": 65280882, "Award ID": "R61HL141787", "Award Amount": 1476965.5, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-30", "CFDA Number": "93.837", "Description": "THE INTERACTION OF BASAL RISK, PHARMACOLOGIC OVULATION INDUCTION, PREGNANCY AND DELIVERY ON HEMOSTATIC BALANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R61HL141787_7529"}, {"internal_id": 65578885, "Award ID": "R61HL141783", "Award Amount": 1420127.33, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-11", "CFDA Number": "93.837", "Description": "OPA1 AN ESTROGEN-MEDIATED MODULATOR OF PLATELET HYPERACTIVATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R61HL141783_7529"}, {"internal_id": 110464616, "Award ID": "R56HL153963", "Award Amount": 357555.58, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-16", "CFDA Number": "93.837", "Description": "FUNCTIONAL CHARACTERIZATION OF CHILDREN WITH CHRONIC THROMBOEMBOLIC DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_R56HL153963_7529"}, {"internal_id": 110862079, "Award ID": "R56HL153068", "Award Amount": 608512.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-23", "CFDA Number": "93.839", "Description": "THE MRN COMPLEX IN LYMPHOCYTE DEVELOPMENT AND GENOME STABILITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R56HL153068_7529"}, {"internal_id": 110463741, "Award ID": "R56HL152365", "Award Amount": 384838.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-16", "CFDA Number": "93.839", "Description": "IMPACT OF CHRONIC INTERMITTENT HYPOXIA ON THE BONE MARROW", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R56HL152365_7529"}, {"internal_id": 110862447, "Award ID": "R56HL149881", "Award Amount": 483726.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-23", "CFDA Number": "93.837", "Description": "REGULATION OF BLOOD COAGULATION BY THE ZPI/PZ ANTICOAGULANT SYSTEM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R56HL149881_7529"}, {"internal_id": 85590916, "Award ID": "R56HL148005", "Award Amount": 400557.05, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-17", "CFDA Number": "93.837", "Description": "MAXIMIZING TRANSFUSION EFFICACY THROUGH NITRIC OXIDE ENHANCEMENT STRATEGIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_R56HL148005_7529"}, {"internal_id": 85589176, "Award ID": "R56HL147867", "Award Amount": 389999.44, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-14", "CFDA Number": "93.837", "Description": "MECHANISM OF INTERFERON GAMMA PRIMED MESENCHYMAL STROMAL CELL EFFEROCYTOSIS OF ACTIVATED T CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R56HL147867_7529"}, {"internal_id": 85588840, "Award ID": "R56HL147852", "Award Amount": 227387.94, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-14", "CFDA Number": "93.837", "Description": "SINGLE NON-INTEGRATING RNA VECTOR FOR GENE EDITING AND REPROGRAMMING OF FANCONI ANEMIA FIBROBLASTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R56HL147852_7529"}, {"internal_id": 85589739, "Award ID": "R56HL147048", "Award Amount": 406767.63, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-19", "CFDA Number": "93.837", "Description": "GUT MICROBIOTA REGULATE BONE LOSS IN SICKLE CELL DISEASE MICE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68c287e4-398a-6c6b-c0db-5ce9430c6ce3-C", "generated_internal_id": "ASST_NON_R56HL147048_7529"}, {"internal_id": 85588611, "Award ID": "R56HL144948", "Award Amount": 293044.61, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-14", "CFDA Number": "93.837", "Description": "FUNCTIONAL ROLE OF CD34 FAMILY IN HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "ME", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "004d72fe-5935-3d05-929b-08def85a886c-C", "generated_internal_id": "ASST_NON_R56HL144948_7529"}, {"internal_id": 69724926, "Award ID": "R56HL139846", "Award Amount": 512783.33, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-20", "CFDA Number": "93.837", "Description": "IMPROVING OUTCOMES IN CF PATIENTS: TOWARD RAPID DETECTION OF P. AERUGINOSA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7eb6683a-d796-f7f5-68c0-ca8f32275b30-C", "generated_internal_id": "ASST_NON_R56HL139846_7529"}, {"internal_id": 49826897, "Award ID": "R56HL136486", "Award Amount": 417491.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-29", "CFDA Number": "93.839", "Description": "MYELOID CELL REGULATION OF PLASMA CELL ENGRAFTMENT INTO BONE MARROW", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_R56HL136486_7529"}, {"internal_id": 49826896, "Award ID": "R56HL136415", "Award Amount": 415520.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-22", "CFDA Number": "93.839", "Description": "NOVEL PATHWAYS IN ISCHEMIC STROKE IN SICKLE CELL ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R56HL136415_7529"}, {"internal_id": 68568321, "Award ID": "R56HL136291", "Award Amount": 586573.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-15", "CFDA Number": "93.837", "Description": "FUNCTIONAL AND STRUCTURAL ANALYSIS OF THE CLOSED AND TWO OPEN STATES OF THE PANX1 CHANNEL.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dbae4064-c48c-5002-9fca-21d077e0f96b-C", "generated_internal_id": "ASST_NON_R56HL136291_7529"}, {"internal_id": 49826894, "Award ID": "R56HL136210", "Award Amount": 510762.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-21", "CFDA Number": "93.837", "Description": "PROTEOLYTIC MECHANISMS OF ARTERIAL REMODELING AND STROKES IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f7c481d7-071a-ead9-3bda-e4e7d1e903a7-C", "generated_internal_id": "ASST_NON_R56HL136210_7529"}, {"internal_id": 49826880, "Award ID": "R56HL133656", "Award Amount": 341988.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-15", "CFDA Number": "93.839", "Description": "IDENTIFYING PRECURSORS TO HEMATOPOIETIC STEM CELLS AND WHERE THEY ARISE IN THE MOUSE EMBRYO", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b710df3-c98e-f245-bbed-8bbbc32a803b-C", "generated_internal_id": "ASST_NON_R56HL133656_7529"}, {"internal_id": 49826872, "Award ID": "R56HL132921", "Award Amount": 386235.0, "Award Type": null, "Base Obligation Date": "2016-09-02", "CFDA Number": "93.839", "Description": "MITOTIC FAILURE IN FANCONI ANEMIA: MECHANISMS AND ROLE IN CARCINOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R56HL132921_7529"}, {"internal_id": 49826870, "Award ID": "R56HL132908", "Award Amount": 259710.0, "Award Type": null, "Base Obligation Date": "2016-08-18", "CFDA Number": "93.839", "Description": "SUBSTANCE P: A CENTRAL MEDIATOR OF CARDIAC FIBROSIS AND DIASTOLIC DYSFUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R56HL132908_7529"}, {"internal_id": 49826869, "Award ID": "R56HL132906", "Award Amount": 402216.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-16", "CFDA Number": "93.839", "Description": "A MICROFLUIDIC PLATFORM TO STUDY SICKLE BLOOD RHEOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R56HL132906_7529"}, {"internal_id": 49826861, "Award ID": "R56HL131946", "Award Amount": 542719.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-15", "CFDA Number": "93.839", "Description": "THE BIOLOGY OF VWF SELF-ASSOCIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "474a19eb-1491-c065-a3ca-a49b264b0d4b-C", "generated_internal_id": "ASST_NON_R56HL131946_7529"}, {"internal_id": 49826857, "Award ID": "R56HL131861", "Award Amount": 390000.0, "Award Type": null, "Base Obligation Date": "2016-09-01", "CFDA Number": "93.839", "Description": "HEMATOPOIETIC STEM CELLS IN OBESITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R56HL131861_7529"}, {"internal_id": 49826856, "Award ID": "R56HL131812", "Award Amount": 405579.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-31", "CFDA Number": "93.839", "Description": "LUNG INJURY REPAIR BY REGULATORY T CELL DHX58/LGP2", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R56HL131812_7529"}, {"internal_id": 49826844, "Award ID": "R56HL131059", "Award Amount": 385272.3, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-15", "CFDA Number": "93.837", "Description": "BIOENGINEERING FACTOR VIII THROUGH ANCESTRAL RECONSTRUCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R56HL131059_7529"}, {"internal_id": 110862634, "Award ID": "R56HL131013", "Award Amount": 474787.87, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-23", "CFDA Number": "93.837", "Description": "DEFINING ROLE OF FANCA IN GENOME INSTABILITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dbae4064-c48c-5002-9fca-21d077e0f96b-C", "generated_internal_id": "ASST_NON_R56HL131013_7529"}, {"internal_id": 49826834, "Award ID": "R56HL130186", "Award Amount": 339746.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-12", "CFDA Number": "93.839", "Description": "VO2 MAX: IN VIVO MODEL FOR FUNCTIONAL RED CELL TESTING. CAN RECESS BE EXPLAINED", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3313e5e7-fa36-d54b-e36d-0e1e09cc0c30-C", "generated_internal_id": "ASST_NON_R56HL130186_7529"}, {"internal_id": 49826815, "Award ID": "R56HL128430", "Award Amount": 347813.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-06", "CFDA Number": "93.839", "Description": "ROLE OF BPHL/HOMOCYSTEINE THIOLACTONASE IN HYPERHOMOCYSTEINEMIA AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R56HL128430_7529"}, {"internal_id": 49826766, "Award ID": "R56HL125449", "Award Amount": 445625.0, "Award Type": null, "Base Obligation Date": "2015-09-04", "CFDA Number": "93.839", "Description": "NOVEL INNATE MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN ALLOGENEIC HCT FOR HEMOGLOBINOPATHIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dbae4064-c48c-5002-9fca-21d077e0f96b-C", "generated_internal_id": "ASST_NON_R56HL125449_7529"}, {"internal_id": 68567269, "Award ID": "R56HL119393", "Award Amount": 495056.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-13", "CFDA Number": "93.839", "Description": "STRUCTURE/FUNCTION DETERMINANTS OF PLATELET GRANULE SECRETION - RESUBMISSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d72b9a8b-635d-44cc-45e8-3f90e8ee45f3-C", "generated_internal_id": "ASST_NON_R56HL119393_7529"}, {"internal_id": 110233539, "Award ID": "R44HL151147", "Award Amount": 1473927.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-11", "CFDA Number": "93.837", "Description": "FVIII POINT-OF-CARE MONITORING DEVICE AND APP", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7c8f6f0e-1431-c41d-4ef9-dd65dc9919ce-C", "generated_internal_id": "ASST_NON_R44HL151147_7529"}, {"internal_id": 96202393, "Award ID": "R44HL149579", "Award Amount": 1495034.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-31", "CFDA Number": "93.837", "Description": "AN ADDITIVE SOLUTION OPTIMIZED FOR ANAEROBIC (HYPOXIC) RBC STORAGE TO MINIMIZE STORAGE LESION DEVELOPMENT.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cf28a47c-22a4-98bc-1f07-c4965c9e998a-C", "generated_internal_id": "ASST_NON_R44HL149579_7529"}, {"internal_id": 80726230, "Award ID": "R44HL147695", "Award Amount": 5484738.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-13", "CFDA Number": "93.837", "Description": "ANTITHROMBOTIC PROTEIN C ACTIVATOR FOR HEMODIALYSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3e58c36a-4ea7-1d07-3915-eb0f0cfe3a8d-C", "generated_internal_id": "ASST_NON_R44HL147695_7529"}, {"internal_id": 81395968, "Award ID": "R44HL146016", "Award Amount": 1664327.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-07", "CFDA Number": "93.837", "Description": "AN INNOVATIVE UNBOUND BILIRUBIN ASSAY TO IDENTIFY BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION (BIND) RISK AS PART OF A COMPREHENSIVE AND NOVEL POINT-OF-CARE NEWBORN SCREENING PANEL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "61f45403-62ab-85ef-d659-50ea3f80e199-C", "generated_internal_id": "ASST_NON_R44HL146016_7529"}, {"internal_id": 78600132, "Award ID": "R44HL145783", "Award Amount": 2960689.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-22", "CFDA Number": "93.837", "Description": "A CLOSED SYSTEM FOR PATHOGEN REDUCTION OF RED BLOOD CELLS FOR TRANSFUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81cc2199-2ea4-7dff-3037-22a94919dfc8-C", "generated_internal_id": "ASST_NON_R44HL145783_7529"}, {"internal_id": 111328700, "Award ID": "R44HL142418", "Award Amount": 1465963.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-28", "CFDA Number": "93.837", "Description": "NOVEL STRATEGIES FOR STORAGE AND RECOVERY OF CADAVERIC BONE MARROW STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "710ccb61-31f3-9108-bd78-4f45872ca1ea-C", "generated_internal_id": "ASST_NON_R44HL142418_7529"}, {"internal_id": 67579416, "Award ID": "R44HL142414", "Award Amount": 1690518.71, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-03", "CFDA Number": "93.837", "Description": "SILICON PHOTONIC BLOOD TYPING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "823672d8-1242-4562-147a-cb4194d4466f-R", "generated_internal_id": "ASST_NON_R44HL142414_7529"}, {"internal_id": 68171124, "Award ID": "R44HL142389", "Award Amount": 3398342.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-24", "CFDA Number": "93.837", "Description": "HLS- A PHASE 1 OPEN-LABEL DOSE-ESCALATION WITH EXPANSION STUDY OF SX-682 IN MDS PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "06958079-310a-645e-90f2-befa0e60ef69-R", "generated_internal_id": "ASST_NON_R44HL142389_7529"}, {"internal_id": 67832443, "Award ID": "R44HL141928", "Award Amount": 2970974.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-16", "CFDA Number": "93.837", "Description": "PRBC CONTAMINANT REMOVAL WITH HEMOCOMPATIBLE POROUS POLYMER BEADS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4e81b5c7-bad9-6cb0-773c-faf82e98c095-C", "generated_internal_id": "ASST_NON_R44HL141928_7529"}, {"internal_id": 68167509, "Award ID": "R44HL140739", "Award Amount": 2725000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-24", "CFDA Number": "93.837", "Description": "HLS-AFFORDABLE, QUANTITATIVE MICROCHIP-ELECTROPHORESIS FOR SICKLE CELL DISEASE SCREENING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "eb44b004-dbc7-4c7e-7d8b-4c0ca5869311-C", "generated_internal_id": "ASST_NON_R44HL140739_7529"}, {"internal_id": 49823616, "Award ID": "R44HL140662", "Award Amount": 3984179.36, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-17", "CFDA Number": "93.837", "Description": "IMPROVING ANTICOAGULATION MONITORING IN PEDIATRIC PATIENTS: USE OF A MICROFLUIDIC PLATFORM TO TEST LOW VOLUME BLOOD SAMPLES OBTAINED BY HEEL-STICK COLLECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "61f45403-62ab-85ef-d659-50ea3f80e199-C", "generated_internal_id": "ASST_NON_R44HL140662_7529"}, {"internal_id": 82036088, "Award ID": "R44HL139187", "Award Amount": 2493273.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-03", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF A NEW CARBOHYDRATE-BASED ANTICOAGULANT DRUG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f812ac7-08c2-2d54-5527-53cf95176983-C", "generated_internal_id": "ASST_NON_R44HL139187_7529"}, {"internal_id": 65894570, "Award ID": "R44HL137605", "Award Amount": 3947560.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-29", "CFDA Number": "93.839", "Description": "CFI PATHOGEN INACTIVATION OF HUMAN PLASMA UNITS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "de84591f-7bba-8102-4425-ffeaf31fbeeb-C", "generated_internal_id": "ASST_NON_R44HL137605_7529"}, {"internal_id": 67833983, "Award ID": "R44HL137514", "Award Amount": 2812000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-17", "CFDA Number": "93.837", "Description": "HLS POTENT, NOVEL INHIBITOR OF FIBRINOLYTIC HEMORRHAGE- PHASE II", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6fb21895-6ab1-a0df-ca4f-63397317487a-R", "generated_internal_id": "ASST_NON_R44HL137514_7529"}, {"internal_id": 49823603, "Award ID": "R44HL136117", "Award Amount": 0.0, "Award Type": null, "Base Obligation Date": "2017-09-21", "CFDA Number": "93.839", "Description": "IMPROVED ORAL P-SELECTIN BLOCKER FOR PROPHYLACTIC SICKLE CELL DISEASE THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "408bd815-228c-513e-1598-5543b80c45ef-R", "generated_internal_id": "ASST_NON_R44HL136117_7529"}, {"internal_id": 49823602, "Award ID": "R44HL136046", "Award Amount": 1213144.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-07", "CFDA Number": "93.839", "Description": "ACOUSTIC SCAFFOLD BIOREACTOR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "11952087-2799-5dc9-c7f2-467ce6e9af40-C", "generated_internal_id": "ASST_NON_R44HL136046_7529"}, {"internal_id": 49823600, "Award ID": "R44HL135993", "Award Amount": 1902274.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-19", "CFDA Number": "93.837", "Description": "ANTITHROMBOTIC THERAPY WITH NO BLEEDING RISK FOR PCI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a0c2ecca-bfeb-48a7-6cfe-61427fdf8775-R", "generated_internal_id": "ASST_NON_R44HL135993_7529"}, {"internal_id": 49823597, "Award ID": "R44HL135896", "Award Amount": 1725000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-24", "CFDA Number": "93.837", "Description": "A NOVEL, NON-CYTOTOXIC, EPIGENETIC THERAPEUTIC FOR SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "202d281a-50fa-c3ac-a1da-998a56a1b325-R", "generated_internal_id": "ASST_NON_R44HL135896_7529"}, {"internal_id": 67833273, "Award ID": "R44HL132702", "Award Amount": 1452062.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-10", "CFDA Number": "93.837", "Description": "DEVELOPING THE REQUIRED BIOMARKERS THAT DEFINE FERROPORTIN TARGET ENGAGEMENT AND IMPACT ON DOWNSTREAM SIGNALING FOR CLINICAL TRANSLATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddb869bd-2dd3-df6c-0bd6-674e05473c19-C", "generated_internal_id": "ASST_NON_R44HL132702_7529"}, {"internal_id": 49823583, "Award ID": "R44HL132348", "Award Amount": 2998013.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-12", "CFDA Number": "93.837", "Description": "PATH TO COMMERCIALIZATION OF  THE FIRST ?OFF THE SHELF? T CELL PRODUCT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7956d7b1-0dda-5b2e-2869-c21da6af5b0e-R", "generated_internal_id": "ASST_NON_R44HL132348_7529"}, {"internal_id": 49823581, "Award ID": "R44HL132172", "Award Amount": 2969757.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-12", "CFDA Number": "93.837", "Description": "REGULATORY APPROVAL & COMMERCIALIZATION OF AN RBC PROCESSING AND STORAGE SYSTEM TO IMPROVE TRANSFUSION THERAPY BY MINIMIZING OXIDATIVE DAMAGE TO RBC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cf28a47c-22a4-98bc-1f07-c4965c9e998a-C", "generated_internal_id": "ASST_NON_R44HL132172_7529"}, {"internal_id": 80401695, "Award ID": "R44HL131338", "Award Amount": 1261442.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-23", "CFDA Number": "93.837", "Description": "SYSTEM AND COMPREHENSIVE APPROACH FOR BLOOD COMPATIBILITY OF MEDICAL DEVICES AND BIOMATERIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "009433c1-62a9-23e1-3396-6ab5728e8718-C", "generated_internal_id": "ASST_NON_R44HL131338_7529"}, {"internal_id": 49823577, "Award ID": "R44HL131050", "Award Amount": 4432950.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-19", "CFDA Number": "93.837", "Description": "ASSESSMENT OF BIOREACTOR-DERIVED HUMAN PLATELET QUALITY, STORAGE PROFILE, SAFETY, AND FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "92548adc-159a-6133-b616-34c17f454466-C", "generated_internal_id": "ASST_NON_R44HL131050_7529"}, {"internal_id": 67314062, "Award ID": "R44HL130805", "Award Amount": 1285249.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-12", "CFDA Number": "93.837", "Description": "THE SMARTBIO SYSTEM FOR THE IMPROVED PRESERVATION OF HUMAN HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "462309eb-a852-9ec4-4aae-8d89e2446704-C", "generated_internal_id": "ASST_NON_R44HL130805_7529"}, {"internal_id": 83797194, "Award ID": "R44HL129543", "Award Amount": 1997541.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-30", "CFDA Number": "93.837", "Description": "RHMFG-E8 AS AN EFFECTIVE ADJUVANT THERAPY FOR HEMORRHAGIC SHOCK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2768c014-6584-e933-9ac2-d0aed8400357-C", "generated_internal_id": "ASST_NON_R44HL129543_7529"}, {"internal_id": 49823570, "Award ID": "R44HL128670", "Award Amount": 992172.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-05", "CFDA Number": "93.839", "Description": "SICKLE SCAN(R) - A RAPID, QUALITATIVE TEST TO AID IN THE DIAGNOSIS OF SICKLE CELL DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "eaed580f-b3c1-63f1-6b7a-625c431a3635-C", "generated_internal_id": "ASST_NON_R44HL128670_7529"}, {"internal_id": 49823568, "Award ID": "R44HL128016", "Award Amount": 2356071.0, "Award Type": null, "Base Obligation Date": "2015-03-14", "CFDA Number": "93.839", "Description": "THERAPEUTIC FACTOR XI BLOCKADE FOR SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3e58c36a-4ea7-1d07-3915-eb0f0cfe3a8d-C", "generated_internal_id": "ASST_NON_R44HL128016_7529"}, {"internal_id": 49823564, "Award ID": "R44HL127843", "Award Amount": 1527748.18, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-14", "CFDA Number": "93.837", "Description": "IMPROVING SAFETY AND EFFICACY OF PLATELET TRANSFUSION THROUGH SYSTEMS BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bf8e1960-d085-0e4a-f012-0328bbd24509-R", "generated_internal_id": "ASST_NON_R44HL127843_7529"}, {"internal_id": 49823560, "Award ID": "R44HL127758", "Award Amount": 2721470.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-14", "CFDA Number": "93.839", "Description": "ANTICOAGULUM CARDIAC RF ABLATION CATHETER (DIRECT PHASE II)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b4bb180f-7acf-97e5-6332-c4a0c2586b99-R", "generated_internal_id": "ASST_NON_R44HL127758_7529"}, {"internal_id": 49823559, "Award ID": "R44HL127734", "Award Amount": 4489760.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-06", "CFDA Number": "93.838", "Description": "RESORBABLE INFERIOR VENA CAVA FILTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f91cc9c2-ce2a-0d81-e1a1-a8e7c5f76847-R", "generated_internal_id": "ASST_NON_R44HL127734_7529"}, {"internal_id": 49823555, "Award ID": "R44HL127572", "Award Amount": 1470108.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-06", "CFDA Number": "93.839", "Description": "HLS - HAND-HELD ADVANCED FUNCTIONAL IMAGER FOR ASSESSING LOCAL TISSUE OXYGENATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c940f9e2-7a48-7e47-3997-756b3a88cfaf-C", "generated_internal_id": "ASST_NON_R44HL127572_7529"}, {"internal_id": 49823554, "Award ID": "R44HL127543", "Award Amount": 3880862.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-08", "CFDA Number": "93.837", "Description": "REAL-TIME MYOGLOBIN SATURATION MEASUREMENT TO ASSESS BENEFIT OF RBC TRANSFUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6b2d4521-e88b-c767-8564-9b6f28db3563-R", "generated_internal_id": "ASST_NON_R44HL127543_7529"}, {"internal_id": 49823552, "Award ID": "R44HL126469", "Award Amount": 0.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-21", "CFDA Number": "93.837", "Description": "POINT OF CARE BREATH TEST TO SCREEN FOR SICKLE CELL DISEASE IN DEVELOPING NATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5c907e0b-815e-82fc-7023-69f96a73a000-C", "generated_internal_id": "ASST_NON_R44HL126469_7529"}, {"internal_id": 49823548, "Award ID": "R44HL126285", "Award Amount": 1500000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-18", "CFDA Number": "93.837", "Description": "AN INNOVATIVE SYSTEM FOR CORD BLOOD STEM CELL ISOLATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "441ee71a-9fc8-7b76-55ee-7f2950844018-C", "generated_internal_id": "ASST_NON_R44HL126285_7529"}, {"internal_id": 49823546, "Award ID": "R44HL126256", "Award Amount": 4298594.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-09", "CFDA Number": "93.837", "Description": "INFECTION AND THROMBOSIS RESISTANT NEEDLE-FREE HEMODIALYSIS ACCESS PORT AND GRAFT USING STAR BIOMATERIALS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3e223eea-435c-c702-abad-872bf855da44-C", "generated_internal_id": "ASST_NON_R44HL126256_7529"}, {"internal_id": 49823545, "Award ID": "R44HL126235", "Award Amount": 5196798.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-31", "CFDA Number": "93.837", "Description": "HLS- FACTOR XII INHIBITOR FOR SURFACE INITIATED THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3e58c36a-4ea7-1d07-3915-eb0f0cfe3a8d-C", "generated_internal_id": "ASST_NON_R44HL126235_7529"}, {"internal_id": 49823543, "Award ID": "R44HL125484", "Award Amount": 4343130.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-06", "CFDA Number": "93.837", "Description": "DIGITAL MICROFLUIDICS - MINIMIZING BLOOD VOLUME FOR PEDIATRIC COAGULATION SCREENING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "61f45403-62ab-85ef-d659-50ea3f80e199-C", "generated_internal_id": "ASST_NON_R44HL125484_7529"}, {"internal_id": 49823537, "Award ID": "R44HL124807", "Award Amount": 1678769.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.839", "Description": "HLS-RUGGED POINT-OF-CARE DEVICE FOR GLOBAL HEMOSTASIS TESTING OF WHOLE BLOOD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7764814b-b03e-f271-e842-a6b1050544ee-R", "generated_internal_id": "ASST_NON_R44HL124807_7529"}, {"internal_id": 49823533, "Award ID": "R44HL123878", "Award Amount": 1484141.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-15", "CFDA Number": "93.839", "Description": "ENABLING POINT OF CARE SCREENING FOR SEPSIS USING RAPID SINGLE CELL ANALYSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "93dcf249-433a-d0f7-6916-9da43faec8c1-C", "generated_internal_id": "ASST_NON_R44HL123878_7529"}, {"internal_id": 49823532, "Award ID": "R44HL123809", "Award Amount": 997560.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-05", "CFDA Number": "93.839", "Description": "DEVELOPING A PAPER-BASED DIAGNOSTIC TEST FOR SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0d8eda23-ca3c-ba0c-32e7-fe2a08397955-C", "generated_internal_id": "ASST_NON_R44HL123809_7529"}, {"internal_id": 49823531, "Award ID": "R44HL123670", "Award Amount": 1000000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-22", "CFDA Number": "93.839", "Description": "RAPID LFIA BLOOD TEST FOR SCD USING HIGHLY SPECIFIC MONOCLONAL ANTIBODIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8f7abd33-a02f-d694-4820-eb4c70a62b2b-C", "generated_internal_id": "ASST_NON_R44HL123670_7529"}, {"internal_id": 85588699, "Award ID": "R44HL123126", "Award Amount": 2996138.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-11", "CFDA Number": "93.837", "Description": "SMALL MOLECULE ANTAGONISTS OF PF4 FOR THE TREATMENT AND PREVENTION OF HIT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "58cbfdac-6c26-acfe-4a3f-0fa682c09a7d-R", "generated_internal_id": "ASST_NON_R44HL123126_7529"}, {"internal_id": 49823526, "Award ID": "R44HL123074", "Award Amount": 1472641.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-15", "CFDA Number": "93.839", "Description": "IMPROVING RED BLOOD CELL TRANSFUSION THROUGH SYSTEMS BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bf8e1960-d085-0e4a-f012-0328bbd24509-R", "generated_internal_id": "ASST_NON_R44HL123074_7529"}, {"internal_id": 49823524, "Award ID": "R44HL123059", "Award Amount": 1992124.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-17", "CFDA Number": "93.839", "Description": "IMPROVED ORAL P-SELECTIN BLOCKER FOR PROPHYLACTIC SICKLE CELL DISEASE THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "408bd815-228c-513e-1598-5543b80c45ef-R", "generated_internal_id": "ASST_NON_R44HL123059_7529"}, {"internal_id": 49823523, "Award ID": "R44HL122028", "Award Amount": 2904725.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-02-21", "CFDA Number": "93.837", "Description": "PRECLINICAL AND CLINICAL EVALUATION OF HUMANIZED NM9405", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NV", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "067df56d-6df4-9480-448a-14836d375f11-R", "generated_internal_id": "ASST_NON_R44HL122028_7529"}, {"internal_id": 49823519, "Award ID": "R44HL119086", "Award Amount": 1499750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-19", "CFDA Number": "93.837", "Description": "SAFETY STUDIES FOR CLINICAL TRIALS OF A BOTANICAL DRUG FOR SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2cd9b0e6-6d10-2172-e63d-231f75627224-R", "generated_internal_id": "ASST_NON_R44HL119086_7529"}, {"internal_id": 49823507, "Award ID": "R44HL117557", "Award Amount": 954976.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.839", "Description": "A NEW HEMAGGLUTINATION METHOD FOR BLOOD GROUPING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5efd5f87-d655-8bbe-b799-46bb9f530740-R", "generated_internal_id": "ASST_NON_R44HL117557_7529"}, {"internal_id": 49823486, "Award ID": "R44HL114148", "Award Amount": 1260128.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-01", "CFDA Number": "93.839", "Description": "NONTHROMBOGENIC, ANTISEPTIC NITRIC OXIDE RELEASING CATHETERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bd3fc16b-a61e-fa8a-8a16-d60619fd3c9d-C", "generated_internal_id": "ASST_NON_R44HL114148_7529"}, {"internal_id": 67833680, "Award ID": "R44HL110448", "Award Amount": 1499692.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-08", "CFDA Number": "93.837", "Description": "CLINICAL TESTING OF THE FIRST SUSPENSION BHK-M CELL PLATFORM DERIVED BIOTHERAPEUTIC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9e2f4487-76d7-2910-a3d3-1618c590b613-C", "generated_internal_id": "ASST_NON_R44HL110448_7529"}, {"internal_id": 49823459, "Award ID": "R44HL106919", "Award Amount": 4983031.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-27", "CFDA Number": "93.837", "Description": "FACTOR XI INHIBITOR FOR THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3e58c36a-4ea7-1d07-3915-eb0f0cfe3a8d-C", "generated_internal_id": "ASST_NON_R44HL106919_7529"}, {"internal_id": 49823458, "Award ID": "R44HL106868", "Award Amount": 2528000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-09-09", "CFDA Number": "93.839", "Description": "CORRELATING TCR DIVERSITY TO IMMUNE RECONSTITUTION AFTER CORD BLOOD TRANSPLANT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2f3333d0-82c2-0699-5c6a-9ecbf64e02a2-C", "generated_internal_id": "ASST_NON_R44HL106868_7529"}, {"internal_id": 49823455, "Award ID": "R44HL106860", "Award Amount": 998420.0, "Award Type": null, "Base Obligation Date": "2014-04-11", "CFDA Number": "93.839", "Description": "NONINVASIVE TOTAL HEMOGLOBIN MONITOR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8188e551-9fe5-136e-dbab-6b85830080b6-C", "generated_internal_id": "ASST_NON_R44HL106860_7529"}, {"internal_id": 49823448, "Award ID": "R44HL103030", "Award Amount": 4217432.08, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-12", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF A POINT OF CARE DIAGNOSTIC TO GUIDE EFFICIENT USAGE OF BLOOD PRODU", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ffeb1a9-2d96-3fc2-7b5d-acf224288b62-C", "generated_internal_id": "ASST_NON_R44HL103030_7529"}, {"internal_id": 49823446, "Award ID": "R44HL103006", "Award Amount": 2874607.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-12", "CFDA Number": "93.837", "Description": "RAPID, NEAR-TRANFUSION TEST FOR BACTERIA IN PLATELETS UNITS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "17d0a4c7-79a9-085a-11b4-2146f0f016fd-C", "generated_internal_id": "ASST_NON_R44HL103006_7529"}, {"internal_id": 49823435, "Award ID": "R44HL099092", "Award Amount": 3972576.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-06-21", "CFDA Number": "93.839", "Description": "STAT PALM-SIZED BLOOD COUNTER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7c8f6f0e-1431-c41d-4ef9-dd65dc9919ce-C", "generated_internal_id": "ASST_NON_R44HL099092_7529"}, {"internal_id": 49823430, "Award ID": "R44HL099010", "Award Amount": 778026.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-15", "CFDA Number": "93.839", "Description": "KERATIN BIOMATERIAL-BASED FLUID FOR TRAUMA RESUSCITATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e2f77dca-a768-b269-bc72-12a606093bc8-C", "generated_internal_id": "ASST_NON_R44HL099010_7529"}, {"internal_id": 49823429, "Award ID": "R44HL097933", "Award Amount": 941944.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-15", "CFDA Number": "93.839", "Description": "A FLOW THROUGH CELL COUNTING ASSAY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5efd5f87-d655-8bbe-b799-46bb9f530740-R", "generated_internal_id": "ASST_NON_R44HL097933_7529"}, {"internal_id": 49823414, "Award ID": "R44HL095315", "Award Amount": 4990232.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-09-16", "CFDA Number": "93.839", "Description": "THERAPEUTIC THROMBIN ANALOGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3e58c36a-4ea7-1d07-3915-eb0f0cfe3a8d-C", "generated_internal_id": "ASST_NON_R44HL095315_7529"}, {"internal_id": 49823397, "Award ID": "R44HL092750", "Award Amount": 895255.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-12", "CFDA Number": "93.837", "Description": "NOVEL METHODS FOR DISSOLVING BLOOD CLOTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6fb21895-6ab1-a0df-ca4f-63397317487a-R", "generated_internal_id": "ASST_NON_R44HL092750_7529"}, {"internal_id": 49823352, "Award ID": "R44HL086293", "Award Amount": 3074677.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-08-21", "CFDA Number": "93.839", "Description": "INTRACAVITARY HEMOSTATIC AGENT FOR NON-COMPRESSIBLE HEMORRHAGE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "94e52cf3-44b9-1632-3107-595151fabf94-C", "generated_internal_id": "ASST_NON_R44HL086293_7529"}, {"internal_id": 98144021, "Award ID": "R43HL155227", "Award Amount": 299953.28, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-18", "CFDA Number": "93.837", "Description": "BIOFE MECHANISM OF ACTION FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "406afb0e-99dd-208a-b4e3-92f4a7857dff-R", "generated_internal_id": "ASST_NON_R43HL155227_7529"}, {"internal_id": 110464049, "Award ID": "R43HL154900", "Award Amount": 420000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-19", "CFDA Number": "93.837", "Description": "INCREASED VALIDATION OF A FIRST METHOD FOR COUNTING TISSUE STEM CELLS SPECIFICALLY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fd2f9f71-1d09-8a6a-e78c-61337c45bac4-R", "generated_internal_id": "ASST_NON_R43HL154900_7529"}, {"internal_id": 108463039, "Award ID": "R43HL154864", "Award Amount": 299991.86, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-10", "CFDA Number": "93.837", "Description": "RAPID DEVELOPMENT OF A LEAD AROMATIC ALDEHYDE DERIVATIVE WITH BOTH OXYGEN DEPENDENT AND NOVEL, OXYGEN INDEPENDENT ANTI-SICKLING EFFECTS: BUILDING ON A PARADIGM SHIFT IN SICKLE CELL DISEASE THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e6333ff5-42e7-956d-1bbd-39bf9fd0b882-R", "generated_internal_id": "ASST_NON_R43HL154864_7529"}, {"internal_id": 96559449, "Award ID": "R43HL152887", "Award Amount": 284735.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-14", "CFDA Number": "93.837", "Description": "MICROFLUIDIC PLATFORM FOR GENE DELIVERY INTO THE T-CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "48b2f26b-831b-4b7c-2b57-3e6310e64640-C", "generated_internal_id": "ASST_NON_R43HL152887_7529"}, {"internal_id": 109189882, "Award ID": "R43HL152838", "Award Amount": 251628.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-18", "CFDA Number": "93.837", "Description": "POINT-OF-CARE DEVICE FOR TESTING NEONATE PLATELET FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ad2af489-0ab8-37f7-0a47-7a5565e31d98-R", "generated_internal_id": "ASST_NON_R43HL152838_7529"}, {"internal_id": 97015224, "Award ID": "R43HL151073", "Award Amount": 373216.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-30", "CFDA Number": "93.837", "Description": "RAPID RECONSTITUTION OF A LYOPHILIZED, BIO-INSPIRED, ARTIFICIAL RED BLOOD CELL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "429963a4-710a-cc20-3f3e-3a77ee532166-R", "generated_internal_id": "ASST_NON_R43HL151073_7529"}, {"internal_id": 95181710, "Award ID": "R43HL150961", "Award Amount": 299962.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-14", "CFDA Number": "93.837", "Description": "PRODRUGS AND DERIVATIVES OF HYDROXYMETHYLFURFURAL (5-HMF) TO DEVELOP A NOVEL, BIOAVAILABLE TREATMENT FOR SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e6333ff5-42e7-956d-1bbd-39bf9fd0b882-R", "generated_internal_id": "ASST_NON_R43HL150961_7529"}, {"internal_id": 97852549, "Award ID": "R43HL150946", "Award Amount": 308559.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-26", "CFDA Number": "93.837", "Description": "PLATELET?PRODUCTION IN A PULMONARY-BASED MICROFLUIDIC?REACTOR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f72bc01a-ba17-4db8-61e8-22406c72a4e1-C", "generated_internal_id": "ASST_NON_R43HL150946_7529"}, {"internal_id": 110862445, "Award ID": "R43HL150906", "Award Amount": 168893.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-24", "CFDA Number": "93.837", "Description": "OPTIMIZATION OF THE EX VIVO 3-DIMENSIONAL CULTURE CONDITIONS THAT CONTROLS THE FORMATION AND DEVELOPMENT OF HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELL POPULATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3a9986b4-3417-f135-b323-9fc16a18af92-C", "generated_internal_id": "ASST_NON_R43HL150906_7529"}, {"internal_id": 86317686, "Award ID": "R43HL149552", "Award Amount": 225000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-20", "CFDA Number": "93.837", "Description": "PARALLELIZED CELL ISOLATION IN A WELL PLATE FORMAT USING RATCHETING CYTOMETRY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d0d8de2d-af93-e60a-860d-b1da63ba624d-C", "generated_internal_id": "ASST_NON_R43HL149552_7529"}, {"internal_id": 83795975, "Award ID": "R43HL149548", "Award Amount": 149851.36, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-19", "CFDA Number": "93.837", "Description": "ON-DEMAND SMARTPHONE APP FOR NON-INVASIVE ANEMIA DETECTION USING ONLY PATIENT-SOURCED PHOTOS IN LOW RESOURCE SETTINGS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "82eac3d9-4e75-4b5b-48e9-53494da366b3-R", "generated_internal_id": "ASST_NON_R43HL149548_7529"}, {"internal_id": 85589956, "Award ID": "R43HL149489", "Award Amount": 293987.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-04", "CFDA Number": "93.837", "Description": "COST EFFECTIVE NUTRITIONAL THERAPY FOR MANAGING SICKLE CELL DISEASE COMPLICATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "60e5e97f-7087-242b-0133-e0a8d8515efa-R", "generated_internal_id": "ASST_NON_R43HL149489_7529"}, {"internal_id": 85589617, "Award ID": "R43HL149446", "Award Amount": 297440.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-04", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF A MULTIPLEX POINT-OF-CARE ASSAY TO IDENTIFY PATIENTS WITH VENOUS THROMBOEMBOLISM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a3fc6920-5302-b700-0120-a5ba924f98ef-R", "generated_internal_id": "ASST_NON_R43HL149446_7529"}, {"internal_id": 97852973, "Award ID": "R43HL147793", "Award Amount": 272302.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-22", "CFDA Number": "93.837", "Description": "DETECTION OF FETAL PLATELETS IN MATERNAL BLOOD USING PLATELET RNA BIOMARKERS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9564a502-1f3c-3621-7180-c2004bc9aaa8-R", "generated_internal_id": "ASST_NON_R43HL147793_7529"}, {"internal_id": 85590470, "Award ID": "R43HL147785", "Award Amount": 227125.55, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-16", "CFDA Number": "93.837", "Description": "NOVEL STRATEGIES FOR ENHANCED DETECTION OF HEMOGLOBINOPATHY CARRIERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fe6fdf70-7e61-a541-bbf5-b860a42b4820-C", "generated_internal_id": "ASST_NON_R43HL147785_7529"}, {"internal_id": 80735372, "Award ID": "R43HL147783", "Award Amount": 225000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-10", "CFDA Number": "93.837", "Description": "ULTRASOUND-FACILITATED ENDOVASCULAR LASER THROMBOLYSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KS", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "44d5b519-b0ff-f8dd-ab63-6ccd5629faaa-R", "generated_internal_id": "ASST_NON_R43HL147783_7529"}, {"internal_id": 81395619, "Award ID": "R43HL147734", "Award Amount": 224671.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-11", "CFDA Number": "93.837", "Description": "AN IN VITRO DIAGNOSTIC ASSAY FOR THE EARLY AND ACCURATE DETECTION OF PLATELET-ACTIVATING ANTIBODIES ASSOCIATED WITH HEPARIN-INDUCED THROMBOCYTOPENIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d405d490-5bfb-9448-e3c8-2a218f1b7d8b-R", "generated_internal_id": "ASST_NON_R43HL147734_7529"}, {"internal_id": 111328712, "Award ID": "R43HL147651", "Award Amount": 198281.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-14", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF LYSYL OXIDASE INHIBITORS FOR THE TREATMENT OF FIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "34b99eef-481f-8061-f6a8-9ce16bb6ea84-R", "generated_internal_id": "ASST_NON_R43HL147651_7529"}, {"internal_id": 81071262, "Award ID": "R43HL145948", "Award Amount": 299935.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-24", "CFDA Number": "93.837", "Description": "SYNTHOPLATE: INTRAVENOUS HEMOSTATIC NANOTECHNOLOGY TO MITIGATE BLEEDING IN THROMBOCYTOPENIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "934fa277-86c9-be71-9a65-32608f588ca9-C", "generated_internal_id": "ASST_NON_R43HL145948_7529"}, {"internal_id": 67580709, "Award ID": "R43HL144261", "Award Amount": 154143.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-15", "CFDA Number": "93.839", "Description": "DEVELOPMENT OF AN ENHANCED, SIMPLIFIED BLOOD COAGULATION TEST TO MONITOR PATIENTS ON DIRECT ORAL ANTI-COAGULANTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5aa3d59c-93a4-14d6-a184-bbda5af2178e-C", "generated_internal_id": "ASST_NON_R43HL144261_7529"}, {"internal_id": 68171407, "Award ID": "R43HL144259", "Award Amount": 219883.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-22", "CFDA Number": "93.837", "Description": "POINT-OF-CARE TESTING OF FIBRINOGEN FOR EARLY DETECTION AND MANAGEMENT OF TRAUMA COAGULOPATHY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b251e087-7a30-b073-80a8-70624b7cc2a8-C", "generated_internal_id": "ASST_NON_R43HL144259_7529"}, {"internal_id": 64141792, "Award ID": "R43HL142418", "Award Amount": 214346.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-08", "CFDA Number": "93.839", "Description": "NOVEL STRATEGIES FOR STORAGE AND RECOVERY OF CADAVERIC BONE MARROW STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "710ccb61-31f3-9108-bd78-4f45872ca1ea-C", "generated_internal_id": "ASST_NON_R43HL142418_7529"}, {"internal_id": 86319093, "Award ID": "R43HL142416", "Award Amount": 157616.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-25", "CFDA Number": "93.839", "Description": "CCR7-DEPLETED ALLOGENEIC PERIPHERAL BLOOD STEM CELL PRODUCT RETAINING EFFECTOR MEMORY T CELLS FOR HEMATOPOIETIC TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3101b8e-8cd2-bf2e-2498-7cd848a18461-R", "generated_internal_id": "ASST_NON_R43HL142416_7529"}, {"internal_id": 86317603, "Award ID": "R43HL142404", "Award Amount": 223898.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-25", "CFDA Number": "93.839", "Description": "HLS- SBIR PHASE I: TARGETED PLATELET-CAPSULE HYBRIDS FOR ON DEMAND TREATMENT IN HEMOPHILIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c9e42e8-fd64-5669-d528-3d7097dc6d89-R", "generated_internal_id": "ASST_NON_R43HL142404_7529"}, {"internal_id": 65281444, "Award ID": "R43HL142402", "Award Amount": 224553.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-30", "CFDA Number": "93.839", "Description": "A REPURPOSED MOLECULE AS AN ORAL THERAPEUTIC TO IMPROVE VASCULAR FLOW IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8cb2a3d7-306d-b78b-84f3-d6b8b5f74809-R", "generated_internal_id": "ASST_NON_R43HL142402_7529"}, {"internal_id": 68168477, "Award ID": "R43HL142396", "Award Amount": 225000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-22", "CFDA Number": "93.837", "Description": "TARGETING INTEGRIN OUTSIDE-IN SIGNALING FOR TREATING SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7cfa80b8-b824-aa62-d661-20244a154126-C", "generated_internal_id": "ASST_NON_R43HL142396_7529"}, {"internal_id": 64141818, "Award ID": "R43HL142371", "Award Amount": 224999.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-08", "CFDA Number": "93.839", "Description": "DMSO-FREE CRYOPRESERVATION OF BONE MARROW-DERIVED STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "SC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8c005f3e-42a1-0b77-4884-ce103031431b-C", "generated_internal_id": "ASST_NON_R43HL142371_7529"}, {"internal_id": 65280753, "Award ID": "R43HL140748", "Award Amount": 224941.0, "Award Type": null, "Base Obligation Date": "2018-03-29", "CFDA Number": "93.839", "Description": "FACTOR VIII (FVIII)-SPECIFIC THERAPEUTIC TREGS AND RELATED CGMP MANUFACTURING PROCESS FOR HEMOPHILIA A PATIENTS WITH INHIBITORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7d85cb1c-07cb-0437-468b-4cb8ef003519-R", "generated_internal_id": "ASST_NON_R43HL140748_7529"}, {"internal_id": 49819993, "Award ID": "R43HL140716", "Award Amount": 254235.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-22", "CFDA Number": "93.839", "Description": "A NOVEL INHIBITOR OF THE CLASSICAL PATHWAY OF COMPLEMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e3ff0da3-2f55-305b-e3cb-db6f7310f714-R", "generated_internal_id": "ASST_NON_R43HL140716_7529"}, {"internal_id": 62420579, "Award ID": "R43HL140686", "Award Amount": 150000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-17", "CFDA Number": "93.839", "Description": "MINIATURIZED GLOBAL COAGULATION ASSAY SYSTEM IN NEONATAL AND PEDIATRIC SETTINGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7a74581f-c079-5331-7e91-7c174fa58c99-R", "generated_internal_id": "ASST_NON_R43HL140686_7529"}, {"internal_id": 62551253, "Award ID": "R43HL139289", "Award Amount": 150000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-03", "CFDA Number": "93.839", "Description": "INNOVATIVE THERAPY FOR ACCELERATED RECOVERY OF DECOMPRESSION SICKNESS PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cd46d921-0c49-1687-3e51-59600617cd13-R", "generated_internal_id": "ASST_NON_R43HL139289_7529"}, {"internal_id": 49819987, "Award ID": "R43HL139250", "Award Amount": 247166.64, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-22", "CFDA Number": "93.837", "Description": "ADMINISTRATIVE SUPPLEMENT TO PROMOTE DIVERSITY FOR DEVELOPMENT OF A ROBUST, COLOR-BASED, DISPOSABLE, STANDALONE ANEMIA TEST FOR LOW-RESOURCE SETTINGS (PARENT GRANT: 1 R43 HL139250-01A1)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "82eac3d9-4e75-4b5b-48e9-53494da366b3-R", "generated_internal_id": "ASST_NON_R43HL139250_7529"}, {"internal_id": 68565291, "Award ID": "R43HL139196", "Award Amount": 345914.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-16", "CFDA Number": "93.839", "Description": "DEVELOPMENT OF A NOVEL SMALL MOLECULE AS A RADIOPROTECTOR FOR TOTAL BODY IRRADIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "69992813-5f90-ac67-9a78-50c57a84e27e-C", "generated_internal_id": "ASST_NON_R43HL139196_7529"}, {"internal_id": 49819985, "Award ID": "R43HL139173", "Award Amount": 224731.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-17", "CFDA Number": "93.839", "Description": "IDENTIFICATION OF THE ANTISICKLING COMPOUNDS IN SCD-101", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2cd9b0e6-6d10-2172-e63d-231f75627224-R", "generated_internal_id": "ASST_NON_R43HL139173_7529"}, {"internal_id": 67579439, "Award ID": "R43HL139171", "Award Amount": 274480.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-04", "CFDA Number": "93.837", "Description": "KYC REDUCES VASCULOPATHY IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af894f59-251b-3a89-013e-d6b4e6c42061-R", "generated_internal_id": "ASST_NON_R43HL139171_7529"}, {"internal_id": 49819982, "Award ID": "R43HL139105", "Award Amount": 299575.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-10", "CFDA Number": "93.837", "Description": "RECOMBINANT PROTHROMBIN THERAPY FOR HEMORRHAGE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "341d6f01-fdcb-518b-6dc5-504b4c9b2159-R", "generated_internal_id": "ASST_NON_R43HL139105_7529"}, {"internal_id": 49819980, "Award ID": "R43HL137589", "Award Amount": 224950.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-09", "CFDA Number": "93.837", "Description": "CROSSOVER STUDY OF AN ORAL TREATMENT FOR SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2cd9b0e6-6d10-2172-e63d-231f75627224-R", "generated_internal_id": "ASST_NON_R43HL137589_7529"}, {"internal_id": 49819973, "Award ID": "R43HL137514", "Award Amount": 351119.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-04", "CFDA Number": "93.839", "Description": "HLS POTENT, NOVEL INHIBITOR OF FIBRINOLYTIC HEMORRHAGE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6fb21895-6ab1-a0df-ca4f-63397317487a-R", "generated_internal_id": "ASST_NON_R43HL137514_7529"}, {"internal_id": 49819969, "Award ID": "R43HL137469", "Award Amount": 277059.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-18", "CFDA Number": "93.839", "Description": "TOXICOKINETICS AND TOXICITY OF CENTHAQUIN IN DOGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "336e94d4-ec32-6148-c3c8-bc25fee289d1-R", "generated_internal_id": "ASST_NON_R43HL137469_7529"}, {"internal_id": 49819968, "Award ID": "R43HL137458", "Award Amount": 300000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-03", "CFDA Number": "93.839", "Description": "INHIBITORS OF THE PHD2 ZINC FINGER TO TREAT ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "58cbfdac-6c26-acfe-4a3f-0fa682c09a7d-R", "generated_internal_id": "ASST_NON_R43HL137458_7529"}, {"internal_id": 49819962, "Award ID": "R43HL135984", "Award Amount": 224634.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-20", "CFDA Number": "93.839", "Description": "STABLE GENE TRANSFER BY RNA DELIVERY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c08513fe-db0f-697e-3ebf-110053c64624-C", "generated_internal_id": "ASST_NON_R43HL135984_7529"}, {"internal_id": 49819961, "Award ID": "R43HL135969", "Award Amount": 224976.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-24", "CFDA Number": "93.839", "Description": "PRECLINICAL EVALUATION OF ANCESTRAL COAGULATION FACTOR VIII", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9e2f4487-76d7-2910-a3d3-1618c590b613-C", "generated_internal_id": "ASST_NON_R43HL135969_7529"}, {"internal_id": 49819926, "Award ID": "R43HL132692", "Award Amount": 216781.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-08", "CFDA Number": "93.839", "Description": "HEPCIDIN ANTAGONIST THERAPY FOR ANEMIA OF CHRONIC DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c498f73a-a834-d1c3-c9c2-78016ac15228-C", "generated_internal_id": "ASST_NON_R43HL132692_7529"}, {"internal_id": 49819908, "Award ID": "R43HL131338", "Award Amount": 257843.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-15", "CFDA Number": "93.839", "Description": "SYSTEM AND COMPREHENSIVE APPROACH FOR BLOOD COMPATIBILITY OF MEDICAL DEVICES AND BIOMATERIALS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "009433c1-62a9-23e1-3396-6ab5728e8718-C", "generated_internal_id": "ASST_NON_R43HL131338_7529"}, {"internal_id": 49819895, "Award ID": "R43HL131065", "Award Amount": 299807.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-07", "CFDA Number": "93.839", "Description": "ORAL CARBON MONOXIDE THERAPEUTIC TO PREVENT VASO-OCCLUSIVE CRISES IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9e676d84-009f-a3fd-ef96-6c4a76be3702-C", "generated_internal_id": "ASST_NON_R43HL131065_7529"}, {"internal_id": 49819894, "Award ID": "R43HL130814", "Award Amount": 222173.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-13", "CFDA Number": "93.837", "Description": "ADAPTABLE AND AUTOMATED LARGE-SCALE MANUFACTURING OF IPSC-DERIVED CELL PRODUCTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a93c42a7-2a35-55f2-1ed8-65592f08ba48-C", "generated_internal_id": "ASST_NON_R43HL130814_7529"}, {"internal_id": 49819893, "Award ID": "R43HL130805", "Award Amount": 264000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-12", "CFDA Number": "93.839", "Description": "THE SMARTBIO SYSTEM FOR THE IMPROVED PRESERVATION OF HUMAN HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "462309eb-a852-9ec4-4aae-8d89e2446704-C", "generated_internal_id": "ASST_NON_R43HL130805_7529"}, {"internal_id": 49819892, "Award ID": "R43HL130123", "Award Amount": 222782.0, "Award Type": null, "Base Obligation Date": "2016-09-14", "CFDA Number": "93.839", "Description": "DEVELOPMENT OF A MICROFLUDIC DEVICE FOR REMOVAL OF GLYCEROL FROM CULTURED RED BLOOD CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "77f94166-012e-26d8-228f-5df785c6073d-R", "generated_internal_id": "ASST_NON_R43HL130123_7529"}, {"internal_id": 49819885, "Award ID": "R43HL129545", "Award Amount": 220991.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-30", "CFDA Number": "93.839", "Description": "DEVELOPMENT OF A BILIVERDIN IX BETA REDUCTASE REDOX INHIBITOR FOR ENHANCED PLATELET PRODUCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9564a502-1f3c-3621-7180-c2004bc9aaa8-R", "generated_internal_id": "ASST_NON_R43HL129545_7529"}, {"internal_id": 49819843, "Award ID": "R43HL125015", "Award Amount": 402588.0, "Award Type": null, "Base Obligation Date": "2015-08-31", "CFDA Number": "93.839", "Description": "AZIRIDINYL GROUPS CONTAINING POLYAMINES AS ANTI-PATHOGEN DEVICE FOR BLOOD PRODUCTS INTENDED FOR TRANSFUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81cc2199-2ea4-7dff-3037-22a94919dfc8-C", "generated_internal_id": "ASST_NON_R43HL125015_7529"}, {"internal_id": 49819841, "Award ID": "R43HL124897", "Award Amount": 325051.0, "Award Type": null, "Base Obligation Date": "2015-08-18", "CFDA Number": "93.839", "Description": "HLS-SMALL MOLECULE DISCOVERY AT NOVEL TARGET FOR FETAL HEMOGLOBIN INDUCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c7c6e950-3dbd-560b-e318-48a53eea2c94-C", "generated_internal_id": "ASST_NON_R43HL124897_7529"}, {"internal_id": 49819824, "Award ID": "R43HL123818", "Award Amount": 413140.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-25", "CFDA Number": "93.839", "Description": "SELF-ASSEMBLING DENSITY GRADIENTS FOR SICKLE CELL DIAGNOSIS IN LOW RESOURCE AREAS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "441e8e36-48e4-b6bc-3103-f74ece8a6d23-C", "generated_internal_id": "ASST_NON_R43HL123818_7529"}, {"internal_id": 49819820, "Award ID": "R43HL123670", "Award Amount": 443012.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-01", "CFDA Number": "93.839", "Description": "RAPID LFIA BLOOD TEST FOR SCD USING HIGHLY SPECIFIC MONOCLONAL ANTIBODIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8f7abd33-a02f-d694-4820-eb4c70a62b2b-C", "generated_internal_id": "ASST_NON_R43HL123670_7529"}, {"internal_id": 49819819, "Award ID": "R43HL123472", "Award Amount": 489072.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-07", "CFDA Number": "93.837", "Description": "ANTIBODY-BASED POINT-OF-CARE DEVICE FOR THE DIAGNOSIS OF SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "01afc18c-ff39-1505-3f53-80be2258d69d-C", "generated_internal_id": "ASST_NON_R43HL123472_7529"}, {"internal_id": 85590938, "Award ID": "R42HL136068", "Award Amount": 1073855.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-17", "CFDA Number": "93.839", "Description": "IN VIVO STUDIES OF A NOVEL HDAC INHIBITOR FOR TREATING HEMOGLOBIN DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "04b46998-7ab9-30e9-4135-49700489ca3f-R", "generated_internal_id": "ASST_NON_R42HL136068_7529"}, {"internal_id": 49815131, "Award ID": "R42HL135965", "Award Amount": 2019830.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-11", "CFDA Number": "93.837", "Description": "ERYTHROMER: NANOSCALE BIO-SYNTHETIC RED CELL SUBSTITUTE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "429963a4-710a-cc20-3f3e-3a77ee532166-R", "generated_internal_id": "ASST_NON_R42HL135965_7529"}, {"internal_id": 111328698, "Award ID": "R42HL129612", "Award Amount": 1864898.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-07", "CFDA Number": "93.837", "Description": "A SMALL MOLECULE INTEGRIN ACTIVATOR TO ENHANCE CORD BLOOD TRANSPLANT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1dcefaac-297b-6487-c3c7-c0dc1f2a44b2-R", "generated_internal_id": "ASST_NON_R42HL129612_7529"}, {"internal_id": 49815121, "Award ID": "R42HL123126", "Award Amount": 1942140.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-11", "CFDA Number": "93.839", "Description": "SMALL MOLECULE ANTAGONISTS OF PF4 FOR THE TREATMENT AND PREVENTION OF HIT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "58cbfdac-6c26-acfe-4a3f-0fa682c09a7d-R", "generated_internal_id": "ASST_NON_R42HL123126_7529"}, {"internal_id": 49815105, "Award ID": "R42HL099150", "Award Amount": 1138113.38, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-13", "CFDA Number": "93.837", "Description": "LENTIVIRAL VECTOR FOR THE TREATMENT OF FANCONI ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "036923b6-1991-68dc-41c1-7834ceb878e9-C", "generated_internal_id": "ASST_NON_R42HL099150_7529"}, {"internal_id": 111328714, "Award ID": "R41HL154735", "Award Amount": 150000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-11", "CFDA Number": "93.837", "Description": "DUAL EXCITATION CATHETER-DELIVERED LASER ULTRASOUND THROMBOLYSIS (DECLUT) FOR DEEP VEIN THROMBOSIS (DVT) TREATMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e8d701d3-5470-069b-ff7a-c472b5fdb35d-R", "generated_internal_id": "ASST_NON_R41HL154735_7529"}, {"internal_id": 108463534, "Award ID": "R41HL152923", "Award Amount": 249310.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-07", "CFDA Number": "93.837", "Description": "DEVELOP HUMANIZED AAV VECTORS FOR LIVER TARGETING AND NEUTRALIZING ANTIBODY EVASION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "07946ba3-1c8c-1c3e-0086-e3b1f49b94e8-C", "generated_internal_id": "ASST_NON_R41HL152923_7529"}, {"internal_id": 96201614, "Award ID": "R41HL151015", "Award Amount": 225000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-05", "CFDA Number": "93.837", "Description": "PORTABLE, AFFORDABLE, QUANTITATIVE MICROCHIP ELECTROPHORESIS SYSTEM FOR INTEGRATED ANEMIA AND HEMOGLOBIN VARIANT TESTING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "eb44b004-dbc7-4c7e-7d8b-4c0ca5869311-C", "generated_internal_id": "ASST_NON_R41HL151015_7529"}, {"internal_id": 97852523, "Award ID": "R41HL150963", "Award Amount": 187099.73, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-22", "CFDA Number": "93.837", "Description": "MULTI-MODAL VENUS CLOT REMOVAL DEVICE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "62ea5738-07ba-c3d0-54a6-f7a731232b6b-R", "generated_internal_id": "ASST_NON_R41HL150963_7529"}, {"internal_id": 110024420, "Award ID": "R41HL147807", "Award Amount": 225000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-26", "CFDA Number": "93.837", "Description": "THE MICELI AGGREGOMETER: A POINT-OF-CARE PLATELET FUNCTION ANALYZER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d2dd96bd-7680-a464-1e0a-5be9e5123710-R", "generated_internal_id": "ASST_NON_R41HL147807_7529"}, {"internal_id": 86318366, "Award ID": "R41HL147737", "Award Amount": 215058.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-21", "CFDA Number": "93.837", "Description": "MULTI-MODAL MECHANISMS OF NOVEL SULFATED NON ANTICOAGULANT HEPARIN INSICKLE CELL DISEASE MANAGEMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b22e3c4e-4f32-7e03-ec04-c2417c195728-C", "generated_internal_id": "ASST_NON_R41HL147737_7529"}, {"internal_id": 85588945, "Award ID": "R41HL145877", "Award Amount": 406403.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-13", "CFDA Number": "93.837", "Description": "SMALL-MOLECULE COMBINATIONSEXPAND HEMATOPOIETIC STEM CELL EX VIVO AND IN VIVO", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "70f46cf7-0248-0e28-daf9-c42cb81de9e9-R", "generated_internal_id": "ASST_NON_R41HL145877_7529"}, {"internal_id": 81395093, "Award ID": "R41HL142451", "Award Amount": 225000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-07", "CFDA Number": "93.837", "Description": "NOVEL AND POTENT SHIP1 INHIBITORS FOR IMPROVING HEMATOLOGIC RECOVERY FOLLOWING MYELOSUPPRESSIVE THERAPIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a1cd304c-7e23-fec5-b411-a09f6a204eee-R", "generated_internal_id": "ASST_NON_R41HL142451_7529"}, {"internal_id": 49814536, "Award ID": "R41HL139234", "Award Amount": 277130.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-12", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF A POEGMA-APTAMER RAPID ONSET ANTICOAGULANT THAT ELIMINATES ANTIGENICITY TO ANTI-PEG ANTIBODIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d30a3627-140a-e706-fb66-225f42aad954-R", "generated_internal_id": "ASST_NON_R41HL139234_7529"}, {"internal_id": 49814535, "Award ID": "R41HL139187", "Award Amount": 224698.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-31", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF A NEW CARBOHYDRATE-BASED ANTICOAGULANT DRUG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f812ac7-08c2-2d54-5527-53cf95176983-C", "generated_internal_id": "ASST_NON_R41HL139187_7529"}, {"internal_id": 49814534, "Award ID": "R41HL138184", "Award Amount": 225000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-20", "CFDA Number": "93.839", "Description": "MICROFABRICATION-BASED BIOMIMETIC APPROACH FOR IN VITRO RED BLOOD CELL MATURATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8c911932-4382-1877-6457-8cbd665dc3bb-R", "generated_internal_id": "ASST_NON_R41HL138184_7529"}, {"internal_id": 49814531, "Award ID": "R41HL136068", "Award Amount": 241742.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-30", "CFDA Number": "93.839", "Description": "NOVEL HDAC INHIBITORS FOR TREATMENT OF HEMOGLOBINOPATHIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "04b46998-7ab9-30e9-4135-49700489ca3f-R", "generated_internal_id": "ASST_NON_R41HL136068_7529"}, {"internal_id": 68167262, "Award ID": "R41HL135942", "Award Amount": 220000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-20", "CFDA Number": "93.837", "Description": "NOVEL TREATMENT FOR DIC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5297f9ca-28a1-7ccd-01a1-6a68a5010a90-R", "generated_internal_id": "ASST_NON_R41HL135942_7529"}, {"internal_id": 49814528, "Award ID": "R41HL134517", "Award Amount": 366484.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-30", "CFDA Number": "93.839", "Description": "DEVELOPMENT OF PAR4 PEPDUCINS AS A NOVEL ANTITHROMBOTIC TREATMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d25ca263-5608-063d-81ae-12f1067c8e71-R", "generated_internal_id": "ASST_NON_R41HL134517_7529"}, {"internal_id": 49814506, "Award ID": "R41HL127543", "Award Amount": 150000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-11", "CFDA Number": "93.839", "Description": "REAL-TIME MYOGLOBIN SATURATION MEASUREMENT TO ASSESS BENEFIT OF RBC TRANSFUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6b2d4521-e88b-c767-8564-9b6f28db3563-R", "generated_internal_id": "ASST_NON_R41HL127543_7529"}, {"internal_id": 49813016, "Award ID": "R37HL077193", "Award Amount": 3563990.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-06-10", "CFDA Number": "93.839", "Description": "TFPI ALPHA AND TFPI BETA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R37HL077193_7529"}, {"internal_id": 49812984, "Award ID": "R37HL058091", "Award Amount": 3198400.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-04-23", "CFDA Number": "93.839", "Description": "EFFECTS OF NITRIC OXIDE IN SICKLE CELL BLOOD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6bb62c37-6b74-a9af-577c-895771e3de6f-C", "generated_internal_id": "ASST_NON_R37HL058091_7529"}, {"internal_id": 49812949, "Award ID": "R37HL039888", "Award Amount": 3514612.45, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-02-18", "CFDA Number": "93.837", "Description": "MOLECULAR BASIS OF BLOOD COAGULATION REGULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R37HL039888_7529"}, {"internal_id": 96558824, "Award ID": "R35HL150826", "Award Amount": 3088233.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-13", "CFDA Number": "93.837", "Description": "INVESTIGATING THE HETEROGENEITY AND COORDINATION OF HEMATOPOIETIC STEM CELLS (DIVERSITY SUPPLEMENT)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_R35HL150826_7529"}, {"internal_id": 95942762, "Award ID": "R35HL150818", "Award Amount": 3764402.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-11", "CFDA Number": "93.837", "Description": "PLATELET EXOCYTOSIS AND ENDOCYTOSIS IN THROMBOSIS AND IMMUNITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c477975b-68db-c3dc-4a79-b95cb9f6ab3e-C", "generated_internal_id": "ASST_NON_R35HL150818_7529"}, {"internal_id": 97852963, "Award ID": "R35HL150797", "Award Amount": 3916546.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-21", "CFDA Number": "93.837", "Description": "MECHANISMS OF INTEGRIN SIGNALING AND A NEW ANTI-PLATELET/ANTI-INFLAMMATORY APPROACH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R35HL150797_7529"}, {"internal_id": 95484232, "Award ID": "R35HL150784", "Award Amount": 3120000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-26", "CFDA Number": "93.837", "Description": "GENETIC AND THERAPEUTIC STUDIES OF HEMOSTATIC AND THROMBOTIC DISORDERS USING ZEBRAFISH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R35HL150784_7529"}, {"internal_id": 96558050, "Award ID": "R35HL150698", "Award Amount": 4223938.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-10", "CFDA Number": "93.837", "Description": "NEW MECHANISTIC INSIGHTS & THERAPEUTIC APPLICATIONS OF MEGAKARYOCYTES/PLATELETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R35HL150698_7529"}, {"internal_id": 78989980, "Award ID": "R35HL145262", "Award Amount": 5435099.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-15", "CFDA Number": "93.837", "Description": "MOLECULAR AND TRANSLATIONAL STUDIES IN HEMATOLOGIC DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "474a19eb-1491-c065-a3ca-a49b264b0d4b-C", "generated_internal_id": "ASST_NON_R35HL145262_7529"}, {"internal_id": 76738561, "Award ID": "R35HL145237", "Award Amount": 3312982.78, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-31", "CFDA Number": "93.837", "Description": "TRANSLATIONAL CONTROL OF MEGAKARYOCYTE AND PLATELET GENE EXPRESSION IN DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OK", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "36c41119-2158-d09a-55ce-00590b81ab14-C", "generated_internal_id": "ASST_NON_R35HL145237_7529"}, {"internal_id": 79433908, "Award ID": "R35HL145000", "Award Amount": 3477719.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-21", "CFDA Number": "93.837", "Description": "ENGINEERING BIOPHYSICAL MICROTECHNOLOGIES FOR HEMATOLOGIC APPLICATIONS IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R35HL145000_7529"}, {"internal_id": 79434171, "Award ID": "R35HL144976", "Award Amount": 3711137.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-22", "CFDA Number": "93.837", "Description": "SMALL GTPASES IN THE BIOLOGY OF PLATELETS AND MEGAKARYOCYTES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R35HL144976_7529"}, {"internal_id": 49811634, "Award ID": "R35HL140031", "Award Amount": 3968388.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-12", "CFDA Number": "93.837", "Description": "MOLECULAR MECHANISM AND TARGETING OF CHRONIC PAIN IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R35HL140031_7529"}, {"internal_id": 49811632, "Award ID": "R35HL140025", "Award Amount": 4740000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-26", "CFDA Number": "93.837", "Description": "BIOCHEMISTRY AND PATHOPHYSIOLOGY OF FACTOR XI AND CONTACT ACTIVATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R35HL140025_7529"}, {"internal_id": 61611363, "Award ID": "R35HL139937", "Award Amount": 5919812.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-26", "CFDA Number": "93.837", "Description": "BASIC INVESTIGATION AND TRANSLATIONAL APPLICATIONS CONCERNING THE CELL AND MOLECULAR BIOLOGY OF BLOOD AND VASCULAR CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R35HL139937_7529"}, {"internal_id": 62550990, "Award ID": "R35HL139926", "Award Amount": 4553040.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-21", "CFDA Number": "93.837", "Description": "TARGETING PYRUVATE KINASE M2: A NOVEL STRATEGY TO COMBAT THROMBO-INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R35HL139926_7529"}, {"internal_id": 61613532, "Award ID": "R35HL139854", "Award Amount": 4965068.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-19", "CFDA Number": "93.837", "Description": "VARIANT HEMOGLOBIN AND CARDIORESPIRATORY REGULATION IN HUMANS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R35HL139854_7529"}, {"internal_id": 49811623, "Award ID": "R35HL139599", "Award Amount": 3039463.13, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-18", "CFDA Number": "93.837", "Description": "CONTROLLING INFLUENCES OF OXYGEN TENSION AND CD26/DPP4 ENZYMATIC ACTIVITY ON REGULATION OF HEMATOPOIETIC STEM/PROGENITOR CELLS AND HEMATOPOIESIS DURING HEALTH, AGEING, AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R35HL139599_7529"}, {"internal_id": 49811621, "Award ID": "R35HL139424", "Award Amount": 5357397.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-26", "CFDA Number": "93.837", "Description": "TIE2-DRIVEN VASCULAR CONTROL IN CRITICAL ILLNESS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_R35HL139424_7529"}, {"internal_id": 49811613, "Award ID": "R35HL135823", "Award Amount": 4761654.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-11", "CFDA Number": "93.837", "Description": "MECHANISMS IN BLOOD CLOTTING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R35HL135823_7529"}, {"internal_id": 49811604, "Award ID": "R35HL135795", "Award Amount": 5720314.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-12", "CFDA Number": "93.837", "Description": "THERAPEUTIC IMPLICATIONS OF MOLECULAR DEFECTS IN BONE MARROW FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R35HL135795_7529"}, {"internal_id": 49811603, "Award ID": "R35HL135793", "Award Amount": 4058472.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-10", "CFDA Number": "93.837", "Description": "THE MOLECULAR GENETICS OF HEMOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R35HL135793_7529"}, {"internal_id": 49811600, "Award ID": "R35HL135787", "Award Amount": 4608441.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-10", "CFDA Number": "93.837", "Description": "DECODING INNATE IMMUNE SIGNALING IN NORMAL AND MYELODYSPLASTIC HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R35HL135787_7529"}, {"internal_id": 49811597, "Award ID": "R35HL135775", "Award Amount": 5452760.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-17", "CFDA Number": "93.837", "Description": "THIOL ISOMERASES IN HEMOSTASIS AND THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_R35HL135775_7529"}, {"internal_id": 49811594, "Award ID": "R35HL135765", "Award Amount": 6195000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-11", "CFDA Number": "93.837", "Description": "HOW INFLAMMATION AND THROMBOSIS FUEL DISEASE AND AGING: FOCUS ON NETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R35HL135765_7529"}, {"internal_id": 49811593, "Award ID": "R35HL135763", "Award Amount": 5717642.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-29", "CFDA Number": "93.837", "Description": "EMERGENCY MYELOPOIESIS PATHWAYS IN THE CONTROL OF BLOOD PRODUCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R35HL135763_7529"}, {"internal_id": 49811592, "Award ID": "R35HL135756", "Award Amount": 6346182.79, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-11", "CFDA Number": "93.837", "Description": "PNEUMONIA BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": 445576.79, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R35HL135756_7529"}, {"internal_id": 49811591, "Award ID": "R35HL135755", "Award Amount": 396250.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-02-14", "CFDA Number": "93.839", "Description": "STRUCTURE-FUNCTION AND ROLES OF PROTEASE-ACTIVATED RECEPTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R35HL135755_7529"}, {"internal_id": 68567505, "Award ID": "R34HL142322", "Award Amount": 836760.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-14", "CFDA Number": "93.837", "Description": "CCR5 ANALYSES IN HIV INFECTED HEMATOLOGY PATIENTS UNDERGOING UMBILICAL CORD BLOOD ALLOGENEIC TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "569197a4-81d0-b264-5640-e9db4cf71fd0-C", "generated_internal_id": "ASST_NON_R34HL142322_7529"}, {"internal_id": 49810572, "Award ID": "R34HL135226", "Award Amount": 661107.79, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-05", "CFDA Number": "93.837", "Description": "THROMBOPROPHYLAXIS WITH ROSUVASTATIN FOLLOWING SURGERY FOR OVARIAN CANCER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_R34HL135226_7529"}, {"internal_id": 49810571, "Award ID": "R34HL135224", "Award Amount": 593820.07, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-05", "CFDA Number": "93.837", "Description": "PRAGMATIC, PREHOSPITAL GROUP O WHOLE BLOOD EARLY RESUSCITATION PILOT TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R34HL135224_7529"}, {"internal_id": 49810567, "Award ID": "R34HL133384", "Award Amount": 736651.86, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-10", "CFDA Number": "93.837", "Description": "FEASIBILITY STUDY RANDOMIZING IST VS URD BMT FOR CHILDREN WITH APLASTIC ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R34HL133384_7529"}, {"internal_id": 49810562, "Award ID": "R34HL128798", "Award Amount": 802554.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-13", "CFDA Number": "93.839", "Description": "A PILOT STUDY OF N-ACETYLCYSTEINE IN SICKLE CELL DISEASE VASO-OCCLUSIVE CRISIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "474a19eb-1491-c065-a3ca-a49b264b0d4b-C", "generated_internal_id": "ASST_NON_R34HL128798_7529"}, {"internal_id": 49810558, "Award ID": "R34HL127156", "Award Amount": 810470.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-05", "CFDA Number": "93.839", "Description": "RISK-ADAPTED THROMBOPROPHYLAXIS OF HOSPITALIZED CANCER PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_R34HL127156_7529"}, {"internal_id": 49810556, "Award ID": "R34HL125804", "Award Amount": 740535.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-27", "CFDA Number": "93.839", "Description": "DOES PLASMA REDUCE BLEEDING IN PATIENTS UNDERGOING INVASIVE PROCEDURES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18e10ac5-0c9e-d0fa-8dbc-a56771e0703d-C", "generated_internal_id": "ASST_NON_R34HL125804_7529"}, {"internal_id": 109278489, "Award ID": "R33HL154133", "Award Amount": 1200060.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-19", "CFDA Number": "93.837", "Description": "NOVEL SMALL MOLECULES TO TREAT DEGENERATIVE LUNG AND BLOOD DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R33HL154133_7529"}, {"internal_id": 109189808, "Award ID": "R33HL154123", "Award Amount": 909601.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-14", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF A NEXT-GENERATION GLYCOMICS PLATFORM TO ENABLE GLYCAN STRUCTURE ANALYSES FOR PRECISION MEDICINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NE", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce6cc294-968c-0136-a2e3-f34319ce4753-C", "generated_internal_id": "ASST_NON_R33HL154123_7529"}, {"internal_id": 109278513, "Award ID": "R33HL154107", "Award Amount": 1102500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-20", "CFDA Number": "93.837", "Description": "IDENTIFICATION OF AN INHIBITOR OF PDI-GPIBALPHA SIGNALING AS A NOVEL ANTITHROMBOINFLAMMATORY AGENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R33HL154107_7529"}, {"internal_id": 97852813, "Award ID": "R33HL147845", "Award Amount": 5206823.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-29", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF A CLINICAL HEMOGLOBIN MODULATOR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9463b1ed-f840-a231-6e87-53299e4dd965-R", "generated_internal_id": "ASST_NON_R33HL147845_7529"}, {"internal_id": 109189838, "Award ID": "R33HL141794", "Award Amount": 2501537.19, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-18", "CFDA Number": "93.837", "Description": "A SYSTEMS BIOLOGY APPROACH TO IDENTIFYING THE MECHANISMS OF SEX HORMONE INDUCED THROMBOEMBOLISM IN PRE-MENOPAUSAL WOMEN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R33HL141794_7529"}, {"internal_id": 96560469, "Award ID": "R33HL141791", "Award Amount": 2111869.92, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-07", "CFDA Number": "93.837", "Description": "MODEL SYSTEM OF ORAL CONTRACEPTIVE-INDUCED VTE: INTEGRATING GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC DISCOVERY WITH FUNCTIONAL BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R33HL141791_7529"}, {"internal_id": 96559916, "Award ID": "R33HL141787", "Award Amount": 2226837.5, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-15", "CFDA Number": "93.837", "Description": "THE INTERACTION OF BASAL RISK, PHARMACOLOGIC OVULATION INDUCTION, PREGNANCY AND DELIVERY ON HEMOSTATIC BALANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R33HL141787_7529"}, {"internal_id": 96560001, "Award ID": "R33HL141783", "Award Amount": 1802904.82, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-15", "CFDA Number": "93.837", "Description": "OPA1 AN ESTROGEN-MEDIATED MODULATOR OF PLATELET HYPERACTIVATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R33HL141783_7529"}, {"internal_id": 49809988, "Award ID": "R33HL120791", "Award Amount": 1721911.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-22", "CFDA Number": "93.839", "Description": "IDENTIFYING GENOME-WIDE ASSOCIATION STUDY-NOMINATED REGULATORS OF ERYTHROPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R33HL120791_7529"}, {"internal_id": 49809981, "Award ID": "R33HL120752", "Award Amount": 1147740.92, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-22", "CFDA Number": "93.837", "Description": "FUNCTIONAL CHARACTERIZATION OF BLOOD CELL ASSOCIATED REGULATORY GWAS HITS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "63e2902a-0c1e-b93c-b96c-01c89b38e2aa-C", "generated_internal_id": "ASST_NON_R33HL120752_7529"}, {"internal_id": 49807063, "Award ID": "R25HL128640", "Award Amount": 382470.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.837", "Description": "PITTSBURGH INTENSIVE TRAINING IN HEMATOLOGY RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R25HL128640_7529"}, {"internal_id": 49807062, "Award ID": "R25HL128639", "Award Amount": 610817.38, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-05", "CFDA Number": "93.837", "Description": "ADVANCED SKILLS DEVELOPMENT IN GLYCO-HEMATOLOGY AND GLYCO-ONCOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_R25HL128639_7529"}, {"internal_id": 49807061, "Award ID": "R25HL128372", "Award Amount": 553330.06, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.837", "Description": "INTEGRATED TRAINING IN DEVELOPMENT AND CLINICAL PRACTICE OF CELL-BASED THERAPIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R25HL128372_7529"}, {"internal_id": 49807028, "Award ID": "R25HL106365", "Award Amount": 4888991.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-09-17", "CFDA Number": "93.837", "Description": "PRIDE-FUNCTIONAL AND APPLIED GENOMICS OF BLOOD DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aca87389-2cb6-91e2-17a4-df7e81a7314d-C", "generated_internal_id": "ASST_NON_R25HL106365_7529"}, {"internal_id": 49806984, "Award ID": "R25HL084665", "Award Amount": 1986816.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-03", "CFDA Number": "93.837", "Description": "SHORT-TERM TRAINING PROGRAM TO INCREASE DIVERSITY IN HEALTH RELATED RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R25HL084665_7529"}, {"internal_id": 49806980, "Award ID": "R25HL007785", "Award Amount": 1825378.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-04-14", "CFDA Number": "93.837", "Description": "BUILDING DIVERSITY IN BIOMEDICAL SCIENCES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1365968e-88a8-9046-4733-6ec9e7f54826-C", "generated_internal_id": "ASST_NON_R25HL007785_7529"}, {"internal_id": 49805780, "Award ID": "R24HL063098", "Award Amount": 9982146.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-12", "CFDA Number": "93.839", "Description": "MAINTENANCE OF ANIMAL MODELS OF HUMAN HEMOPHILIA AND VWD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R24HL063098_7529"}, {"internal_id": 109189819, "Award ID": "R21HL154026", "Award Amount": 442750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-18", "CFDA Number": "93.837", "Description": "THE STRUCTURAL BASIS FOR PAR1 BIASED SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R21HL154026_7529"}, {"internal_id": 111229131, "Award ID": "R21HL153655", "Award Amount": 262500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-24", "CFDA Number": "93.837", "Description": "ELUCIDATING THE ROLE OF INHERITED COMPLEMENT SYSTEM DEFECTS IN THE MOLECULAR PATHOPHYSIOLOGY OF SEPSIS AND PURPURA FULMINANS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_R21HL153655_7529"}, {"internal_id": 100874546, "Award ID": "R21HL153409", "Award Amount": 423500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-15", "CFDA Number": "93.837", "Description": "PLATELET-REGULATED IMMUNE RESPONSES IN NEONATES FOLLOWING TRANSFUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R21HL153409_7529"}, {"internal_id": 95943172, "Award ID": "R21HL152350", "Award Amount": 420688.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-12", "CFDA Number": "93.837", "Description": "ENCAPSULATED PLATELETS IN CAST HYDROGELS (EPIC) TO MEASURE SINGLE PLATELET STRUCTURE-FUNCTION RELATIONSHIPS IN OLD AGE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R21HL152350_7529"}, {"internal_id": 96560369, "Award ID": "R21HL152313", "Award Amount": 411631.11, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-10", "CFDA Number": "93.837", "Description": "HBS OLIGOMERS AS A THERAPEUTIC TARGET IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R21HL152313_7529"}, {"internal_id": 107114917, "Award ID": "R21HL152147", "Award Amount": 435687.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-27", "CFDA Number": "93.837", "Description": "INSTRUMENTING BLOOD PLATELETS: NANOSENSORS FOR CUMULATIVE SHEAR AND COMPRESSION MEASUREMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c8e3c1b2-847b-fd38-8430-6da62d956103-C", "generated_internal_id": "ASST_NON_R21HL152147_7529"}, {"internal_id": 93911910, "Award ID": "R21HL150678", "Award Amount": 446244.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-23", "CFDA Number": "93.837", "Description": "DEFINING HUMAN HEMATOPOIETIC CELLS VIA TRANSCRIPTOMES AND METHODS TO ISOLATE THEM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R21HL150678_7529"}, {"internal_id": 100874956, "Award ID": "R21HL150642", "Award Amount": 458659.87, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-05", "CFDA Number": "93.837", "Description": "ANALYSIS OF TRANSCRIPTION AND SPLICING COORDINATION DURING ERYTHROPOEISIS USING SINGLE MOLECULE RNA-SEQ", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R21HL150642_7529"}, {"internal_id": 95484488, "Award ID": "R21HL150636", "Award Amount": 432712.21, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-26", "CFDA Number": "93.837", "Description": "SINGLE CELL SPATIAL CHARACTERIZATION OF THE HUMAN BONE MARROW MICROENVIRONMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R21HL150636_7529"}, {"internal_id": 93242667, "Award ID": "R21HL150575", "Award Amount": 470180.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-18", "CFDA Number": "93.837", "Description": "IMPACT OF EMPERIPOLESIS ON PLATELET FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R21HL150575_7529"}, {"internal_id": 111328710, "Award ID": "R21HL150487", "Award Amount": 242704.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-03", "CFDA Number": "93.837", "Description": "REPRODUCTIVE CARE IN WOMEN WITH SICKLE CELL DISEASE - USE OF SECONDARY DATA TO INVESTIGATE RISK OF CONTRACEPTION-RELATED THROMBOSIS AND THE IMPACT OF HYDROXYUREA ON PREGNANCY OUTCOMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "24042a1a-03ec-326e-b5c2-89242d7c209d-C", "generated_internal_id": "ASST_NON_R21HL150487_7529"}, {"internal_id": 111328711, "Award ID": "R21HL150454", "Award Amount": 178414.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-07", "CFDA Number": "93.837", "Description": "EXAMINING MORTALITY RISK AND CAUSE OF DEATH AMONG CALIFORNIA'S NEWBORN SCREENING IDENTIFIED COHORT WITH SICKLE CELL TRAIT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6e936f0c-2b79-ac43-ec63-eaaa116f78c8-C", "generated_internal_id": "ASST_NON_R21HL150454_7529"}, {"internal_id": 93243365, "Award ID": "R21HL150154", "Award Amount": 420750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-14", "CFDA Number": "93.837", "Description": "CENTRIFUGATION-FREE WASHING AND VOLUME-REDUCTION OF PLATELET CONCENTRATE UNITS USING HIGH-THROUGHPUT MICROFLUIDIC TECHNOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a95b9572-dc03-ba8d-34a5-edc32a8efc03-C", "generated_internal_id": "ASST_NON_R21HL150154_7529"}, {"internal_id": 95943142, "Award ID": "R21HL150032", "Award Amount": 413877.98, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-05", "CFDA Number": "93.837", "Description": "MIRAGES: METABOLIC INVESTIGATION OF RED BLOOD CELLS AS A FUNCTION OF AGING, GENETICS, ENVIRONMENT, AND STORAGE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R21HL150032_7529"}, {"internal_id": 80401750, "Award ID": "R21HL146299", "Award Amount": 428998.71, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-23", "CFDA Number": "93.837", "Description": "CRYO-ET STRUCTURAL STUDIES OF PLATELETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R21HL146299_7529"}, {"internal_id": 77189135, "Award ID": "R21HL145636", "Award Amount": 540937.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-18", "CFDA Number": "93.837", "Description": "ACOUSTIC SEPARATION OF PERIPHERAL BLOOD FOR CELLULAR THERAPY OF SICKLE CELL ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R21HL145636_7529"}, {"internal_id": 83115659, "Award ID": "R21HL145426", "Award Amount": 229649.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-08", "CFDA Number": "93.837", "Description": "HAEMAPA: CHARACTERIZING ALTERNATIVE POLYADENYLATION IN HUMAN BLOOD CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R21HL145426_7529"}, {"internal_id": 81071519, "Award ID": "R21HL145377", "Award Amount": 245171.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-01", "CFDA Number": "93.837", "Description": "CLINICAL IMPACT OF RED CELL STORAGE AGE: INDIVIDUAL PATIENT DATA META-ANALYSIS OF FOUR RECENT LARGE RANDOMIZED TRIALS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R21HL145377_7529"}, {"internal_id": 76738189, "Award ID": "R21HL145319", "Award Amount": 435374.73, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-21", "CFDA Number": "93.837", "Description": "HARMFUL EFFECTS OF TRANSFUSION-INDUCED IRON OVERLOAD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R21HL145319_7529"}, {"internal_id": 68565194, "Award ID": "R21HL145232", "Award Amount": 232911.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-07", "CFDA Number": "93.837", "Description": "MODULATION OF IRON OVERLOAD BY HEPCIDIN AND ERYTHROFERRONE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b710df3-c98e-f245-bbed-8bbbc32a803b-C", "generated_internal_id": "ASST_NON_R21HL145232_7529"}, {"internal_id": 68567670, "Award ID": "R21HL144991", "Award Amount": 150165.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-10", "CFDA Number": "93.839", "Description": "THE ROLE OF P53 IN IRON OVERLOAD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ad990d53-dba6-60b8-30bf-48cdeeb15c1c-C", "generated_internal_id": "ASST_NON_R21HL144991_7529"}, {"internal_id": 69718204, "Award ID": "R21HL144973", "Award Amount": 245624.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-19", "CFDA Number": "93.837", "Description": "ANTI-MULLERIAN HORMONE IN THE FEMALE PARTICIPANTS OF THE MULTI-CENTER STUDY OF HYDROXYUREA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R21HL144973_7529"}, {"internal_id": 79434504, "Award ID": "R21HL144224", "Award Amount": 445125.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-23", "CFDA Number": "93.837", "Description": "ENGINEERED PROTEIN OXYGEN CARRIERS: A NOVEL BLOOD SUBSTITUTE FOR TRAUMA CARE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R21HL144224_7529"}, {"internal_id": 67313636, "Award ID": "R21HL143096", "Award Amount": 239491.23, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-09", "CFDA Number": "93.837", "Description": "PERSONALIZED MOLECULAR APPROACHES TO DISEASE MONITORING AND MAINTENANCE THERAPIES FOR MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) PATIENTS UNDERGOING ALLOGENEIC BONE MARROW TRANSP", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R21HL143096_7529"}, {"internal_id": 67579350, "Award ID": "R21HL143025", "Award Amount": 444107.73, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-31", "CFDA Number": "93.837", "Description": "SIGNALING AND TRANSCRIPTIONAL CONTROL OF T FOLLICULAR HELPER CELLS AND RBC ALLOIMMUNIZATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R21HL143025_7529"}, {"internal_id": 65579347, "Award ID": "R21HL141016", "Award Amount": 457531.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-13", "CFDA Number": "93.837", "Description": "POTENTIALS OF A NEWLY ENGINEERED DEVICE FOR TREATMENT OF NEONATAL THROMBOCYTOPENIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R21HL141016_7529"}, {"internal_id": 49801191, "Award ID": "R21HL140531", "Award Amount": 438969.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-22", "CFDA Number": "93.837", "Description": "RISK OF VENOUS THROMBOEMBOLISM FOLLOWING DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA: DIFFERENCES BY RACE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R21HL140531_7529"}, {"internal_id": 67580221, "Award ID": "R21HL140314", "Award Amount": 227963.29, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-27", "CFDA Number": "93.837", "Description": "INCORPORATING PATIENT REPORTED OUTCOMES INTO INDIVIDUALIZED PROGNOSTICATION TOOLS FOR SURVIVAL AND QUALITY OF LIFE IN TRANSPLANT PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R21HL140314_7529"}, {"internal_id": 49801180, "Award ID": "R21HL140274", "Award Amount": 257709.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-15", "CFDA Number": "93.839", "Description": "PREDICTING INCIDENT STROKE USING BLOOD BIOMARKERS OF BRAIN INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R21HL140274_7529"}, {"internal_id": 49801179, "Award ID": "R21HL140269", "Award Amount": 227428.54, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-15", "CFDA Number": "93.837", "Description": "ORIGIN AND EVOLUTION OF VIROME IN DEVELOPMENT OF POST-TRANSFUSION HEPATITIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "24042a1a-03ec-326e-b5c2-89242d7c209d-C", "generated_internal_id": "ASST_NON_R21HL140269_7529"}, {"internal_id": 68565922, "Award ID": "R21HL140268", "Award Amount": 362743.31, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-10", "CFDA Number": "93.663", "Description": "CLINICAL ANALYSIS OF TREM-LIKE TRANSCRIPT-1 IN LARGE COHORTS OF PATIENTS FROM THE NHLBI BIOREPOSITORY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4b0f7689-aaf8-396f-d4b3-b944796d133f-C", "generated_internal_id": "ASST_NON_R21HL140268_7529"}, {"internal_id": 67315121, "Award ID": "R21HL140260", "Award Amount": 246000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-09", "CFDA Number": "93.837", "Description": "TNF-UMOD INTERACTIONS AND SUSCEPTIBILITY TO SALT-INDUCED HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f00078f8-f585-79c7-3349-6773e6685d91-C", "generated_internal_id": "ASST_NON_R21HL140260_7529"}, {"internal_id": 49801178, "Award ID": "R21HL140213", "Award Amount": 229500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-14", "CFDA Number": "93.837", "Description": "LATEXIN IN HUMAN HEMATOPOIETIC STEM CELL EXPANSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c477975b-68db-c3dc-4a79-b95cb9f6ab3e-C", "generated_internal_id": "ASST_NON_R21HL140213_7529"}, {"internal_id": 49801174, "Award ID": "R21HL139934", "Award Amount": 248373.07, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-12", "CFDA Number": "93.837", "Description": "BIOMARKERS FOR RISK OF CHRONIC GRAFT-VERSUS-HOST DISEASE OCCURRENCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R21HL139934_7529"}, {"internal_id": 68172004, "Award ID": "R21HL139864", "Award Amount": 413710.16, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-27", "CFDA Number": "93.837", "Description": "AUTOLOGOUS RED BLOOD CELLS FOR TRANSFUSION IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R21HL139864_7529"}, {"internal_id": 67833278, "Award ID": "R21HL139695", "Award Amount": 489499.95, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-07", "CFDA Number": "93.837", "Description": "A MODEL NICHE SYSTEM TO EXPAND PLATELETS FOR TRANSFUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "644797d6-c94c-9e2c-b40a-a4cda190c447-C", "generated_internal_id": "ASST_NON_R21HL139695_7529"}, {"internal_id": 67579312, "Award ID": "R21HL138710", "Award Amount": 412500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-27", "CFDA Number": "93.837", "Description": "PEPTIDE INHIBITORS OF OXIDATIVE HEME TOXICITY IN ACUTE HEMOLYSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d97dff14-1826-f436-5817-b2496b9c59da-C", "generated_internal_id": "ASST_NON_R21HL138710_7529"}, {"internal_id": 49801169, "Award ID": "R21HL138062", "Award Amount": 415605.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-11", "CFDA Number": "93.839", "Description": "MICROVASCULAR CEREBRAL BLOOD FLOW MEASURED WITH DIFFUSE CORRELATION SPECTROSCOPY IN CHILDREN WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R21HL138062_7529"}, {"internal_id": 49801163, "Award ID": "R21HL137439", "Award Amount": 74040.47, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-04", "CFDA Number": "93.837", "Description": "CLINICAL OUTCOMES OF ZIKA VIRUS IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aac0d53c-fc30-bb05-192d-4bb66ca0eae1-C", "generated_internal_id": "ASST_NON_R21HL137439_7529"}, {"internal_id": 49801161, "Award ID": "R21HL136272", "Award Amount": 768273.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-19", "CFDA Number": "93.839", "Description": "DEVELOPING HIGH AFFINITY LIGANDS OF GLYCAN BINDING PROTEINS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R21HL136272_7529"}, {"internal_id": 49801160, "Award ID": "R21HL136271", "Award Amount": 611426.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-23", "CFDA Number": "93.839", "Description": "RAPID SEQUENCING OF SULFATED GLYCANS BY CE-MS/MS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5d50a1e7-6c45-607b-669d-580246737467-C", "generated_internal_id": "ASST_NON_R21HL136271_7529"}, {"internal_id": 67580484, "Award ID": "R21HL135545", "Award Amount": 274850.61, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-03", "CFDA Number": "93.837", "Description": "RELATIONSHIP OF AMBIENT AIR POLLUTION EXPOSURES WITH VASO-OCCLUSIVE PAIN CRISES IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e04c3b49-28c8-efb6-f8ea-b4c853900d6f-C", "generated_internal_id": "ASST_NON_R21HL135545_7529"}, {"internal_id": 49801155, "Award ID": "R21HL135367", "Award Amount": 241978.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-24", "CFDA Number": "93.839", "Description": "WHOLE GENOME SEQUENCE ANALYSIS OF GENETIC FACTORS FOR STROKE, HYPERTENSION, AND FETAL HEMOGLOBIN IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8303ed9b-9fb4-3e90-ca81-50bbcf400948-C", "generated_internal_id": "ASST_NON_R21HL135367_7529"}, {"internal_id": 49801152, "Award ID": "R21HL135285", "Award Amount": 459250.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-26", "CFDA Number": "93.837", "Description": "MOLECULAR BASIS OF TRANSFUSION-INDUCED AUTO-IMMUNITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R21HL135285_7529"}, {"internal_id": 49801149, "Award ID": "R21HL133891", "Award Amount": 397693.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-30", "CFDA Number": "93.837", "Description": "ENDOTYPES OF THROMBOCYTOPENIA IN THE CRITICALLY ILL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R21HL133891_7529"}, {"internal_id": 49801143, "Award ID": "R21HL133584", "Award Amount": 352053.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-29", "CFDA Number": "93.839", "Description": "THE PRODUCTION OF MICROPARTICLES DURING RBC STORAGE AND THEIR IMPACT ON ENDOTHELIAL PHENOTYPE IN-VITRO AND IN-VIVO", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R21HL133584_7529"}, {"internal_id": 49801139, "Award ID": "R21HL132642", "Award Amount": 398156.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-06", "CFDA Number": "93.839", "Description": "AN OBJECTIVE NONINVASIVE SINGLE-CELL METHOD TO IDENTIFY HSC DIFFERENTIATION STAGE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2c3d8c8a-27ef-b1e9-7164-bbfa490faa27-C", "generated_internal_id": "ASST_NON_R21HL132642_7529"}, {"internal_id": 49801129, "Award ID": "R21HL131554", "Award Amount": 761454.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-15", "CFDA Number": "93.839", "Description": "SOFTWARE FOR AUTOMATED INTERPRETATION OF HEPARAN SULFATE TANDEM MASS SPECTRA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R21HL131554_7529"}, {"internal_id": 49801128, "Award ID": "R21HL131553", "Award Amount": 582000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-15", "CFDA Number": "93.839", "Description": "USING CRISPR-CAS9 TECHNOLOGY TO DEVELOP A MUTANT CELL LIBRARY FOR HEPARAN SULFATE STRUCTURE-FUNCTION STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5d50a1e7-6c45-607b-669d-580246737467-C", "generated_internal_id": "ASST_NON_R21HL131553_7529"}, {"internal_id": 49801117, "Award ID": "R21HL130818", "Award Amount": 434808.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-08", "CFDA Number": "93.839", "Description": "DISSECTING THE ORIGINS OF FETAL HEMOGLOBIN MODULATION OF SICKLE CELL VASO-OCCLUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R21HL130818_7529"}, {"internal_id": 49801096, "Award ID": "R21HL129063", "Award Amount": 356430.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-10", "CFDA Number": "93.839", "Description": "DIRECT ACTIVATION OF HEMATOPOIETIC TRANSCRIPTION FACTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "358711ab-dfdd-d789-9d79-6eaf11629381-C", "generated_internal_id": "ASST_NON_R21HL129063_7529"}, {"internal_id": 49801094, "Award ID": "R21HL129033", "Award Amount": 237328.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-05", "CFDA Number": "93.839", "Description": "INCIDENCE OF MALIGNANCIES IN CALIFORNIANS WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2f11d9-030b-5288-d89f-1f6fd7f111f3-C", "generated_internal_id": "ASST_NON_R21HL129033_7529"}, {"internal_id": 49801093, "Award ID": "R21HL129028", "Award Amount": 244785.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-16", "CFDA Number": "93.839", "Description": "ANALYSIS OF THE IMPACT OF MISSED DOSES OF VENOUS THROMBOEMBOLISM PROPHYLAXIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R21HL129028_7529"}, {"internal_id": 49801089, "Award ID": "R21HL129019", "Award Amount": 180189.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-28", "CFDA Number": "93.839", "Description": "QUALITY OF REPRODUCTIVE CARE IN WOMEN WITH VON WILLEBRAND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "24042a1a-03ec-326e-b5c2-89242d7c209d-C", "generated_internal_id": "ASST_NON_R21HL129019_7529"}, {"internal_id": 49801086, "Award ID": "R21HL128871", "Award Amount": 244662.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-03", "CFDA Number": "93.839", "Description": "BIOMARKER PROFILES OF SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R21HL128871_7529"}, {"internal_id": 49801085, "Award ID": "R21HL128863", "Award Amount": 433625.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-20", "CFDA Number": "93.839", "Description": "MASSIVE TRANSFUSION EPIDEMIOLOGY AND OUTCOMES IN CHILDREN (MATIC) STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R21HL128863_7529"}, {"internal_id": 49801070, "Award ID": "R21HL127495", "Award Amount": 422120.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-08", "CFDA Number": "93.839", "Description": "ENGINEERED CARS TARGETING FVIII-SPECIFIC T AND B CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3e4caa6c-ea4b-e402-0001-860fad11861b-C", "generated_internal_id": "ASST_NON_R21HL127495_7529"}, {"internal_id": 49801034, "Award ID": "R21HL125018", "Award Amount": 448919.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-25", "CFDA Number": "93.839", "Description": "BISPECIFIC CYTOTOXIC LYMPHOCYTES IN HIV-RELATED LYMPHOMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c9d7554-cb59-0dff-6547-d9102319b537-C", "generated_internal_id": "ASST_NON_R21HL125018_7529"}, {"internal_id": 49801025, "Award ID": "R21HL124260", "Award Amount": 435325.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-07", "CFDA Number": "93.839", "Description": "VALIDATING THE LINK BETWEEN NXPH2 AND ALLOIMMUNIZATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aac0d53c-fc30-bb05-192d-4bb66ca0eae1-C", "generated_internal_id": "ASST_NON_R21HL124260_7529"}, {"internal_id": 49801017, "Award ID": "R21HL123641", "Award Amount": 228110.0, "Award Type": null, "Base Obligation Date": "2015-07-31", "CFDA Number": "93.839", "Description": "GENETIC MODIFIERS OF TRANSFUSIONAL IRON OVERLOAD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R21HL123641_7529"}, {"internal_id": 49801014, "Award ID": "R21HL123491", "Award Amount": 228351.0, "Award Type": null, "Base Obligation Date": "2015-07-10", "CFDA Number": "93.839", "Description": "DISCIS STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R21HL123491_7529"}, {"internal_id": 49800845, "Award ID": "R21HL112678", "Award Amount": 246742.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-05-07", "CFDA Number": "93.839", "Description": "SERUM BIOMARKERS ASSOCIATED WITH PHENOTYPIC EXPRESSION OF HEMOCHROMATOSIS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6c187478-165a-1db6-d6e6-2be34431a2b3-C", "generated_internal_id": "ASST_NON_R21HL112678_7529"}, {"internal_id": 49784439, "Award ID": "R18HL112737", "Award Amount": 3331112.49, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-13", "CFDA Number": "93.837", "Description": "ENHANCING USE OF HYDROXYUREA IN SICKLE CELL DISEASE USING PATIENT NAVIGATORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_R18HL112737_7529"}, {"internal_id": 98487173, "Award ID": "R15HL150722", "Award Amount": 323262.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-22", "CFDA Number": "93.837", "Description": "STRUCTURAL INVESTIGATION OF HUMAN FACTOR IX ZYMOGEN ACTIVATION BY TF.VIIA AND FXIA:FXIA DIMER COMPLEXES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1ebd38d0-dcb9-749e-ab67-d7eff9806174-C", "generated_internal_id": "ASST_NON_R15HL150722_7529"}, {"internal_id": 93242865, "Award ID": "R15HL150666", "Award Amount": 441137.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-08", "CFDA Number": "93.839", "Description": "IDENTIFYING STRUCTURAL DIFFERENCES BETWEEN FIBRINOGEN AND FIBRIN TO PROVIDE NOVEL THERAPEUTIC TARGETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6c418087-59c2-1135-0b45-91d24c024b93-C", "generated_internal_id": "ASST_NON_R15HL150666_7529"}, {"internal_id": 82036609, "Award ID": "R15HL148842", "Award Amount": 438279.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-08", "CFDA Number": "93.839", "Description": "IDENTIFYING THE FUNCTION OF THE FIBRIN(OGEN) ALPHA-C CONNECTOR REGION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6c418087-59c2-1135-0b45-91d24c024b93-C", "generated_internal_id": "ASST_NON_R15HL148842_7529"}, {"internal_id": 82470413, "Award ID": "R15HL147265", "Award Amount": 437864.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-27", "CFDA Number": "93.839", "Description": "IMPROVEMENT OF CRISPR-CAS9 SPECIFICITY THROUGH ALLOSTERIC MODULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c2dad418-5c95-0983-b787-d49413633e9c-C", "generated_internal_id": "ASST_NON_R15HL147265_7529"}, {"internal_id": 80401307, "Award ID": "R15HL147135", "Award Amount": 840290.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-25", "CFDA Number": "93.837", "Description": "BACTERIAL AND HOST FACTORS MEDIATING RED BLOOD CELL INVASION BY FRANCISELLA TULARENSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WV", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68571b18-966b-2eb5-cb5e-5537ec61fd21-C", "generated_internal_id": "ASST_NON_R15HL147135_7529"}, {"internal_id": 67580531, "Award ID": "R15HL146779", "Award Amount": 547870.77, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-27", "CFDA Number": "93.837", "Description": "EXPERIMENTAL AND MATHEMATICAL MODELING OF CD8 T CELL DYNAMICS IN AUTOIMMUNE DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e5d977d0-85fb-65b4-d649-335857133b76-C", "generated_internal_id": "ASST_NON_R15HL146779_7529"}, {"internal_id": 49783394, "Award ID": "R15HL138544", "Award Amount": 422252.38, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-12", "CFDA Number": "93.837", "Description": "SYNTHESIS OF BIOMIMETIC PROTEOGLYCAN AND ITS ANTITHROMBOTIC ACTIVITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c41f39dd-d8c9-9cf8-ed06-da1b5beee326-C", "generated_internal_id": "ASST_NON_R15HL138544_7529"}, {"internal_id": 49783390, "Award ID": "R15HL137134", "Award Amount": 826472.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-31", "CFDA Number": "93.837", "Description": "THE ACUTE EFFECTS OF SNAKE VENOM CRISP TOXINS ON BLOOD AND LYMPHATIC ENDOTHELIAL CELL PERMEABILITY:  NEW INSIGHTS INTO THE PATHOPHYSIOLOGY OF SNAKEBITE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4dc327fd-35c8-b645-5e09-0c3eaad37180-C", "generated_internal_id": "ASST_NON_R15HL137134_7529"}, {"internal_id": 49783385, "Award ID": "R15HL135695", "Award Amount": 436366.07, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-14", "CFDA Number": "93.837", "Description": "GFI1-MEDIATED INHIBITION OF THE CYTOSTATIC EFFECT OF TGF? IN THE HEMATOPOIETIC SYSTEM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1f5108d9-5286-7556-c916-694becf718e8-C", "generated_internal_id": "ASST_NON_R15HL135695_7529"}, {"internal_id": 49783384, "Award ID": "R15HL135675", "Award Amount": 960000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-14", "CFDA Number": "93.837", "Description": "MECHANISMS AND OUTCOMES OF ERYTHROCYTE NECROPTOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75f993f4-9d28-509d-60fb-d159eb223f6d-C", "generated_internal_id": "ASST_NON_R15HL135675_7529"}, {"internal_id": 49783383, "Award ID": "R15HL135658", "Award Amount": 774517.16, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-27", "CFDA Number": "93.837", "Description": "STRUCTURAL AND BIOCHEMICAL STUDIES OF BLOOD COAGULATION FACTOR VIII TO OVERCOME THE IMMUNE RESPONSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "62fe7877-ce39-5c02-0334-28f8f0da00b9-C", "generated_internal_id": "ASST_NON_R15HL135658_7529"}, {"internal_id": 49783378, "Award ID": "R15HL133880", "Award Amount": 431388.08, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-31", "CFDA Number": "93.837", "Description": "EVALUATION OF INVERTEBRATE HEMOGLOBINS AS EFFECTIVE, SAFE, AND ULTRA-STABLE BLOOD SUBSTITUTES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5d3e00c3-06a2-64c0-397d-0912a81a2978-C", "generated_internal_id": "ASST_NON_R15HL133880_7529"}, {"internal_id": 49783360, "Award ID": "R15HL127636", "Award Amount": 903183.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-31", "CFDA Number": "93.839", "Description": "NOVEL APPROACHES TO THE MODULATION OF PROTEASE-ACTIVATED RECEPTOR (PAR) SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "93823bac-b8d2-7860-f871-2884c7daa75f-C", "generated_internal_id": "ASST_NON_R15HL127636_7529"}, {"internal_id": 49783355, "Award ID": "R15HL126113", "Award Amount": 437648.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-01", "CFDA Number": "93.839", "Description": "FUNCTION AND REGULATION OF THE FANCONI ANEMIA PATHWAY IN DNA REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ceec5ef7-d6a5-28f0-e23f-ec61155b7078-C", "generated_internal_id": "ASST_NON_R15HL126113_7529"}, {"internal_id": 49783344, "Award ID": "R15HL121786", "Award Amount": 519529.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-12", "CFDA Number": "93.837", "Description": "ANALYSIS OF STEM CELL FATE IN THE ABSENCE OF THE WNT ANTAGONIST, SCLEROSTIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e5d977d0-85fb-65b4-d649-335857133b76-C", "generated_internal_id": "ASST_NON_R15HL121786_7529"}, {"internal_id": 49783343, "Award ID": "R15HL121779", "Award Amount": 436500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-29", "CFDA Number": "93.839", "Description": "UNDERSTANDING THE IMPACT OF DISEASE CAUSING MUTATIONS IN FIX", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c41f39dd-d8c9-9cf8-ed06-da1b5beee326-C", "generated_internal_id": "ASST_NON_R15HL121779_7529"}, {"internal_id": 49783337, "Award ID": "R15HL120068", "Award Amount": 1277727.57, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-05", "CFDA Number": "93.837", "Description": "FIBRIN CLOT ARCHITECTURE REGULATED BY FACTOR XIII", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3c9476c3-c39d-74de-31b6-2c9a10197e11-C", "generated_internal_id": "ASST_NON_R15HL120068_7529"}, {"internal_id": 49783336, "Award ID": "R15HL120032", "Award Amount": 293622.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-02", "CFDA Number": "93.839", "Description": "THE ROLE OF INOSITOL POLYPHOSPHATE 4 PHOSPHATASE IN PLATELET FUNCTIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a5afa4de-eafc-44af-5fff-cfdaec94dca4-C", "generated_internal_id": "ASST_NON_R15HL120032_7529"}, {"internal_id": 49783302, "Award ID": "R15HL104593", "Award Amount": 663670.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-07-15", "CFDA Number": "93.839", "Description": "REGULATION AND FUNCTION OF NUCLEAR ENVELOPE PROTEINS IN MYELOPOIESIS AND LEUKEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f7fcd53-a62a-0ccf-e3e6-c6b54ddb6fd2-C", "generated_internal_id": "ASST_NON_R15HL104593_7529"}, {"internal_id": 49783275, "Award ID": "R15HL093680", "Award Amount": 1098420.04, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-07", "CFDA Number": "93.837", "Description": "EFFECTS OF HIBERNATION ON HEMOSTASIS IN 13-LINED GROUND SQUIRRELS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fc36ac55-b81f-5ed2-ca8d-cfde15d642f6-C", "generated_internal_id": "ASST_NON_R15HL093680_7529"}, {"internal_id": 49783262, "Award ID": "R15HL054269", "Award Amount": 2104230.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-08-07", "CFDA Number": "93.837", "Description": "A PUTATIVE HEPARIN RECEPTOR IN SMOOTH MUSCLE CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e8a1ed30-c6e7-a26e-e0a9-0a292a9ed2c8-C", "generated_internal_id": "ASST_NON_R15HL054269_7529"}, {"internal_id": 111229129, "Award ID": "R13HL154589", "Award Amount": 10000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-02", "CFDA Number": "93.837", "Description": "ISEH 49TH ANNUAL SCIENTIFIC MEETING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bae8fdb3-281d-8a02-2871-0dc12605dda0-R", "generated_internal_id": "ASST_NON_R13HL154589_7529"}, {"internal_id": 100873920, "Award ID": "R13HL154544", "Award Amount": 10000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-12", "CFDA Number": "93.839", "Description": "TAXI-CAB: TRANSFUSION AND ANEMIA EXPERT INITIATIVE - CONTROL/AVOIDANCE OF BLEEDING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R13HL154544_7529"}, {"internal_id": 100873876, "Award ID": "R13HL154346", "Award Amount": 10000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-12", "CFDA Number": "93.837", "Description": "HEMOGLOBIN SWITCHING MEETING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R13HL154346_7529"}, {"internal_id": 95943524, "Award ID": "R13HL152473", "Award Amount": 9600.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-15", "CFDA Number": "93.837", "Description": "HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "26eb2b26-f47e-582b-f630-555df416109f-C", "generated_internal_id": "ASST_NON_R13HL152473_7529"}, {"internal_id": 92603290, "Award ID": "R13HL150867", "Award Amount": 15000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-03", "CFDA Number": "93.837", "Description": "2020 PLASMINOGEN ACTIVATION AND EXTRACELLULAR PROTEOLYSIS GORDON RESEARCH CONFERENCE AND GORDON RESEARCH SEMINAR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "234b0bf7-6dda-7f84-f2b9-918a2cc6cba3-C", "generated_internal_id": "ASST_NON_R13HL150867_7529"}, {"internal_id": 82470372, "Award ID": "R13HL149316", "Award Amount": 20000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-18", "CFDA Number": "93.837", "Description": "CELLULAR THERAPIES AND NOVEL BLOOD PRODUCTS IN TRAUMA AND CRITICAL CARE MEDICINE: THE FUTURE OF TRANSFUSION MEDICINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R13HL149316_7529"}, {"internal_id": 64141547, "Award ID": "R13HL142275", "Award Amount": 10000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-08", "CFDA Number": "93.839", "Description": "FASEB SRC ON FUNCTIONAL DISULFIDE BONDS IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aec82df6-57e1-0dc8-4366-42d51f4039ff-C", "generated_internal_id": "ASST_NON_R13HL142275_7529"}, {"internal_id": 64141771, "Award ID": "R13HL142080", "Award Amount": 32760.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-10", "CFDA Number": "93.839", "Description": "2018 HEMOSTASIS GORDON RESEARCH CONFERENCE AND GORDON RESEARCH SEMINAR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "234b0bf7-6dda-7f84-f2b9-918a2cc6cba3-C", "generated_internal_id": "ASST_NON_R13HL142080_7529"}, {"internal_id": 49779972, "Award ID": "R13HL140902", "Award Amount": 8925.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-13", "CFDA Number": "93.839", "Description": "KININ2018CLE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R13HL140902_7529"}, {"internal_id": 49779963, "Award ID": "R13HL138960", "Award Amount": 13500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-25", "CFDA Number": "93.839", "Description": "JUNIOR INVESTIGATORS PROGRAMS FOR THE 46TH ANNUAL INTERNATIONAL SOCIETY FOR EXPERIMENTAL HEMATOLOGY (ISEH) SCIENTIFIC MEETING.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bae8fdb3-281d-8a02-2871-0dc12605dda0-R", "generated_internal_id": "ASST_NON_R13HL138960_7529"}, {"internal_id": 49779961, "Award ID": "R13HL138732", "Award Amount": 30000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-23", "CFDA Number": "93.839", "Description": "2018 PLASMINOGEN ACTIVATION AND EXTRACELLULAR PROTEOLYSIS GORDON RESEARCH CONFERENCE AND GORDON RESEARCH SEMINAR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "234b0bf7-6dda-7f84-f2b9-918a2cc6cba3-C", "generated_internal_id": "ASST_NON_R13HL138732_7529"}, {"internal_id": 49779960, "Award ID": "R13HL138729", "Award Amount": 12106.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-15", "CFDA Number": "93.839", "Description": "CONFERENCE ON PHYSIOLOGY AND PATHOPHYSIOLOGY OF SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7048f108-0d10-6e94-9aae-10e3d37683ae-C", "generated_internal_id": "ASST_NON_R13HL138729_7529"}, {"internal_id": 49779939, "Award ID": "R13HL135868", "Award Amount": 18700.0, "Award Type": null, "Base Obligation Date": "2016-12-28", "CFDA Number": "93.839", "Description": "2017 THE CELL BIOLOGY OF MEGAKARYOCYTES & PLATELETS GORDON RESEARCH CONFERENCE & GORDON RESEARCH SEMINAR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "234b0bf7-6dda-7f84-f2b9-918a2cc6cba3-C", "generated_internal_id": "ASST_NON_R13HL135868_7529"}, {"internal_id": 49779926, "Award ID": "R13HL134187", "Award Amount": 20000.0, "Award Type": null, "Base Obligation Date": "2016-06-15", "CFDA Number": "93.839", "Description": "2016 CRTI SUMMER WORKSHOP", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "83b96572-fce6-73fc-a5f4-ccfbf759df87-C", "generated_internal_id": "ASST_NON_R13HL134187_7529"}, {"internal_id": 107114757, "Award ID": "R03HL156574", "Award Amount": 177000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-30", "CFDA Number": "93.837", "Description": "MULTI-FACETED ROLES OF AN ATYPICAL KINASE RIOK2 IN ERYTHROPOIESIS AND MYELODYPLASTIC SYNDROMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "be067fa7-a493-7bea-f9cc-e29bd2ccc74a-C", "generated_internal_id": "ASST_NON_R03HL156574_7529"}, {"internal_id": 108463009, "Award ID": "R03HL154829", "Award Amount": 149504.7, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-11", "CFDA Number": "93.837", "Description": "ENHANCING B CELL MATURATION AND FUNCTION USING BISPHOSPHONATES IN HIV", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R03HL154829_7529"}, {"internal_id": 103894714, "Award ID": "R03HL154205", "Award Amount": 155987.11, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-21", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF COMPUTER AIDED DECISION SUPPORT AND EHR ALERTS FOR DOAC PRESCRIBING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R03HL154205_7529"}, {"internal_id": 86316358, "Award ID": "R03HL148295", "Award Amount": 158000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-23", "CFDA Number": "93.837", "Description": "MERGING TEMPORAL CHANGES IN CLINICAL INFORMATICS, TRANSCRIPTOMICS, AND CYTOKINE PROFILES TO UNDERSTAND THE HOST RESPONSE TO BACTEREMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "HI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d192652e-3551-3991-1674-6885c846fff2-C", "generated_internal_id": "ASST_NON_R03HL148295_7529"}, {"internal_id": 79639169, "Award ID": "R03HL146877", "Award Amount": 149957.08, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-15", "CFDA Number": "93.837", "Description": "SCTAWARE: A COMPREHENSIVE PROGRAM TO INCREASE SICKLE CELL TRAIT KNOWLEDGE AND AWARENESS AMONG PARENTS OF INFANTS IDENTIFIED BY NEWBORN SCREENING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "24042a1a-03ec-326e-b5c2-89242d7c209d-C", "generated_internal_id": "ASST_NON_R03HL146877_7529"}, {"internal_id": 82469980, "Award ID": "R03HL146788", "Award Amount": 159900.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-29", "CFDA Number": "93.837", "Description": "CELL-FREE HEMOGLOBIN IN SICKLE CELL ACUTE KIDNEY INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R03HL146788_7529"}, {"internal_id": 69725103, "Award ID": "R03HL145253", "Award Amount": 158500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-21", "CFDA Number": "93.837", "Description": "DEFINING THE MECHANISMS BY WHICH BRCA1 MAINTAINS GENOMIC STABILITY IN HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R03HL145253_7529"}, {"internal_id": 69724897, "Award ID": "R03HL145226", "Award Amount": 163750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-25", "CFDA Number": "93.837", "Description": "THE ROLE OF STROMAL CYP26 IN MYELODYSPLASTIC SYNDROMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R03HL145226_7529"}, {"internal_id": 68568038, "Award ID": "R03HL145193", "Award Amount": 155652.59, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-17", "CFDA Number": "93.837", "Description": "PAINIMATION: AN INNOVATIVE, TECHNOLOGY-BASED METHOD FOR MEASURING PAIN QUALITY, LOCATION AND SEVERITY IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R03HL145193_7529"}, {"internal_id": 68564897, "Award ID": "R03HL144898", "Award Amount": 72585.76, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-11", "CFDA Number": "93.837", "Description": "IMMUNE CHECKPOINT ABNORMALITIES IN HUMAN SUBJECTS WITH CLONAL HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R03HL144898_7529"}, {"internal_id": 110024044, "Award ID": "R03HL144897", "Award Amount": 148796.1, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-24", "CFDA Number": "93.837", "Description": "VARIABILITY IN NEUTROPHIL ACTIVATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R03HL144897_7529"}, {"internal_id": 69717337, "Award ID": "R03HL144485", "Award Amount": 148445.83, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-19", "CFDA Number": "93.837", "Description": "ACUTE KIDNEY INJURY DURING SICKLE CELL CRISIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R03HL144485_7529"}, {"internal_id": 49774694, "Award ID": "R03HL138321", "Award Amount": 166500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-11", "CFDA Number": "93.837", "Description": "THE IMPACT OF HEMOGLOBIN S ON RED BLOOD CELL NITRIC OXIDE PRODUCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6c10cf51-1fb6-c52e-c48f-8fcef0f37eff-C", "generated_internal_id": "ASST_NON_R03HL138321_7529"}, {"internal_id": 49774693, "Award ID": "R03HL138310", "Award Amount": 155000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-18", "CFDA Number": "93.839", "Description": "CORTICOSTEROID EFFECTS ON BACTERIAL BEHAVIORS IN THE RESPIRATORY TRACT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R03HL138310_7529"}, {"internal_id": 49774690, "Award ID": "R03HL136797", "Award Amount": 161692.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-26", "CFDA Number": "93.839", "Description": "ADVANCING DIAGNOSTICS AND THERAPEUTICS IN BONE MARROW FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R03HL136797_7529"}, {"internal_id": 49774682, "Award ID": "R03HL135454", "Award Amount": 159900.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-09", "CFDA Number": "93.839", "Description": "MITOPHAGY AS POTENTIAL TARGET IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R03HL135454_7529"}, {"internal_id": 100874840, "Award ID": "R01HL154580", "Award Amount": 2158702.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-08", "CFDA Number": "93.837", "Description": "DEVELOPMENTAL ACTIVATION OF THE INFLAMMASOME CONTROLS HEMATOPOIETIC STEM CELL PRODUCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL154580_7529"}, {"internal_id": 100874813, "Award ID": "R01HL154579", "Award Amount": 2795968.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-10", "CFDA Number": "93.837", "Description": "MECHANISTIC INFLAMMATORY PATHWAYS IN GRAFT VERSUS HOST DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL154579_7529"}, {"internal_id": 108463037, "Award ID": "R01HL154385", "Award Amount": 2979909.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-10", "CFDA Number": "93.837", "Description": "STRUCTURAL AND NUCLEOTIDE VARIATION AS GENOMIC RISKS FOR VENOUS THROMBOSIS: TOPMED AND INVENT COLLABORATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL154385_7529"}, {"internal_id": 108463093, "Award ID": "R01HL154150", "Award Amount": 2018417.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-12", "CFDA Number": "93.837", "Description": "MULTIFIDELITY AND MULTISCALE MODELING OF THE SPLEEN FUNCTION IN SICKLE CELL DISEASE WITH IN VITRO, EX VIVO AND IN VIVO VALIDATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "378fe7f9-e157-cd75-80cc-97cbe1a426db-C", "generated_internal_id": "ASST_NON_R01HL154150_7529"}, {"internal_id": 98486256, "Award ID": "R01HL154034", "Award Amount": 1252146.91, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-30", "CFDA Number": "93.837", "Description": "EXAMINING THE MECHANISMS OF RBC ALLOIMMUNIZATION HYPERRESPONDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL154034_7529"}, {"internal_id": 109189931, "Award ID": "R01HL153723", "Award Amount": 3043120.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-18", "CFDA Number": "93.837", "Description": "MIDAS: MICROANGIOPATHY, ENDOTHELIAL DAMAGE IN ADULTS UNDERGOING STEM CELL TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL153723_7529"}, {"internal_id": 98143451, "Award ID": "R01HL153487", "Award Amount": 2274292.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-12", "CFDA Number": "93.837", "Description": "UNDERSTANDING THE ROLE OF STELLATE CELLS IN THE LIVER HEMATOPOIETIC STEM CELL NICHE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL153487_7529"}, {"internal_id": 97852978, "Award ID": "R01HL153386", "Award Amount": 3789939.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-29", "CFDA Number": "93.837", "Description": "IMPROVING SCIENTIFIC RIGOR OF RENAL CLINICAL ENDPOINTS FOR SICKLE CELL ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL153386_7529"}, {"internal_id": 97852368, "Award ID": "R01HL153235", "Award Amount": 1675000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-01", "CFDA Number": "93.837", "Description": "MECHANISMS OF PLATELET REPROGRAMMING DURING INFLUENZA INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68a12c06-0ac5-9595-eda2-d8647ffda5d0-C", "generated_internal_id": "ASST_NON_R01HL153235_7529"}, {"internal_id": 98486552, "Award ID": "R01HL153161", "Award Amount": 1599000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-24", "CFDA Number": "93.837", "Description": "PATHWAYS OF CELL-FREE HEMOGLOBIN IN SICKLE CELL NEPHROPATHY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL153161_7529"}, {"internal_id": 110024791, "Award ID": "R01HL153073", "Award Amount": 2456035.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-28", "CFDA Number": "93.837", "Description": "TRANSFUSION-RELATED IMMUNOMODULATION INFLUENCES INFECTIOUS DISEASE OUTCOMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aac0d53c-fc30-bb05-192d-4bb66ca0eae1-C", "generated_internal_id": "ASST_NON_R01HL153073_7529"}, {"internal_id": 107115248, "Award ID": "R01HL153072", "Award Amount": 1462757.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-31", "CFDA Number": "93.837", "Description": "ROLE OF TRPM8 IN COLD-STORED PLATELET TRANSFUSIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "474a19eb-1491-c065-a3ca-a49b264b0d4b-C", "generated_internal_id": "ASST_NON_R01HL153072_7529"}, {"internal_id": 96203211, "Award ID": "R01HL152636", "Award Amount": 2198718.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-19", "CFDA Number": "93.837", "Description": "BIOMECHANICAL ACTIVATION OF YAP INDUCES HEMATOPOIETIC STEM CELL PRODUCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL152636_7529"}, {"internal_id": 97471814, "Award ID": "R01HL152632", "Award Amount": 1574791.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-06", "CFDA Number": "93.837", "Description": "IDENTIFICATION OF NEW GENETIC CAUSES OF CONGENITAL NEUTROPENIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL152632_7529"}, {"internal_id": 97470208, "Award ID": "R01HL152605", "Award Amount": 2378830.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-08", "CFDA Number": "93.837", "Description": "COPII DEPENDENT REGULATION OF T CELL ALLOIMMUNITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL152605_7529"}, {"internal_id": 96559908, "Award ID": "R01HL152314", "Award Amount": 2456497.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-16", "CFDA Number": "93.837", "Description": "HBB GENE-EDITING FOR TREATING SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7c6d4e6a-e5c4-b348-571b-42f4d585f5a8-C", "generated_internal_id": "ASST_NON_R01HL152314_7529"}, {"internal_id": 96203263, "Award ID": "R01HL152200", "Award Amount": 3111595.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-26", "CFDA Number": "93.837", "Description": "VON WILLEBRAND FACTOR IN TRAUMATIC BRAIN INJURY AND ASSOCIATED COAGULOPATHY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "474a19eb-1491-c065-a3ca-a49b264b0d4b-C", "generated_internal_id": "ASST_NON_R01HL152200_7529"}, {"internal_id": 96204517, "Award ID": "R01HL152180", "Award Amount": 1574688.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-19", "CFDA Number": "93.837", "Description": "THE ROLE OF KMT2C/MLL3 IN HEMATOPOIETIC STEM CELL SELF-RENEWAL, COMMITMENT AND EXHAUSTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL152180_7529"}, {"internal_id": 111328713, "Award ID": "R01HL152161", "Award Amount": 2889543.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-23", "CFDA Number": "93.837", "Description": "ADOPTIVE T LYMPHOCYTE ADMINISTRATION FOR CHRONIC NOROVIRUS TREATMENT FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cf018231-59a5-d301-ae96-b0817a8ee227-C", "generated_internal_id": "ASST_NON_R01HL152161_7529"}, {"internal_id": 96203022, "Award ID": "R01HL152131", "Award Amount": 936000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-26", "CFDA Number": "93.837", "Description": "MODULATION OF PROTEIN METHYLATION TO IMPROVE HEMATOPOIETIC STEM CELL ENGRAFTMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL152131_7529"}, {"internal_id": 96203596, "Award ID": "R01HL152099", "Award Amount": 2494486.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-19", "CFDA Number": "93.837", "Description": "THE ROLE OF ERYTHROBLASTIC ISLANDS IN ANEMIA OF INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL152099_7529"}, {"internal_id": 96204630, "Award ID": "R01HL152066", "Award Amount": 1767356.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-31", "CFDA Number": "93.837", "Description": "COMPREHENSIVE CHARACTERIZATION OF MISSENSE MUTANTS IN FACTOR IX", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL152066_7529"}, {"internal_id": 96557583, "Award ID": "R01HL151984", "Award Amount": 2772494.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-09", "CFDA Number": "93.837", "Description": "AN INTEGRATED COMPUTATIONAL AND EXPERIMENTAL APPROACH TO UNDERSTANDING THE HEMOSTATIC RESPONSE DURING TREATMENT OF BLEEDING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL151984_7529"}, {"internal_id": 97015285, "Award ID": "R01HL151858", "Award Amount": 1571600.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-21", "CFDA Number": "93.837", "Description": "ENABLING PEDIATRIC LEUKAPHERESIS WITH HIGH-THROUGHPUT MICROFLUIDIC TECHNOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a95b9572-dc03-ba8d-34a5-edc32a8efc03-C", "generated_internal_id": "ASST_NON_R01HL151858_7529"}, {"internal_id": 97014901, "Award ID": "R01HL151777", "Award Amount": 2292622.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-30", "CFDA Number": "93.837", "Description": "EMBRYONIC NATURAL KILLER CELL DEVELOPMENT AND FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL151777_7529"}, {"internal_id": 97471176, "Award ID": "R01HL151765", "Award Amount": 3490315.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-06", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF 211ASTATINE-CONJUGATED ANTI-CD45 ANTIBODY-BASED CONDITIONING FOR HEMATOPOIETIC STEM CELL GENE THERAPY AND EDITING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "569197a4-81d0-b264-5640-e9db4cf71fd0-C", "generated_internal_id": "ASST_NON_R01HL151765_7529"}, {"internal_id": 97852356, "Award ID": "R01HL151651", "Award Amount": 2556982.96, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-20", "CFDA Number": "93.837", "Description": "FUNCTIONAL AND MOLECULAR BASIS OF INEFFECTIVE ERYTHROPOIESIS IN SF3B1-MUTANT MYELODYSPLASTIC SYNDROMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "569197a4-81d0-b264-5640-e9db4cf71fd0-C", "generated_internal_id": "ASST_NON_R01HL151651_7529"}, {"internal_id": 96559281, "Award ID": "R01HL151629", "Award Amount": 1803994.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-10", "CFDA Number": "93.837", "Description": "GENE EDITING VS NEUTROPHIL ELASTASE INHIBITORS FOR TREATMENT OF ELANE ASSOCIATED NEUTROPENIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL151629_7529"}, {"internal_id": 97014917, "Award ID": "R01HL151617", "Award Amount": 1806632.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-23", "CFDA Number": "93.837", "Description": "3-O-SULFATION OF HEPARAN SULFATE AS A REGULAR OF PROTEIN FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5d50a1e7-6c45-607b-669d-580246737467-C", "generated_internal_id": "ASST_NON_R01HL151617_7529"}, {"internal_id": 96559038, "Award ID": "R01HL151473", "Award Amount": 1448899.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-16", "CFDA Number": "93.837", "Description": "BIOINSPIRED ANTIFOULING AND THROMBORESISTANT POLYMERS FOR BLOOD-CONTACTING INTERFACES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5d50a1e7-6c45-607b-669d-580246737467-C", "generated_internal_id": "ASST_NON_R01HL151473_7529"}, {"internal_id": 95943072, "Award ID": "R01HL151392", "Award Amount": 1485000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-15", "CFDA Number": "93.837", "Description": "SAFER AND MORE EFFECTIVE FIX THERAPEUTICS: IMPACT OF CODON OPTIMIZATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c41f39dd-d8c9-9cf8-ed06-da1b5beee326-C", "generated_internal_id": "ASST_NON_R01HL151392_7529"}, {"internal_id": 96558475, "Award ID": "R01HL151390", "Award Amount": 1535722.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-08", "CFDA Number": "93.837", "Description": "A NOVEL IMMUNOMETABOLISM-REGULATORY AXIS IN INFLAMMATORY HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL151390_7529"}, {"internal_id": 98487236, "Award ID": "R01HL151365", "Award Amount": 1449000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-25", "CFDA Number": "93.837", "Description": "PREBIOTICS TO OPTIMIZE THE MICROBIOTA AND IMPROVE OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL151365_7529"}, {"internal_id": 97471602, "Award ID": "R01HL151334", "Award Amount": 1844368.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-11", "CFDA Number": "93.837", "Description": "THE ROLE OF JADE IN HBO COMPLEXES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL151334_7529"}, {"internal_id": 86317026, "Award ID": "R01HL151260", "Award Amount": 3352210.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-20", "CFDA Number": "93.839", "Description": "UNDERSTANDING THE COMPLEXITY OF GENE DOSAGE IMBALANCE IN DOWN SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL151260_7529"}, {"internal_id": 110024182, "Award ID": "R01HL151195", "Award Amount": 2188496.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-27", "CFDA Number": "93.837", "Description": "ROLE OF MACROPHAGE POLARIZATION IN MULTI-ORGAN FIBROSIS OF CHRONIC GVHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL151195_7529"}, {"internal_id": 95942517, "Award ID": "R01HL151077", "Award Amount": 3183529.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-15", "CFDA Number": "93.837", "Description": "ULTRASOUND-MEDIATED GENE DELIVERY TO ACHIEVE THERAPEUTIC CORRECTION OF HEMOPHILIA A", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_R01HL151077_7529"}, {"internal_id": 96202875, "Award ID": "R01HL150882", "Award Amount": 2359772.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-26", "CFDA Number": "93.837", "Description": "CONSTRAINED FETAL HEMATOPOIESIS AND CLONAL RESTRICTION IN FANCONI ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL150882_7529"}, {"internal_id": 82469387, "Award ID": "R01HL150832", "Award Amount": 2127892.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-23", "CFDA Number": "93.837", "Description": "STAT3 INHIBITION AS A THERAPEUTIC STRATEGY AGAINST MDS STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_R01HL150832_7529"}, {"internal_id": 98487274, "Award ID": "R01HL150729", "Award Amount": 1955143.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-02", "CFDA Number": "93.837", "Description": "THE ROLE OF PLECKSTRIN-2 AS A FUNCTIONAL NODE IN MYELOID PROLIFERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL150729_7529"}, {"internal_id": 98144189, "Award ID": "R01HL150707", "Award Amount": 1962864.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-09", "CFDA Number": "93.837", "Description": "THE ROLE OF ER ASSOCIATED DEGRADATION (ERAD) IN HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL150707_7529"}, {"internal_id": 93243711, "Award ID": "R01HL150669", "Award Amount": 3474638.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-18", "CFDA Number": "93.837", "Description": "RECTIFYING SPLICING MUTATIONS IN BLOOD DISORDERS BY GENE EDITING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL150669_7529"}, {"internal_id": 82054784, "Award ID": "R01HL150624", "Award Amount": 1574634.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-09", "CFDA Number": "93.837", "Description": "MOLECULAR MECHANISMS UNDERLYING CLONAL EXPANSION OF HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL150624_7529"}, {"internal_id": 93911862, "Award ID": "R01HL150553", "Award Amount": 2996617.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-23", "CFDA Number": "93.837", "Description": "GENE EDITING ELANE TO UNDERSTAND AND TREAT SEVERE CONGENITAL NEUTROPENIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL150553_7529"}, {"internal_id": 95180591, "Award ID": "R01HL150515", "Award Amount": 2255788.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-13", "CFDA Number": "93.837", "Description": "PLATELETS IN VASCULAR INJURY REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL150515_7529"}, {"internal_id": 95942542, "Award ID": "R01HL150392", "Award Amount": 1734912.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-05", "CFDA Number": "93.837", "Description": "PURINERGIC REGULATION OF INNATE IMMUNITY TO PROMOTE VENOUS HOMEOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL150392_7529"}, {"internal_id": 95180753, "Award ID": "R01HL150194", "Award Amount": 918000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-07", "CFDA Number": "93.837", "Description": "MECHANISMS OF ERYTHROID REMISSION IN DIAMOND BLACKFAN ANEMIA (DBA)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "709ff727-128e-6ef1-a5e4-77234d839c39-C", "generated_internal_id": "ASST_NON_R01HL150194_7529"}, {"internal_id": 94714399, "Award ID": "R01HL150190", "Award Amount": 1856590.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-17", "CFDA Number": "93.837", "Description": "THE ROLE OF MICROHOMOLOGY-MEDIATED END JOINING IN FANCONI ANEMIA PATHOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b75e8e34-d319-7e14-e393-0587157fa214-C", "generated_internal_id": "ASST_NON_R01HL150190_7529"}, {"internal_id": 93243746, "Award ID": "R01HL150146", "Award Amount": 1579552.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-09", "CFDA Number": "93.837", "Description": "STRUCTURAL STUDIES OF BETA-2 GLYCOPROTEIN I IN THE ANTIPHOSPHOLIPID SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b7dfaba3-c263-11dd-cbe2-5abe1968badc-C", "generated_internal_id": "ASST_NON_R01HL150146_7529"}, {"internal_id": 93242933, "Award ID": "R01HL150145", "Award Amount": 1975128.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-10", "CFDA Number": "93.837", "Description": "TARGETING THE COMPROMISED BRAIN ENDOTHELIAL BARRIER FUNCTION DURING CEREBRAL MALARIA WITH AT2 RECEPTOR AGONISTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c07787b9-15d4-d1eb-4f0c-2e0b30320bfb-C", "generated_internal_id": "ASST_NON_R01HL150145_7529"}, {"internal_id": 110233614, "Award ID": "R01HL150078", "Award Amount": 1485000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-08", "CFDA Number": "93.837", "Description": "ROLE OF BONE MARROW TREGS IN MAINTAINING STROMAL CELL FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL150078_7529"}, {"internal_id": 108463244, "Award ID": "R01HL150040", "Award Amount": 1675000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-05", "CFDA Number": "93.837", "Description": "MTOR AND VEGFR2 PATHWAYS IN HHT PATHOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f9f0ca2a-aa8d-05a3-861f-1f3e215d88e8-C", "generated_internal_id": "ASST_NON_R01HL150040_7529"}, {"internal_id": 95181260, "Award ID": "R01HL149966", "Award Amount": 1741823.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-18", "CFDA Number": "93.837", "Description": "NEW TOOLS TO DECIPHER THE ROLE OF LNCRNAS AND THEIR PROTEIN INTERACTOMES IN HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL149966_7529"}, {"internal_id": 94236697, "Award ID": "R01HL149954", "Award Amount": 2115912.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-08", "CFDA Number": "93.837", "Description": "EPIGENETIC REGULATIONS OF MACROPHAGE DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL149954_7529"}, {"internal_id": 93911915, "Award ID": "R01HL149907", "Award Amount": 1198905.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-31", "CFDA Number": "93.837", "Description": "CHROMATIN STATE ALTERATIONS IN FANCONI ANEMIA HEMATOLOGIC DISEASE AND BONE MARROW FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8f7c7d27-684d-9b39-0e46-80a8c294c54a-C", "generated_internal_id": "ASST_NON_R01HL149907_7529"}, {"internal_id": 111328716, "Award ID": "R01HL149893", "Award Amount": 1596780.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-27", "CFDA Number": "93.837", "Description": "THE ROLE OF PTPN11 IN MYELOFIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL149893_7529"}, {"internal_id": 97853265, "Award ID": "R01HL149860", "Award Amount": 1311000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-28", "CFDA Number": "93.837", "Description": "PLATELET CLEC-2 IN ARTERIAL THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OK", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "36c41119-2158-d09a-55ce-00590b81ab14-C", "generated_internal_id": "ASST_NON_R01HL149860_7529"}, {"internal_id": 93242427, "Award ID": "R01HL149855", "Award Amount": 1522513.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-10", "CFDA Number": "93.837", "Description": "IN VIVO REGULATION OF FACTOR IXA BY PROTEIN S IN HEMOPHILIA AND SYSTEMIC HYPERCOAGULABILITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL149855_7529"}, {"internal_id": 109278495, "Award ID": "R01HL149833", "Award Amount": 2579748.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-20", "CFDA Number": "93.837", "Description": "TARGETED EXPRESSION OF FACTOR VIII IN LIVER SINUSOIDAL ENDOTHELIAL CELLS FOR GENE THERAPY FOR HEMOPHILIA A", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL149833_7529"}, {"internal_id": 93912041, "Award ID": "R01HL149751", "Award Amount": 972000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-23", "CFDA Number": "93.837", "Description": "EPIGENETIC REGULATION OF THROMBOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "07c08a07-af34-2853-20eb-9d2594ed7b35-C", "generated_internal_id": "ASST_NON_R01HL149751_7529"}, {"internal_id": 95943311, "Award ID": "R01HL149714", "Award Amount": 2639727.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-04", "CFDA Number": "93.837", "Description": "INTERACTIONS BETWEEN THE ADORA2B/SPHK1AXIS AND THE AE1-HB SWITCH IN RED BLOOD CELL AGING IN VIVO AND IN VITRO", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL149714_7529"}, {"internal_id": 92603711, "Award ID": "R01HL149670", "Award Amount": 3106384.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-11-27", "CFDA Number": "93.837", "Description": "LEVERAGING ARTIFICIAL INTELLIGENCE SOLUTIONS TO DEVELOP DIGITAL BIOMARKERS FOR PRECISION TRAUMA RESUSCITATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2f11d9-030b-5288-d89f-1f6fd7f111f3-C", "generated_internal_id": "ASST_NON_R01HL149670_7529"}, {"internal_id": 95484176, "Award ID": "R01HL149667", "Award Amount": 2812131.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-20", "CFDA Number": "93.837", "Description": "TARGETING DYRK1A TO PROMOTE DONOR-INDEPENDENT PLATELET PRODUCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL149667_7529"}, {"internal_id": 80400875, "Award ID": "R01HL149511", "Award Amount": 2982867.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-19", "CFDA Number": "93.837", "Description": "A NOVEL PLASMINOGEN RECEPTOR PROMOTES ADIPOSE FUNCTION AND METABOLIC HOMEOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL149511_7529"}, {"internal_id": 96559374, "Award ID": "R01HL149365", "Award Amount": 1507527.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-16", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF FETAL HEMOGLOBIN INDUCERS TARGETING EPIGENETIC AND OXIDATIVE STRESS MECHANISMS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aca87389-2cb6-91e2-17a4-df7e81a7314d-C", "generated_internal_id": "ASST_NON_R01HL149365_7529"}, {"internal_id": 82036310, "Award ID": "R01HL149318", "Award Amount": 924667.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-12", "CFDA Number": "93.837", "Description": "ROLE OF PHF6 IN NORMAL HEMATOPOIESIS AND HEMATOPOIETIC STEM CELL BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c0534dd6-007b-cfc7-2a77-9b3602a48251-C", "generated_internal_id": "ASST_NON_R01HL149318_7529"}, {"internal_id": 81728458, "Award ID": "R01HL148852", "Award Amount": 2779440.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-24", "CFDA Number": "93.837", "Description": "DISSECTING THE CANONICAL AND NON-CANONICAL FUNCTIONS OF TET2 IN HEMATOPOIETIC STEM CELLS AND HEMATOLOGIC DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_R01HL148852_7529"}, {"internal_id": 81728604, "Award ID": "R01HL148755", "Award Amount": 2694640.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-28", "CFDA Number": "93.837", "Description": "STRUCTURAL BASIS OF VON WILLEBRAND FACTOR BIOLOGY AND PHYSICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL148755_7529"}, {"internal_id": 82036482, "Award ID": "R01HL148565", "Award Amount": 3684959.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-12", "CFDA Number": "93.837", "Description": "CLONAL HEMATOPOIESIS IN THE WOMENS HEALTH INITIATIVE MEMORY STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "569197a4-81d0-b264-5640-e9db4cf71fd0-C", "generated_internal_id": "ASST_NON_R01HL148565_7529"}, {"internal_id": 81395568, "Award ID": "R01HL148352", "Award Amount": 964000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-05", "CFDA Number": "93.837", "Description": "IRON CATALYZED H2S AND ITS PREVALENCE IN HEMOLYTIC AND IRON OVERLOAD DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL148352_7529"}, {"internal_id": 81071887, "Award ID": "R01HL148333", "Award Amount": 3073590.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-24", "CFDA Number": "93.837", "Description": "THE MOLECULAR PATHOPHYSIOLOGY OF THE CONGENITAL DYSERYTHROPOIETIC ANEMIAS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL148333_7529"}, {"internal_id": 82054119, "Award ID": "R01HL148280", "Award Amount": 1850230.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-12", "CFDA Number": "93.837", "Description": "THIOL ISOMERASES AND ERO1? IN SICKLE CELL VASO-OCCLUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL148280_7529"}, {"internal_id": 97471410, "Award ID": "R01HL148227", "Award Amount": 2506876.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-15", "CFDA Number": "93.837", "Description": "MECHANISMS OF MECHANO-CHEMICAL RUPTURE OF BLOOD CLOTS AND THROMBI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL148227_7529"}, {"internal_id": 81071743, "Award ID": "R01HL148164", "Award Amount": 3914162.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-25", "CFDA Number": "93.837", "Description": "PREVENTING GVHD BY INHIBITION OF ALLOANTIGEN PRESENTATION IN THE GUT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "569197a4-81d0-b264-5640-e9db4cf71fd0-C", "generated_internal_id": "ASST_NON_R01HL148164_7529"}, {"internal_id": 86317594, "Award ID": "R01HL148151", "Award Amount": 8911691.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-23", "CFDA Number": "93.837", "Description": "THE IMPACT OF OXIDATIVE STRESS ON ERYTHOCYTE BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL148151_7529"}, {"internal_id": 81071587, "Award ID": "R01HL148120", "Award Amount": 2331996.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-22", "CFDA Number": "93.837", "Description": "MOLECULAR BASIS OF THE HUMORAL IMMUNE RESPONSE IN HEPARIN-INDUCED THROMBOCYTOPENIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R01HL148120_7529"}, {"internal_id": 96201382, "Award ID": "R01HL148096", "Award Amount": 2618545.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-27", "CFDA Number": "93.837", "Description": "NOVEL FUNCTIONS OF THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL148096_7529"}, {"internal_id": 81395937, "Award ID": "R01HL148054", "Award Amount": 4052278.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-05", "CFDA Number": "93.837", "Description": "LINKING ENDOTYPES AND OUTCOMES IN PEDIATRIC ACUTE RESPIRATORY DISTRESS SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL148054_7529"}, {"internal_id": 98144084, "Award ID": "R01HL148014", "Award Amount": 2489267.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-09", "CFDA Number": "93.837", "Description": "THE NOVEL MECHANISMS OF THROMBOSIS FORMATION IN MYELOPROLIFERATIVE DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL148014_7529"}, {"internal_id": 96203674, "Award ID": "R01HL148012", "Award Amount": 2050115.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-19", "CFDA Number": "93.837", "Description": "THE ROLES OF MDIA2 IN HEMATOPOIETIC STEM AND PROGENITOR CELL ENGRAFTMENT AND MIGRATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_R01HL148012_7529"}, {"internal_id": 81395248, "Award ID": "R01HL147978", "Award Amount": 1573228.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-07", "CFDA Number": "93.837", "Description": "FUNCTIONS OF JARID2 IN NORMAL AND NEOPLASTIC HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL147978_7529"}, {"internal_id": 108463601, "Award ID": "R01HL147880", "Award Amount": 1615000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-05", "CFDA Number": "93.837", "Description": "THE THERAPEUTIC POTENTIAL OF COLD STORED PLATELETS IN REGULATING VASCULAR INSTABILITY IN TRAUMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL147880_7529"}, {"internal_id": 83115843, "Award ID": "R01HL147879", "Award Amount": 3358236.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-14", "CFDA Number": "93.837", "Description": "RH GENOTYPE MATCHED RED CELL TRANSFUSIONS FOR PATIENTS WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL147879_7529"}, {"internal_id": 82470234, "Award ID": "R01HL147855", "Award Amount": 1780793.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-30", "CFDA Number": "93.837", "Description": "CLOT-TARGETED ANTITHROMBOTICS FOR VENOUS THROMBOPROPHYLAXIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_R01HL147855_7529"}, {"internal_id": 96203389, "Award ID": "R01HL147852", "Award Amount": 954000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-19", "CFDA Number": "93.837", "Description": "SINGLE NON-INTEGRATING RNA VECTOR FOR GENE EDITING AND REPROGRAMMING OF FANCONI ANEMIA FIBROBLASTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL147852_7529"}, {"internal_id": 81072197, "Award ID": "R01HL147821", "Award Amount": 1989780.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-20", "CFDA Number": "93.837", "Description": "ALLOSTERIC EQUILIBRIA OF THROMBIN AND ITS PRECURSORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b7dfaba3-c263-11dd-cbe2-5abe1968badc-C", "generated_internal_id": "ASST_NON_R01HL147821_7529"}, {"internal_id": 82469758, "Award ID": "R01HL147584", "Award Amount": 2673220.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-26", "CFDA Number": "93.837", "Description": "THIRD-PARTY ?OFF THE SHELF? MATURE OR PRECURSOR CAR T CELLS TO PREVENT OR TREAT MALIGNANT RELAPSE AFTER ALLO HCT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b514fc3a-d769-87e9-75ea-7a6766afb5ee-C", "generated_internal_id": "ASST_NON_R01HL147584_7529"}, {"internal_id": 79434345, "Award ID": "R01HL147562", "Award Amount": 3350172.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-04", "CFDA Number": "93.837", "Description": "TARGETING MECHANISMS CONTRIBUTING TO VASCULAR DYSFUNCTION AND PAIN IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b710df3-c98e-f245-bbed-8bbbc32a803b-C", "generated_internal_id": "ASST_NON_R01HL147562_7529"}, {"internal_id": 79433254, "Award ID": "R01HL147536", "Award Amount": 2541976.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-25", "CFDA Number": "93.837", "Description": "SMALL MOLECULES TARGETING RHOA FOR PLATELET COLD STORAGE IN CANCER CARE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL147536_7529"}, {"internal_id": 83795835, "Award ID": "R01HL147525", "Award Amount": 2031298.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-27", "CFDA Number": "93.837", "Description": "IDENTIFICATION OF A DAMAGING SUBSET OF NEUTROPHILS THAT ARISES IN SEPTIC PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "RI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f21f887-ca03-f1f2-6e30-1c1498f78b9e-C", "generated_internal_id": "ASST_NON_R01HL147525_7529"}, {"internal_id": 93243023, "Award ID": "R01HL147324", "Award Amount": 3303923.02, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-18", "CFDA Number": "93.837", "Description": "NONGENOTOXIC CONDITIONING FOR GENE THERAPY AND ALLOGENEIC TRANSPLANTATION IN FANCONI ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_R01HL147324_7529"}, {"internal_id": 80729302, "Award ID": "R01HL147149", "Award Amount": 694291.77, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-09", "CFDA Number": "93.837", "Description": "MECHANISM OF VENOUS THROMBOSIS IN PANCREATIC CANCER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL147149_7529"}, {"internal_id": 82469914, "Award ID": "R01HL147147", "Award Amount": 2951552.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-18", "CFDA Number": "93.837", "Description": "DIRECT DETECTION AND CHARACTERIZATION OF THROMBOSIS IN VIVO", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2f11d9-030b-5288-d89f-1f6fd7f111f3-C", "generated_internal_id": "ASST_NON_R01HL147147_7529"}, {"internal_id": 68566663, "Award ID": "R01HL147124", "Award Amount": 1629465.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-06", "CFDA Number": "93.837", "Description": "MODULATING HSC-NICHE INTERACTIONS TO UNDERSTAND AGING AND IMPROVE TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL147124_7529"}, {"internal_id": 78598790, "Award ID": "R01HL147081", "Award Amount": 955526.42, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-01", "CFDA Number": "93.837", "Description": "REGULATION OF TISSUE RESIDENT MACROPHAGE DEVELOPMENT BY IL-7R SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_R01HL147081_7529"}, {"internal_id": 93242561, "Award ID": "R01HL147028", "Award Amount": 1195300.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-09", "CFDA Number": "93.837", "Description": "DEVELOPING NEXT GENERATION SYNTHETIC NUCLEIC ACID ANALOGOUS FOR SICKLE CELL DISEASE GENE EDITING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f7d4a874-2ab3-85f8-4c06-002c8728886d-C", "generated_internal_id": "ASST_NON_R01HL147028_7529"}, {"internal_id": 76737930, "Award ID": "R01HL146832", "Award Amount": 1492750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-21", "CFDA Number": "93.837", "Description": "MECHANISMS OF NEURODEGENERATION BY A FIBRINOGEN-CONTAINING PROTEIN COMPLEX DURING TRAUMATIC BRAIN INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ceec5ef7-d6a5-28f0-e23f-ec61155b7078-C", "generated_internal_id": "ASST_NON_R01HL146832_7529"}, {"internal_id": 94714508, "Award ID": "R01HL146722", "Award Amount": 110066.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-30", "CFDA Number": "93.837", "Description": "NOVEL ROLES FOR PHOSPHOINOSITIDE SIGNALING IN ALPHA-GRANULE BIOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL146722_7529"}, {"internal_id": 83103345, "Award ID": "R01HL146701", "Award Amount": 2022121.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-12", "CFDA Number": "93.837", "Description": "TARGETED TREATMENT OF THROMBOTIC OCCLUSIONS USING A DUAL-DELIVERY MICROGEL THERAPEUTIC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4b0ff0c-e3a2-f597-7ab0-1c78e1010874-C", "generated_internal_id": "ASST_NON_R01HL146701_7529"}, {"internal_id": 86318802, "Award ID": "R01HL146668", "Award Amount": 2913713.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-23", "CFDA Number": "93.837", "Description": "IMAGING AND BLOOD BIOMARKERS TO PREDICT GRAFT FAILURE AFTER HSCT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL146668_7529"}, {"internal_id": 80401074, "Award ID": "R01HL146664", "Award Amount": 1660993.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-26", "CFDA Number": "93.837", "Description": "TET2-MEDIATED TRANSCRIPTIONAL AND EPIGENETIC CONTROL OF NORMAL AND MALIGNANT HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c0534dd6-007b-cfc7-2a77-9b3602a48251-C", "generated_internal_id": "ASST_NON_R01HL146664_7529"}, {"internal_id": 79434102, "Award ID": "R01HL146642", "Award Amount": 2535803.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-22", "CFDA Number": "93.837", "Description": "MECHANISM AND FUNCTION OF ENDOPLASMIC RETICULUM PROTEIN QUALITY CONTROL MACHINERY IN THE MAINTENANCE OF HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL146642_7529"}, {"internal_id": 80725598, "Award ID": "R01HL146632", "Award Amount": 1101946.28, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-08", "CFDA Number": "93.837", "Description": "BONE MARROW NICHE DYSFUNCTION IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e71a3a2e-7355-cc73-4dd7-2c5fef917d86-C", "generated_internal_id": "ASST_NON_R01HL146632_7529"}, {"internal_id": 94713846, "Award ID": "R01HL146559", "Award Amount": 1736284.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-27", "CFDA Number": "93.837", "Description": "ERO1 ALPHA IN PLATELET ACTIVITY AND THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL146559_7529"}, {"internal_id": 79638736, "Award ID": "R01HL146552", "Award Amount": 907250.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-08", "CFDA Number": "93.837", "Description": "TRACKING CLONAL DYNAMICS DURING HEMATOPOIESIS: MECHANISTIC INSIGHT VIA MODELING AND DATA ANALYSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R01HL146552_7529"}, {"internal_id": 78991224, "Award ID": "R01HL146549", "Award Amount": 2467595.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-18", "CFDA Number": "93.837", "Description": "PATHWAY MAPS OF PLATELET PHENOTYPE AND FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R01HL146549_7529"}, {"internal_id": 97468622, "Award ID": "R01HL146544", "Award Amount": 584878.36, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-04", "CFDA Number": "93.837", "Description": "ROLE OF NEWLY DISCOVERED SLFN14 IN MEGAKARYOPOIESIS AND PLATELET DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "753b4a63-1dfe-a327-a837-d9cf4908b025-C", "generated_internal_id": "ASST_NON_R01HL146544_7529"}, {"internal_id": 78599099, "Award ID": "R01HL146540", "Award Amount": 1907178.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-27", "CFDA Number": "93.837", "Description": "MECHANISMS THAT REGULATE SELF-RENEWAL AND PROLIFERATION IN HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL146540_7529"}, {"internal_id": 82036217, "Award ID": "R01HL146530", "Award Amount": 2418992.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-03", "CFDA Number": "93.837", "Description": "MOLECULAR BASIS OF HYPOXIA-INDUCED EXCESSIVE ERYTHROCYTOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL146530_7529"}, {"internal_id": 94714365, "Award ID": "R01HL146528", "Award Amount": 913661.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-29", "CFDA Number": "93.837", "Description": "METABOLIC CONTROL OF ERYTHROID DIFFERENTIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f12508df-b414-7a41-54a0-3351d8ed6cb0-C", "generated_internal_id": "ASST_NON_R01HL146528_7529"}, {"internal_id": 98143111, "Award ID": "R01HL146508", "Award Amount": 1851997.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-10", "CFDA Number": "93.837", "Description": "STRUCTURE-RESOLVED MECHANISTIC PHENOTYPING OF VON WILLEBRAND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL146508_7529"}, {"internal_id": 94714429, "Award ID": "R01HL146500", "Award Amount": 3397630.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-28", "CFDA Number": "93.837", "Description": "NEXT GENERATION FUNCTIONAL GENOMICS OF HEMATOLOGY TRAITS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": 400263.0, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL146500_7529"}, {"internal_id": 93912015, "Award ID": "R01HL146478", "Award Amount": 1545110.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-27", "CFDA Number": "93.837", "Description": "A CHROMATIN-BASED TIMER CONTROLLING T-CELL DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL146478_7529"}, {"internal_id": 82470692, "Award ID": "R01HL146442", "Award Amount": 3122910.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-24", "CFDA Number": "93.837", "Description": "PIMT1 IN RED BLOOD CELL AGING IN VIVO AND IN VITRO", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL146442_7529"}, {"internal_id": 97468332, "Award ID": "R01HL146392", "Award Amount": 1387775.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-06", "CFDA Number": "93.837", "Description": "UNDERSTANDING OF A NEUROPHENOTYPE IN HEMOPHILIA A", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R01HL146392_7529"}, {"internal_id": 81728438, "Award ID": "R01HL146377", "Award Amount": 1889613.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-24", "CFDA Number": "93.837", "Description": "MALARIA VARIANT SURFACE ANTIGEN EXPRESSION AND VULNERABILITY TO DISEASE IN MALIAN CHILDREN WITH HEMOGLOBIN C TRAIT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R01HL146377_7529"}, {"internal_id": 78598598, "Award ID": "R01HL146354", "Award Amount": 1755000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-01", "CFDA Number": "93.837", "Description": "ROADMAP 2.0: A RANDOMIZED CONTROLLED TRIAL USING A TECHNOLOGY-MEDIATED PLATFORM IN FAMILY CAREGIVERS OF BMT PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL146354_7529"}, {"internal_id": 68171797, "Award ID": "R01HL146338", "Award Amount": 2546266.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-25", "CFDA Number": "93.837", "Description": "ALLOREACTIVE AND AUTOREACTIVE IMMUNE-MEDIATED MECHANISMS OF IMPAIRED EPITHELIAL REGENERATION IN THE GI TRACT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b514fc3a-d769-87e9-75ea-7a6766afb5ee-C", "generated_internal_id": "ASST_NON_R01HL146338_7529"}, {"internal_id": 76737918, "Award ID": "R01HL146226", "Award Amount": 1178364.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-26", "CFDA Number": "93.837", "Description": "FIBRINOLYSIS EVALUATION IN A-TREAT (?FEAT? STUDY)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL146226_7529"}, {"internal_id": 76908570, "Award ID": "R01HL146137", "Award Amount": 2153914.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-11", "CFDA Number": "93.837", "Description": "TARGETING NOVEL PATHWAYS IN JMML", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL146137_7529"}, {"internal_id": 76738339, "Award ID": "R01HL145883", "Award Amount": 2233444.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-03", "CFDA Number": "93.837", "Description": "ROLES OF TET2-DEPENDENT DNA DEMETHYLATION INTERMEDIATES IN HEMATOLOGICAL MALIGNANCIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c0534dd6-007b-cfc7-2a77-9b3602a48251-C", "generated_internal_id": "ASST_NON_R01HL145883_7529"}, {"internal_id": 67314441, "Award ID": "R01HL145780", "Award Amount": 1923835.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-16", "CFDA Number": "93.837", "Description": "HMGA CHROMATIN REMODELING PROTEINS IN TUMOR PROGRESSION IN MYELOPROLIFERATIVE NEOPLASMS (MPN)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL145780_7529"}, {"internal_id": 76738291, "Award ID": "R01HL145754", "Award Amount": 2262950.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-04", "CFDA Number": "93.837", "Description": "CRITICAL ROLE OF TCF-1 ON THE EPIGENETIC IDENTITY OF MEMORY T CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL145754_7529"}, {"internal_id": 76908688, "Award ID": "R01HL145714", "Award Amount": 1765000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-07", "CFDA Number": "93.837", "Description": "DEFINING LNCRNA FUNCTION IN NORMAL AND SHWACHMAN DIAMOND SYNDROME MYELOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "be067fa7-a493-7bea-f9cc-e29bd2ccc74a-C", "generated_internal_id": "ASST_NON_R01HL145714_7529"}, {"internal_id": 82054722, "Award ID": "R01HL145451", "Award Amount": 1331331.72, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-11", "CFDA Number": "93.837", "Description": "PATROLLING MONOCYTES IN SICKLE PAIN CRISIS AND FOLLOWING TRANSFUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "644797d6-c94c-9e2c-b40a-a4cda190c447-C", "generated_internal_id": "ASST_NON_R01HL145451_7529"}, {"internal_id": 81071870, "Award ID": "R01HL145290", "Award Amount": 2053230.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-31", "CFDA Number": "93.837", "Description": "MESODERMAL COMMITMENT OF THE DEFINITIVE HEMATOPOIETIC PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL145290_7529"}, {"internal_id": 77189327, "Award ID": "R01HL145283", "Award Amount": 2031129.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-01", "CFDA Number": "93.837", "Description": "THE ROLE OF DNA METHYLATION MODIFIERS IN SHAPING THE HEMATOPOIETIC DIFFERENTIATION TOPOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL145283_7529"}, {"internal_id": 76472503, "Award ID": "R01HL145276", "Award Amount": 2844525.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-18", "CFDA Number": "93.837", "Description": "HARNESSING ENDOGENOUS MECHANISMS OF THYMIC REGENERATION TOBOOST IMMUNE FUNCTION IN RECIPIENTS OF HEMATOPOIETIC CELL TRANSPLANT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "569197a4-81d0-b264-5640-e9db4cf71fd0-C", "generated_internal_id": "ASST_NON_R01HL145276_7529"}, {"internal_id": 83115654, "Award ID": "R01HL145154", "Award Amount": 1899858.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-15", "CFDA Number": "93.837", "Description": "ROLES AND THERAPEUTIC POTENTIAL OF CD150HIGH NICHE-ASSOCIATED REGULATORY T CELLS IN BONE MARROW INJURY AND ENGRAFTMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_R01HL145154_7529"}, {"internal_id": 81071938, "Award ID": "R01HL145053", "Award Amount": 2139846.62, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-03", "CFDA Number": "93.837", "Description": "INVESTIGATE THE IMPACT OF THIRD-HAND SMOKE ON PLATELET FUNCTION AND THROMBOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c1c743b-7fc2-7937-67a3-54194e22c2fc-C", "generated_internal_id": "ASST_NON_R01HL145053_7529"}, {"internal_id": 96203051, "Award ID": "R01HL145031", "Award Amount": 1528140.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-19", "CFDA Number": "93.837", "Description": "DEEP SUPERCOOLING OF RED BLOOD CELLS: TOWARDS PRACTICAL LONG TERM STORAGE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL145031_7529"}, {"internal_id": 76909142, "Award ID": "R01HL144970", "Award Amount": 946474.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-07", "CFDA Number": "93.837", "Description": "SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF HOMOGENOUS ULTRA-LOW MOLECULAR WEIGHT HEPARINS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL144970_7529"}, {"internal_id": 77188972, "Award ID": "R01HL144957", "Award Amount": 1906250.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-01", "CFDA Number": "93.837", "Description": "MITOCHONDRIAL FUSION PROTEIN MFN2 PREVENTS PLATELET DEATH AND DYSFUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_R01HL144957_7529"}, {"internal_id": 76738203, "Award ID": "R01HL144780", "Award Amount": 2145244.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-05", "CFDA Number": "93.837", "Description": "TRANSCRIPTIONAL RESPONSE TO SIGNALING DURING HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL144780_7529"}, {"internal_id": 76738205, "Award ID": "R01HL144752", "Award Amount": 929668.17, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-03", "CFDA Number": "93.837", "Description": "ENHANCING BONE MARROW TRANSPLANTATION WITH HIGHLY ENGRAFTABLE HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL144752_7529"}, {"internal_id": 76909372, "Award ID": "R01HL144712", "Award Amount": 1565823.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-07", "CFDA Number": "93.837", "Description": "EPIGENETIC REGULATION OF HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "47ed9961-3300-5ed7-bb62-e5359d99eaf9-C", "generated_internal_id": "ASST_NON_R01HL144712_7529"}, {"internal_id": 78599184, "Award ID": "R01HL144661", "Award Amount": 2229255.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-15", "CFDA Number": "93.837", "Description": "OPTIMIZATION OF AAV VECTOR TO DELIVER FVA FOR HEMOPHILIA WITH INHIBITORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL144661_7529"}, {"internal_id": 76738669, "Award ID": "R01HL144653", "Award Amount": 2243750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-26", "CFDA Number": "93.837", "Description": "CELLULAR AND FUNCTIONAL IMPACT OF SAMD9L MUTATIONS ON HEMATOPOIESIS AND MYELODYSPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bccd984e-68ff-4e70-2020-f0129e4b9ecc-C", "generated_internal_id": "ASST_NON_R01HL144653_7529"}, {"internal_id": 100875003, "Award ID": "R01HL144641", "Award Amount": 928317.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-07", "CFDA Number": "93.837", "Description": "MICRORNA-BASED EPIGENETIC APPROACH TO INDUCE FETAL HEMOGLOBIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7bb49047-7166-d4e3-8873-4218d87cf06c-C", "generated_internal_id": "ASST_NON_R01HL144641_7529"}, {"internal_id": 82469368, "Award ID": "R01HL144620", "Award Amount": 3132701.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-01", "CFDA Number": "93.837", "Description": "RED BLOOD CELL RELEASED ATP IN DISTURBED BLOOD FLOW-INITIATED SITE SPECIFIC VASCULAR INFLAMMATION AND ATHEROSCLEROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "47ed9961-3300-5ed7-bb62-e5359d99eaf9-C", "generated_internal_id": "ASST_NON_R01HL144620_7529"}, {"internal_id": 83116121, "Award ID": "R01HL144574", "Award Amount": 1560000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-07", "CFDA Number": "93.837", "Description": "MECHANISM FOR FEEDBACK REGULATION OF G PROTEIN-COUPLED RECEPTOR SIGNALING IN PLATELETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_R01HL144574_7529"}, {"internal_id": 77189015, "Award ID": "R01HL144556", "Award Amount": 2441145.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-16", "CFDA Number": "93.837", "Description": "THE ROLE OF AMP-ACTIVATED PROTEIN KINASE IN GVHD-CAUSING T CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL144556_7529"}, {"internal_id": 79433667, "Award ID": "R01HL144552", "Award Amount": 1817366.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-26", "CFDA Number": "93.837", "Description": "NOVEL THERAPEUTICS FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KS", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1a1108fb-0099-a708-6def-aa6d101c8ba8-C", "generated_internal_id": "ASST_NON_R01HL144552_7529"}, {"internal_id": 94714038, "Award ID": "R01HL144550", "Award Amount": 2180596.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-24", "CFDA Number": "93.837", "Description": "THE MONOCYTE/MACROPHAGE ROLE IN EXPERIMENTAL DEEP VEIN THROMBOSIS RESOLUTION AND VEIN WALL INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL144550_7529"}, {"internal_id": 83103868, "Award ID": "R01HL144528", "Award Amount": 2164800.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-05", "CFDA Number": "93.837", "Description": "GLYCOCALYX REPAIR IN SEPSIS USING LIPOSOMAL CARRIERS OF PREASSEMBLED GLYCOCALYX", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f00078f8-f585-79c7-3349-6773e6685d91-C", "generated_internal_id": "ASST_NON_R01HL144528_7529"}, {"internal_id": 82470251, "Award ID": "R01HL144501", "Award Amount": 3023305.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-18", "CFDA Number": "93.837", "Description": "THE IMPACT OF ILLNESS AND MEDICAL TREATMENTS ON THE ALLOANTIBODY RESPONSE TO PLATELET TRANSFUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aac0d53c-fc30-bb05-192d-4bb66ca0eae1-C", "generated_internal_id": "ASST_NON_R01HL144501_7529"}, {"internal_id": 76909064, "Award ID": "R01HL144436", "Award Amount": 2511224.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-07", "CFDA Number": "93.837", "Description": "MOLECULAR TARGETING OF ERYTHROID PROGENITOR CELLS IN NORMAL AND DISORDERED HUMAN ERYTHROPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f9f0ca2a-aa8d-05a3-861f-1f3e215d88e8-C", "generated_internal_id": "ASST_NON_R01HL144436_7529"}, {"internal_id": 83115530, "Award ID": "R01HL144428", "Award Amount": 2202344.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-12", "CFDA Number": "93.837", "Description": "IMMUNOBIOLOGY OF ALLOIMMUNIZATION BY PLATELET TRANSFUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL144428_7529"}, {"internal_id": 67314181, "Award ID": "R01HL144113", "Award Amount": 4578281.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-18", "CFDA Number": "93.837", "Description": "CONTACT PATHWAY ACTIVATION ON VASCULAR DEVICES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R01HL144113_7529"}, {"internal_id": 78599848, "Award ID": "R01HL144002", "Award Amount": 2301774.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-27", "CFDA Number": "93.837", "Description": "HARNESSING PLATELET-ENDOTHELIAL INTERACTIONS FOR STEM CELL DELIVERY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "527dc5e1-a727-1176-3f89-8c897c34dd95-C", "generated_internal_id": "ASST_NON_R01HL144002_7529"}, {"internal_id": 66995429, "Award ID": "R01HL143806", "Award Amount": 2848073.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-03", "CFDA Number": "93.837", "Description": "VASCULAR DELIVERY OF NANOCARRIERS BY ERYTHROCYRES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL143806_7529"}, {"internal_id": 67580297, "Award ID": "R01HL143794", "Award Amount": 2668943.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-01", "CFDA Number": "93.837", "Description": "CONFORMATIONAL ACTIVATION OF VON WILLEBRAND FACTOR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL143794_7529"}, {"internal_id": 82469912, "Award ID": "R01HL143424", "Award Amount": 2039264.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-29", "CFDA Number": "93.837", "Description": "EFFECTOR T-CELL TRAFFICKING IN GRAFT-VERSUS-HOST DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL143424_7529"}, {"internal_id": 67833471, "Award ID": "R01HL143349", "Award Amount": 2507483.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-06", "CFDA Number": "93.837", "Description": "GRAFT-VERSUS-HOST DISEASE: LOCAL MAINTENANCE IN TARGET TISSUES BY TISSUE RESIDENT MEMORY-TYPE CELLS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL143349_7529"}, {"internal_id": 79433401, "Award ID": "R01HL143297", "Award Amount": 3164628.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-22", "CFDA Number": "93.837", "Description": "MOLECULAR UNDERSTANDING OF MEMBRANE SENSORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL143297_7529"}, {"internal_id": 68170115, "Award ID": "R01HL143020", "Award Amount": 2610230.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-27", "CFDA Number": "93.837", "Description": "NANOCHELATION THERAPIES FOR IRON OVERLOAD DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f7fcd53-a62a-0ccf-e3e6-c6b54ddb6fd2-C", "generated_internal_id": "ASST_NON_R01HL143020_7529"}, {"internal_id": 66994874, "Award ID": "R01HL142998", "Award Amount": 2285351.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-20", "CFDA Number": "93.837", "Description": "IMPROVING THE INTERACTION OF HEMATOPOIETIC STEM CELLS WITH THE PERIVASCULAR NICHE TO PROMOTE ENGRAFTMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL142998_7529"}, {"internal_id": 80724905, "Award ID": "R01HL142997", "Award Amount": 1848315.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-14", "CFDA Number": "93.837", "Description": "EPIGENETIC MODULATION IN SEPTIC IMMUNOSUPPRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL142997_7529"}, {"internal_id": 67833246, "Award ID": "R01HL142976", "Award Amount": 3158483.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-16", "CFDA Number": "93.837", "Description": "MEKK3 SIGNALING IN HEMOGENIC ENDOTHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL142976_7529"}, {"internal_id": 66198962, "Award ID": "R01HL142975", "Award Amount": 5525072.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-20", "CFDA Number": "93.837", "Description": "REGULATION OF PROTEIN C PATHWAYS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL142975_7529"}, {"internal_id": 81395479, "Award ID": "R01HL142959", "Award Amount": 2092404.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-05", "CFDA Number": "93.837", "Description": "REGULATION OF PLATELET REACTIVITY BY S1P SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_R01HL142959_7529"}, {"internal_id": 66487024, "Award ID": "R01HL142804", "Award Amount": 1906250.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-31", "CFDA Number": "93.866", "Description": "TRANSLATIONAL CONTROL OF MEGAKARYOCYTE AND PLATELET FUNCTION IN SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_R01HL142804_7529"}, {"internal_id": 67833552, "Award ID": "R01HL142799", "Award Amount": 1943750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-08", "CFDA Number": "93.837", "Description": "INHIBITION OF PAR2 AS THERAPEUTIC APPROACH TO ENHANCE ANTI-VIRAL IMMUNE RESPONSES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL142799_7529"}, {"internal_id": 79638967, "Award ID": "R01HL142791", "Award Amount": 8150793.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-05", "CFDA Number": "93.837", "Description": "A PHASE I CLINICAL TRIAL TESTING FEASIBILITY OF HEMATOPOIETIC STEM CELL GENE THERAPY USING PLATELET FACTOR VIII TO SAFELY IMPROVE HEMOSTASIS FOR SEVERE HEMOPHILIA A WITH INHIBITORY ANTIBODIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL142791_7529"}, {"internal_id": 67314519, "Award ID": "R01HL142782", "Award Amount": 1995240.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-15", "CFDA Number": "93.837", "Description": "REGULATION OF HEMATOPOIESIS BY CUX1", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_R01HL142782_7529"}, {"internal_id": 67314655, "Award ID": "R01HL142772", "Award Amount": 2645096.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-13", "CFDA Number": "93.837", "Description": "PLATELETS IN CANCER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL142772_7529"}, {"internal_id": 67579614, "Award ID": "R01HL142671", "Award Amount": 4079399.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-28", "CFDA Number": "93.837", "Description": "IMPROVE 2: INHALED MOMETASONE TO PROMOTE REDUCTION IN VASO-OCCLUSIVE EVENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL142671_7529"}, {"internal_id": 68168247, "Award ID": "R01HL142665", "Award Amount": 1980548.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-28", "CFDA Number": "93.837", "Description": "MOLECULAR DETERMINANTS OF HEMOGENIC ENDOTHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL142665_7529"}, {"internal_id": 68171131, "Award ID": "R01HL142657", "Award Amount": 3697965.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-23", "CFDA Number": "93.837", "Description": "INVESTIGATING THE ROLE OF THE MICROBIOME AND INFLAMMATION IN ACUTE AND CHRONIC PAIN IN PATIENTS WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL142657_7529"}, {"internal_id": 67580301, "Award ID": "R01HL142647", "Award Amount": 1892506.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-31", "CFDA Number": "93.837", "Description": "ROLE OF MYELOID KLF2 IN ANTIPHOSPHOLIPID ANTIBODY-MEDIATED THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R01HL142647_7529"}, {"internal_id": 80725268, "Award ID": "R01HL142640", "Award Amount": 1733371.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-09", "CFDA Number": "93.837", "Description": "INFLAMMASOME ACTIVATION TRIGGERS SYSTEMIC COAGULATION IN SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c1c743b-7fc2-7937-67a3-54194e22c2fc-C", "generated_internal_id": "ASST_NON_R01HL142640_7529"}, {"internal_id": 68169531, "Award ID": "R01HL142637", "Award Amount": 1589030.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-31", "CFDA Number": "93.837", "Description": "EPIGENETIC, TRANSCRIPTIONAL, AND MICROENVIRONMENTAL DETERMINANTS OF HUMAN HSC SELF-RENEWAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL142637_7529"}, {"internal_id": 67832832, "Award ID": "R01HL142604", "Award Amount": 1555000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-12", "CFDA Number": "93.837", "Description": "MECHANISMS OF COAGULATION-DEPENDENT PATHOLOGIES IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL142604_7529"}, {"internal_id": 80400887, "Award ID": "R01HL142587", "Award Amount": 1565000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-19", "CFDA Number": "93.837", "Description": "POLYMICROBIAL INTERACTIONS IN THE RESPIRATORY TRACT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7eb6683a-d796-f7f5-68c0-ca8f32275b30-C", "generated_internal_id": "ASST_NON_R01HL142587_7529"}, {"internal_id": 67832757, "Award ID": "R01HL142272", "Award Amount": 3155347.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-16", "CFDA Number": "93.837", "Description": "INTEGRATED COAGULATION SENSING TO PREDICT HEMORRHAGE AND GUIDE TRANSFUSIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL142272_7529"}, {"internal_id": 67832462, "Award ID": "R01HL142213", "Award Amount": 2005736.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-08", "CFDA Number": "93.837", "Description": "SYNDECAN REGULATION OF SEPSIS HOST DEFENSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL142213_7529"}, {"internal_id": 76738523, "Award ID": "R01HL142152", "Award Amount": 2541180.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-21", "CFDA Number": "93.837", "Description": "ERK5 AND CD36 LINK OXIDATIVE STRESS TO PLATELET DYSFUNCTION AND ISCHEMIC INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL142152_7529"}, {"internal_id": 65280682, "Award ID": "R01HL142122", "Award Amount": 2287007.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-30", "CFDA Number": "93.837", "Description": "STRUCTURE-BASED DESIGN OF RATIONAL PF4 INHIBITORS IN HIT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL142122_7529"}, {"internal_id": 67579188, "Award ID": "R01HL141967", "Award Amount": 2286591.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-03", "CFDA Number": "93.837", "Description": "FORWARD VIEWING CATHETER-DELIVERED MICROBUBBLE ENHANCED SONOTHROMBOLYSIS (FV-CAMUS)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4b0ff0c-e3a2-f597-7ab0-1c78e1010874-C", "generated_internal_id": "ASST_NON_R01HL141967_7529"}, {"internal_id": 76472482, "Award ID": "R01HL141966", "Award Amount": 1600000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-14", "CFDA Number": "93.837", "Description": "ROLE OF E3 UBIQUITIN LIGASE RNF133 IN T CELL FUNCTION AND TOLERANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "07c08a07-af34-2853-20eb-9d2594ed7b35-C", "generated_internal_id": "ASST_NON_R01HL141966_7529"}, {"internal_id": 76738142, "Award ID": "R01HL141950", "Award Amount": 2180504.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-28", "CFDA Number": "93.837", "Description": "ROLE OF LINCRNAS IN HSC FUNCTION AND LEUKEMOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c0534dd6-007b-cfc7-2a77-9b3602a48251-C", "generated_internal_id": "ASST_NON_R01HL141950_7529"}, {"internal_id": 65579296, "Award ID": "R01HL141944", "Award Amount": 947990.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-18", "CFDA Number": "93.837", "Description": "INTEGRATIVE COMPUTATIONAL BIOLOGY APPROACHES TO IDENTIFY FUNCTIONAL DETERMINANTS OF PLATELET AGGREGATION IN AFRICAN AMERICANS AND EUROPEAN AMERICANS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL141944_7529"}, {"internal_id": 65578908, "Award ID": "R01HL141943", "Award Amount": 1975000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-12", "CFDA Number": "93.837", "Description": "ISLET CELL AND ST2 AXIS DYSREGULATION IN POST-TRANSPLANT DIABETES MELLITUS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL141943_7529"}, {"internal_id": 66199224, "Award ID": "R01HL141934", "Award Amount": 2658480.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-11", "CFDA Number": "93.837", "Description": "OVERCOMING ANTI-PEG IMMUNITY TO RESTORE PROLONGED CIRCULATION AND EFFICACY OF PEGYLATED THERAPEUTICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL141934_7529"}, {"internal_id": 65894919, "Award ID": "R01HL141900", "Award Amount": 1516500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-27", "CFDA Number": "93.837", "Description": "PET FIBRIN IMAGING OF DVT AND PE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL141900_7529"}, {"internal_id": 68568234, "Award ID": "R01HL141880", "Award Amount": 2437500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-07", "CFDA Number": "93.837", "Description": "MECHANISMS OF HEMATOPOIETIC ACUTE RADIATION SYNDROME INDUCTION AND RADIOPROTECTION THROUGH SPHINGOSINE 1-PHOSPHATE RECEPTOR 1 SIGNAL MODULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e83c70bf-5580-4458-00fc-fb4f3d77119d-C", "generated_internal_id": "ASST_NON_R01HL141880_7529"}, {"internal_id": 66199259, "Award ID": "R01HL141850", "Award Amount": 1559583.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-18", "CFDA Number": "93.837", "Description": "MOLECULAR AND STRUCTURAL RECOGNITION IN FACTOR VIIA INDUCED COAGULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R01HL141850_7529"}, {"internal_id": 80401042, "Award ID": "R01HL141805", "Award Amount": 1902396.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-17", "CFDA Number": "93.837", "Description": "A GENETICALLY ENGINEERED HUMAN FETAL LIVER NICHE AS A NOVEL PLATFORM FOR BIOMANUFACTURING OF HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL141805_7529"}, {"internal_id": 65894622, "Award ID": "R01HL141781", "Award Amount": 2340859.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-03", "CFDA Number": "93.837", "Description": "APPROACH FOR IN VIVO GENE DELIVERY INTO HEMATOPOIETIC STEM CELLS FOR HEMOPHILIA A THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL141781_7529"}, {"internal_id": 80734839, "Award ID": "R01HL141774", "Award Amount": 3708380.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-16", "CFDA Number": "93.837", "Description": "UNDERSTANDING AND ADDRESSING THE SOCIAL DETERMINANTS OF HEALTH FOR FAMILIES OF CHILDREN WITH SICKLE CELL ANEMIA WITHIN PEDIATRIC HEMATOLOGY DIVERSITY SUPPLEMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "54768301-b245-c1c5-66ec-e0c90b049cc4-C", "generated_internal_id": "ASST_NON_R01HL141774_7529"}, {"internal_id": 68170814, "Award ID": "R01HL141759", "Award Amount": 2161341.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-20", "CFDA Number": "93.837", "Description": "MAINTENANCE AND EXPANSION OF LONG-TERM HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL141759_7529"}, {"internal_id": 66995048, "Award ID": "R01HL141752", "Award Amount": 1987025.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-25", "CFDA Number": "93.837", "Description": "ACCELERATED LOW DOSE THROMBOLYTIC CATHETER DIRECTED SONOTHROMBOLYSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL141752_7529"}, {"internal_id": 67833791, "Award ID": "R01HL141513", "Award Amount": 2411905.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-08", "CFDA Number": "93.837", "Description": "ROLE REVERSAL OF MAVS IN BACTERIAL SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL141513_7529"}, {"internal_id": 65281187, "Award ID": "R01HL141491", "Award Amount": 2340505.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-29", "CFDA Number": "93.837", "Description": "CD138 REGULATES COMPETITION OF ANTIBODY SECRETING CELLS FOR SURVIVAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_R01HL141491_7529"}, {"internal_id": 77190846, "Award ID": "R01HL141432", "Award Amount": 2561953.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-18", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF FIRST-IN-CLASS ST2 INHIBITORS FOR TREATING GRAFT-VERSUS-HOST DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7bb49047-7166-d4e3-8873-4218d87cf06c-C", "generated_internal_id": "ASST_NON_R01HL141432_7529"}, {"internal_id": 64141729, "Award ID": "R01HL141424", "Award Amount": 2453041.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-13", "CFDA Number": "93.837", "Description": "IN VIVO STUDIES OF MEGAKARYOCYTE MICRORNAS REGULATING PLATELET NUMBER AND INTEGRIN ACTIVATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_R01HL141424_7529"}, {"internal_id": 64141403, "Award ID": "R01HL141418", "Award Amount": 1590000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-09", "CFDA Number": "93.837", "Description": "NORMAL AND PATHOLOGICAL HEMATOPOIETIC STEM CELLS IN OBESITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL141418_7529"}, {"internal_id": 66800073, "Award ID": "R01HL141408", "Award Amount": 3964092.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-14", "CFDA Number": "93.837", "Description": "MTOR AS A CENTRAL REGULATOR OF IMCD PATHOGENESIS AND NOVEL THERAPEUTIC TARGET", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL141408_7529"}, {"internal_id": 65579218, "Award ID": "R01HL141402", "Award Amount": 2573445.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-09", "CFDA Number": "93.837", "Description": "NOVEL GROWTH FACTOR REGULATORS OF EARLY ERYTHROPOIEISIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68a12c06-0ac5-9595-eda2-d8647ffda5d0-C", "generated_internal_id": "ASST_NON_R01HL141402_7529"}, {"internal_id": 62551058, "Award ID": "R01HL141399", "Award Amount": 1949167.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-28", "CFDA Number": "93.837", "Description": "THE MOLECULAR GENETICS OF VENOUS THROMBOEMBOLIC DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL141399_7529"}, {"internal_id": 69724612, "Award ID": "R01HL141379", "Award Amount": 2134132.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-19", "CFDA Number": "93.837", "Description": "INFLAMMATION AS DETERMINANT OF CLONAL SELECTION IN MPN PROGRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e71a3a2e-7355-cc73-4dd7-2c5fef917d86-C", "generated_internal_id": "ASST_NON_R01HL141379_7529"}, {"internal_id": 83797111, "Award ID": "R01HL141366", "Award Amount": 2168016.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-29", "CFDA Number": "93.837", "Description": "PLATELET ALPHAIIBBETA3 ACTIVATION AND ITS THERAPEUTIC TARGETING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL141366_7529"}, {"internal_id": 68566861, "Award ID": "R01HL141351", "Award Amount": 1944850.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-11", "CFDA Number": "93.837", "Description": "ALDH ACTIVATION TO TREAT FANCONI ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL141351_7529"}, {"internal_id": 62551407, "Award ID": "R01HL141336", "Award Amount": 2162500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-03", "CFDA Number": "93.837", "Description": "TARGETING PROTEIN ACETYLATION AS A THERAPEUTIC APPROACH FOR MDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e71a3a2e-7355-cc73-4dd7-2c5fef917d86-C", "generated_internal_id": "ASST_NON_R01HL141336_7529"}, {"internal_id": 66487422, "Award ID": "R01HL141335", "Award Amount": 2273200.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-30", "CFDA Number": "93.837", "Description": "DEFINING INITIATING FACTORS RESPONSIBLE FOR THE DEVELOPMENT OF FVIII INHIBITORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL141335_7529"}, {"internal_id": 77189996, "Award ID": "R01HL141326", "Award Amount": 2595717.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-30", "CFDA Number": "93.837", "Description": "ROLE OF AN INTEGRATOR-EGR AXIS IN THE REGULATION OF MYELOID ENHANCERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ad990d53-dba6-60b8-30bf-48cdeeb15c1c-C", "generated_internal_id": "ASST_NON_R01HL141326_7529"}, {"internal_id": 77190690, "Award ID": "R01HL141291", "Award Amount": 3152180.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-28", "CFDA Number": "93.837", "Description": "USING GENOMICS AND FUNCTIONAL BIOLOGY TO UNDERSTAND FIBRINOGEN AND ITS EFFECT ON THROMBOTIC AND ATHEROSCLEROTIC OUTCOMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9adce466-3b6d-ecdb-7412-8082d6529b1f-C", "generated_internal_id": "ASST_NON_R01HL141291_7529"}, {"internal_id": 80750635, "Award ID": "R01HL141290", "Award Amount": 2626345.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-08", "CFDA Number": "93.837", "Description": "THROMBOSIS AND BLEEDING RISK ASSESSMENT IN MEDICAL INPATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb0c0b67-cf3f-8e71-00cf-883ce0aa9a3c-C", "generated_internal_id": "ASST_NON_R01HL141290_7529"}, {"internal_id": 68169488, "Award ID": "R01HL141112", "Award Amount": 1987500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-30", "CFDA Number": "93.837", "Description": "STUDIES OF MRNA TRANSLATIONAL REGULATIONS IN ERYTHROPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL141112_7529"}, {"internal_id": 67314054, "Award ID": "R01HL141106", "Award Amount": 2221962.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-17", "CFDA Number": "93.866", "Description": "NOVEL MECHANISMS OF PLATELET MODIFIED MONOCYTE PHENOTYPE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL141106_7529"}, {"internal_id": 68566390, "Award ID": "R01HL141094", "Award Amount": 2960871.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-14", "CFDA Number": "93.837", "Description": "CRITICAL ROLE OF BASOPHILS IN THE ENHANCEMENT OF THE INNATE IMMUNE RESPONSE DURING SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_R01HL141094_7529"}, {"internal_id": 80401485, "Award ID": "R01HL141080", "Award Amount": 3102370.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-19", "CFDA Number": "93.837", "Description": "MECHANISMS OF PLATELET EXOSOME-MEDIATED ACUTE CHEST SYNDROME IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL141080_7529"}, {"internal_id": 69723960, "Award ID": "R01HL140971", "Award Amount": 2748934.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-20", "CFDA Number": "93.837", "Description": "SPINGOLIPIDS IN HIV-ASSOCIATED CHRONIC OBSTRUCTIVE PULMONARY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL140971_7529"}, {"internal_id": 79433560, "Award ID": "R01HL140961", "Award Amount": 2329868.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-22", "CFDA Number": "93.837", "Description": "HYPERGLYCEMIA MEDIATED MYELOPROLIFERATIVE DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL140961_7529"}, {"internal_id": 67315196, "Award ID": "R01HL140953", "Award Amount": 2367254.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-17", "CFDA Number": "93.837", "Description": "TARGETING IRE-1A/XBP-1 AXIS FOR CONTROL OF CHRONIC GVHD AND LEUKEMIA RELAPSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL140953_7529"}, {"internal_id": 49759423, "Award ID": "R01HL140921", "Award Amount": 1908378.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-16", "CFDA Number": "93.837", "Description": "IMMUNOREGULATORY AND EFFECTOR ROLES OF NATURAL KILLER CELL SUBSETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2f11d9-030b-5288-d89f-1f6fd7f111f3-C", "generated_internal_id": "ASST_NON_R01HL140921_7529"}, {"internal_id": 49759421, "Award ID": "R01HL140837", "Award Amount": 1524791.11, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-09", "CFDA Number": "93.837", "Description": "SELECTIVE DELETION OF NEUTROPHIL NADPH OXIDASE AND INNATE RESPONSES TO ASPERGILLUS FUMIGATUS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL140837_7529"}, {"internal_id": 49759418, "Award ID": "R01HL140625", "Award Amount": 2845664.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-08", "CFDA Number": "93.837", "Description": "USE OF FORWARD GENETIC APPROACHES TO IDENTIFY BABESIA RECEPTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "644797d6-c94c-9e2c-b40a-a4cda190c447-C", "generated_internal_id": "ASST_NON_R01HL140625_7529"}, {"internal_id": 49759417, "Award ID": "R01HL140622", "Award Amount": 3914530.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-05", "CFDA Number": "93.837", "Description": "IKAROS REGULATION: STUDY ON HEMO-LYMPHOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL140622_7529"}, {"internal_id": 68171527, "Award ID": "R01HL140589", "Award Amount": 2997761.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-31", "CFDA Number": "93.837", "Description": "REDEFINING CLINICAL VISCOSITY IN SICKLE CELL DISEASEBY LEVERAGING MICROFLUIDIC TECHNOLOGIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL140589_7529"}, {"internal_id": 67833725, "Award ID": "R01HL140526", "Award Amount": 2816679.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-06", "CFDA Number": "93.837", "Description": "USING A SMALL MOLECULE IRON TRANSPORTER TO UNDERSTAND AND TREAT FPN1 DEFICIENCIES IN MICE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2c3d8c8a-27ef-b1e9-7164-bbfa490faa27-C", "generated_internal_id": "ASST_NON_R01HL140526_7529"}, {"internal_id": 49759406, "Award ID": "R01HL140295", "Award Amount": 3184860.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-07", "CFDA Number": "93.837", "Description": "CLINICAL TRIAL OF AAV8-MEDIATED FVIII GENE TRANSFER FOR HEMOPHILIA A", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bccd984e-68ff-4e70-2020-f0129e4b9ecc-C", "generated_internal_id": "ASST_NON_R01HL140295_7529"}, {"internal_id": 62420116, "Award ID": "R01HL139847", "Award Amount": 2345148.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-08", "CFDA Number": "93.837", "Description": "MOLECULAR INTERACTIONS OF FVIII AND VWF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R01HL139847_7529"}, {"internal_id": 94714128, "Award ID": "R01HL139825", "Award Amount": 2275552.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-27", "CFDA Number": "93.837", "Description": "GENOMICS OF MEGAKARYOCYTE AND PLATELET BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL139825_7529"}, {"internal_id": 65578846, "Award ID": "R01HL139824", "Award Amount": 3026819.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-10", "CFDA Number": "93.837", "Description": "NOVEL ANTI-HCMV STRATEGIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e5b43944-be6e-5bdd-7962-fa368b8b5699-C", "generated_internal_id": "ASST_NON_R01HL139824_7529"}, {"internal_id": 79433645, "Award ID": "R01HL139819", "Award Amount": 2139040.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-21", "CFDA Number": "93.837", "Description": "CLONAL HEMATOPOIESIS AND ACCELERATED METABOLIC DYSFUNCTION IN OBESITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL139819_7529"}, {"internal_id": 76738347, "Award ID": "R01HL139818", "Award Amount": 1947875.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-27", "CFDA Number": "93.837", "Description": "BIRC5 AS A REGULATOR OF NK CELL DEVELOPMENT AND IMMUNE FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f360f59f-4329-903a-affb-d7870b1503be-C", "generated_internal_id": "ASST_NON_R01HL139818_7529"}, {"internal_id": 77189279, "Award ID": "R01HL139756", "Award Amount": 2437234.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-18", "CFDA Number": "93.837", "Description": "NONENZYMATIC GENE EDITING IN TREATMENT OF HEREDITY SPHEROCYTOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL139756_7529"}, {"internal_id": 49759383, "Award ID": "R01HL139730", "Award Amount": 2175052.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-14", "CFDA Number": "93.837", "Description": "MECHANISTIC EVALUATIONS OF ILC2 CELLS FOR THE TREATMENT/PREVENTION OF GVHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL139730_7529"}, {"internal_id": 49759376, "Award ID": "R01HL139685", "Award Amount": 2143332.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-16", "CFDA Number": "93.837", "Description": "PERINATAL STROKE: EFFECTS OF BIOACTIVE LIPIDS ON IMMUNE-NEUROVASCULAR AXIS AND BRAIN REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL139685_7529"}, {"internal_id": 65894678, "Award ID": "R01HL139605", "Award Amount": 1555850.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-24", "CFDA Number": "93.837", "Description": "NEW GENERATION BLOOD EXCHANGE DEVICES FOR ENHANCING TISSUE REGENERATION AND HEALTH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2f14ac11-bc8d-d1e9-d103-1585414b0792-C", "generated_internal_id": "ASST_NON_R01HL139605_7529"}, {"internal_id": 68167121, "Award ID": "R01HL139555", "Award Amount": 2233007.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-20", "CFDA Number": "93.837", "Description": "RED BLOOD CELL ENDOTHELIAL NITRIC OXIDE ATTENUATES INSULIN RESISTANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL139555_7529"}, {"internal_id": 66487433, "Award ID": "R01HL139554", "Award Amount": 2594630.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-21", "CFDA Number": "93.837", "Description": "MOLECULAR MECHANISM OF PROTEIN C ACTIVATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b7dfaba3-c263-11dd-cbe2-5abe1968badc-C", "generated_internal_id": "ASST_NON_R01HL139554_7529"}, {"internal_id": 61614142, "Award ID": "R01HL139553", "Award Amount": 2943148.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-01", "CFDA Number": "93.837", "Description": "ANALYSIS OF WHOLE GENOME SEQUENCE AND HEMOSTASIS PHENOTYPES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9adce466-3b6d-ecdb-7412-8082d6529b1f-C", "generated_internal_id": "ASST_NON_R01HL139553_7529"}, {"internal_id": 67313561, "Award ID": "R01HL139552", "Award Amount": 3263777.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-18", "CFDA Number": "93.838", "Description": "MOLECULAR AND GENETIC BASIS OF DEEP VENOUS THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": 779063.0, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL139552_7529"}, {"internal_id": 49759369, "Award ID": "R01HL139543", "Award Amount": 2364284.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-18", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF REAL-TIME, NON-INVASIVE PHOTOACOUSTIC IMAGING TO RAPIDLY DETECT AND TRACK PERINATAL FOCAL STROKE AT BIRTH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL139543_7529"}, {"internal_id": 67579224, "Award ID": "R01HL139501", "Award Amount": 1585000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-30", "CFDA Number": "93.837", "Description": "CYTOSKELETON AND PLATELET CLEARANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL139501_7529"}, {"internal_id": 49759364, "Award ID": "R01HL139492", "Award Amount": 1606875.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-12", "CFDA Number": "93.837", "Description": "PLACENTAL MEDIATED MECHANISMS OF PERINATAL BRAIN INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL139492_7529"}, {"internal_id": 49759363, "Award ID": "R01HL139489", "Award Amount": 2372017.36, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-15", "CFDA Number": "93.837", "Description": "NEUROCOGNITIVE EFFECTS OF IRON DEFICIENCY IN BLOOD DONORS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL139489_7529"}, {"internal_id": 68172099, "Award ID": "R01HL139487", "Award Amount": 2115582.21, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-20", "CFDA Number": "93.837", "Description": "THERAPEUTIC TARGETING OF MDS STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_R01HL139487_7529"}, {"internal_id": 49759360, "Award ID": "R01HL139472", "Award Amount": 3433201.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-10", "CFDA Number": "93.837", "Description": "DOES BIOCOMPATIBILITY CONTRIBUTE TO TRANSFUSION-RELATED ADVERSE EFFECTS?", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cf018231-59a5-d301-ae96-b0817a8ee227-C", "generated_internal_id": "ASST_NON_R01HL139472_7529"}, {"internal_id": 49759359, "Award ID": "R01HL139448", "Award Amount": 1300946.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-15", "CFDA Number": "93.839", "Description": "ROLE OF THE ENDOTHELIUM AND NEUTROPHILS IN THE PROTHROMBOTIC NATURE OF HIT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL139448_7529"}, {"internal_id": 49759354, "Award ID": "R01HL139337", "Award Amount": 2257740.36, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-20", "CFDA Number": "93.837", "Description": "FUNCTIONAL ANALYSIS OF RED BLOOD CELL DETERMINANTS OF PLASMODIUM INVASION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f5f39b56-5a70-1fe5-798f-b53ffca1e353-C", "generated_internal_id": "ASST_NON_R01HL139337_7529"}, {"internal_id": 62420247, "Award ID": "R01HL139056", "Award Amount": 1383567.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-06", "CFDA Number": "93.839", "Description": "MOLECULAR DETERMINANTS OF ENDOTHELIAL TRANSITION INTO ENGRAFTABLE HEMATOPOIETIC CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL139056_7529"}, {"internal_id": 49759348, "Award ID": "R01HL139008", "Award Amount": 2163940.35, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-02", "CFDA Number": "93.837", "Description": "CANNABINOID-MEDIATED MITIGATION OF GRAFT VERSUS HOST DISEASE: ROLES OF CB2 RECEPTORS AND ADENOSINE SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL139008_7529"}, {"internal_id": 49759347, "Award ID": "R01HL139007", "Award Amount": 2311586.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-24", "CFDA Number": "93.837", "Description": "SYNTHETIC HEMOSTATS FOR TRAUMA TREATMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL139007_7529"}, {"internal_id": 111328709, "Award ID": "R01HL138714", "Award Amount": 2035362.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-07", "CFDA Number": "93.837", "Description": "IMPACT OF ANEMIA AND ITS TREATMENT ON GUT INJURY IN PRETERM INFANTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL138714_7529"}, {"internal_id": 49759332, "Award ID": "R01HL138656", "Award Amount": 2894693.98, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-28", "CFDA Number": "93.838", "Description": "ENGINEERING IPSC-RBCS FOR TRANSFUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": 298115.98, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL138656_7529"}, {"internal_id": 49759321, "Award ID": "R01HL138543", "Award Amount": 371648.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-21", "CFDA Number": "93.839", "Description": "THE EFFECT OF NEONATAL ANEMIA AND ITS TREATMENTS ON BRAIN DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL138543_7529"}, {"internal_id": 49759301, "Award ID": "R01HL138423", "Award Amount": 2464710.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-16", "CFDA Number": "93.837", "Description": "MECHANISM OF CEREBRAL VACULOPATHY AND STROKE IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c572d765-16bd-66ab-db02-66828218aab7-C", "generated_internal_id": "ASST_NON_R01HL138423_7529"}, {"internal_id": 49759293, "Award ID": "R01HL138225", "Award Amount": 1597326.89, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-24", "CFDA Number": "93.837", "Description": "TRACING THE DEVELOPMENTAL ORIGIN OF HEMATOPOIETIC STEM CELL HETEROGENEITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_R01HL138225_7529"}, {"internal_id": 49759289, "Award ID": "R01HL138179", "Award Amount": 1290267.1, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-23", "CFDA Number": "93.837", "Description": "PLATELET ENDOCYTOSIS IN INNATE IMMUNITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c477975b-68db-c3dc-4a79-b95cb9f6ab3e-C", "generated_internal_id": "ASST_NON_R01HL138179_7529"}, {"internal_id": 49759287, "Award ID": "R01HL138116", "Award Amount": 2875118.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-09", "CFDA Number": "93.837", "Description": "PEGYLATED MEGAHEMOGLOBIN FOR USE AS A RED BLOOD CELL SUBSTITUTE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL138116_7529"}, {"internal_id": 49759284, "Award ID": "R01HL138090", "Award Amount": 2889098.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-16", "CFDA Number": "93.837", "Description": "LINEAGES AND PATHOPHYSIOLOGY OF CLONAL HISTIOCYTIC DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b514fc3a-d769-87e9-75ea-7a6766afb5ee-C", "generated_internal_id": "ASST_NON_R01HL138090_7529"}, {"internal_id": 49759280, "Award ID": "R01HL137991", "Award Amount": 2018418.75, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-24", "CFDA Number": "93.837", "Description": "THE BIOLOGY OF VWF SELF-ASSOCIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "474a19eb-1491-c065-a3ca-a49b264b0d4b-C", "generated_internal_id": "ASST_NON_R01HL137991_7529"}, {"internal_id": 49759279, "Award ID": "R01HL137990", "Award Amount": 751899.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-02", "CFDA Number": "93.839", "Description": "MOLECULAR INSIGHT OF ERYTHROCYTE HYPOXIC METABOLIC REPROGRAMMING IN CHRONIC KIDNEY DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9adce466-3b6d-ecdb-7412-8082d6529b1f-C", "generated_internal_id": "ASST_NON_R01HL137990_7529"}, {"internal_id": 49759276, "Award ID": "R01HL137930", "Award Amount": 1564314.55, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-16", "CFDA Number": "93.837", "Description": "ROLE OF RBC REACTIVE OXYGEN SPECIES AND THEIR VICIOUS CYCLE IN SICKLE VASCULOPATHY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL137930_7529"}, {"internal_id": 49759272, "Award ID": "R01HL137919", "Award Amount": 2428922.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-09", "CFDA Number": "93.837", "Description": "THE INTERFERON-BETA (IFN-BETA)/SETDB2 EPIGENETIC AXIS REGULATES INFLAMMATION AND METABOLISM IN DIABETIC WOUNDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL137919_7529"}, {"internal_id": 49759270, "Award ID": "R01HL137913", "Award Amount": 3314905.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-11", "CFDA Number": "93.837", "Description": "NOVEL PET/CT AND TREATMENT STRATEGIES TO REDUCE PTS FOLLOWING DVT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL137913_7529"}, {"internal_id": 66800690, "Award ID": "R01HL137910", "Award Amount": 1530000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-14", "CFDA Number": "93.837", "Description": "HDAC6 REGULATION OF ICAM-1 EXPRESSION AND ENDOTHELIAL INFLAMMATORY SIGNALING IN SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c477975b-68db-c3dc-4a79-b95cb9f6ab3e-C", "generated_internal_id": "ASST_NON_R01HL137910_7529"}, {"internal_id": 49759269, "Award ID": "R01HL137848", "Award Amount": 5983916.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-09-05", "CFDA Number": "93.837", "Description": "GENE THERAPY TARGETING BCL11A TO INDUCE FETAL HEMOGLOBIN AND REDUCE SICKLE HEMOGLOBIN IN PATIENTS WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL137848_7529"}, {"internal_id": 65894624, "Award ID": "R01HL137799", "Award Amount": 2654701.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-25", "CFDA Number": "93.837", "Description": "THROMBOCYTOPOIESIS IN DIABETES:  ROLE OF DAMAGE ASSOCIATED MOLECULAR PATTERNS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL137799_7529"}, {"internal_id": 49759261, "Award ID": "R01HL137793", "Award Amount": 1906250.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-24", "CFDA Number": "93.837", "Description": "MOLECULAR CONSEQUENCES OF TELOMERASE DYSFUNCTION DURING HEMATOPOIETIC DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL137793_7529"}, {"internal_id": 66996804, "Award ID": "R01HL137721", "Award Amount": 951573.3, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-25", "CFDA Number": "93.837", "Description": "NOVEL FUNCTIONAL PROTEIN TYROSINE PHOSPHATASES IN PLATELETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb9c32ae-42fd-5fe8-5d84-b798a26bb49d-C", "generated_internal_id": "ASST_NON_R01HL137721_7529"}, {"internal_id": 76738619, "Award ID": "R01HL137695", "Award Amount": 1951348.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-03", "CFDA Number": "93.837", "Description": "TARGETED ABROGATION OF THE FXII-UPAR-PAKT2 AXIS IN NEUTROPHILS FOR TREATMENT OF CHRONIC WOUNDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R01HL137695_7529"}, {"internal_id": 49759248, "Award ID": "R01HL137674", "Award Amount": 2330857.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-30", "CFDA Number": "93.837", "Description": "A THERANOSTIC APPROACH FOR RISK STRATIFICATION AND INTERVENTION OF DEEP VEIN THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL137674_7529"}, {"internal_id": 61614664, "Award ID": "R01HL137376", "Award Amount": 1815084.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-01", "CFDA Number": "93.837", "Description": "RUNX1 HAPLODEFICIENCY, ENDOCYTOSIS AND VESICLE TRANSPORT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb9c32ae-42fd-5fe8-5d84-b798a26bb49d-C", "generated_internal_id": "ASST_NON_R01HL137376_7529"}, {"internal_id": 49759238, "Award ID": "R01HL137373", "Award Amount": 1503666.86, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-20", "CFDA Number": "93.837", "Description": "SEPARATION OF GVH AND GVL RESPONSES USING ALLOREACTIVE CD8 ITREGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "SC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "04a78f04-ee86-46df-5fbf-c71e46ed8479-C", "generated_internal_id": "ASST_NON_R01HL137373_7529"}, {"internal_id": 49759231, "Award ID": "R01HL137335", "Award Amount": 1683000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-02", "CFDA Number": "93.837", "Description": "ENGINEERING CELLULAR IMMUNOTHERAPY TO MODULATE IMMUNE RESPONSES IN HEMOPHILIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL137335_7529"}, {"internal_id": 65894855, "Award ID": "R01HL137223", "Award Amount": 2458716.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-28", "CFDA Number": "93.837", "Description": "ANALYSIS OF RNA BINDING PROTEINS DIRECTING HEMATOPOIETIC STEM CELL FATE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL137223_7529"}, {"internal_id": 49759218, "Award ID": "R01HL137219", "Award Amount": 3217189.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-05", "CFDA Number": "93.837", "Description": "DISSECTING SPLICING FACTOR MUTATIONS IN IPSCS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL137219_7529"}, {"internal_id": 49759215, "Award ID": "R01HL137207", "Award Amount": 1984285.32, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-07", "CFDA Number": "93.837", "Description": "NOVEL SMALL G PROTEIN PATHWAY REGULATORS OF GPVI SIGNALING IN PLATELETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb9c32ae-42fd-5fe8-5d84-b798a26bb49d-C", "generated_internal_id": "ASST_NON_R01HL137207_7529"}, {"internal_id": 49759211, "Award ID": "R01HL137193", "Award Amount": 2955973.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-24", "CFDA Number": "93.837", "Description": "HEMORRHAGE CONTROL IN THE IRREVERSIBLE ANTICOAGULATED PATIENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2439d942-d439-953a-5588-98392dd15217-C", "generated_internal_id": "ASST_NON_R01HL137193_7529"}, {"internal_id": 49759207, "Award ID": "R01HL137128", "Award Amount": 1133048.29, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-22", "CFDA Number": "93.837", "Description": "ANCESTRAL SEQUENCE RECONSTRUCTION ENGINEERING OF COAGULATION FACTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL137128_7529"}, {"internal_id": 49759193, "Award ID": "R01HL136969", "Award Amount": 1337005.83, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-26", "CFDA Number": "93.837", "Description": "ERYTHROCYTE METABOLOMIC PROFILING REVEALS NEW INSIGHT AND APPROACHES TO PROMOTE OXYGEN DELIVERY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9adce466-3b6d-ecdb-7412-8082d6529b1f-C", "generated_internal_id": "ASST_NON_R01HL136969_7529"}, {"internal_id": 49759156, "Award ID": "R01HL136662", "Award Amount": 2374413.89, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-15", "CFDA Number": "93.837", "Description": "CELLULAR IMPACT OF X-LINKED DYSKERATOSIS CONGENITA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_R01HL136662_7529"}, {"internal_id": 49759153, "Award ID": "R01HL136652", "Award Amount": 2307089.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-21", "CFDA Number": "93.837", "Description": "BIODEGRADABLE NANOPARTICLES, A GENOME EDITING PLATFORM TO TREAT HEMOPHILIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL136652_7529"}, {"internal_id": 76908993, "Award ID": "R01HL136622", "Award Amount": 2025987.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-08", "CFDA Number": "93.837", "Description": "THE ROLE OF ERYTHROCYTE MITOCHONDRIAL RETENTION IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL136622_7529"}, {"internal_id": 49759136, "Award ID": "R01HL136572", "Award Amount": 2033658.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-01", "CFDA Number": "93.837", "Description": "REGULATION OF SHORT-LIVED MYELOID CELLS BY THE NOVEL LONG NON-CODING RNA MORRBID", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL136572_7529"}, {"internal_id": 49759133, "Award ID": "R01HL136560", "Award Amount": 1556000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-14", "CFDA Number": "93.837", "Description": "NEUREGULIN SIGNALING IN MYELOID CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "ME", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "004d72fe-5935-3d05-929b-08def85a886c-C", "generated_internal_id": "ASST_NON_R01HL136560_7529"}, {"internal_id": 66199561, "Award ID": "R01HL136529", "Award Amount": 1597507.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-04", "CFDA Number": "93.837", "Description": "CELLULAR CROSSTALK IN THE HEMATOPOIETIC MICROENVIRONMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL136529_7529"}, {"internal_id": 49759128, "Award ID": "R01HL136512", "Award Amount": 2080097.36, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-10", "CFDA Number": "93.837", "Description": "COMPLEMENT AND CR2/CD21 IN THE IMMUNE PATHOGENESIS OF HIT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL136512_7529"}, {"internal_id": 49759126, "Award ID": "R01HL136504", "Award Amount": 1906250.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-02-10", "CFDA Number": "93.837", "Description": "TEMPORAL CHANGES IN MECHANISMS OF HSC SELF-RENEWAL AND MYELOID LEUKEMOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL136504_7529"}, {"internal_id": 49759123, "Award ID": "R01HL136484", "Award Amount": 2547229.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-15", "CFDA Number": "93.837", "Description": "CEREBROVASCULAR RESERVE AND WHITE MATTER DISEASE IN PATIENTS WITH ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6c10cf51-1fb6-c52e-c48f-8fcef0f37eff-C", "generated_internal_id": "ASST_NON_R01HL136484_7529"}, {"internal_id": 49759122, "Award ID": "R01HL136480", "Award Amount": 3036942.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-06", "CFDA Number": "93.837", "Description": "THE PRO-INFLAMMATORY EFFECTS OF ACUTE EXERCISE IN CHILDREN WITH SICKLE CELL ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "db0f99e3-8b04-ae0e-7470-8dc3317c23d2-C", "generated_internal_id": "ASST_NON_R01HL136480_7529"}, {"internal_id": 67833785, "Award ID": "R01HL136430", "Award Amount": 1683273.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-13", "CFDA Number": "93.837", "Description": "VWF - MECHANISMS OF REGULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R01HL136430_7529"}, {"internal_id": 64141393, "Award ID": "R01HL136420", "Award Amount": 1913662.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-11", "CFDA Number": "93.837", "Description": "THE ROLE OF THE PAFC SUBUNIT CDC73 IN NORMAL HEMATOPOIESIS AND TRANSFORMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL136420_7529"}, {"internal_id": 82471232, "Award ID": "R01HL136415", "Award Amount": 1601074.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-31", "CFDA Number": "93.837", "Description": "NOVEL PATHWAYS IN ISCHEMIC STROKE IN SICKLE CELL ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL136415_7529"}, {"internal_id": 49759113, "Award ID": "R01HL136395", "Award Amount": 2734972.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-10", "CFDA Number": "93.866", "Description": "REGULATION OF INFLAMMATION BY THE FIBRINOLYTIC SYSTEM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL136395_7529"}, {"internal_id": 49759112, "Award ID": "R01HL136394", "Award Amount": 3314612.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-28", "CFDA Number": "93.837", "Description": "VASCULAR THIOL ISOMERASES IN THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_R01HL136394_7529"}, {"internal_id": 49759106, "Award ID": "R01HL136375", "Award Amount": 2306155.23, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-14", "CFDA Number": "93.837", "Description": "NEW CHROMATIN INSULATORS AND ENHANCERS FOR GENE THERAPY OF THE HEMOGLOBINOPATHIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL136375_7529"}, {"internal_id": 49759104, "Award ID": "R01HL136363", "Award Amount": 1905885.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-19", "CFDA Number": "93.837", "Description": "A PATH TO THROMBOSIS IN PRIMARY MYELOFIBROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL136363_7529"}, {"internal_id": 49759102, "Award ID": "R01HL136333", "Award Amount": 1928821.26, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-05-01", "CFDA Number": "93.837", "Description": "THE CONTRIBUTION OFINFECTION TO PRELEUKEMIC CLONAL HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL136333_7529"}, {"internal_id": 49759095, "Award ID": "R01HL136255", "Award Amount": 2225893.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-16", "CFDA Number": "93.837", "Description": "FOXO3 REGULATION OF NORMAL AND STRESS ERYTHROPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL136255_7529"}, {"internal_id": 49759079, "Award ID": "R01HL136135", "Award Amount": 6025224.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-17", "CFDA Number": "93.837", "Description": "NOVEL GENE EDITING APPROACHES FOR HEMOGLOBINOPATHIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "569197a4-81d0-b264-5640-e9db4cf71fd0-C", "generated_internal_id": "ASST_NON_R01HL136135_7529"}, {"internal_id": 49759073, "Award ID": "R01HL135895", "Award Amount": 1819177.01, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-01", "CFDA Number": "93.837", "Description": "CANNABINOID MODULATION OF HYPERALGESIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL135895_7529"}, {"internal_id": 49759065, "Award ID": "R01HL135853", "Award Amount": 2814202.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-14", "CFDA Number": "93.837", "Description": "PRENATAL CELL AND GENE THERAPY FOR HEMOPHILIA A", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "623a4232-bd5e-fb60-cf01-48cd08a5a593-C", "generated_internal_id": "ASST_NON_R01HL135853_7529"}, {"internal_id": 67579392, "Award ID": "R01HL135607", "Award Amount": 1580886.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-24", "CFDA Number": "93.837", "Description": "HOMOLOGOUS RECOMBINATION MEDIATED GENE CORRECTION FOR THE HEMOGLOBINOPATHIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL135607_7529"}, {"internal_id": 49759044, "Award ID": "R01HL135575", "Award Amount": 1547615.79, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-11", "CFDA Number": "93.837", "Description": "EXAMINATION OF INITIATING FACTORS THAT REGULATE RED BLOOD CELL ALLOIMMUNIZATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL135575_7529"}, {"internal_id": 49759042, "Award ID": "R01HL135564", "Award Amount": 2861436.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-10", "CFDA Number": "93.837", "Description": "MOLECULAR AND GENETIC ANALYSIS OF NOVEL SLICER-DEPENDENT MIRNA PATHWAYS IN BLOOD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b514fc3a-d769-87e9-75ea-7a6766afb5ee-C", "generated_internal_id": "ASST_NON_R01HL135564_7529"}, {"internal_id": 66487131, "Award ID": "R01HL135325", "Award Amount": 2344360.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-01", "CFDA Number": "93.837", "Description": "CD27/CD70 MEDIATED NEGATIVE REGULATION OF INFLAMMATORY T CELL RESPONSES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R01HL135325_7529"}, {"internal_id": 49759025, "Award ID": "R01HL135294", "Award Amount": 2267820.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-19", "CFDA Number": "93.837", "Description": "GLYCOPROTEIN IB IN VASCULAR BIOLOGY AND HOST DEFENSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL135294_7529"}, {"internal_id": 49759024, "Award ID": "R01HL135292", "Award Amount": 1484604.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-15", "CFDA Number": "93.837", "Description": "INVESTIGATING THE HETEROGENEOUS AGING OF INDIVIDUAL HEMATOPOIETIC STEM CELL CLONES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_R01HL135292_7529"}, {"internal_id": 61613389, "Award ID": "R01HL135287", "Award Amount": 1684376.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-03", "CFDA Number": "93.837", "Description": "IN VIVO GENE EDITING OF HEMATOPOIETIC STEM AND PROGENITOR CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e8ca50f1-0aae-b095-4264-91527196f368-C", "generated_internal_id": "ASST_NON_R01HL135287_7529"}, {"internal_id": 49759023, "Award ID": "R01HL135254", "Award Amount": 1551610.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-23", "CFDA Number": "93.837", "Description": "EXPERIMENT-BASED MULTI-SCALE MODELING OF THE TENSILE AND COMPRESSIVE DEFORMATIONS OF FIBRIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL135254_7529"}, {"internal_id": 49759022, "Award ID": "R01HL135248", "Award Amount": 1916100.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-23", "CFDA Number": "93.837", "Description": "REGULATION OF RBC ALLOIMMUNIZATION BY NATURALLY OCCURRING AND ADAPTIVE ANTIBODIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL135248_7529"}, {"internal_id": 49759015, "Award ID": "R01HL135205", "Award Amount": 4277763.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-28", "CFDA Number": "93.837", "Description": "WNT SIGNALING IN HEMATOPOIETIC DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL135205_7529"}, {"internal_id": 49759010, "Award ID": "R01HL135160", "Award Amount": 1766245.5, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-28", "CFDA Number": "93.837", "Description": "PROTECTION AND MITIGATION OF BONE MARROW FAILURE BY ANGIOGENIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "34640ee3-dce1-9923-6e06-25f6c48e1690-C", "generated_internal_id": "ASST_NON_R01HL135160_7529"}, {"internal_id": 49758982, "Award ID": "R01HL135039", "Award Amount": 3166154.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-17", "CFDA Number": "93.837", "Description": "MITOCHONDRIAL REGULATION OF HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL135039_7529"}, {"internal_id": 49758981, "Award ID": "R01HL135035", "Award Amount": 1875000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-28", "CFDA Number": "93.837", "Description": "THROMBOSUPPRESSIVE MECHANISMS OF NOVEL MUTANTS DISCOVERED THROUGH AN ENU MUTAGENESIS SCREEN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "48daf3ab-82a8-30af-8bdd-7bc3f35e54ec-C", "generated_internal_id": "ASST_NON_R01HL135035_7529"}, {"internal_id": 49758966, "Award ID": "R01HL134971", "Award Amount": 2187610.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-15", "CFDA Number": "93.837", "Description": "THE ROLE OF NOTCH SIGNALING IN FETAL HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL134971_7529"}, {"internal_id": 49758965, "Award ID": "R01HL134970", "Award Amount": 1791563.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-14", "CFDA Number": "93.837", "Description": "MOLECULAR AND CELLULAR BIOLOGY OF MEGAKARYOCYTES IN NORMAL AND NEOPLASTIC HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3313e5e7-fa36-d54b-e36d-0e1e09cc0c30-C", "generated_internal_id": "ASST_NON_R01HL134970_7529"}, {"internal_id": 49758964, "Award ID": "R01HL134959", "Award Amount": 1450000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-19", "CFDA Number": "93.837", "Description": "INVESTIGATING THE DYSFUNCTION OF THE CEREBRAL MICROVASCULATURE IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c926c0d8-8c77-28e2-fb9e-2889e1116d26-C", "generated_internal_id": "ASST_NON_R01HL134959_7529"}, {"internal_id": 49758963, "Award ID": "R01HL134952", "Award Amount": 2068375.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-11", "CFDA Number": "93.837", "Description": "DYSREGULATED NFKB PATHWAY SIGNALING IN MYELOPROLIFERATIVE NEOPLASMS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL134952_7529"}, {"internal_id": 49758952, "Award ID": "R01HL134899", "Award Amount": 2274240.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-02-18", "CFDA Number": "93.837", "Description": "ENGINEERING NITRIC OXIDE RELEASING POLYMER WITH IMMOBILIZED THROMBIN INHIBITOR FOR BLOOD CONTACTING APPLICATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5d50a1e7-6c45-607b-669d-580246737467-C", "generated_internal_id": "ASST_NON_R01HL134899_7529"}, {"internal_id": 49758951, "Award ID": "R01HL134896", "Award Amount": 2297500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-15", "CFDA Number": "93.837", "Description": "ROLE OF TLR2 IN REGULATING NORMAL AND PREMALIGNANT HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL134896_7529"}, {"internal_id": 49758949, "Award ID": "R01HL134894", "Award Amount": 2871107.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-21", "CFDA Number": "93.837", "Description": "POPULATION GENOMIC VARIATION, FUNCTIONAL BIOLOGY, AND THE RISK OF VENOUS THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL134894_7529"}, {"internal_id": 49758945, "Award ID": "R01HL134880", "Award Amount": 1624932.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-02", "CFDA Number": "93.837", "Description": "INFLAMMATORY REGULATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS TO ENHANCE INNATE IMMUNITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL134880_7529"}, {"internal_id": 49758934, "Award ID": "R01HL134839", "Award Amount": 2808777.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-17", "CFDA Number": "93.837", "Description": "IN VIVO RNA-MEDIATED GENE EDITING OF HEMOPHILIA A", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL134839_7529"}, {"internal_id": 49758931, "Award ID": "R01HL134829", "Award Amount": 1013064.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-04", "CFDA Number": "93.839", "Description": "THE ROLE OF GLYCANS IN THROMBOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL134829_7529"}, {"internal_id": 49758905, "Award ID": "R01HL134691", "Award Amount": 2076579.65, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-16", "CFDA Number": "93.837", "Description": "CYOKINE CONTROL OF RED BLOOD CELL ALLOIMMUNIZATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL134691_7529"}, {"internal_id": 69724793, "Award ID": "R01HL134684", "Award Amount": 1695000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-20", "CFDA Number": "93.837", "Description": "GENERATION OF CULTURED RBCS WITH RARE PHENOTYPES FOR TRANSFUSION FROM SOURCES USUALLY DISCARDED DURING REGULAR BLOOD DONATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL134684_7529"}, {"internal_id": 49758898, "Award ID": "R01HL134653", "Award Amount": 1918973.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-15", "CFDA Number": "93.837", "Description": "EFFECT OF BLOOD DONOR SEX AND TESTOSTERONE ON PREDISPOSITION TO HEMOLYSIS IN STORED RED BLOOD CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aac0d53c-fc30-bb05-192d-4bb66ca0eae1-C", "generated_internal_id": "ASST_NON_R01HL134653_7529"}, {"internal_id": 49758896, "Award ID": "R01HL134617", "Award Amount": 1560000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-28", "CFDA Number": "93.837", "Description": "BLOOD STEM CELL AGING AND BIOMARKER STUDIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL134617_7529"}, {"internal_id": 49758891, "Award ID": "R01HL134544", "Award Amount": 3130776.92, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-25", "CFDA Number": "93.310", "Description": "CELLULAR MEDIATORS OF VASCULAR INFLAMMATION IN TREATED HIV-INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL134544_7529"}, {"internal_id": 49758890, "Award ID": "R01HL134539", "Award Amount": 3282542.06, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-23", "CFDA Number": "93.837", "Description": "A SYSTEMS BIOLOGY APPROACH TO FINGERPRINT HIV IMMUNE DEFENSE IN ELITE CONTROLLERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL134539_7529"}, {"internal_id": 49758877, "Award ID": "R01HL134321", "Award Amount": 4726762.82, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-09", "CFDA Number": "93.837", "Description": "INTRAOSSEOUS DELIVERY OF LENTIVIRAL VECTORS FOR HEMOPHILIA A GENE THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_R01HL134321_7529"}, {"internal_id": 49758874, "Award ID": "R01HL134236", "Award Amount": 2513132.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-24", "CFDA Number": "93.837", "Description": "TRANSCRIPTIONAL CONTROL OF MONOCYTE DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1ab7ef77-dc1b-636f-13b5-a16c421f1438-C", "generated_internal_id": "ASST_NON_R01HL134236_7529"}, {"internal_id": 49758873, "Award ID": "R01HL134211", "Award Amount": 2867299.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-25", "CFDA Number": "93.837", "Description": "MALARIA CHEMOPREVENTION IN CHILDREN WITH SICKLE CELL ANEMIA IN WESTERN KENYA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL134211_7529"}, {"internal_id": 49758863, "Award ID": "R01HL134043", "Award Amount": 2568153.43, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-25", "CFDA Number": "93.837", "Description": "CRITICAL REGULATORY CIRCUITS IN BLOOD FORMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "ME", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "023bc6ff-e791-fc8c-47cb-ebca0c5a7fa7-C", "generated_internal_id": "ASST_NON_R01HL134043_7529"}, {"internal_id": 49758858, "Award ID": "R01HL133923", "Award Amount": 2266897.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-31", "CFDA Number": "93.837", "Description": "TARGETING PAR4 IN THROMBOTIC DISORDERS:PHARMACOGENOMIC APPROACH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4a536007-27e4-2194-a125-f4b8c55294db-C", "generated_internal_id": "ASST_NON_R01HL133923_7529"}, {"internal_id": 49758855, "Award ID": "R01HL133896", "Award Amount": 5013401.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-21", "CFDA Number": "93.837", "Description": "DISPLACE: DISSEMINATION AND IMPLEMENTATION OF STROKE PREVENTION LOOKING AT THE CARE ENVIRONMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL133896_7529"}, {"internal_id": 49758852, "Award ID": "R01HL133864", "Award Amount": 2418325.64, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-29", "CFDA Number": "93.837", "Description": "NOVEL ROLE OF SMOOTH MUSCLE B5 REDUCTASE IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL133864_7529"}, {"internal_id": 49758844, "Award ID": "R01HL133828", "Award Amount": 2216968.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-17", "CFDA Number": "93.837", "Description": "REGULATION OF PROTEIN UBIQUITINATION IN HEMATOPOIETIC CYTOKINE SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL133828_7529"}, {"internal_id": 49758843, "Award ID": "R01HL133823", "Award Amount": 2228816.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-23", "CFDA Number": "93.837", "Description": "TARGETING T-CELL COSTIMULATION AND CYTOKINE ACTIVATION TO PREVENT GVHD AND PRESERVE GVL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL133823_7529"}, {"internal_id": 49758834, "Award ID": "R01HL133728", "Award Amount": 1925000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-02", "CFDA Number": "93.837", "Description": "HUMAN EXOMICS GENOTYPING-DRIVEN DISCOVERY AND CHARACTERIZATION OF PROTEINS RELATED TO CLINICAL THROMBOSIS, BLOOD COAGULATION AND THROMBIN GENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL133728_7529"}, {"internal_id": 49758825, "Award ID": "R01HL133668", "Award Amount": 1761129.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-27", "CFDA Number": "93.837", "Description": "SMALL GTPASES IN MEGAKARYOCYTE BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL133668_7529"}, {"internal_id": 49758812, "Award ID": "R01HL133574", "Award Amount": 1921462.78, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-25", "CFDA Number": "93.837", "Description": "STANDARDIZED MONITORING OF CELLULAR ADHESION TO IMPROVE CLINICAL CARE IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R01HL133574_7529"}, {"internal_id": 49758811, "Award ID": "R01HL133560", "Award Amount": 1483508.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-02", "CFDA Number": "93.837", "Description": "SYSTEMATIC IDENTIFICATION OF HEMATOPOIETIC STEM CELL EXPANSION FACTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f2defd6b-38d0-6c66-8586-39b99ba99117-C", "generated_internal_id": "ASST_NON_R01HL133560_7529"}, {"internal_id": 65894351, "Award ID": "R01HL133559", "Award Amount": 1580000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-03", "CFDA Number": "93.837", "Description": "MECHANISMS OF NECROSIS REGULATION OF HEMATOPOIETIC STEM CELL FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL133559_7529"}, {"internal_id": 49758801, "Award ID": "R01HL133462", "Award Amount": 1677342.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-16", "CFDA Number": "93.837", "Description": "NOVEL INNATE MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN ALLOGENEIC HCT FOR HEMOGLOBINOPATHIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dbae4064-c48c-5002-9fca-21d077e0f96b-C", "generated_internal_id": "ASST_NON_R01HL133462_7529"}, {"internal_id": 49758797, "Award ID": "R01HL133406", "Award Amount": 1674376.13, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-21", "CFDA Number": "93.837", "Description": "DEREGULATION OF SF3B1 FUNCTION BY RECURRENT HEAT DOMAIN MUTATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL133406_7529"}, {"internal_id": 49758795, "Award ID": "R01HL133350", "Award Amount": 1721875.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-29", "CFDA Number": "93.837", "Description": "MECHANISMS OF CIS-ACTING HBF REGULATION IN SICKLE CELL ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "54768301-b245-c1c5-66ec-e0c90b049cc4-C", "generated_internal_id": "ASST_NON_R01HL133350_7529"}, {"internal_id": 49758794, "Award ID": "R01HL133348", "Award Amount": 1670000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-25", "CFDA Number": "93.837", "Description": "REGULATION OF INNATE IMMUNITY BY COAGULATION RECEPTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R01HL133348_7529"}, {"internal_id": 49758790, "Award ID": "R01HL133334", "Award Amount": 3604782.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-15", "CFDA Number": "93.837", "Description": "CHRONIC THROMBUS ABLATION WITH HISTOTRIPSY AND THROMBOLYTICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_R01HL133334_7529"}, {"internal_id": 49758788, "Award ID": "R01HL133327", "Award Amount": 3116321.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-12", "CFDA Number": "93.837", "Description": "SLEEP AND PAIN IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL133327_7529"}, {"internal_id": 49758787, "Award ID": "R01HL133325", "Award Amount": 2446722.1, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-25", "CFDA Number": "93.837", "Description": "IMMUNE RESPONSE TO RBC ANTIGENS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL133325_7529"}, {"internal_id": 49758770, "Award ID": "R01HL133191", "Award Amount": 2845326.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-10", "CFDA Number": "93.837", "Description": "ORAL TOLERANCE FOR HEMOPHILIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL133191_7529"}, {"internal_id": 49758752, "Award ID": "R01HL133113", "Award Amount": 2025000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-01", "CFDA Number": "93.837", "Description": "COMPLEMENTOPATHIES: GENOTYPE AND PHENOTYPE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL133113_7529"}, {"internal_id": 49758740, "Award ID": "R01HL133049", "Award Amount": 3822820.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-05", "CFDA Number": "93.837", "Description": "RED BLOOD CELLS FROM IRON-DEFICIENT DONORS: RECOVERY AND STORAGE QUALITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL133049_7529"}, {"internal_id": 49758734, "Award ID": "R01HL133024", "Award Amount": 1066092.52, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-31", "CFDA Number": "93.837", "Description": "MECHANISMS REGULATING ALLOIMMUNIZATION AND TOLERANCE WITH PATHOGEN REDUCTION AND TRANSFUSION OF ALLOGENEIC PLATELETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aac0d53c-fc30-bb05-192d-4bb66ca0eae1-C", "generated_internal_id": "ASST_NON_R01HL133024_7529"}, {"internal_id": 49758733, "Award ID": "R01HL133022", "Award Amount": 1601875.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-20", "CFDA Number": "93.837", "Description": "EFFECT OF PLATELET TRANSFUSIONS ON NEONATAL INTESTINAL INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL133022_7529"}, {"internal_id": 49758732, "Award ID": "R01HL133021", "Award Amount": 1724208.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-15", "CFDA Number": "93.837", "Description": "MODULATING ENDOTHELIAL-SPECIFIC SIGNALING TO ENHANCE FUNCTIONAL HEMATOPOIESIS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5d1577c2-fc74-51c9-43ec-a9c902241b4c-C", "generated_internal_id": "ASST_NON_R01HL133021_7529"}, {"internal_id": 49758725, "Award ID": "R01HL133003", "Award Amount": 1559825.72, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-05", "CFDA Number": "93.837", "Description": "HEME-INDUCED PLATELET MTROS DRIVES TSP1 RELEASE TO ACCELERATE PH PATHOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL133003_7529"}, {"internal_id": 49758720, "Award ID": "R01HL132988", "Award Amount": 1884004.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-25", "CFDA Number": "93.837", "Description": "THE ROLE OF IL-6 IN EXPERIMENTAL POST THROMBOTIC SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL132988_7529"}, {"internal_id": 49758715, "Award ID": "R01HL132951", "Award Amount": 1675000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-21", "CFDA Number": "93.837", "Description": "RESPONSIVENESS AND NON-RESPONSIVENESS TO TRANSFUSED RBCS IN MICE AND HUMANS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL132951_7529"}, {"internal_id": 49758713, "Award ID": "R01HL132947", "Award Amount": 3051810.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-20", "CFDA Number": "93.837", "Description": "THROMBOSIS GENETICS IN AFRICAN AMERICANS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL132947_7529"}, {"internal_id": 49758710, "Award ID": "R01HL132921", "Award Amount": 1775879.34, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-19", "CFDA Number": "93.837", "Description": "MITOTIC FAILURE IN FANCONI ANEMIA: MECHANISMS AND ROLE IN CARCINOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL132921_7529"}, {"internal_id": 49758706, "Award ID": "R01HL132906", "Award Amount": 3918218.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-07", "CFDA Number": "93.837", "Description": "A MICROFLUIDIC PLATFORM TO STUDY SICKLE BLOOD RHEOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL132906_7529"}, {"internal_id": 49758703, "Award ID": "R01HL132891", "Award Amount": 2490706.59, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-20", "CFDA Number": "93.837", "Description": "NONHUMAN PRIMATE MODEL FOR PRECLINICAL EVALUATION OF HAPLOTYPE-BASED IPSC BANKING FOR HLA-MATCHED BLOOD PRODUCTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL132891_7529"}, {"internal_id": 49758683, "Award ID": "R01HL132791", "Award Amount": 3776636.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-05", "CFDA Number": "93.837", "Description": "HIV-SPECIFIC EX-VIVO EXPANDED T CELL THERAPY (HXTC) TO DEPLETE THE LATENT RESERVOIR OF PERSISTENT HIV INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL132791_7529"}, {"internal_id": 49758671, "Award ID": "R01HL132557", "Award Amount": 2319049.5, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-18", "CFDA Number": "93.837", "Description": "BIOLOGY AND APPLICATION OF PLATELET-DELIVERED FACTOR VIII", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL132557_7529"}, {"internal_id": 49758654, "Award ID": "R01HL132392", "Award Amount": 1937500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-29", "CFDA Number": "93.837", "Description": "ONCOGENIC NRAS SIGNALING IN LEUKEMIC STEM CELL TRANSFORMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL132392_7529"}, {"internal_id": 49758646, "Award ID": "R01HL132350", "Award Amount": 2594623.15, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-29", "CFDA Number": "93.837", "Description": "THE COLONIC MICROBIOTA AND IMMUNITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_R01HL132350_7529"}, {"internal_id": 49758641, "Award ID": "R01HL132325", "Award Amount": 1739996.92, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-16", "CFDA Number": "93.837", "Description": "THROMBOTIC COMPLICATION OF UREMIA: ROLE OF PROTHROMBOTIC UREMIC SOLUTES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "54768301-b245-c1c5-66ec-e0c90b049cc4-C", "generated_internal_id": "ASST_NON_R01HL132325_7529"}, {"internal_id": 49758629, "Award ID": "R01HL132251", "Award Amount": 1661167.78, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-31", "CFDA Number": "93.837", "Description": "THE ROLES AND REGULATION OF BRCA1 IN HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_R01HL132251_7529"}, {"internal_id": 49758621, "Award ID": "R01HL132198", "Award Amount": 2171736.27, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-26", "CFDA Number": "93.837", "Description": "METABOLIC DYSFUNCTION REGULATES MITOPHAGY-DEPENDENT NECROPTOSIS IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL132198_7529"}, {"internal_id": 49758620, "Award ID": "R01HL132194", "Award Amount": 1930781.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-02-14", "CFDA Number": "93.837", "Description": "NF-KB SIGNALING IN THE CONTROL OF HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R01HL132194_7529"}, {"internal_id": 49758616, "Award ID": "R01HL132171", "Award Amount": 1490423.71, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-16", "CFDA Number": "93.837", "Description": "NOVEL REGULATION OF CLEC-2 SIGNALING IN PLATELETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb9c32ae-42fd-5fe8-5d84-b798a26bb49d-C", "generated_internal_id": "ASST_NON_R01HL132171_7529"}, {"internal_id": 49758604, "Award ID": "R01HL132074", "Award Amount": 1980648.73, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-10", "CFDA Number": "93.837", "Description": "REGULATION OF HEMATOPOIETIC STEM CELLS AND LEUKEMIA STEM CELLS BY THROMBOPOIETIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL132074_7529"}, {"internal_id": 49758602, "Award ID": "R01HL132071", "Award Amount": 2447781.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-22", "CFDA Number": "93.837", "Description": "NOVEL SPLICEOSOMAL DEFECTS IN MYELODYSPLASTIC SYNDROMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL132071_7529"}, {"internal_id": 49758599, "Award ID": "R01HL132037", "Award Amount": 1887000.52, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-22", "CFDA Number": "93.837", "Description": "ADVANCED THROMBORESISTANT/BACTERICIDAL CATHETERS VIA ELECTROMODULATED NO RELEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL132037_7529"}, {"internal_id": 49758595, "Award ID": "R01HL132019", "Award Amount": 3290655.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-30", "CFDA Number": "93.837", "Description": "SINGLE-PLATELET ANALYSIS OF MECHANO-RECEPTION BY GPIB ALPHA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f7c481d7-071a-ead9-3bda-e4e7d1e903a7-C", "generated_internal_id": "ASST_NON_R01HL132019_7529"}, {"internal_id": 49758575, "Award ID": "R01HL131836", "Award Amount": 3913688.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-23", "CFDA Number": "93.837", "Description": "STRUCTURAL TRANSITION OF CELLULAR INTEGRINS AND APPLICATIONS THEREOF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R01HL131836_7529"}, {"internal_id": 49758574, "Award ID": "R01HL131835", "Award Amount": 3385988.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-15", "CFDA Number": "93.837", "Description": "FUNCTIONAL AND MOLECULAR DISSECTION OF MUTANT CALRETICULIN IN MYELOPROLIFERATIVE NEOPLASMS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL131835_7529"}, {"internal_id": 49758572, "Award ID": "R01HL131833", "Award Amount": 946030.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-01", "CFDA Number": "93.839", "Description": "MECHANISMS REGULATING FACTOR V ACTIVATION AND FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL131833_7529"}, {"internal_id": 49758559, "Award ID": "R01HL131768", "Award Amount": 2438647.78, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-07", "CFDA Number": "93.837", "Description": "STATISTICAL METHODS FOR ANALYSIS OF SINGLE-CELL VARIABILITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81e3f12d-5809-de22-dbd3-10b61910a90c-C", "generated_internal_id": "ASST_NON_R01HL131768_7529"}, {"internal_id": 49758556, "Award ID": "R01HL131750", "Award Amount": 2175785.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-10", "CFDA Number": "93.837", "Description": "MULTISCALE PREDICTIVE MODELING OF BLOOD CELL DAMAGE WITH EXPERIMENTAL VERIFICATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e8a1ed30-c6e7-a26e-e0a9-0a292a9ed2c8-C", "generated_internal_id": "ASST_NON_R01HL131750_7529"}, {"internal_id": 49758554, "Award ID": "R01HL131744", "Award Amount": 3264464.86, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-05", "CFDA Number": "93.837", "Description": "MOLECULAR GENETICS OF DYSKERATOSIS CONGENITA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL131744_7529"}, {"internal_id": 49758550, "Award ID": "R01HL131731", "Award Amount": 3604908.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-06", "CFDA Number": "93.837", "Description": "IDENTIFYING PREDICTORS OF POOR HEALTH-RELATED QUALITY-OF-LIFE AMONG PEDIATRIC HEMATOPOIETIC STEM CELL DONORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL131731_7529"}, {"internal_id": 49758548, "Award ID": "R01HL131729", "Award Amount": 3972906.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-20", "CFDA Number": "93.837", "Description": "STRUCTURES AND CONFORMATIONAL EQUILIBRIA OF INTEGRIN ALPHA5 BETA1", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL131729_7529"}, {"internal_id": 49758547, "Award ID": "R01HL131720", "Award Amount": 2742232.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-27", "CFDA Number": "93.837", "Description": "FRACTIONATION OF AGED RBCS BASED ON HEMOGLOBIN CONTENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL131720_7529"}, {"internal_id": 49758542, "Award ID": "R01HL131690", "Award Amount": 4014492.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-27", "CFDA Number": "93.837", "Description": "CHARACTERIZATION OF ENZYMES IN THE VITAMIN K CYCLE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL131690_7529"}, {"internal_id": 49758534, "Award ID": "R01HL131655", "Award Amount": 1525000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-12", "CFDA Number": "93.839", "Description": "REGULATION OF HEMATOPOIETIC NICHES BY TGF FAMILY SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL131655_7529"}, {"internal_id": 49758533, "Award ID": "R01HL131654", "Award Amount": 1670000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-25", "CFDA Number": "93.837", "Description": "KINDLIN-3 SIGNALING IN BLOOD CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R01HL131654_7529"}, {"internal_id": 49758530, "Award ID": "R01HL131645", "Award Amount": 1379723.06, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-15", "CFDA Number": "93.837", "Description": "BIOMECHANICAL STIMULATION OF HEMOGENIC ENDOTHELIAL CELLS TO DEVELOP CLINICAL-GRADE HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL131645_7529"}, {"internal_id": 49758515, "Award ID": "R01HL131579", "Award Amount": 1943106.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-30", "CFDA Number": "93.837", "Description": "CONTEMPORARY VENOUS THROMBOEMBOLISM TREATMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL131579_7529"}, {"internal_id": 49758493, "Award ID": "R01HL131444", "Award Amount": 1557386.68, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-15", "CFDA Number": "93.837", "Description": "THE ROLE OF EVI1-INDUCED HYPERMETHYLATION IN LEUKEMOGENESIS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R01HL131444_7529"}, {"internal_id": 49758489, "Award ID": "R01HL131414", "Award Amount": 2421226.76, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-22", "CFDA Number": "93.837", "Description": "IMPAIRED COLLATERAL VESSEL FORMATION IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL131414_7529"}, {"internal_id": 49758476, "Award ID": "R01HL131093", "Award Amount": 5080854.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-24", "CFDA Number": "93.837", "Description": "ENHANCING IMMUNE REGULATION IN GENE THERAPY FOR HEMOPHILIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL131093_7529"}, {"internal_id": 49758470, "Award ID": "R01HL131013", "Award Amount": 1411432.82, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-23", "CFDA Number": "93.837", "Description": "DEFINING ROLE OF FANCONI ANEMIA COMPLEMENTATION GROUP A PROTEIN IN DNA REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dbae4064-c48c-5002-9fca-21d077e0f96b-C", "generated_internal_id": "ASST_NON_R01HL131013_7529"}, {"internal_id": 49758466, "Award ID": "R01HL130995", "Award Amount": 2901470.82, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-05", "CFDA Number": "93.837", "Description": "GERMLINE MUTATIONS OF PTPN11 (SHP-2) IN THE STEM CELL MICROENVIRONMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL130995_7529"}, {"internal_id": 49758460, "Award ID": "R01HL130937", "Award Amount": 1969939.18, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-19", "CFDA Number": "93.837", "Description": "GENETIC CHARACTERIZATION OF OSTEOBLAST-INDUCED LEUKEMIAS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL130937_7529"}, {"internal_id": 49758459, "Award ID": "R01HL130918", "Award Amount": 2683585.27, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-06", "CFDA Number": "93.837", "Description": "PLATELET-LIKE PARTICLES FOR AUGMENTING HEMOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f7c481d7-071a-ead9-3bda-e4e7d1e903a7-C", "generated_internal_id": "ASST_NON_R01HL130918_7529"}, {"internal_id": 49758452, "Award ID": "R01HL130871", "Award Amount": 1930375.25, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-28", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF HIGHLY EFFICIENT FACTOR VIII MINI-GENE THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL130871_7529"}, {"internal_id": 49758450, "Award ID": "R01HL130864", "Award Amount": 1559646.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-09", "CFDA Number": "93.837", "Description": "LIVER-MEDIATED CLEARANCE OF LOW MOLECULAR WEIGHT HEPARINS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NE", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b80a61bf-aab0-2f35-db05-67fd682ea201-C", "generated_internal_id": "ASST_NON_R01HL130864_7529"}, {"internal_id": 49758448, "Award ID": "R01HL130856", "Award Amount": 2459998.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-23", "CFDA Number": "93.837", "Description": "POSTNATAL CELL-BASED THERAPIES FOR HEMOPHILIA A", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "623a4232-bd5e-fb60-cf01-48cd08a5a593-C", "generated_internal_id": "ASST_NON_R01HL130856_7529"}, {"internal_id": 49758437, "Award ID": "R01HL130793", "Award Amount": 2103195.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-09", "CFDA Number": "93.839", "Description": "MEGAKARYOCYTE TRANSCRIPTION FACTOR ACTIVATION TO ENHANCE IN VITRO PLATELET PRODUCTION FROM HUMAN IPSCS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL130793_7529"}, {"internal_id": 49758436, "Award ID": "R01HL130770", "Award Amount": 1608863.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-10", "CFDA Number": "93.839", "Description": "UNIVERSAL DONOR MEGAKARYOCYTES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL130770_7529"}, {"internal_id": 49758435, "Award ID": "R01HL130764", "Award Amount": 5005612.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-14", "CFDA Number": "93.837", "Description": "CLINICAL GRADE CULTURED RARE RED BLOOD CELLS AS REAGENTS AND FUTURE TRANSFUSION SUPPORT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_R01HL130764_7529"}, {"internal_id": 49758434, "Award ID": "R01HL130763", "Award Amount": 1454973.46, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-15", "CFDA Number": "93.837", "Description": "NITRIC OXIDE AND MICROVASCULAR DYSFUNCTION IN SEVERE MALARIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL130763_7529"}, {"internal_id": 49758433, "Award ID": "R01HL130760", "Award Amount": 1730126.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-10", "CFDA Number": "93.837", "Description": "GENERATING HUMAN CORD-BLOOD-DERIVED FUNCTIONAL MEGAKARYOCYTES AND PLATELETS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL130760_7529"}, {"internal_id": 49758432, "Award ID": "R01HL130750", "Award Amount": 2141264.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-15", "CFDA Number": "93.837", "Description": "VARIANT SURFACE ANTIGENS IN CEREBRAL MALARIA PATHOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R01HL130750_7529"}, {"internal_id": 49758430, "Award ID": "R01HL130733", "Award Amount": 2740952.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-31", "CFDA Number": "93.837", "Description": "SEQUENCE ANALYSIS OF HEMATOLOGICAL TRAITS IN AFRICAN AMERICANS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL130733_7529"}, {"internal_id": 49758429, "Award ID": "R01HL130724", "Award Amount": 3485201.03, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-15", "CFDA Number": "93.837", "Description": "B CELL RESPONSES IN HEPARIN-INDUCED THROMBOCYTOPENIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R01HL130724_7529"}, {"internal_id": 49758426, "Award ID": "R01HL130698", "Award Amount": 2149392.69, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-06", "CFDA Number": "93.837", "Description": "OPTIMIZATION OF EX VIVO- AND IN VIVO- GENERATED PLATELETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL130698_7529"}, {"internal_id": 49758425, "Award ID": "R01HL130678", "Award Amount": 2017250.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-15", "CFDA Number": "93.839", "Description": "DISCOVERY OF NOVEL VASCULAR THERAPIES TARGETING PFEMP1-MEDIATED CYTOADHESION IN SEVERE MALARIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL130678_7529"}, {"internal_id": 49758424, "Award ID": "R01HL130676", "Award Amount": 1839106.93, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-09", "CFDA Number": "93.837", "Description": "GENETICALLY ENHANCED HUMAN ERYTHROCYTES GENERATED FROM EXPANDABLE STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL130676_7529"}, {"internal_id": 49758423, "Award ID": "R01HL130670", "Award Amount": 1802215.22, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-05", "CFDA Number": "93.837", "Description": "ERYTHROID PRECURSOR SELF-RENEWAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL130670_7529"}, {"internal_id": 49758421, "Award ID": "R01HL130649", "Award Amount": 1968333.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-15", "CFDA Number": "93.837", "Description": "BRAIN VASCULAR DYSFUNCTION IN CEREBRAL MALARIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b6dc42ce-58e8-f765-63c8-78a4ac68629d-R", "generated_internal_id": "ASST_NON_R01HL130649_7529"}, {"internal_id": 49758420, "Award ID": "R01HL130630", "Award Amount": 2095995.79, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-15", "CFDA Number": "93.837", "Description": "BETA-CATENIN SIGNALING IN ENDOTHELIAL CELLS DURING CEREBRAL MALARIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c07787b9-15d4-d1eb-4f0c-2e0b30320bfb-C", "generated_internal_id": "ASST_NON_R01HL130630_7529"}, {"internal_id": 49758419, "Award ID": "R01HL130624", "Award Amount": 1821385.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-15", "CFDA Number": "93.839", "Description": "VASCULAR DYSFUNCTION IN THE PATHOGENESIS OF SEVERE MALARIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "55f37363-0a0a-cf69-f770-ef6464f3ff05-C", "generated_internal_id": "ASST_NON_R01HL130624_7529"}, {"internal_id": 49758412, "Award ID": "R01HL130550", "Award Amount": 1928408.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-09", "CFDA Number": "93.839", "Description": "CONTROLLING AN ONTOGENIC MASTERSWITCH TO MAXIMIZE THROMBOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL130550_7529"}, {"internal_id": 49758399, "Award ID": "R01HL130488", "Award Amount": 2217586.92, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-11", "CFDA Number": "93.837", "Description": "3D HUMAN-BASED MICROVESSEL BED FOR THE STUDY OF PLASMODIUM FALCIPARUM INTERACTING WITH VESSEL WALL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_R01HL130488_7529"}, {"internal_id": 49758395, "Award ID": "R01HL130472", "Award Amount": 1740000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-11", "CFDA Number": "93.837", "Description": "PATHOGENESIS OF ELANE-ASSOCIATED NEUTROPENIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL130472_7529"}, {"internal_id": 49758390, "Award ID": "R01HL130448", "Award Amount": 1526274.97, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-01", "CFDA Number": "93.837", "Description": "DESIGN OF LESS IMMUNOGENIC FACTOR VIII PROTEINS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3e4caa6c-ea4b-e402-0001-860fad11861b-C", "generated_internal_id": "ASST_NON_R01HL130448_7529"}, {"internal_id": 49758389, "Award ID": "R01HL130446", "Award Amount": 1574298.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-28", "CFDA Number": "93.839", "Description": "ALLOSTERIC REGULATION OF ADAMTS13", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL130446_7529"}, {"internal_id": 49758381, "Award ID": "R01HL130404", "Award Amount": 1139684.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-10", "CFDA Number": "93.839", "Description": "RAP1 SIGNALING IN PLATELET HOMEOSTASIS AND VASCULAR HEMOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL130404_7529"}, {"internal_id": 49758377, "Award ID": "R01HL130388", "Award Amount": 1340638.06, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-15", "CFDA Number": "93.837", "Description": "IMPROVING THE AVAILABILITY OF YOUNGER UNRELATED HEMATOPOIETIC STEM CELL DONORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL130388_7529"}, {"internal_id": 49758368, "Award ID": "R01HL130330", "Award Amount": 1768372.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-22", "CFDA Number": "93.837", "Description": "PROTEOSTATIC MECHANISMS OF RESISTANCE IN MALARIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "65f6d07a-5df8-713f-2495-b8e648f44f20-C", "generated_internal_id": "ASST_NON_R01HL130330_7529"}, {"internal_id": 49758328, "Award ID": "R01HL130142", "Award Amount": 1619790.78, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-03", "CFDA Number": "93.837", "Description": "MECHANISTIC STUDIES AND TRANSLATIONAL APPLICATIONS OF STRESS SIGNALING IN ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL130142_7529"}, {"internal_id": 49758327, "Award ID": "R01HL130139", "Award Amount": 2132445.95, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-26", "CFDA Number": "93.837", "Description": "MECHANISMS CONTROLLING TRANSFUSION-ASSOCIATED ANTIBODY RESPONSES IN SCD ALLOIMMUNIZATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "644797d6-c94c-9e2c-b40a-a4cda190c447-C", "generated_internal_id": "ASST_NON_R01HL130139_7529"}, {"internal_id": 49758318, "Award ID": "R01HL130090", "Award Amount": 1584293.76, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-23", "CFDA Number": "93.837", "Description": "DYNAMIC REGULATION OF THROMBOSIS BY THE PLATELET PROTEOME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL130090_7529"}, {"internal_id": 49758309, "Award ID": "R01HL130054", "Award Amount": 1020928.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-28", "CFDA Number": "93.839", "Description": "GENERATION OF ALLOANTIGEN-SPECIFIC DESIGNER PLATELETS FOR DIAGNOSTIC AND INVESTIGATIVE USE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R01HL130054_7529"}, {"internal_id": 49758304, "Award ID": "R01HL130040", "Award Amount": 3009788.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-19", "CFDA Number": "93.837", "Description": "IN VIVO HEMATOPOIETIC STEM CELL GENE THERAPY OF BETA-THALASSEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL130040_7529"}, {"internal_id": 49758301, "Award ID": "R01HL130034", "Award Amount": 1616821.86, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-23", "CFDA Number": "93.837", "Description": "THE CEBPA ENHANCER IN NORMAL HEMATOPOIESIS AND PROGRESSION TO AML", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL130034_7529"}, {"internal_id": 49758298, "Award ID": "R01HL130018", "Award Amount": 1589338.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-19", "CFDA Number": "93.837", "Description": "MECHANISMS OF GLYCOSAMINOGLYCAN-CATALYZED PROTEASE INACTIVATION BY SERPINS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL130018_7529"}, {"internal_id": 49758273, "Award ID": "R01HL129763", "Award Amount": 1550000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.839", "Description": "SHP2 AND PTEN IN LEUKEMIA AND ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL129763_7529"}, {"internal_id": 49758265, "Award ID": "R01HL129506", "Award Amount": 3548244.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-20", "CFDA Number": "93.837", "Description": "IMMUNE PRIVILEGE OF THE HEMATOPOIEITIC STEM CELL NICHE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_R01HL129506_7529"}, {"internal_id": 49758264, "Award ID": "R01HL129472", "Award Amount": 2566726.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-05-12", "CFDA Number": "93.837", "Description": "SELECTION OF ALLOGENEIC HEMATOPOIETIC CELL DONOR BASED ON KIR AND HLA GENOTYPES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b514fc3a-d769-87e9-75ea-7a6766afb5ee-C", "generated_internal_id": "ASST_NON_R01HL129472_7529"}, {"internal_id": 49758261, "Award ID": "R01HL129241", "Award Amount": 5243582.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-07", "CFDA Number": "93.837", "Description": "MR-DERIVED CEREBRAL BLOOD FLOW AND OXYGEN METABOLISM TO STRATIFY STROKE RISK IN PEDIATRIC SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL129241_7529"}, {"internal_id": 49758255, "Award ID": "R01HL129179", "Award Amount": 1813465.75, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.837", "Description": "PLATELET-INSPIRED DELIVERY SYSTEM FOR TARGETED THROMBOLYTIC THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R01HL129179_7529"}, {"internal_id": 65894565, "Award ID": "R01HL129141", "Award Amount": 1986420.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-30", "CFDA Number": "93.837", "Description": "A MICROFLUIDICS-BASED PARADIGM FOR CLINICAL LENTIVECTOR GENE TRANSFER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL129141_7529"}, {"internal_id": 49758248, "Award ID": "R01HL129132", "Award Amount": 2588105.55, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-11", "CFDA Number": "93.837", "Description": "GENETIC STUDIES OF BLOOD CELL TRAITS IN MULTI-ETHNIC COHORTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL129132_7529"}, {"internal_id": 49758244, "Award ID": "R01HL129061", "Award Amount": 5417613.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-04", "CFDA Number": "93.837", "Description": "PATHOLOGICAL B CELLS: NOVEL STRATEGIES TO PREVENT AND TREAT CHRONIC GVHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL129061_7529"}, {"internal_id": 49758241, "Award ID": "R01HL129011", "Award Amount": 1925000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-13", "CFDA Number": "93.839", "Description": "HUMAN TYR-TRNA SYNTHETASE AS A POTENT EFFECTOR OF MEGAKARYOCYTOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL129011_7529"}, {"internal_id": 49758233, "Award ID": "R01HL128895", "Award Amount": 1980180.35, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.837", "Description": "STRUCTURAL ANALYSIS OF THE HIT IMMUNE COMPLEX", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL128895_7529"}, {"internal_id": 49758231, "Award ID": "R01HL128850", "Award Amount": 4245903.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-15", "CFDA Number": "93.837", "Description": "CLONAL ANALYSIS OF HEMATOPOIETIC STEM AND PROGENITOR BIOLOGY IN SITU", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL128850_7529"}, {"internal_id": 49758193, "Award ID": "R01HL128580", "Award Amount": 1531250.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-11", "CFDA Number": "93.837", "Description": "IMPROVING VASCULAR FUNCTION AND BACTERIAL CLEARANCE DURING INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL128580_7529"}, {"internal_id": 49758189, "Award ID": "R01HL128551", "Award Amount": 1680000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-30", "CFDA Number": "93.837", "Description": "CROSSTALK BETWEEN T CELLS AND INFLAMED ENDOTHELIUM: REGULATION BY CRK FAMILY PROTEINS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL128551_7529"}, {"internal_id": 49758167, "Award ID": "R01HL128452", "Award Amount": 4113109.71, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-07", "CFDA Number": "93.837", "Description": "VASCULAR NETWORKS GENETICALLY ENGINEERED FOR PROTEIN DRUG DELIVERY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL128452_7529"}, {"internal_id": 49758166, "Award ID": "R01HL128447", "Award Amount": 1906245.02, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-11", "CFDA Number": "93.837", "Description": "RETINOIDS IN HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL128447_7529"}, {"internal_id": 49758157, "Award ID": "R01HL128390", "Award Amount": 1714947.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-14", "CFDA Number": "93.839", "Description": "PLATELET CLEC-2 REGULATION OF VASCULAR INTEGRITY DURING INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OK", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "36c41119-2158-d09a-55ce-00590b81ab14-C", "generated_internal_id": "ASST_NON_R01HL128390_7529"}, {"internal_id": 49758151, "Award ID": "R01HL128371", "Award Amount": 3689221.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-18", "CFDA Number": "93.837", "Description": "MECHANISMS OF INFLAMMATION IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL128371_7529"}, {"internal_id": 49758134, "Award ID": "R01HL128297", "Award Amount": 3355833.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-07", "CFDA Number": "93.837", "Description": "PULMONARY ARTERIOLE OCCLUSION BY PLATELET-NEUTROPHIL MICRO-EMBOLI IN ACUTE CHEST SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL128297_7529"}, {"internal_id": 49758129, "Award ID": "R01HL128264", "Award Amount": 3331868.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-28", "CFDA Number": "93.839", "Description": "LIFESTYLE EFFECTS ON HEMATOPOIESIS AND ATHEROSCLEROSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL128264_7529"}, {"internal_id": 49758124, "Award ID": "R01HL128239", "Award Amount": 6404471.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-24", "CFDA Number": "93.837", "Description": "GENETIC AND MOLECULAR BASIS FOR SRSF2 MUTATIONS IN MYELODYSPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "569197a4-81d0-b264-5640-e9db4cf71fd0-C", "generated_internal_id": "ASST_NON_R01HL128239_7529"}, {"internal_id": 49758123, "Award ID": "R01HL128237", "Award Amount": 1742600.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-30", "CFDA Number": "93.837", "Description": "A PSGL-1 GLYCOPEPTIDE MIMETIC FOR TREATMENT OF VENOUS THROMBOEMBOLISM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_R01HL128237_7529"}, {"internal_id": 49758122, "Award ID": "R01HL128234", "Award Amount": 1583697.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-23", "CFDA Number": "93.837", "Description": "AN INTEGRATIVE APPROACH TO FUNCTIONALIZE GWAS HITS IN MI AND STROKE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_R01HL128234_7529"}, {"internal_id": 49758113, "Award ID": "R01HL128173", "Award Amount": 2475856.03, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-15", "CFDA Number": "93.837", "Description": "MULTISCALE MODELING OF MYELODYSPLASTIC SYNDROMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_R01HL128173_7529"}, {"internal_id": 49758109, "Award ID": "R01HL128158", "Award Amount": 3092712.69, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-23", "CFDA Number": "93.837", "Description": "DECIPHERING MOLECULAR DETERMINANTS OF VASCULAR HETEROGENEITY FOR ORGAN REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL128158_7529"}, {"internal_id": 49758107, "Award ID": "R01HL128155", "Award Amount": 2235945.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-27", "CFDA Number": "93.839", "Description": "ROLE OF TETHERIN IN HIV-ASSOCIATED THROMSOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ee8636d0-3f78-fbb3-4346-eb49aabbb2b3-C", "generated_internal_id": "ASST_NON_R01HL128155_7529"}, {"internal_id": 49758106, "Award ID": "R01HL128139", "Award Amount": 1917006.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-17", "CFDA Number": "93.839", "Description": "DEVELOPMENT OF CLINICALLY FEASIBLE ULTRASOUND-MEDIATED GENE THERAPY FOR HEMOPHILIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_R01HL128139_7529"}, {"internal_id": 49758104, "Award ID": "R01HL128119", "Award Amount": 3032223.72, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-02", "CFDA Number": "93.837", "Description": "LENTIVIRAL VECTOR-BASED GENE THERAPY AND THE HOST GENETIC BACKGROUND", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL128119_7529"}, {"internal_id": 49758096, "Award ID": "R01HL128064", "Award Amount": 2594200.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-25", "CFDA Number": "93.839", "Description": "SPECIFICATION OF HEMOGENIC ENDOTHELIAL CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL128064_7529"}, {"internal_id": 49758092, "Award ID": "R01HL128046", "Award Amount": 2122868.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-17", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF NOVEL STRATEGY FOR TREATMENT OF STEROID REFRACTORY GVHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL128046_7529"}, {"internal_id": 49758087, "Award ID": "R01HL127895", "Award Amount": 2104236.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-29", "CFDA Number": "93.837", "Description": "THE ROLE OF CHROMATIN STRUCTURE IN DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_R01HL127895_7529"}, {"internal_id": 49758082, "Award ID": "R01HL127766", "Award Amount": 3146307.09, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-11", "CFDA Number": "93.837", "Description": "BLOOD DONOR COMPETENCE, AUTONOMY AND RELATEDNESS ENHANCEMENT (BLOOD DONOR CARE)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c5a7a8b2-6594-d1dd-547b-4d52ca715071-C", "generated_internal_id": "ASST_NON_R01HL127766_7529"}, {"internal_id": 49758051, "Award ID": "R01HL127449", "Award Amount": 1683893.21, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-31", "CFDA Number": "93.837", "Description": "ENDOCYTIC REGULATION OF INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68c287e4-398a-6c6b-c0db-5ce9430c6ce3-C", "generated_internal_id": "ASST_NON_R01HL127449_7529"}, {"internal_id": 49758039, "Award ID": "R01HL127351", "Award Amount": 2379438.42, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-28", "CFDA Number": "93.837", "Description": "EZH2-MEDIATED EPIGENETIC EFFECTS AND ALLOIMMUNITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb9c32ae-42fd-5fe8-5d84-b798a26bb49d-C", "generated_internal_id": "ASST_NON_R01HL127351_7529"}, {"internal_id": 49758009, "Award ID": "R01HL127107", "Award Amount": 3609044.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-08", "CFDA Number": "93.837", "Description": "NEUROVASCULAR DETERMINANTS OF COGNITIVE FUNCTION IN ADULTS WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL127107_7529"}, {"internal_id": 49758001, "Award ID": "R01HL127041", "Award Amount": 1435923.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-11", "CFDA Number": "93.837", "Description": "FUNCTIONAL DYNAMICS OF THROMBIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL127041_7529"}, {"internal_id": 49757988, "Award ID": "R01HL126974", "Award Amount": 3757653.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-12", "CFDA Number": "93.837", "Description": "FIBRINOGEN AND FACTOR XIII IN VENOUS THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL126974_7529"}, {"internal_id": 49757982, "Award ID": "R01HL126947", "Award Amount": 1574675.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-26", "CFDA Number": "93.837", "Description": "EPIGENETIC BIOMARKERS OF RESPONSE TO AZACYTIDINE IN MYELODYSPLASTIC SYNDROMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dbae4064-c48c-5002-9fca-21d077e0f96b-C", "generated_internal_id": "ASST_NON_R01HL126947_7529"}, {"internal_id": 49757981, "Award ID": "R01HL126945", "Award Amount": 1692790.85, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-19", "CFDA Number": "93.837", "Description": "ATTENUATING THE OXIDATIVE AND MYOCARDIAL SIDE-EFFECTS OF ACELLULAR HEMOGLOBIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL126945_7529"}, {"internal_id": 49757969, "Award ID": "R01HL126900", "Award Amount": 3330724.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-31", "CFDA Number": "93.837", "Description": "RESTORATION AND FUNCTION OF S-NITROSOTHIOL IN STORED BLOOD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R01HL126900_7529"}, {"internal_id": 49757961, "Award ID": "R01HL126864", "Award Amount": 1490000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-01", "CFDA Number": "93.839", "Description": "UPSTREAM PRIMING OF PLATELETS FOR ADHESION TO BIOMATERIALS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_R01HL126864_7529"}, {"internal_id": 49757958, "Award ID": "R01HL126850", "Award Amount": 2100000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-23", "CFDA Number": "93.837", "Description": "NOVEL FACTOR VIII VARIANTS FOR IMPROVED EFFICACY IN GENE THERAPY FOR HEMOPHILIA A", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL126850_7529"}, {"internal_id": 49757952, "Award ID": "R01HL126810", "Award Amount": 1864976.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-28", "CFDA Number": "93.837", "Description": "MECHANISM OF TYPE 4 COLLAGEN INTERACTIONS WITH VON WILLEBRAND FACTOR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL126810_7529"}, {"internal_id": 49757938, "Award ID": "R01HL126743", "Award Amount": 1670000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-29", "CFDA Number": "93.837", "Description": "ENDOCYTOSIS IN PLATELET AND MEGAKARYOCYTE BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R01HL126743_7529"}, {"internal_id": 49757931, "Award ID": "R01HL126727", "Award Amount": 3205564.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-05-06", "CFDA Number": "93.837", "Description": "ANITGEN SPECIFIC HUMAN T REGULATORY CELL SUPPRESSION OF CCR6 POSITIVE TH17 CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3e4caa6c-ea4b-e402-0001-860fad11861b-C", "generated_internal_id": "ASST_NON_R01HL126727_7529"}, {"internal_id": 49757930, "Award ID": "R01HL126724", "Award Amount": 1833330.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-07", "CFDA Number": "93.839", "Description": "PATHOGENESIS OF THROMBOTIC MICROANGIOPATHY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL126724_7529"}, {"internal_id": 49757916, "Award ID": "R01HL126645", "Award Amount": 2033163.02, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-28", "CFDA Number": "93.837", "Description": "MRP-14, CD36 AND THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R01HL126645_7529"}, {"internal_id": 49757909, "Award ID": "R01HL126589", "Award Amount": 1687607.11, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-08", "CFDA Number": "93.837", "Description": "COST EFFECTIVENESS ANALYSIS OF STEM CELL TRANSPLANT IN OLDER MDS PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_R01HL126589_7529"}, {"internal_id": 49757908, "Award ID": "R01HL126585", "Award Amount": 1471216.89, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-16", "CFDA Number": "93.837", "Description": "BLOOD BASED BIOMARKERS OF INJURY AND OUTCOME IN THE PREHOSPITAL TXA FOR TBI TRIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R01HL126585_7529"}, {"internal_id": 49757905, "Award ID": "R01HL126559", "Award Amount": 3284302.78, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-12", "CFDA Number": "93.837", "Description": "NOVEL ROLE OF OCCLUDIN AND PERICYTES IN ISCHEMIC STROKE IN HIV INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": 148376.0, "Infrastructure Obligations": null, "recipient_id": "dbae4064-c48c-5002-9fca-21d077e0f96b-C", "generated_internal_id": "ASST_NON_R01HL126559_7529"}, {"internal_id": 49757899, "Award ID": "R01HL126547", "Award Amount": 2964497.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-12", "CFDA Number": "93.839", "Description": "THE EFFECTS OF ART ON PLATELETS AND HIV-ASSOCIATED THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_R01HL126547_7529"}, {"internal_id": 49757897, "Award ID": "R01HL126542", "Award Amount": 2286021.15, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-15", "CFDA Number": "93.837", "Description": "TARGETED ANTICOAGULANT THERAPY TO REDUCE INFLAMMATION IN TREATED HIV DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f10584e0-4a99-ce44-a15c-ccb5c8c8b3f5-C", "generated_internal_id": "ASST_NON_R01HL126542_7529"}, {"internal_id": 49757896, "Award ID": "R01HL126538", "Award Amount": 3777655.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-26", "CFDA Number": "93.837", "Description": "CARDIOVASCULAR, PULMONARY & HEMATOLOGICAL DISEASE IN HIV: PREVENTION & TREATMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL126538_7529"}, {"internal_id": 49757890, "Award ID": "R01HL126518", "Award Amount": 3134656.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-24", "CFDA Number": "93.837", "Description": "GTPASES AS MOLECULAR GATEKEEPERS OF CYTOSKELETAL AND CELLULAR POLARIZATION DURING ENDOTHELIAL TUBULOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_R01HL126518_7529"}, {"internal_id": 49757876, "Award ID": "R01HL126166", "Award Amount": 3557495.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-10", "CFDA Number": "93.837", "Description": "ROLE OF INTERLEUKIN 23 IN GASTROINTESTINAL GVHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL126166_7529"}, {"internal_id": 49757873, "Award ID": "R01HL126130", "Award Amount": 1923016.9, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-23", "CFDA Number": "93.837", "Description": "EFFECTS OF BLOOD CONSERVATION AND DONOR CHARACTERISTICS ON TRANSFUSED PATIENT OUTCOMES IN A LARGE COMMUNITY HOSPITAL NETWORK", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d192652e-3551-3991-1674-6885c846fff2-C", "generated_internal_id": "ASST_NON_R01HL126130_7529"}, {"internal_id": 49757871, "Award ID": "R01HL126124", "Award Amount": 1527209.66, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-10", "CFDA Number": "93.837", "Description": "PLATELET AADACL1 IN THROMBOSIS, LIPIDOMICS AND SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL126124_7529"}, {"internal_id": 49757866, "Award ID": "R01HL126076", "Award Amount": 2123956.91, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-15", "CFDA Number": "93.837", "Description": "PROTECTING FETUSES AND NEWBORNS FROM MATERNAL RBC ALLOANTIBODIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL126076_7529"}, {"internal_id": 49757859, "Award ID": "R01HL125957", "Award Amount": 2529398.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-15", "CFDA Number": "93.837", "Description": "VWF ACTIVITY: MOLECULAR BIOLOGY, ETHNIC DIVERSITY AND DISEASE ASSOCIATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "474a19eb-1491-c065-a3ca-a49b264b0d4b-C", "generated_internal_id": "ASST_NON_R01HL125957_7529"}, {"internal_id": 49757852, "Award ID": "R01HL125886", "Award Amount": 5215139.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-24", "CFDA Number": "93.837", "Description": "ANTIDOTE FOR INHALED CO POISONING BASED ON MUTATIONALLY ENGINEERED NEUROGLOBIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL125886_7529"}, {"internal_id": 49757836, "Award ID": "R01HL125774", "Award Amount": 899050.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-11", "CFDA Number": "93.839", "Description": "IDENTIFICATION OF NOVEL THERAPEUTICS FOR HEMOSTATIC DISORDERS USING ZEBRAFISH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL125774_7529"}, {"internal_id": 49757835, "Award ID": "R01HL125761", "Award Amount": 4106423.32, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-25", "CFDA Number": "93.837", "Description": "CHILDHOOD ADVERSITY AND CARDIOVASCULAR HEALTH AMONG PUERTO RICAN YOUTH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL125761_7529"}, {"internal_id": 49757833, "Award ID": "R01HL125749", "Award Amount": 1519918.1, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-02", "CFDA Number": "93.837", "Description": "DIRECTED EVOLUTION OF AAV VECTORS FOR HEMOPHILIA TO EVADE NEUTRALIZATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL125749_7529"}, {"internal_id": 49757827, "Award ID": "R01HL125710", "Award Amount": 1903839.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-05-15", "CFDA Number": "93.839", "Description": "A NOVEL PROGRAM OF UBIQUITINATION IN GLOBAL REMODELING OF THE ERYTHROID PROTEOME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81e3f12d-5809-de22-dbd3-10b61910a90c-C", "generated_internal_id": "ASST_NON_R01HL125710_7529"}, {"internal_id": 49757809, "Award ID": "R01HL125571", "Award Amount": 2804817.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-01", "CFDA Number": "93.837", "Description": "REGULATION OF THE INTESTINAL STEM CELL COMPARTMENT AFTER HEMATOPOIETIC TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b514fc3a-d769-87e9-75ea-7a6766afb5ee-C", "generated_internal_id": "ASST_NON_R01HL125571_7529"}, {"internal_id": 49757807, "Award ID": "R01HL125527", "Award Amount": 1763375.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-01", "CFDA Number": "93.837", "Description": "STEM CELL-SPECIFIC TRANSCRIPTIONAL CONTROL BY DYSKERIN RIBONUCLEOPROTEIN COMPLEX", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL125527_7529"}, {"internal_id": 49757792, "Award ID": "R01HL125422", "Award Amount": 1035556.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-17", "CFDA Number": "93.839", "Description": "MACROMOLECULAR RECOGNITION IN BLOOD COAGULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL125422_7529"}, {"internal_id": 49757786, "Award ID": "R01HL125371", "Award Amount": 3350254.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-15", "CFDA Number": "93.837", "Description": "ENDOTHELIAL GLYCOCALYX RECONSTITUTION DURING SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL125371_7529"}, {"internal_id": 49757785, "Award ID": "R01HL125356", "Award Amount": 3422019.84, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-15", "CFDA Number": "93.837", "Description": "NEW STRATEGIES FOR TREATING SEPTIC VASCULOPATHY, INFLAMMATION AND THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL125356_7529"}, {"internal_id": 49757784, "Award ID": "R01HL125353", "Award Amount": 3858085.53, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-15", "CFDA Number": "93.837", "Description": "THE FUNCTIONAL ROLE OF THE CPLA2ALPHA/C1P INTERACTION IN SEPSIS RESOLUTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ceec5ef7-d6a5-28f0-e23f-ec61155b7078-C", "generated_internal_id": "ASST_NON_R01HL125353_7529"}, {"internal_id": 49757783, "Award ID": "R01HL125352", "Award Amount": 3567463.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-15", "CFDA Number": "93.837", "Description": "GLYCOPROTEIN REMODELING IN THE VASCULOPATHY AND COAGULOPATHY OF SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2e3fd571-0484-5e6b-3e26-4381689012c6-C", "generated_internal_id": "ASST_NON_R01HL125352_7529"}, {"internal_id": 49757782, "Award ID": "R01HL125350", "Award Amount": 3180430.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-15", "CFDA Number": "93.837", "Description": "REPAIR MECHANISMS OF SEPSIS INDUCED ENDOTHELIAL DYSFUNCTION AND LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL125350_7529"}, {"internal_id": 49757781, "Award ID": "R01HL125339", "Award Amount": 2822906.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-12", "CFDA Number": "93.837", "Description": "NANO-AGENT FOR PHOTOACOUSTIC THERANOSTICS OF DIALYSIS GRAFT/FISTULA OCCLUSIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL125339_7529"}, {"internal_id": 49757777, "Award ID": "R01HL125279", "Award Amount": 1480000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-30", "CFDA Number": "93.839", "Description": "NON-PLATELET P2Y RECEPTOR IN VASCULAR INFLAMMATION AND THROMBOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dff5ea13-87ef-1d23-7ba0-fbf570ef2475-C", "generated_internal_id": "ASST_NON_R01HL125279_7529"}, {"internal_id": 49757776, "Award ID": "R01HL125275", "Award Amount": 4215520.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-15", "CFDA Number": "93.837", "Description": "TARGETING THE ENDOTHELIUM IN SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_R01HL125275_7529"}, {"internal_id": 49757775, "Award ID": "R01HL125265", "Award Amount": 3913600.03, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-17", "CFDA Number": "93.837", "Description": "NEUTROPHIL-ENDOTHELIAL INTERACTIONS AND BARRIER FUNCTION IN SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL125265_7529"}, {"internal_id": 49757767, "Award ID": "R01HL125183", "Award Amount": 2515885.69, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-05-12", "CFDA Number": "93.837", "Description": "IMPROVING ENGRAFTMENT OF HEMATOPOIETIC STEM CELL GENE THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_R01HL125183_7529"}, {"internal_id": 49757763, "Award ID": "R01HL125089", "Award Amount": 4854670.89, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-01", "CFDA Number": "93.837", "Description": "EHR ANTICOAGULANTS PHARMACOVIGILANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f7fcd53-a62a-0ccf-e3e6-c6b54ddb6fd2-C", "generated_internal_id": "ASST_NON_R01HL125089_7529"}, {"internal_id": 49757751, "Award ID": "R01HL125030", "Award Amount": 1540000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-06", "CFDA Number": "93.839", "Description": "SURVIVAL OF THE FITTEST HSPC REPOPULATING CLONES BY ANTI-HIV-1 GENE-MODIFICATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R01HL125030_7529"}, {"internal_id": 49757749, "Award ID": "R01HL125016", "Award Amount": 1484238.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-06", "CFDA Number": "93.839", "Description": "ROLE OF PD-1H MEDIATED MONOCYTE ACTIVATION IN HIV PATHOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30f9aa19-2773-fb77-2e44-59c99374edf2-C", "generated_internal_id": "ASST_NON_R01HL125016_7529"}, {"internal_id": 49757748, "Award ID": "R01HL125005", "Award Amount": 5234194.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-02", "CFDA Number": "93.837", "Description": "INHIBITION OF HIV-1 IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ab2545e4-42db-b0e5-c4ac-2382eeaf8c92-C", "generated_internal_id": "ASST_NON_R01HL125005_7529"}, {"internal_id": 49757745, "Award ID": "R01HL124945", "Award Amount": 3151300.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-26", "CFDA Number": "93.839", "Description": "HL-PHENOTYPIC CHARACTERIZATION OF CHRONIC PAIN IN ADULTS WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL124945_7529"}, {"internal_id": 49757727, "Award ID": "R01HL124315", "Award Amount": 1512834.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.837", "Description": "ULTRA-RARE CELL IN VIVO FLOW CYTOMETRY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4787a47d-4e7a-9c8a-99e6-91ba7f4c9b8b-C", "generated_internal_id": "ASST_NON_R01HL124315_7529"}, {"internal_id": 49757717, "Award ID": "R01HL124232", "Award Amount": 1891897.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-10", "CFDA Number": "93.839", "Description": "DISSECTING THE GENETICS OF HUMAN HEMOSTATIC DISORDERS USING ZEBRAFISH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL124232_7529"}, {"internal_id": 49757714, "Award ID": "R01HL124209", "Award Amount": 2210417.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-21", "CFDA Number": "93.837", "Description": "DEFINING THE ROLES OF RIPK1 AND RIPK3 IN EMERGENCY HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL124209_7529"}, {"internal_id": 49757709, "Award ID": "R01HL124159", "Award Amount": 4227972.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-15", "CFDA Number": "93.837", "Description": "PHOSPHATASE AND TENSIN HOMOLOG PTEN ACTIONS IN POLYMICROBIAL SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL124159_7529"}, {"internal_id": 49757706, "Award ID": "R01HL124122", "Award Amount": 2058022.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-17", "CFDA Number": "93.837", "Description": "OXIDIZED LOW-DENSITY LIPOPROTEIN IMPAIRS BONE MARROW STEM CELL SURVIVAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01HL124122_7529"}, {"internal_id": 49757703, "Award ID": "R01HL124112", "Award Amount": 6024330.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.837", "Description": "MICROBIOTA-FOCUSED STRATEGIES TO MITIGATE GVHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "07c08a07-af34-2853-20eb-9d2594ed7b35-C", "generated_internal_id": "ASST_NON_R01HL124112_7529"}, {"internal_id": 49757702, "Award ID": "R01HL124106", "Award Amount": 3102639.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-01", "CFDA Number": "93.837", "Description": "NANOSCIENCE OF 'SELF' - REDUCTIONIST APPROACHES TO HCD47 INHIBITION OF PHAGOCYTES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL124106_7529"}, {"internal_id": 49757695, "Award ID": "R01HL124078", "Award Amount": 1518767.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-26", "CFDA Number": "93.837", "Description": "RED CELL TRANSFUSION-ASSOCIATED NECROTIZING ENTEROCOLITIS IN PREMATURE INFANTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL124078_7529"}, {"internal_id": 49757692, "Award ID": "R01HL124055", "Award Amount": 3278132.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-15", "CFDA Number": "93.837", "Description": "MEMBRANE PHOSPHOLIPIDS: THE KEY REGULATOR OF TISSUE FACTOR ENCRYPTION/DECRYPTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6605b60b-2165-8c36-e954-428aa458f579-C", "generated_internal_id": "ASST_NON_R01HL124055_7529"}, {"internal_id": 49757687, "Award ID": "R01HL124018", "Award Amount": 1533523.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-12", "CFDA Number": "93.839", "Description": "NOVEL PLATELET FUNCTIONS FOR IN T-CELL HELPER CELL RESPONSES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_R01HL124018_7529"}, {"internal_id": 49757686, "Award ID": "R01HL124015", "Award Amount": 3171058.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-12-19", "CFDA Number": "93.837", "Description": "LATEXIN FUNCTION IN THE MAINTENANCE AND REGENERATION OF THE HEMATOPOIETIC SYSTEM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "644797d6-c94c-9e2c-b40a-a4cda190c447-C", "generated_internal_id": "ASST_NON_R01HL124015_7529"}, {"internal_id": 49757685, "Award ID": "R01HL123984", "Award Amount": 1557592.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-13", "CFDA Number": "93.837", "Description": "GPIBALPHA SHEDDING AND PLATELET CLEARANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL123984_7529"}, {"internal_id": 49757676, "Award ID": "R01HL123927", "Award Amount": 1533513.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-24", "CFDA Number": "93.839", "Description": "CROSSTALK BETWEEN MEMBRANE TRAFFIC PROTEINS AND INTEGRIN ACTIVATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c477975b-68db-c3dc-4a79-b95cb9f6ab3e-C", "generated_internal_id": "ASST_NON_R01HL123927_7529"}, {"internal_id": 49757672, "Award ID": "R01HL123912", "Award Amount": 1697924.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-02", "CFDA Number": "93.839", "Description": "ALPHA-DEFENSINS IN PERIOPERATIVE THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL123912_7529"}, {"internal_id": 49757671, "Award ID": "R01HL123904", "Award Amount": 2024043.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-31", "CFDA Number": "93.839", "Description": "RNA HELICASE MUTATIONS IN MYELODYSPLASTIC SYNDROME: NEW THERAPEUTIC TARGET", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL123904_7529"}, {"internal_id": 49757624, "Award ID": "R01HL123340", "Award Amount": 5170897.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-17", "CFDA Number": "93.837", "Description": "THE ROLE OF AUTOPHAGY GENE ATG16L1 IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - RESUBMISSION - 1", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c07787b9-15d4-d1eb-4f0c-2e0b30320bfb-C", "generated_internal_id": "ASST_NON_R01HL123340_7529"}, {"internal_id": 49757620, "Award ID": "R01HL123326", "Award Amount": 1928999.76, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-05", "CFDA Number": "93.837", "Description": "DIRECT IN VIVO BONE MARROW TRANSFER OF LENTIVIRAL VECTOR TO CORRECT HEMOPHILIA A", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_R01HL123326_7529"}, {"internal_id": 49757611, "Award ID": "R01HL123098", "Award Amount": 1789070.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-11", "CFDA Number": "93.839", "Description": "TRANSCRIPTIONAL CONTROL OF ENDOTHELIUM IN APS BY KRUPPEL LIKE FACTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL123098_7529"}, {"internal_id": 49757610, "Award ID": "R01HL123096", "Award Amount": 5251856.75, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-10", "CFDA Number": "93.837", "Description": "INTERVENTIONS TO REDUCE HYPERCOAGULABILITY IN OLD SIV-INFECTED NHPS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL123096_7529"}, {"internal_id": 49757579, "Award ID": "R01HL122815", "Award Amount": 3688288.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-27", "CFDA Number": "93.837", "Description": "PLATELET MITOCHONDRIAL FUNCTION IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL122815_7529"}, {"internal_id": 49757576, "Award ID": "R01HL122788", "Award Amount": 1973297.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.839", "Description": "IMMUNOPATHOLOGY OF ITP", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "644797d6-c94c-9e2c-b40a-a4cda190c447-C", "generated_internal_id": "ASST_NON_R01HL122788_7529"}, {"internal_id": 49757570, "Award ID": "R01HL122760", "Award Amount": 1496244.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-10", "CFDA Number": "93.837", "Description": "IL-22: A THERAPEUTIC CYTOKINE FOR THE AMELIORATION OF PULMONARY INFLUENZA INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce600306-35f6-a322-8af6-77e17ec30fe9-C", "generated_internal_id": "ASST_NON_R01HL122760_7529"}, {"internal_id": 49757555, "Award ID": "R01HL122661", "Award Amount": 3880006.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-25", "CFDA Number": "93.837", "Description": "MECHANISMS OF GRANULOCYTE HOMEOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL122661_7529"}, {"internal_id": 49757530, "Award ID": "R01HL122483", "Award Amount": 3028070.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-20", "CFDA Number": "93.837", "Description": "FUNCTIONAL ROLE OF TETRASPANIN CD82 IN HEMATOPOIETIC STEM CELL INTERACTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NM", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a5b5888e-f4b5-655c-bd88-d970f969d7c9-C", "generated_internal_id": "ASST_NON_R01HL122483_7529"}, {"internal_id": 49757515, "Award ID": "R01HL122401", "Award Amount": 1509318.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-04-15", "CFDA Number": "93.839", "Description": "IN VIVO ROLE OF PLATELETS IN BACTERIAL BLOOD INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e3c1ed59-3cba-7d4e-6d41-7c63d1579cae-C", "generated_internal_id": "ASST_NON_R01HL122401_7529"}, {"internal_id": 49757482, "Award ID": "R01HL122216", "Award Amount": 1541228.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-01", "CFDA Number": "93.839", "Description": "INDUCING NK CELLS TO REMEMBER AND FIGHT CANCER", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL122216_7529"}, {"internal_id": 49757476, "Award ID": "R01HL122167", "Award Amount": 1661221.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-19", "CFDA Number": "93.837", "Description": "EFFECT OF BLOOD TRANSFUSION PRACTICES ON CEREBRAL AND SOMATIC OXIMETRY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL122167_7529"}, {"internal_id": 49757473, "Award ID": "R01HL122157", "Award Amount": 1598707.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-05-15", "CFDA Number": "93.837", "Description": "TRPM2 MEDIATES NEUTROPHIL TRANSENDOTHELIAL MIGRATION AND INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL122157_7529"}, {"internal_id": 49757470, "Award ID": "R01HL122148", "Award Amount": 2411304.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-05", "CFDA Number": "93.837", "Description": "INNOVATIVE MULTIGENERATIONAL HOUSEHOLD INTERVENTION TO REDUCE STROKE AND CVD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "358711ab-dfdd-d789-9d79-6eaf11629381-C", "generated_internal_id": "ASST_NON_R01HL122148_7529"}, {"internal_id": 49757453, "Award ID": "R01HL121718", "Award Amount": 3472042.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-09", "CFDA Number": "93.837", "Description": "STRUCTURAL AND FUNCTIONAL BASIS OF THE VITAMIN K CYCLE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL121718_7529"}, {"internal_id": 49757447, "Award ID": "R01HL121650", "Award Amount": 1228036.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-15", "CFDA Number": "93.839", "Description": "SPATIAL REGULATION OF PLATELET ACTIVATION BY PODOPLANIN-CLEC2 SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL121650_7529"}, {"internal_id": 49757445, "Award ID": "R01HL121570", "Award Amount": 2074893.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-24", "CFDA Number": "93.839", "Description": "MODELING CHROMOSOME 7 LOSS IN MYELODYSPLASIA-IPSCS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL121570_7529"}, {"internal_id": 49757444, "Award ID": "R01HL121568", "Award Amount": 2724985.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-22", "CFDA Number": "93.839", "Description": "NAIVE T CELL DEPLETION TO PREVENT GRAFT-VERSUS-HOST DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_R01HL121568_7529"}, {"internal_id": 49757436, "Award ID": "R01HL121415", "Award Amount": 2472116.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-15", "CFDA Number": "93.839", "Description": "T CELL IMMUNOREGULATION OF ALLOIMMUNIZATION IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "644797d6-c94c-9e2c-b40a-a4cda190c447-C", "generated_internal_id": "ASST_NON_R01HL121415_7529"}, {"internal_id": 49757435, "Award ID": "R01HL121387", "Award Amount": 2923463.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-01-12", "CFDA Number": "93.839", "Description": "STRUCTURAL BASIS OF PROTEASE-ACTIVATED RECEPTOR FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL121387_7529"}, {"internal_id": 49757434, "Award ID": "R01HL121386", "Award Amount": 1651000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-12", "CFDA Number": "93.839", "Description": "CHARACTERIZING MECHANISMS OF SICKLE CELL CRISIS VIA DYNAMIC OPTICAL ASSAY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "959819d4-fcbb-189c-44a9-a2fc0644251a-C", "generated_internal_id": "ASST_NON_R01HL121386_7529"}, {"internal_id": 49757427, "Award ID": "R01HL121323", "Award Amount": 1947026.62, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-07", "CFDA Number": "93.837", "Description": "PLATELET GRANULE FORMATION AND FUNCTION IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL121323_7529"}, {"internal_id": 49757424, "Award ID": "R01HL121275", "Award Amount": 1594000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-01", "CFDA Number": "93.839", "Description": "THE SAFETY OF RED BLOOD CELL TRANSFUSIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL121275_7529"}, {"internal_id": 49757420, "Award ID": "R01HL121264", "Award Amount": 1959769.59, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-30", "CFDA Number": "93.837", "Description": "ENDOTHELIALIZED MICROFLUIDICS FOR SICKLE CELL DISEASE RESEARCH & DRUG DISCOVERY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL121264_7529"}, {"internal_id": 49757416, "Award ID": "R01HL121232", "Award Amount": 3128589.26, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-08", "CFDA Number": "93.837", "Description": "POINT-OF-CARE RBC WASHING TO PREVENT TRANSFUSION-RELATED PULMONARY COMPLICATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL121232_7529"}, {"internal_id": 49757410, "Award ID": "R01HL121212", "Award Amount": 3538700.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-02-08", "CFDA Number": "93.837", "Description": "HETEROMULTIVALENT PEPTIDE-LIPID NANOCONSTRUCTS AS ARTIFICIAL PLATELET ANALOGS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R01HL121212_7529"}, {"internal_id": 49757406, "Award ID": "R01HL121134", "Award Amount": 2564196.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-19", "CFDA Number": "93.838", "Description": "DRUG DELIVERY BY CARRIER ERYTHROCYTES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL121134_7529"}, {"internal_id": 49757387, "Award ID": "R01HL120948", "Award Amount": 1539206.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-01-22", "CFDA Number": "93.839", "Description": "FUNCTIONAL PHENOTYPING OF HUMAN GENETIC VARIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL120948_7529"}, {"internal_id": 49757385, "Award ID": "R01HL120922", "Award Amount": 2112393.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-01-22", "CFDA Number": "93.839", "Description": "THE ROLE OF NUCLEASES IN INTERSTRAND CROSSLINK REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cc63b807-2bf8-905f-48e2-a3b33fcd281b-C", "generated_internal_id": "ASST_NON_R01HL120922_7529"}, {"internal_id": 49757369, "Award ID": "R01HL120728", "Award Amount": 2715060.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-01", "CFDA Number": "93.837", "Description": "A SYSTEMS BIOLOGY APPROACH TO PREDICTING BLEEDING IN HEMOPHILIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cc5207ca-4d78-1308-62c7-b425dd44275c-C", "generated_internal_id": "ASST_NON_R01HL120728_7529"}, {"internal_id": 49757367, "Award ID": "R01HL120724", "Award Amount": 3748178.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.837", "Description": "BALANCED SIGNALING CUES TO GUIDE CELL TRANSITIONS IN THE BLOOD LINEAGE CONTINUUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL120724_7529"}, {"internal_id": 49757334, "Award ID": "R01HL119867", "Award Amount": 2125780.07, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-31", "CFDA Number": "93.837", "Description": "BLOOD COAGULATION MONITORING AT THE POINT OF CARE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL119867_7529"}, {"internal_id": 49757302, "Award ID": "R01HL119523", "Award Amount": 2715709.67, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-25", "CFDA Number": "93.837", "Description": "ROLE OF THE THROMBIN PAR-1 PATHWAY IN VIRAL INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL119523_7529"}, {"internal_id": 49757297, "Award ID": "R01HL119485", "Award Amount": 1975607.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-05-02", "CFDA Number": "93.837", "Description": "NOVEL VIRUSES AND VIRAL DYNAMICS IN MULTIPLE TRANSFUSION RECIPIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "24042a1a-03ec-326e-b5c2-89242d7c209d-C", "generated_internal_id": "ASST_NON_R01HL119485_7529"}, {"internal_id": 49757296, "Award ID": "R01HL119479", "Award Amount": 5942001.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-05", "CFDA Number": "93.837", "Description": "FUNCTIONS, MECHANISMS, AND THERAPEUTIC POTENTIAL OF CHROMATIN LOOPING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL119479_7529"}, {"internal_id": 49757288, "Award ID": "R01HL119439", "Award Amount": 2760193.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-18", "CFDA Number": "93.839", "Description": "X-LINKED DYSKERATOSIS CONGENITA AND RIBOSOMAL FRAMESHIFTING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e04c3b49-28c8-efb6-f8ea-b4c853900d6f-C", "generated_internal_id": "ASST_NON_R01HL119439_7529"}, {"internal_id": 49757286, "Award ID": "R01HL119404", "Award Amount": 1684908.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-03-15", "CFDA Number": "93.839", "Description": "PROGRAMMING HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL119404_7529"}, {"internal_id": 49757285, "Award ID": "R01HL119393", "Award Amount": 1430247.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-27", "CFDA Number": "93.839", "Description": "STRUCTURE/FUNCTION DETERMINANTS OF PLATELET GRANULE SECRETION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d72b9a8b-635d-44cc-45e8-3f90e8ee45f3-C", "generated_internal_id": "ASST_NON_R01HL119393_7529"}, {"internal_id": 49757283, "Award ID": "R01HL119374", "Award Amount": 3807419.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-23", "CFDA Number": "93.837", "Description": "ENDOGENOUS SUPPRESSION OF INTEGRIN SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_R01HL119374_7529"}, {"internal_id": 49757252, "Award ID": "R01HL119102", "Award Amount": 3023875.57, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-08", "CFDA Number": "93.837", "Description": "KINETIC MODELING AND SINGLE-CELL MOLECULAR MECHANISMS OF EARLY T-CELL COMMITMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "74bac010-0a24-8f82-8021-0fa16ab4bc6d-C", "generated_internal_id": "ASST_NON_R01HL119102_7529"}, {"internal_id": 49757251, "Award ID": "R01HL119099", "Award Amount": 3412295.39, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-31", "CFDA Number": "93.837", "Description": "SYSTEMS BIOLOGY ANALYSIS OF HUMAN ERYTHROPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "be067fa7-a493-7bea-f9cc-e29bd2ccc74a-C", "generated_internal_id": "ASST_NON_R01HL119099_7529"}, {"internal_id": 49757250, "Award ID": "R01HL119096", "Award Amount": 3477361.09, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-17", "CFDA Number": "93.837", "Description": "PLATELET SYSTEMS BIOLOGY IN HEALTH AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3313e5e7-fa36-d54b-e36d-0e1e09cc0c30-C", "generated_internal_id": "ASST_NON_R01HL119096_7529"}, {"internal_id": 49757244, "Award ID": "R01HL119056", "Award Amount": 1544187.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-15", "CFDA Number": "93.839", "Description": "FGF SIGNALING IN THE SPECIFICATION AND EMERGENCE OF HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL119056_7529"}, {"internal_id": 49757237, "Award ID": "R01HL118979", "Award Amount": 5370330.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-04-11", "CFDA Number": "93.837", "Description": "ENHANCING TREG THERAPEUTIC EFFICACY IN GVHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL118979_7529"}, {"internal_id": 49757226, "Award ID": "R01HL118742", "Award Amount": 1504218.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-20", "CFDA Number": "93.839", "Description": "FIBRONECTIN ALTERNATIVE SPLICING IN THROMBOSIS AND INFLAMMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0b441d38-e3c0-de89-ee08-69fc9e6ee58a-C", "generated_internal_id": "ASST_NON_R01HL118742_7529"}, {"internal_id": 49757216, "Award ID": "R01HL118593", "Award Amount": 1853976.0, "Award Type": null, "Base Obligation Date": "2013-07-28", "CFDA Number": "93.839", "Description": "REGULATION AND FUNCTION OF PDK1-AKT-PYK2 AXIS IN PLATELETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb9c32ae-42fd-5fe8-5d84-b798a26bb49d-C", "generated_internal_id": "ASST_NON_R01HL118593_7529"}, {"internal_id": 49757210, "Award ID": "R01HL118557", "Award Amount": 1436682.96, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-31", "CFDA Number": "93.837", "Description": "A NOVEL REGULATORY ROLE OF PROTEIN S IN BLOOD COAGULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "LA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6a863c9b-365c-816d-1f3a-a0096107ff16-C", "generated_internal_id": "ASST_NON_R01HL118557_7529"}, {"internal_id": 49757206, "Award ID": "R01HL118526", "Award Amount": 4408026.88, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-24", "CFDA Number": "93.837", "Description": "FUNCTIONAL ROLE OF PROTEIN DISULFIDE ISOMERASE ISOFORMS IN PLATELETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb9c32ae-42fd-5fe8-5d84-b798a26bb49d-C", "generated_internal_id": "ASST_NON_R01HL118526_7529"}, {"internal_id": 49757183, "Award ID": "R01HL118356", "Award Amount": 3114003.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-03-31", "CFDA Number": "93.839", "Description": "GENE TRANSCRIPTS AND PROTEOMICS IN FAMILIES WITH PLATELET HYPERAGGREGATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL118356_7529"}, {"internal_id": 49757171, "Award ID": "R01HL118281", "Award Amount": 1887139.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-25", "CFDA Number": "93.839", "Description": "INVESTIGATIONS OF CONSEQUENCES OF U2AF1 MUTATIONS IN MDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL118281_7529"}, {"internal_id": 49757142, "Award ID": "R01HL118049", "Award Amount": 3886342.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-05", "CFDA Number": "93.839", "Description": "DEVELOPMENT OF PROGNOSTIC PLATELET RNA BIOMARKERS TO TAILOR ANTIPLATELET THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL118049_7529"}, {"internal_id": 49757112, "Award ID": "R01HL117855", "Award Amount": 1568328.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-06-06", "CFDA Number": "93.839", "Description": "GVL RESISTANCE:  IMMUNE SELECTION, T CELL IGNORANCE AND T CELL EXHAUSTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL117855_7529"}, {"internal_id": 49757105, "Award ID": "R01HL117807", "Award Amount": 1488937.0, "Award Type": null, "Base Obligation Date": "2014-05-01", "CFDA Number": "93.839", "Description": "COMPOSITION AND FUNCTIONS OF THE INTEGRIN ACTIVATION COMPLEX", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL117807_7529"}, {"internal_id": 49757098, "Award ID": "R01HL117737", "Award Amount": 2444676.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-02-28", "CFDA Number": "93.839", "Description": "MICROCHIMERISM AS ALLOIMMUNITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_R01HL117737_7529"}, {"internal_id": 49757093, "Award ID": "R01HL117722", "Award Amount": 2343298.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-11-28", "CFDA Number": "93.839", "Description": "PLATELET AND COAGULATION ACTIVATION IN RESPONSE TO VASCULAR INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL117722_7529"}, {"internal_id": 49757088, "Award ID": "R01HL117639", "Award Amount": 2692872.32, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-10", "CFDA Number": "93.837", "Description": "BIOSYNTHETIC AND FUNCTIONAL CONSEQUENCES OF VON WILLEBRAND DISEASE MUTATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "474a19eb-1491-c065-a3ca-a49b264b0d4b-C", "generated_internal_id": "ASST_NON_R01HL117639_7529"}, {"internal_id": 49757078, "Award ID": "R01HL117329", "Award Amount": 1864314.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-09-20", "CFDA Number": "93.839", "Description": "ELIMINATING MEDIATORS OF TOXICITY FROM STORED BLOOD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a95b9572-dc03-ba8d-34a5-edc32a8efc03-C", "generated_internal_id": "ASST_NON_R01HL117329_7529"}, {"internal_id": 49757058, "Award ID": "R01HL117132", "Award Amount": 1663737.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-04-09", "CFDA Number": "93.839", "Description": "PROTEIN C PATHWAY FUNCTION IN HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R01HL117132_7529"}, {"internal_id": 49757052, "Award ID": "R01HL117061", "Award Amount": 1721481.9, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-06-01", "CFDA Number": "93.837", "Description": "REGULATION OF PLATELET INTEGRIN SIGNALING IN HEMOSTASIS AND THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL117061_7529"}, {"internal_id": 49757041, "Award ID": "R01HL116916", "Award Amount": 1587256.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-19", "CFDA Number": "93.839", "Description": "PREVENTION AND MANAGEMENT OF PERIOPERATIVE PULMONARY EMBOLISM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL116916_7529"}, {"internal_id": 49757032, "Award ID": "R01HL116854", "Award Amount": 3365686.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-31", "CFDA Number": "93.839", "Description": "GENETIC AND ENVIRONMENTAL RISK FACTORS FOR VENOUS THROMBOEMBOLISM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL116854_7529"}, {"internal_id": 49757019, "Award ID": "R01HL116713", "Award Amount": 1747418.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-20", "CFDA Number": "93.839", "Description": "MICRORNA FUNCTION IN HUMAN MEGAKARYOCYTES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_R01HL116713_7529"}, {"internal_id": 49756998, "Award ID": "R01HL116524", "Award Amount": 1743796.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-16", "CFDA Number": "93.839", "Description": "PLATELETS AND THEIR MICROPARTICLES IN THE INFLAMED MICROCIRCULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL116524_7529"}, {"internal_id": 49756984, "Award ID": "R01HL116452", "Award Amount": 2136683.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-10", "CFDA Number": "93.839", "Description": "THE ROLE OF THE SF3B1 SPLICING FACTOR IN CHRONIC LYMPHOCYTIC LEUKEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "be067fa7-a493-7bea-f9cc-e29bd2ccc74a-C", "generated_internal_id": "ASST_NON_R01HL116452_7529"}, {"internal_id": 49756978, "Award ID": "R01HL116392", "Award Amount": 2056613.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-29", "CFDA Number": "93.839", "Description": "HEMATOPOIETIC REGULATION THROUGH OTT1-DEPENDENT ALTERNATIVE SPLICING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68a12c06-0ac5-9595-eda2-d8647ffda5d0-C", "generated_internal_id": "ASST_NON_R01HL116392_7529"}, {"internal_id": 49756970, "Award ID": "R01HL116352", "Award Amount": 1498252.0, "Award Type": null, "Base Obligation Date": "2012-09-25", "CFDA Number": "93.839", "Description": "RHO GTPASES IN TERMINAL ERYTHROID MATURATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL116352_7529"}, {"internal_id": 49756965, "Award ID": "R01HL116329", "Award Amount": 1657376.0, "Award Type": null, "Base Obligation Date": "2012-09-25", "CFDA Number": "93.839", "Description": "THE HUMAN GLUCOCORTICOID RECEPTOR AND NORMAL AND PATHOLOGICAL TERMINAL ERYTHROID", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL116329_7529"}, {"internal_id": 49756959, "Award ID": "R01HL116291", "Award Amount": 1715809.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-08", "CFDA Number": "93.839", "Description": "BMT CTN 1101 ANCILLARY COST-EFFECTIVENESS ANALYSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_R01HL116291_7529"}, {"internal_id": 49756952, "Award ID": "R01HL116221", "Award Amount": 3355189.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-29", "CFDA Number": "93.839", "Description": "IPSC-BASED BLOOD REGENERATIVE THERAPIES FOR AIDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL116221_7529"}, {"internal_id": 49756951, "Award ID": "R01HL116217", "Award Amount": 3767098.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-07-20", "CFDA Number": "93.839", "Description": "ENGRAFTMENT AND IN VIVO SELECTION OF HIV-PROTECTED STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_R01HL116217_7529"}, {"internal_id": 49756926, "Award ID": "R01HL115557", "Award Amount": 2292233.93, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-06-14", "CFDA Number": "93.837", "Description": "HARMFUL EFFECTS OF RED BLOOD CELL TRANSFUSIONS ARE MEDIATED BY IRON", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL115557_7529"}, {"internal_id": 49756912, "Award ID": "R01HL115247", "Award Amount": 3777250.67, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-07-24", "CFDA Number": "93.866", "Description": "HYPERGLYCEMIA, THROMBOXANE AND PLATELET ACTIVITY IN DIABETES MELLITUS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL115247_7529"}, {"internal_id": 49756903, "Award ID": "R01HL115187", "Award Amount": 1572381.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-31", "CFDA Number": "93.839", "Description": "NOVEL THERAPEUTICS FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL115187_7529"}, {"internal_id": 49756901, "Award ID": "R01HL115158", "Award Amount": 2088814.4, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-25", "CFDA Number": "93.837", "Description": "REGULATION OF CHROMATIN STRUCTURE DYNAMICS IN HEMATOPOIETIC AND LEUKEMIC STEM CEL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "427ea0fd-a29e-756b-4973-911cb119bc8d-C", "generated_internal_id": "ASST_NON_R01HL115158_7529"}, {"internal_id": 49756897, "Award ID": "R01HL115145", "Award Amount": 1966799.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-25", "CFDA Number": "93.839", "Description": "YES1 AS A QUIESCENCE REGULATOR IN HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_R01HL115145_7529"}, {"internal_id": 49756891, "Award ID": "R01HL115128", "Award Amount": 3317857.0, "Award Type": null, "Base Obligation Date": "2013-07-30", "CFDA Number": "93.839", "Description": "EVALUATION OF PLURIPOTENT STEM CELL-DERIVED BLOOD CELLS IN NONHUMAN PRIMATE MODEL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_R01HL115128_7529"}, {"internal_id": 49756874, "Award ID": "R01HL114994", "Award Amount": 2552493.94, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-31", "CFDA Number": "93.837", "Description": "ADOPTIVE TRANSFER OF DONOR TREGS SPECIFIC AGAINST HOST ALLOANTIGENS FOR PRESENTIO", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dda62fdb-6501-1ff0-613d-ceb8e9bb2d48-C", "generated_internal_id": "ASST_NON_R01HL114994_7529"}, {"internal_id": 49756825, "Award ID": "R01HL114697", "Award Amount": 2151187.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-07-16", "CFDA Number": "93.839", "Description": "REGULATION OF AUTOPHAGY BY AMPK, HSP90-CDC37 AND ULK1 IN ERYTHROID CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bccd984e-68ff-4e70-2020-f0129e4b9ecc-C", "generated_internal_id": "ASST_NON_R01HL114697_7529"}, {"internal_id": 49756814, "Award ID": "R01HL114591", "Award Amount": 2565000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-20", "CFDA Number": "93.839", "Description": "REGULATORY T CELLS IN ALLOGENEIC TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL114591_7529"}, {"internal_id": 49756812, "Award ID": "R01HL114582", "Award Amount": 1016212.0, "Award Type": null, "Base Obligation Date": "2014-07-15", "CFDA Number": "93.839", "Description": "ROLE OF TRAF6 IN MYELODYSPLASTIC SYNDROMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL114582_7529"}, {"internal_id": 49756810, "Award ID": "R01HL114567", "Award Amount": 4376329.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-08", "CFDA Number": "93.837", "Description": "HEME TOXICITY AND VASO-OCCLUSION IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL114567_7529"}, {"internal_id": 49756809, "Award ID": "R01HL114564", "Award Amount": 2226981.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-15", "CFDA Number": "93.839", "Description": "ENHANCEMENT OF STEM CELL TRANSPLANTS USING CAR.CD30-REDIRECTED T LYMPHOCYTES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL114564_7529"}, {"internal_id": 49756801, "Award ID": "R01HL114525", "Award Amount": 1862987.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-25", "CFDA Number": "93.839", "Description": "PREVENTION OF PLATELET ALLOIMMUNIZATION BY COSTIMULATORY BLOCKADE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "474a19eb-1491-c065-a3ca-a49b264b0d4b-C", "generated_internal_id": "ASST_NON_R01HL114525_7529"}, {"internal_id": 49756800, "Award ID": "R01HL114518", "Award Amount": 2045050.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-28", "CFDA Number": "93.839", "Description": "PREVENTING GASTRODUODENAL BLEEDING IN ORAL ANTICOAGULANT USERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL114518_7529"}, {"internal_id": 49756790, "Award ID": "R01HL114408", "Award Amount": 1863178.0, "Award Type": null, "Base Obligation Date": "2013-07-27", "CFDA Number": "93.839", "Description": "GENETICS OF AUTOIMMUNE HEMOLYTIC ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL114408_7529"}, {"internal_id": 49756788, "Award ID": "R01HL114405", "Award Amount": 1938381.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-31", "CFDA Number": "93.839", "Description": "ROLE OF 12-LIPOXYGENASE IN PLATELET REACTIVITY AND TYPE 2 DIABETES MELLITUS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL114405_7529"}, {"internal_id": 49756778, "Award ID": "R01HL114343", "Award Amount": 1557007.0, "Award Type": null, "Base Obligation Date": "2013-05-27", "CFDA Number": "93.839", "Description": "REGULATION OF HEMATOPOIETIC STEM CELL MAINTENANCE AND SURVIVAL BY NKAP", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R01HL114343_7529"}, {"internal_id": 49756775, "Award ID": "R01HL114152", "Award Amount": 2202500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-02-13", "CFDA Number": "93.839", "Description": "NOVEL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION SYSTEM DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb9c32ae-42fd-5fe8-5d84-b798a26bb49d-C", "generated_internal_id": "ASST_NON_R01HL114152_7529"}, {"internal_id": 49756738, "Award ID": "R01HL113574", "Award Amount": 1481132.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-10", "CFDA Number": "93.839", "Description": "METABOLITES, SICKLE CELL DISEASE, AND NOVEL THERAPEUTICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9adce466-3b6d-ecdb-7412-8082d6529b1f-C", "generated_internal_id": "ASST_NON_R01HL113574_7529"}, {"internal_id": 49756718, "Award ID": "R01HL113351", "Award Amount": 2354131.18, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-07-13", "CFDA Number": "93.837", "Description": "CRITICAL ROLE OF CHYMASE IN THE REGULATION OF INFLAMMATION AND SURVIVAL IN SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_R01HL113351_7529"}, {"internal_id": 49756711, "Award ID": "R01HL113304", "Award Amount": 1862610.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-03-22", "CFDA Number": "93.839", "Description": "STABILITY AND POTENCY OF LAP+FOXP3+TREGS AS NOVEL CELL THERAPY FOR GVHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9adce466-3b6d-ecdb-7412-8082d6529b1f-C", "generated_internal_id": "ASST_NON_R01HL113304_7529"}, {"internal_id": 49756697, "Award ID": "R01HL113188", "Award Amount": 3438726.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-16", "CFDA Number": "93.837", "Description": "ASK1 A NOVEL REGULATOR OF PLATELET FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8668e79f-a6ac-f586-b519-d1e69f717615-C", "generated_internal_id": "ASST_NON_R01HL113188_7529"}, {"internal_id": 49756686, "Award ID": "R01HL113066", "Award Amount": 1457946.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-25", "CFDA Number": "93.839", "Description": "DOSE-DEPENDENT ACTIVATION OF THE MEK/ERK PATHWAY IN HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_R01HL113066_7529"}, {"internal_id": 49756659, "Award ID": "R01HL112937", "Award Amount": 1877768.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-06-04", "CFDA Number": "93.837", "Description": "ROLE OF COMPLEMENT REGULATOR PROPERDIN IN THE INTERACTION BETWEEN PLATELETS AND L", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e3c1ed59-3cba-7d4e-6d41-7c63d1579cae-C", "generated_internal_id": "ASST_NON_R01HL112937_7529"}, {"internal_id": 49756658, "Award ID": "R01HL112921", "Award Amount": 1516658.0, "Award Type": null, "Base Obligation Date": "2013-06-13", "CFDA Number": "93.839", "Description": "MAST CELLS IN DENGUE PATHOLOGY AND PREVENTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL112921_7529"}, {"internal_id": 49756648, "Award ID": "R01HL112873", "Award Amount": 1468875.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-29", "CFDA Number": "93.839", "Description": "ROLE OF MATERNAL PLATELETS IN THE PLACENTA AND PREGNANCY COMPLICATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL112873_7529"}, {"internal_id": 49756644, "Award ID": "R01HL112836", "Award Amount": 2082745.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-16", "CFDA Number": "93.839", "Description": "THE OPPOSING ROLES OF IL-10 AND IFN-GAMMA IN MACROPHAGE ACTIVATION SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL112836_7529"}, {"internal_id": 49756636, "Award ID": "R01HL112792", "Award Amount": 3662326.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-26", "CFDA Number": "93.837", "Description": "ABERRANT MEGAKARYOPOIESIS IN THE MYELOPROLIFERATIVE NEOPLASMS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bccd984e-68ff-4e70-2020-f0129e4b9ecc-C", "generated_internal_id": "ASST_NON_R01HL112792_7529"}, {"internal_id": 49756635, "Award ID": "R01HL112791", "Award Amount": 1485179.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-24", "CFDA Number": "93.839", "Description": "REGULATION OF THE IL-33 RECEPTOR, ST2L, BY PROTEIN STABILITY IN SEPTIC INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL112791_7529"}, {"internal_id": 49756634, "Award ID": "R01HL112790", "Award Amount": 2069946.82, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-12", "CFDA Number": "93.837", "Description": "PATHOBIOLOGY OF INCOMPATIBLE TRANSFUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "474a19eb-1491-c065-a3ca-a49b264b0d4b-C", "generated_internal_id": "ASST_NON_R01HL112790_7529"}, {"internal_id": 49756633, "Award ID": "R01HL112788", "Award Amount": 1477494.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-25", "CFDA Number": "93.839", "Description": "BIOACTIVE LIPIDS IN STEM CELL HOMING AND MOBILIZATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3c9476c3-c39d-74de-31b6-2c9a10197e11-C", "generated_internal_id": "ASST_NON_R01HL112788_7529"}, {"internal_id": 49756625, "Award ID": "R01HL112719", "Award Amount": 2156128.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-02-10", "CFDA Number": "93.837", "Description": "MOLECULAR BIOLOGY OF MYELOID DIFFERENTIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_R01HL112719_7529"}, {"internal_id": 49756614, "Award ID": "R01HL112633", "Award Amount": 4685365.66, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-02-15", "CFDA Number": "93.837", "Description": "VON WILLEBRAND FACTOR IN SICKLE CELL DISEASE PATHOPHYSIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "474a19eb-1491-c065-a3ca-a49b264b0d4b-C", "generated_internal_id": "ASST_NON_R01HL112633_7529"}, {"internal_id": 49756610, "Award ID": "R01HL112614", "Award Amount": 4076361.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-29", "CFDA Number": "93.839", "Description": "COMPARATIVE EFFECTIVENESS IN THE DIAGNOSIS OF VWD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R01HL112614_7529"}, {"internal_id": 49756606, "Award ID": "R01HL112597", "Award Amount": 3742085.0, "Award Type": null, "Base Obligation Date": "2011-11-25", "CFDA Number": "93.839", "Description": "MESENCHYMAL STEM CELLS IN THE PREVENTION OF THROMBOSIS AND NEOINTIMAL HYPERPLASIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NE", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aa1efd22-2d00-6e2e-3ada-bfb839ed9539-C", "generated_internal_id": "ASST_NON_R01HL112597_7529"}, {"internal_id": 49756599, "Award ID": "R01HL112294", "Award Amount": 1823056.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-02-29", "CFDA Number": "93.839", "Description": "ROLE OF TET2 IN NORMAL HEMATOPOIESIS AND PATHOGENESIS OF MYELOID MALIGNANCIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dbae4064-c48c-5002-9fca-21d077e0f96b-C", "generated_internal_id": "ASST_NON_R01HL112294_7529"}, {"internal_id": 49756589, "Award ID": "R01HL112064", "Award Amount": 5083639.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-16", "CFDA Number": "93.837", "Description": "A FAMILY-BASED EXOME SEQUENCING APPROACH TO IDENTIFY PLATELET AGGREGATION GENES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_R01HL112064_7529"}, {"internal_id": 49756588, "Award ID": "R01HL111969", "Award Amount": 4049591.0, "Award Type": null, "Base Obligation Date": "2011-12-30", "CFDA Number": "93.839", "Description": "BIOMARKERS OF INFLAMMATION AND VASO-OCCLUSION IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1ab7ef77-dc1b-636f-13b5-a16c421f1438-C", "generated_internal_id": "ASST_NON_R01HL111969_7529"}, {"internal_id": 49756568, "Award ID": "R01HL111682", "Award Amount": 1566735.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-16", "CFDA Number": "93.839", "Description": "NOVEL MECHANISMS OF IMMUNE ACTIVATION FOLLOWING ALLOGENEIC, HEMATOPOIETIC STEM CE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R01HL111682_7529"}, {"internal_id": 49756564, "Award ID": "R01HL111659", "Award Amount": 2318964.0, "Award Type": null, "Base Obligation Date": "2011-12-30", "CFDA Number": "93.839", "Description": "ENDOTHELIAL DYSFUNCTION IN THE PATHOGENESIS OF SICKLE CELL NEPHROPATHY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL111659_7529"}, {"internal_id": 49756563, "Award ID": "R01HL111656", "Award Amount": 5838110.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-02-01", "CFDA Number": "93.837", "Description": "VASCULAR-TARGETED GENOMIC AND GENETIC STRATEGIES FOR ACUTE CHEST SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL111656_7529"}, {"internal_id": 49756558, "Award ID": "R01HL111614", "Award Amount": 1686008.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-28", "CFDA Number": "93.838", "Description": "MECHANISTIC ROLE OF CD36 IN THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL111614_7529"}, {"internal_id": 49756545, "Award ID": "R01HL111501", "Award Amount": 3538847.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-12-30", "CFDA Number": "93.837", "Description": "THE ROLE OF THE T CELL RECEPTOR IN REGULATORY T CELL HOMEOSTASIS AND EXPANSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL111501_7529"}, {"internal_id": 49756526, "Award ID": "R01HL111372", "Award Amount": 3053749.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-12-30", "CFDA Number": "93.839", "Description": "PLGF-HIF1A-MIRNA AXIS IN SICKLE PULMONARY HYPERTENSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_R01HL111372_7529"}, {"internal_id": 49756515, "Award ID": "R01HL111266", "Award Amount": 1512941.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-07-18", "CFDA Number": "93.839", "Description": "MECHANISMS OF HEMATOPOIETIC STEM CELL MAINTENANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL111266_7529"}, {"internal_id": 49756514, "Award ID": "R01HL111264", "Award Amount": 1472452.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-14", "CFDA Number": "93.839", "Description": "MECHANISMS OF HBF ACTIVATION BY NON-DELETIONAL HPFH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KS", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1a1108fb-0099-a708-6def-aa6d101c8ba8-C", "generated_internal_id": "ASST_NON_R01HL111264_7529"}, {"internal_id": 49756508, "Award ID": "R01HL111192", "Award Amount": 2001972.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-07-12", "CFDA Number": "93.839", "Description": "THE ROLE OF MEIS1 IN HEMATOPOIESIS AND HEMATOPOIETIC TRANSFORMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL111192_7529"}, {"internal_id": 49756499, "Award ID": "R01HL111130", "Award Amount": 7170273.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-16", "CFDA Number": "93.837", "Description": "MECHANISMS OF FIBROSIS AND LYMPHATIC DYSFUNCTION IN POST-SURGICAL LYMPHEDEMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b514fc3a-d769-87e9-75ea-7a6766afb5ee-C", "generated_internal_id": "ASST_NON_R01HL111130_7529"}, {"internal_id": 49756466, "Award ID": "R01HL110806", "Award Amount": 2079295.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-07-20", "CFDA Number": "93.839", "Description": "REGULATING HEMATOPOIETIC STEM CELL HOMEOSTASIS THROUGH GSK-3", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL110806_7529"}, {"internal_id": 49756415, "Award ID": "R01HL109599", "Award Amount": 2011698.0, "Award Type": null, "Base Obligation Date": "2011-07-21", "CFDA Number": "93.839", "Description": "TRANSFUSION OF DONOR EFFECTOR MEMORY T CELLS FOR GVL AND IMMUNE RECONSTITUTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL109599_7529"}, {"internal_id": 49756412, "Award ID": "R01HL109568", "Award Amount": 3372441.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-01-04", "CFDA Number": "93.837", "Description": "HUMAN PLATELET DEFECTS IN TRANSCRIPTION FACTOR RUNX1 HAPLODEFICIENCY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb9c32ae-42fd-5fe8-5d84-b798a26bb49d-C", "generated_internal_id": "ASST_NON_R01HL109568_7529"}, {"internal_id": 49756394, "Award ID": "R01HL109448", "Award Amount": 7933233.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-07-07", "CFDA Number": "93.837", "Description": "PET IMAGING OF THROMBUS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R01HL109448_7529"}, {"internal_id": 49756393, "Award ID": "R01HL109442", "Award Amount": 3457989.0, "Award Type": null, "Base Obligation Date": "2011-07-21", "CFDA Number": "93.839", "Description": "ORAL THERAPY FOR HEMOPHILIA A", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R01HL109442_7529"}, {"internal_id": 49756294, "Award ID": "R01HL108307", "Award Amount": 2161845.0, "Award Type": null, "Base Obligation Date": "2011-04-18", "CFDA Number": "93.839", "Description": "STATINS FOR PREVENTION OF GVHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_R01HL108307_7529"}, {"internal_id": 49756276, "Award ID": "R01HL108102", "Award Amount": 1905707.0, "Award Type": null, "Base Obligation Date": "2011-05-23", "CFDA Number": "93.839", "Description": "FANCONI ANEMIA AS A MODEL FOR SUSCEPTIBILITY TO HUMAN PAPILLOMAVIRUS INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL108102_7529"}, {"internal_id": 49756273, "Award ID": "R01HL107974", "Award Amount": 2381405.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-11-25", "CFDA Number": "93.839", "Description": "LENTIVIRUS-BASED POSITIVE/NEGATIVE SELECTION IN MINIMALLY ABLATIVE TRANSPLANTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL107974_7529"}, {"internal_id": 49756264, "Award ID": "R01HL107904", "Award Amount": 7339702.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-07-08", "CFDA Number": "93.837", "Description": "ORAL IMMUNE MODULATORY THERAPY USING ANTIGENS BIOENCAPSULATED IN PLANT CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL107904_7529"}, {"internal_id": 49756214, "Award ID": "R01HL107483", "Award Amount": 2851842.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-12-30", "CFDA Number": "93.837", "Description": "FACTOR VIIA INTERACTION WITH ENDOTHELIAL CELL PROTEIN C RECEPTOR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6605b60b-2165-8c36-e954-428aa458f579-C", "generated_internal_id": "ASST_NON_R01HL107483_7529"}, {"internal_id": 49756206, "Award ID": "R01HL107386", "Award Amount": 4236383.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-03-10", "CFDA Number": "93.837", "Description": "MECHANISMS OF ACUTE LUNG INJURY FROM BLOOD TRANSFUSIONS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL107386_7529"}, {"internal_id": 49756165, "Award ID": "R01HL106812", "Award Amount": 3106884.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-01-07", "CFDA Number": "93.839", "Description": "ROLES OF RICTOR IN MTOR SIGNALING  DIFFERENTIATION & IMMUNE MEMORY VIA AKT & PKC", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL106812_7529"}, {"internal_id": 49756142, "Award ID": "R01HL106192", "Award Amount": 2128239.0, "Award Type": null, "Base Obligation Date": "2011-09-21", "CFDA Number": "93.839", "Description": "MECHANISMS OF ENDOTHELIAL BARRIER PHENOTYPES IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL106192_7529"}, {"internal_id": 49756139, "Award ID": "R01HL106186", "Award Amount": 1906222.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-02-15", "CFDA Number": "93.839", "Description": "MOLECULAR MECHANISM OF PLATELET DENSE GRANULE BIOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "94d3fccc-8494-b483-af28-4af0be6ed7f8-C", "generated_internal_id": "ASST_NON_R01HL106186_7529"}, {"internal_id": 49756132, "Award ID": "R01HL106074", "Award Amount": 2086172.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-11-26", "CFDA Number": "93.839", "Description": "REGULATION OF VON WILLEBRAND FACTOR - PLATELET BINDING BY FORCE AND INTERDOMAIN I", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL106074_7529"}, {"internal_id": 49756108, "Award ID": "R01HL105914", "Award Amount": 9791247.34, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-01-07", "CFDA Number": "93.837", "Description": "WHOLE GENOME ASSOCIATION ANALYSIS OF HEMATOPOIETIC CELL TRANSPLANT (HCT) OUTCOME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_R01HL105914_7529"}, {"internal_id": 49756086, "Award ID": "R01HL105704", "Award Amount": 5890567.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-03-31", "CFDA Number": "93.837", "Description": "BROAD DETECTION OF INFECTIOUS AGENTS IN BLOOD BY MICROARRAYS AND DEEP SEQUENCING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_R01HL105704_7529"}, {"internal_id": 49755985, "Award ID": "R01HL104165", "Award Amount": 5620366.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-11-26", "CFDA Number": "93.837", "Description": "STRUCTURE-FUNCTION OF CYTOPROTECTIVE COAGULATION PROTEASES AND THEIR RECEPTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL104165_7529"}, {"internal_id": 49755928, "Award ID": "R01HL103827", "Award Amount": 4299712.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-12-09", "CFDA Number": "93.837", "Description": "O-FUCOSE MODIFIED NOTCH AS A REGULATOR OF THE HEMATOPOIETIC STEM CELL HOMEOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R01HL103827_7529"}, {"internal_id": 49755883, "Award ID": "R01HL103419", "Award Amount": 7384767.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-08-26", "CFDA Number": "93.837", "Description": "BLOOD SYSTEMS BIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL103419_7529"}, {"internal_id": 49755881, "Award ID": "R01HL103411", "Award Amount": 6030400.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-09-02", "CFDA Number": "93.837", "Description": "SYSTEMS BIOLOGY OF GLYCOSYLATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f94a8263-c1eb-718b-03c5-bb8a878692fd-C", "generated_internal_id": "ASST_NON_R01HL103411_7529"}, {"internal_id": 49755860, "Award ID": "R01HL102497", "Award Amount": 3435611.24, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-09-18", "CFDA Number": "93.837", "Description": "ROLE OF HEPARIN BINDING GROWTH FACTORS IN VASCULAR LEAKAGE AND FATAL BLEEDING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL102497_7529"}, {"internal_id": 49755858, "Award ID": "R01HL102482", "Award Amount": 4580282.75, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-04-26", "CFDA Number": "93.837", "Description": "VARIATION IN PLATELET FUNCTION: THE GENETICS OF PLATELET GENE EXPRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_R01HL102482_7529"}, {"internal_id": 49755801, "Award ID": "R01HL102035", "Award Amount": 5285107.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-06-03", "CFDA Number": "93.837", "Description": "PLATELET-DERIVED FVIII GENE THERAPY OF HEMOPHILIA A", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL102035_7529"}, {"internal_id": 49755791, "Award ID": "R01HL101972", "Award Amount": 6446734.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-07-06", "CFDA Number": "93.837", "Description": "CHARACTERIZATION OF COAGULATION FACTOR-PLATELET INTERACTIONS: ROLE OF FXI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_R01HL101972_7529"}, {"internal_id": 49755787, "Award ID": "R01HL101917", "Award Amount": 5303025.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-04-01", "CFDA Number": "93.837", "Description": "PROTEASE ACTIVATED RECEPTOR SIGNALING BY COAGULATION PROTEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OK", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "36c41119-2158-d09a-55ce-00590b81ab14-C", "generated_internal_id": "ASST_NON_R01HL101917_7529"}, {"internal_id": 49755709, "Award ID": "R01HL098316", "Award Amount": 5053030.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-01-29", "CFDA Number": "93.837", "Description": "THE FANCONI ANEMIA PATHWAY: ROLE IN DNA INTERSTRAND CROSS-LINK REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81e3f12d-5809-de22-dbd3-10b61910a90c-C", "generated_internal_id": "ASST_NON_R01HL098316_7529"}, {"internal_id": 49755690, "Award ID": "R01HL098217", "Award Amount": 4090362.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-08-09", "CFDA Number": "93.837", "Description": "THE ROLE OF PROTEASE ACTIVATED RECEPTORS ON PLATELETS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R01HL098217_7529"}, {"internal_id": 49755681, "Award ID": "R01HL098141", "Award Amount": 2309555.0, "Award Type": null, "Base Obligation Date": "2009-09-21", "CFDA Number": "93.839", "Description": "CAMKII AS A MECHANISM & INTERVENTION TARGET FOR SICKLE CELL PAIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL098141_7529"}, {"internal_id": 49755668, "Award ID": "R01HL098032", "Award Amount": 9377016.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-09-17", "CFDA Number": "93.837", "Description": "STORAGE LESION IN BANKED BLOOD DUE TO DISRUPTION OF NITRIC OXIDE HOMEOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL098032_7529"}, {"internal_id": 49755613, "Award ID": "R01HL097088", "Award Amount": 5387429.58, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-07-08", "CFDA Number": "93.837", "Description": "NEXT GENERATION OF RECOMBINANT AAV SEROTYPE VECTORS FOR GENE THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_R01HL097088_7529"}, {"internal_id": 49755502, "Award ID": "R01HL096305", "Award Amount": 3452427.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-01-29", "CFDA Number": "93.837", "Description": "ROLE OF PGE2 AND OTHER EICOSANOIDS IN HEMATOPOIETIC STEM CELL FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL096305_7529"}, {"internal_id": 49755495, "Award ID": "R01HL096062", "Award Amount": 5553975.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-06-17", "CFDA Number": "93.837", "Description": "ACTIVATION OF THE BETA-3 INTEGRINS: ROLE OF THE KINDLINS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL096062_7529"}, {"internal_id": 49755463, "Award ID": "R01HL095791", "Award Amount": 9871212.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-01-25", "CFDA Number": "93.837", "Description": "NOVEL BIOLOGIC THERAPIES FOR BMT: MECHANISTIC EVALUATION IN RHESUS MACAQUES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL095791_7529"}, {"internal_id": 49755452, "Award ID": "R01HL095722", "Award Amount": 3858981.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-05-27", "CFDA Number": "93.837", "Description": "ENGINEERED INDUCTION OF A STEM CELL HOMING RESPONSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R01HL095722_7529"}, {"internal_id": 49755441, "Award ID": "R01HL095685", "Award Amount": 3758961.13, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-03-26", "CFDA Number": "93.837", "Description": "ROLE OF JAK2V617F IN THE PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01HL095685_7529"}, {"internal_id": 49755439, "Award ID": "R01HL095675", "Award Amount": 4822124.57, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-07-28", "CFDA Number": "93.837", "Description": "LNK REGULATORY FUNCTIONS IN HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_R01HL095675_7529"}, {"internal_id": 49755406, "Award ID": "R01HL095479", "Award Amount": 5215557.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-09-16", "CFDA Number": "93.839", "Description": "ADVERSE EFFECTS OF RBC TRANSFUSIONS:  A UNIFYING HYPOTHESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL095479_7529"}, {"internal_id": 49755282, "Award ID": "R01HL094505", "Award Amount": 5141084.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-12-22", "CFDA Number": "93.837", "Description": "ER-TO-GOLGI TRANSPORT OF COAGULATION FACTORS V AND VIII", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL094505_7529"}, {"internal_id": 49755269, "Award ID": "R01HL094463", "Award Amount": 5225013.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-02-06", "CFDA Number": "93.837", "Description": "IN VITRO SYNTHESIS OF RECOMBINANT HEPARAN SULFATE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_R01HL094463_7529"}, {"internal_id": 49755240, "Award ID": "R01HL094311", "Award Amount": 3437399.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-08-06", "CFDA Number": "93.839", "Description": "CONTROL OF FIBROBLAST FUNCTION BY PROSTAGLANDIN E2 AND PLASMINOGEN ACTIVATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL094311_7529"}, {"internal_id": 49755158, "Award ID": "R01HL093234", "Award Amount": 4361018.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-12", "CFDA Number": "93.839", "Description": "ANGIOPOIETIN MECHANISMS IN SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_R01HL093234_7529"}, {"internal_id": 49755157, "Award ID": "R01HL093231", "Award Amount": 3577630.18, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-05-07", "CFDA Number": "93.837", "Description": "FUNCTIONAL PKC ISOFORMS IN PLATELETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb9c32ae-42fd-5fe8-5d84-b798a26bb49d-C", "generated_internal_id": "ASST_NON_R01HL093231_7529"}, {"internal_id": 49755055, "Award ID": "R01HL092565", "Award Amount": 2978974.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-05", "CFDA Number": "93.839", "Description": "IMMUNOREGULATORY NETWORKS AND HIV PATHOGENESIS", "Place of Performance Country Code": "CAN", "Place of Performance State Code": null, "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "43b0e41c-a519-8b18-53c9-383a2e043d70-C", "generated_internal_id": "ASST_NON_R01HL092565_7529"}, {"internal_id": 49755013, "Award ID": "R01HL092173", "Award Amount": 10406607.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-05-19", "CFDA Number": "93.837", "Description": "GENETIC AND ENVIRONMENTAL DETERMINANTS OF WARFARIN RESPONSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R01HL092173_7529"}, {"internal_id": 49754909, "Award ID": "R01HL091724", "Award Amount": 7679142.94, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-12-17", "CFDA Number": "93.837", "Description": "BIOCHEMISTRY OF LEUKEMIA VIRUS CORE BINDING FACTOR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL091724_7529"}, {"internal_id": 49754827, "Award ID": "R01HL090933", "Award Amount": 2806939.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-06-16", "CFDA Number": "93.837", "Description": "TRANSLATIONAL STUDIES OF THE PLATELET SPECIFIC RECEPTOR TREM LIKE TRANSCRIPT (TLT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "48daf3ab-82a8-30af-8bdd-7bc3f35e54ec-C", "generated_internal_id": "ASST_NON_R01HL090933_7529"}, {"internal_id": 49754789, "Award ID": "R01HL090775", "Award Amount": 3383230.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-12-17", "CFDA Number": "93.839", "Description": "ROLE OF CROSS-PRESENTATION BY APCS IN MODULATING GRAFT-VERSUS-LEUKEMIA RESPONSES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL090775_7529"}, {"internal_id": 49754748, "Award ID": "R01HL090586", "Award Amount": 3939023.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-06-22", "CFDA Number": "93.837", "Description": "DUAL DIRECT INHIBITORS OF THROMBIN AND FACTOR XA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_R01HL090586_7529"}, {"internal_id": 49754720, "Award ID": "R01HL090036", "Award Amount": 3400253.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-21", "CFDA Number": "93.839", "Description": "MLL FUNCTION IN THE MAINTENANCE OF THE BLOOD FORMING SYSTEM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R01HL090036_7529"}, {"internal_id": 49754718, "Award ID": "R01HL089966", "Award Amount": 5801437.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-16", "CFDA Number": "93.837", "Description": "ERYTHROPOIETIN RECEPTOR SIGNALING IN ERYTHROPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_R01HL089966_7529"}, {"internal_id": 49754621, "Award ID": "R01HL089456", "Award Amount": 7796185.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-01-16", "CFDA Number": "93.837", "Description": "MULTI-SCALE MODEL OF THORMBOSIS IN ARTIFICIAL CIRCULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8c3617e9-a213-5748-732e-c98dc05d3232-C", "generated_internal_id": "ASST_NON_R01HL089456_7529"}, {"internal_id": 49754579, "Award ID": "R01HL089224", "Award Amount": 7116666.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-09-04", "CFDA Number": "93.837", "Description": "CARBOHYDRATE-MEDIATED PLATELET CLEARANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": 495000.0, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R01HL089224_7529"}, {"internal_id": 49754464, "Award ID": "R01HL088256", "Award Amount": 6842503.92, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-12-03", "CFDA Number": "93.837", "Description": "ROLE OF RAB27 IN GRANULOCYTE FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": 434000.0, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL088256_7529"}, {"internal_id": 49754361, "Award ID": "R01HL087216", "Award Amount": 4455926.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-22", "CFDA Number": "93.837", "Description": "MECHANISMS OF HEMOGLOBIN ADAPTATION TO HYPOXIA IN HIGH-ALTITUDE RODENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NE", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b80a61bf-aab0-2f35-db05-67fd682ea201-C", "generated_internal_id": "ASST_NON_R01HL087216_7529"}, {"internal_id": 49754327, "Award ID": "R01HL086998", "Award Amount": 4613576.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-08-08", "CFDA Number": "93.837", "Description": "ENDOTHELIAL PROGENITOR CELL TRANSPLANT TO ACCELERATE HEMATOPOIETIC RECOVERY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_R01HL086998_7529"}, {"internal_id": 49754047, "Award ID": "R01HL085107", "Award Amount": 2759322.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-10", "CFDA Number": "93.839", "Description": "TREATMENT OF LEUKOCYTE ADHESION DEFICIENCY BY FOAMY VIRUS VECTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL085107_7529"}, {"internal_id": 49753871, "Award ID": "R01HL083464", "Award Amount": 5823362.14, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-12-05", "CFDA Number": "93.837", "Description": "CAPPING ACTIN GROWTH IN ERYTHROID AND NONERYTHROID CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DE", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "88f4772d-e0bd-42e6-ed20-c3144d3bace8-C", "generated_internal_id": "ASST_NON_R01HL083464_7529"}, {"internal_id": 49753793, "Award ID": "R01HL083072", "Award Amount": 2537458.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-06", "CFDA Number": "93.839", "Description": "DENDRITIC CELL SUBSETS AND PATHS OF MATURATION IN GVHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_R01HL083072_7529"}, {"internal_id": 49753774, "Award ID": "R01HL082945", "Award Amount": 5600024.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-03", "CFDA Number": "93.837", "Description": "FUNCTIONAL GENOMIC DISSECTION OF REFRACTORY ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "be067fa7-a493-7bea-f9cc-e29bd2ccc74a-C", "generated_internal_id": "ASST_NON_R01HL082945_7529"}, {"internal_id": 49753752, "Award ID": "R01HL082808", "Award Amount": 5792042.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-12-05", "CFDA Number": "93.837", "Description": "STRUCTURE AND FUNCTION OF PLATELET GLYCOPROTEIN LB-IX-V COMPLEX", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01HL082808_7529"}, {"internal_id": 49753713, "Award ID": "R01HL082517", "Award Amount": 4859416.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-12-05", "CFDA Number": "93.837", "Description": "SULFONYLUREA RECEPTOR 1 (SUR1)- A NOVEL THERAPEUTIC TAR*", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R01HL082517_7529"}, {"internal_id": 49753656, "Award ID": "R01HL081613", "Award Amount": 2553512.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-10", "CFDA Number": "93.839", "Description": "SERINE / THREONINE PHOSPHATASES AND PLATELET PHYSIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_R01HL081613_7529"}, {"internal_id": 49753619, "Award ID": "R01HL081326", "Award Amount": 3241166.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-05", "CFDA Number": "93.837", "Description": "FACTOR XL IN VASCULAR THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL081326_7529"}, {"internal_id": 49753584, "Award ID": "R01HL081093", "Award Amount": 3366872.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-12-14", "CFDA Number": "93.839", "Description": "VITAMIN K OXIDOREDUCTASE: FUNCTION AND PHYSIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL081093_7529"}, {"internal_id": 49753577, "Award ID": "R01HL081046", "Award Amount": 7733664.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-05", "CFDA Number": "93.837", "Description": "PROTEOMIC ANALYSIS OF PLASMINOGEN RECEPTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL081046_7529"}, {"internal_id": 49753522, "Award ID": "R01HL080442", "Award Amount": 2782948.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-02", "CFDA Number": "93.839", "Description": "MECHANISMS REGULATING MEGAKARYOCYTE ENDOMITOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_R01HL080442_7529"}, {"internal_id": 49753504, "Award ID": "R01HL080264", "Award Amount": 4227355.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2006-12-11", "CFDA Number": "93.839", "Description": "CALPAIN AND BETA3 CYTOPLASMIC DOMAIN IN PLATELET INTEGRIN SIGNALING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL080264_7529"}, {"internal_id": 49753442, "Award ID": "R01HL079585", "Award Amount": 3373220.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-05-14", "CFDA Number": "93.839", "Description": "BIOGENESIS AND REGULATION OF HUMAN TELOMERASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2f14ac11-bc8d-d1e9-d103-1585414b0792-C", "generated_internal_id": "ASST_NON_R01HL079585_7529"}, {"internal_id": 49753437, "Award ID": "R01HL079571", "Award Amount": 4031339.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-23", "CFDA Number": "93.837", "Description": "THE DBA REGISTRY: A VITAL TOOL FOR THE STUDY OF DBA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f9f0ca2a-aa8d-05a3-861f-1f3e215d88e8-C", "generated_internal_id": "ASST_NON_R01HL079571_7529"}, {"internal_id": 49753382, "Award ID": "R01HL079118", "Award Amount": 3929864.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-11", "CFDA Number": "93.839", "Description": "ROLES OF MRE11 IN LYMPHOCYTE DEVELOPMENT AND DNA REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL079118_7529"}, {"internal_id": 49753244, "Award ID": "R01HL077258", "Award Amount": 2251344.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-04-25", "CFDA Number": "93.839", "Description": "VON WILLEBRAND FACTOR STRUCTURE AND FUNCTION UNDER FLUID FLOW", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f94a8263-c1eb-718b-03c5-bb8a878692fd-C", "generated_internal_id": "ASST_NON_R01HL077258_7529"}, {"internal_id": 49753231, "Award ID": "R01HL077177", "Award Amount": 2262160.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-02-28", "CFDA Number": "93.839", "Description": "NOVEL MECHANISMS OF C-KIT REGULATION IN MAST CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL077177_7529"}, {"internal_id": 49753215, "Award ID": "R01HL076712", "Award Amount": 3928412.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-06-30", "CFDA Number": "93.839", "Description": "ROLE OF FA PROTEIN COMPLEXES IN HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R01HL076712_7529"}, {"internal_id": 49753119, "Award ID": "R01HL075092", "Award Amount": 3942376.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-12-05", "CFDA Number": "93.837", "Description": "INTEGRINS IN ENDOTHELIAL RESPONSE TO FLUID SHEAR STRESS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01HL075092_7529"}, {"internal_id": 49753062, "Award ID": "R01HL073838", "Award Amount": 3369551.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-24", "CFDA Number": "93.839", "Description": "RAAV-MEDIATED GENE THERAPY FOR HEMOPHILLIA B", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bccd984e-68ff-4e70-2020-f0129e4b9ecc-C", "generated_internal_id": "ASST_NON_R01HL073838_7529"}, {"internal_id": 49753060, "Award ID": "R01HL073813", "Award Amount": 2958029.0, "Award Type": null, "Base Obligation Date": "2008-07-24", "CFDA Number": "93.839", "Description": "STUDIES ON THE ANTICOAGULANT PROPERTIES OF THROMBIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b7dfaba3-c263-11dd-cbe2-5abe1968badc-C", "generated_internal_id": "ASST_NON_R01HL073813_7529"}, {"internal_id": 49753008, "Award ID": "R01HL072966", "Award Amount": 1141069.0, "Award Type": null, "Base Obligation Date": "2011-08-09", "CFDA Number": "93.839", "Description": "STATISTICAL METHODS FOR LONGITUDINAL STUDIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL072966_7529"}, {"internal_id": 49752941, "Award ID": "R01HL071625", "Award Amount": 5942747.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-28", "CFDA Number": "93.837", "Description": "ACTIVATION OF BLOOD AND ENDOTHELIAL CELL A5B3 INTEGRIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL071625_7529"}, {"internal_id": 49752933, "Award ID": "R01HL071544", "Award Amount": 1539130.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-27", "CFDA Number": "93.839", "Description": "MECHANISM OF STAPHYLOCOAGULASE-ACTIVATED BLOOD CLOTTING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL071544_7529"}, {"internal_id": 49752907, "Award ID": "R01HL071021", "Award Amount": 5605248.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-03-24", "CFDA Number": "93.837", "Description": "IN VIVO MOLECULAR MRI OF ATHEROTHROMBOTIC LESIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL071021_7529"}, {"internal_id": 49752854, "Award ID": "R01HL070227", "Award Amount": 3976179.38, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-12-17", "CFDA Number": "93.837", "Description": "DEVELOPMENT AND PHARMACOLOGY OF NOVEL LIPIDIC RAHF", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f94a8263-c1eb-718b-03c5-bb8a878692fd-C", "generated_internal_id": "ASST_NON_R01HL070227_7529"}, {"internal_id": 49752842, "Award ID": "R01HL069990", "Award Amount": 1234071.0, "Award Type": null, "Base Obligation Date": "2012-09-26", "CFDA Number": "93.839", "Description": "PROLONGED AND SEVERE THROMBOCYTOPENIA IN NEONATES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL069990_7529"}, {"internal_id": 49752835, "Award ID": "R01HL069929", "Award Amount": 4670153.0, "Award Type": null, "Base Obligation Date": "2007-06-04", "CFDA Number": "93.839", "Description": "STRATEGIES TO ENHANCE IMMUNE RECONSTITUTION AFTER BMT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b514fc3a-d769-87e9-75ea-7a6766afb5ee-C", "generated_internal_id": "ASST_NON_R01HL069929_7529"}, {"internal_id": 49752821, "Award ID": "R01HL069630", "Award Amount": 3065779.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-07", "CFDA Number": "93.839", "Description": "TRAFFICKING SIGNALS IN P. FALCIPARUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "65f6d07a-5df8-713f-2495-b8e648f44f20-C", "generated_internal_id": "ASST_NON_R01HL069630_7529"}, {"internal_id": 49752816, "Award ID": "R01HL069438", "Award Amount": 7265953.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-01-22", "CFDA Number": "93.837", "Description": "ADHESION MECHANISMS MEDIATING SICKLE CELL VASOOCCLUSION IN VIVO", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_R01HL069438_7529"}, {"internal_id": 49752811, "Award ID": "R01HL069234", "Award Amount": 3158230.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-10", "CFDA Number": "93.839", "Description": "GAMMA GLOBIN INDUCTION: MOLECULAR AND CELL-BASED STRATEGIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aca87389-2cb6-91e2-17a4-df7e81a7314d-C", "generated_internal_id": "ASST_NON_R01HL069234_7529"}, {"internal_id": 49752778, "Award ID": "R01HL068835", "Award Amount": 6248312.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-12-31", "CFDA Number": "93.837", "Description": "ASSOCIATION OF TISSUE FACTOR PATHWAY INHIBITOR WITH ENDOTHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R01HL068835_7529"}, {"internal_id": 49752744, "Award ID": "R01HL068130", "Award Amount": 6176255.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2006-12-16", "CFDA Number": "93.837", "Description": "CYTOSKELETAL MECHANISMS OF PLATELET FORMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL068130_7529"}, {"internal_id": 49752703, "Award ID": "R01HL067395", "Award Amount": 5084292.78, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-05-31", "CFDA Number": "93.837", "Description": "GENETIC DISSECTION OF DROSOPHILA HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_R01HL067395_7529"}, {"internal_id": 49752660, "Award ID": "R01HL066310", "Award Amount": 3495068.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-01", "CFDA Number": "93.839", "Description": "HIF- 2ALPHA, HYPOXIC GENE REGULATION, AND ANGIOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL066310_7529"}, {"internal_id": 49752602, "Award ID": "R01HL065449", "Award Amount": 2930398.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-02-09", "CFDA Number": "93.839", "Description": "POST-TRANSCRIPTIONAL CONTROLS IN MAMMALIAN ERYTHROID DIFFERENTIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_R01HL065449_7529"}, {"internal_id": 49752599, "Award ID": "R01HL065440", "Award Amount": 7061507.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-05", "CFDA Number": "93.839", "Description": "MAINTENANCE OF GENE EXPRESSION IN THE RED CELL LINEAGE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_R01HL065440_7529"}, {"internal_id": 49752585, "Award ID": "R01HL065222", "Award Amount": 4517827.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-31", "CFDA Number": "93.839", "Description": "DEVELOPMENT AND ANALYSIS OF APTAMER-ANTIDOTE PAIRS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_R01HL065222_7529"}, {"internal_id": 49752543, "Award ID": "R01HL064603", "Award Amount": 2634502.0, "Award Type": null, "Base Obligation Date": "2008-08-28", "CFDA Number": "93.839", "Description": "AUGMENTATION OF GVL REACTIVITY WITHOUT GVHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_R01HL064603_7529"}, {"internal_id": 49752530, "Award ID": "R01HL064274", "Award Amount": 8282423.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-03-20", "CFDA Number": "93.837", "Description": "HEPATIC GENE TRANSFER FOR TREATMENT OF HEMOPHILIAS A&B", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_R01HL064274_7529"}, {"internal_id": 49752497, "Award ID": "R01HL063736", "Award Amount": 3388245.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-15", "CFDA Number": "93.839", "Description": "HEMATOPOIETIC COMMITMENT:  MOLECULAR MECHANISMS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL063736_7529"}, {"internal_id": 49752482, "Award ID": "R01HL063199", "Award Amount": 5213361.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-06-25", "CFDA Number": "93.837", "Description": "RECOGNITION OF FIBRINOGEN BY LEUKOCYTE INTEGRINS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18ebe923-151d-7095-dfea-7767365ba71d-C", "generated_internal_id": "ASST_NON_R01HL063199_7529"}, {"internal_id": 49752469, "Award ID": "R01HL062996", "Award Amount": 4817941.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-08", "CFDA Number": "93.837", "Description": "PLATELET ACTIVATING FACTOR AND EPIDERMIC CYTOTOXICITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9cbb9d2c-e166-3303-6189-6280f83b64a4-C", "generated_internal_id": "ASST_NON_R01HL062996_7529"}, {"internal_id": 49752449, "Award ID": "R01HL062565", "Award Amount": 4554677.93, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-12-26", "CFDA Number": "93.837", "Description": "SERPIN REGULATION OF COAGULATION PROTEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OK", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "36c41119-2158-d09a-55ce-00590b81ab14-C", "generated_internal_id": "ASST_NON_R01HL062565_7529"}, {"internal_id": 49752440, "Award ID": "R01HL062350", "Award Amount": 3627245.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-06-26", "CFDA Number": "93.839", "Description": "PLATELET ACTIVATION SIGNALING VIA GPIB-IX AND 14-3-3", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R01HL062350_7529"}, {"internal_id": 49752434, "Award ID": "R01HL062248", "Award Amount": 2927862.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-08-31", "CFDA Number": "93.839", "Description": "INDUCTION AND SPECIFICATION OF HEMATOPOIETIC MESODERM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_R01HL062248_7529"}, {"internal_id": 49752433, "Award ID": "R01HL062244", "Award Amount": 2247556.0, "Award Type": null, "Base Obligation Date": "2007-04-10", "CFDA Number": "93.839", "Description": "CHEMOENZYMATIC SYNTHESIS OF GLYCOSAMINOGLYCAN OLIGOS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d3be7d3a-ba4a-8f04-76e3-df70beba3000-C", "generated_internal_id": "ASST_NON_R01HL062244_7529"}, {"internal_id": 49752385, "Award ID": "R01HL060961", "Award Amount": 4067598.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-01", "CFDA Number": "93.837", "Description": "ROLE OF BAND 3 IN MALARIA INVASION OF RED BLOOD CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1365968e-88a8-9046-4733-6ec9e7f54826-C", "generated_internal_id": "ASST_NON_R01HL060961_7529"}, {"internal_id": 49752369, "Award ID": "R01HL060742", "Award Amount": 4598275.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-08", "CFDA Number": "93.839", "Description": "FUNCTIONAL COOPERATION OF TISSUE FACTOR AND INTEGRINS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL060742_7529"}, {"internal_id": 49752302, "Award ID": "R01HL058837", "Award Amount": 3680126.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-06-30", "CFDA Number": "93.839", "Description": "PHYSIOLOGY AND MOLECULAR BIOLOGY OF FACTOR XI", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_R01HL058837_7529"}, {"internal_id": 49752243, "Award ID": "R01HL056819", "Award Amount": 2993513.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-29", "CFDA Number": "93.839", "Description": "ANTI-THROMBOGENIC MEMBRANE-MIMETIC ASSEMBLIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_R01HL056819_7529"}, {"internal_id": 49752233, "Award ID": "R01HL056652", "Award Amount": 3593813.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-08-21", "CFDA Number": "93.839", "Description": "MOLECULAR MECHANISMS OF PLATELET EXOCYTOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c477975b-68db-c3dc-4a79-b95cb9f6ab3e-C", "generated_internal_id": "ASST_NON_R01HL056652_7529"}, {"internal_id": 49752229, "Award ID": "R01HL056595", "Award Amount": 4192567.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-06-19", "CFDA Number": "93.837", "Description": "ADHESIVE SIGNALING BY PLATELET BETA-3 INTEGRINS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01HL056595_7529"}, {"internal_id": 49752226, "Award ID": "R01HL056416", "Award Amount": 3427278.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-29", "CFDA Number": "93.839", "Description": "MECHANISMS OF SYNERGISTIC REGULATION OF STEM/PROGENITORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_R01HL056416_7529"}, {"internal_id": 49752211, "Award ID": "R01HL056067", "Award Amount": 5435382.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-15", "CFDA Number": "93.837", "Description": "T CELL TARGETING FOR GVHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R01HL056067_7529"}, {"internal_id": 49752210, "Award ID": "R01HL056051", "Award Amount": 4863831.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-28", "CFDA Number": "93.837", "Description": "FIBRIN(OGEN) STRUCTURE AND INTERACTIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_R01HL056051_7529"}, {"internal_id": 49752200, "Award ID": "R01HL055666", "Award Amount": 3107512.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-12-15", "CFDA Number": "93.839", "Description": "STRUCTURE-FUNCTION ANALYSIS OF THE GAMMA CARBOXYLASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_R01HL055666_7529"}, {"internal_id": 49752189, "Award ID": "R01HL055374", "Award Amount": 5285734.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-14", "CFDA Number": "93.837", "Description": "THE BIOLOGY OF NEUROSERPIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_R01HL055374_7529"}, {"internal_id": 49752186, "Award ID": "R01HL055337", "Award Amount": 6598259.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-20", "CFDA Number": "93.837", "Description": "HEMANGIOGLAST DEVELOPMENT AND REGULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R01HL055337_7529"}, {"internal_id": 49752133, "Award ID": "R01HL052725", "Award Amount": 3327975.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-15", "CFDA Number": "93.837", "Description": "MOLECULAR PATHOGENESIS OF FANCONI ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "be067fa7-a493-7bea-f9cc-e29bd2ccc74a-C", "generated_internal_id": "ASST_NON_R01HL052725_7529"}, {"internal_id": 49752127, "Award ID": "R01HL052246", "Award Amount": 7578142.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2006-12-14", "CFDA Number": "93.838", "Description": "STRUCTURE AND FUNCTION OF PROTEIN C", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_R01HL052246_7529"}, {"internal_id": 49752084, "Award ID": "R01HL049413", "Award Amount": 5200784.24, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-04-22", "CFDA Number": "93.837", "Description": "STUDIES ON THROMBIN ALLOSTERY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b7dfaba3-c263-11dd-cbe2-5abe1968badc-C", "generated_internal_id": "ASST_NON_R01HL049413_7529"}, {"internal_id": 49752068, "Award ID": "R01HL048801", "Award Amount": 3659895.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-08-27", "CFDA Number": "93.839", "Description": "EMBRYONIC HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL048801_7529"}, {"internal_id": 49752048, "Award ID": "R01HL047014", "Award Amount": 3228869.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-12-13", "CFDA Number": "93.839", "Description": "MECHANISMS OF CLOTTING FACTOR ASSEMBLY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2c3d8c8a-27ef-b1e9-7164-bbfa490faa27-C", "generated_internal_id": "ASST_NON_R01HL047014_7529"}, {"internal_id": 49752017, "Award ID": "R01HL044491", "Award Amount": 3724368.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-01-13", "CFDA Number": "93.837", "Description": "EPO REGULATED ERYTHROPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "95461d50-d116-e3a5-b390-021971a75d58-C", "generated_internal_id": "ASST_NON_R01HL044491_7529"}, {"internal_id": 49752003, "Award ID": "R01HL042493", "Award Amount": 2471684.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-03-14", "CFDA Number": "93.839", "Description": "FIBRINOLYTIC COFACTOR FUNCTION OF PROTEIN S100A10/P11", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_R01HL042493_7529"}, {"internal_id": 49751994, "Award ID": "R01HL040926", "Award Amount": 4213769.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-17", "CFDA Number": "93.839", "Description": "MOLECULAR BIOLOGY AND FUNCTION OF PECAM-1", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R01HL040926_7529"}, {"internal_id": 49751934, "Award ID": "R01HL034363", "Award Amount": 3882761.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-04-13", "CFDA Number": "93.839", "Description": "CELLULAR REGULATION OF SELECTIN-LIGAND INTERACTIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OK", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "36c41119-2158-d09a-55ce-00590b81ab14-C", "generated_internal_id": "ASST_NON_R01HL034363_7529"}, {"internal_id": 49751917, "Award ID": "R01HL032259", "Award Amount": 6041776.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-03-29", "CFDA Number": "93.837", "Description": "MOLECULAR ANALYSIS OF NORMAL AND THALASSEMIC DNA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_R01HL032259_7529"}, {"internal_id": 49751914, "Award ID": "R01HL031823", "Award Amount": 5993874.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-08-08", "CFDA Number": "93.837", "Description": "PHYSIOLOGY OF FELINE LEUKEMIA VIRUS C RECEPTOR, FLVCR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R01HL031823_7529"}, {"internal_id": 49751845, "Award ID": "R01HL019278", "Award Amount": 10608896.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-05", "CFDA Number": "93.837", "Description": "INTEGRIN ALPHAIIBBETA3 STRUCTURE, ACTIVATION, AND LIGAND BINDING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cc63b807-2bf8-905f-48e2-a3b33fcd281b-C", "generated_internal_id": "ASST_NON_R01HL019278_7529"}, {"internal_id": 49751833, "Award ID": "R01HL013629", "Award Amount": 5174538.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-06", "CFDA Number": "93.837", "Description": "HEMORRHAGIC DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_R01HL013629_7529"}, {"internal_id": 49751831, "Award ID": "R01HL013423", "Award Amount": 4396701.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-30", "CFDA Number": "93.837", "Description": "PLASMINOGEN AND PLASMIN: STRUCTURE AND FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "65f6d07a-5df8-713f-2495-b8e648f44f20-C", "generated_internal_id": "ASST_NON_R01HL013423_7529"}, {"internal_id": 49735085, "Award ID": "R01DK102165", "Award Amount": 1388989.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-09-13", "CFDA Number": "93.839", "Description": "DYSREGULATED MICRORNA FUNCTION IN DIAMOND BLACKFAN ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "be067fa7-a493-7bea-f9cc-e29bd2ccc74a-C", "generated_internal_id": "ASST_NON_R01DK102165_7529"}, {"internal_id": 111229133, "Award ID": "R00HL148646", "Award Amount": 746998.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-21", "CFDA Number": "93.837", "Description": "SYSTEMATIC MULTIDISCIPLINARY APPROACH TO STUDY TRAUMATIC BLEEDING AS A COMPLEX STRUCTURAL AND BIOMECHANICAL PROBLEM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "83d0dcf4-2a9e-ab83-7a4e-b740e9121600-C", "generated_internal_id": "ASST_NON_R00HL148646_7529"}, {"internal_id": 96203385, "Award ID": "R00HL143165", "Award Amount": 793660.01, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-01", "CFDA Number": "93.837", "Description": "VASCULAR PANNEXIN 1 IN ISCHEMIC STROKE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "34640ee3-dce1-9923-6e06-25f6c48e1690-C", "generated_internal_id": "ASST_NON_R00HL143165_7529"}, {"internal_id": 83103977, "Award ID": "R00HL136924", "Award Amount": 747000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-07", "CFDA Number": "93.837", "Description": "MECHANISTIC AND FUNCTIONAL DISSECTION OF MYELOID BLOOD CANCERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_R00HL136924_7529"}, {"internal_id": 67580020, "Award ID": "R00HL136870", "Award Amount": 995916.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-03", "CFDA Number": "93.839", "Description": "THE MULTIFACETED ROLE OF THE FANCONI ANEMIA TUMOR SUPPRESSOR PATHWAY IN FACILITATING DNA REPLICATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6bb8cb92-7a60-db8e-9071-a22cdf2ab031-C", "generated_internal_id": "ASST_NON_R00HL136870_7529"}, {"internal_id": 96201364, "Award ID": "R00HL136784", "Award Amount": 748064.48, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-27", "CFDA Number": "93.837", "Description": "THE RACIAL DISPARITY IN PLATELET PAR4 SIGNALING ENHANCES THROMBUS FORMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_R00HL136784_7529"}, {"internal_id": 111229124, "Award ID": "R00HL135740", "Award Amount": 746998.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-11-28", "CFDA Number": "93.837", "Description": "TOWARDS IMPROVING BONE MARROW TRANSPLANTATION VIA INHIBITION OF 15-PGDH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_R00HL135740_7529"}, {"internal_id": 111229127, "Award ID": "R00HL135265", "Award Amount": 747000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-06", "CFDA Number": "93.837", "Description": "PLATELET-HYALURONAN INTERACTIONS AS REGULATORS OF INFLAMMATION AND THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_R00HL135265_7529"}, {"internal_id": 83116189, "Award ID": "R00HL133458", "Award Amount": 1043911.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-04", "CFDA Number": "93.837", "Description": "THE ROLE OF WNT SIGNALING IN NORMAL AND ABNORMAL HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1534837f-0cc1-e0a9-60cc-45f58c9fb55d-C", "generated_internal_id": "ASST_NON_R00HL133458_7529"}, {"internal_id": 49705503, "Award ID": "R00HL133453", "Award Amount": 746972.64, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-05", "CFDA Number": "93.837", "Description": "ERYTHROCYTE SUBVERSION BY MALARIA PARASITE EXPORTED EFFECTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7148b6ec-c422-d557-aa04-0c8488cc6775-C", "generated_internal_id": "ASST_NON_R00HL133453_7529"}, {"internal_id": 65280669, "Award ID": "R00HL129193", "Award Amount": 730265.03, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-22", "CFDA Number": "93.837", "Description": "PROTEIN S ANTICOAGULANT ACTIVITY: BIOCHEMICAL MECHANISMS AND STRUCTURAL STUDIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "KY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c477975b-68db-c3dc-4a79-b95cb9f6ab3e-C", "generated_internal_id": "ASST_NON_R00HL129193_7529"}, {"internal_id": 49705488, "Award ID": "R00HL128944", "Award Amount": 746998.38, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-23", "CFDA Number": "93.837", "Description": "THE IMPORTANCE OF INHOMOGENEITY IN THE PATHOGENESIS OF LUNG INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_R00HL128944_7529"}, {"internal_id": 49705480, "Award ID": "R00HL125884", "Award Amount": 681087.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-11", "CFDA Number": "93.839", "Description": "MECHANICALLY CONTROLLED RELEASE OF HEMATOPOIETIC FACTORS FROM MESENCHYMAL STROMAL CELLS FOR BLOOD REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_R00HL125884_7529"}, {"internal_id": 49705477, "Award ID": "R00HL125668", "Award Amount": 744457.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-26", "CFDA Number": "93.839", "Description": "PI3K SIGNALING IN REGULATION OF CD8 T CELL SENESCENCE AND DEATH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R00HL125668_7529"}, {"internal_id": 49705467, "Award ID": "R00HL123638", "Award Amount": 733155.64, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-26", "CFDA Number": "93.837", "Description": "MOLECULAR PROGRAMMING OF IMMUNOLOGICAL MEMORY IN HUMAN NATURAL KILLER CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_R00HL123638_7529"}, {"internal_id": 49705443, "Award ID": "R00HL121087", "Award Amount": 747000.26, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-26", "CFDA Number": "93.837", "Description": "NETWORK MEDICINE APPROACHES TO CACHEXIA IN COPD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_R00HL121087_7529"}, {"internal_id": 49705439, "Award ID": "R00HL119638", "Award Amount": 746998.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-19", "CFDA Number": "93.837", "Description": "SINGLE-CELL ANALYSIS OF IMMUNE CELL FATE DECISION MAKING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_R00HL119638_7529"}, {"internal_id": 49705431, "Award ID": "R00HL119559", "Award Amount": 746994.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-14", "CFDA Number": "93.839", "Description": "MACROPHAGE REGULATION OF THE HEMATOPOIETIC STEM CELL NICHE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_R00HL119559_7529"}, {"internal_id": 49705425, "Award ID": "R00HL118157", "Award Amount": 747000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-01-15", "CFDA Number": "93.839", "Description": "REGULATION OF ERYTHROID TERMINAL DIFFERENTIATION BY LONG NONCODING RNAS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_R00HL118157_7529"}, {"internal_id": 49705406, "Award ID": "R00HL114732", "Award Amount": 638380.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-03-07", "CFDA Number": "93.839", "Description": "STUDYING A BONE MARROW FAILURE DISEASE USING PATIENT-SPECIFIC IPS CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_R00HL114732_7529"}, {"internal_id": 49705404, "Award ID": "R00HL114719", "Award Amount": 549568.0, "Award Type": null, "Base Obligation Date": "2015-04-27", "CFDA Number": "93.839", "Description": "EXAMINATION OF THE FINAL STAGES OF PLATELET PRODUCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_R00HL114719_7529"}, {"internal_id": 49705399, "Award ID": "R00HL113104", "Award Amount": 730656.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-03-07", "CFDA Number": "93.839", "Description": "LINEAGE BIAS AND CLONAL EXPANSION OF HEMATOPOIETIC STEM CELL DIFFERENTIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_R00HL113104_7529"}, {"internal_id": 49705272, "Award ID": "R00HL090706", "Award Amount": 714408.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-17", "CFDA Number": "93.839", "Description": "CYTOKINE DYSREGULATION IN AUTOIMMUNE HEMOLYTIC ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e5d977d0-85fb-65b4-d649-335857133b76-C", "generated_internal_id": "ASST_NON_R00HL090706_7529"}, {"internal_id": 49666373, "Award ID": "P50HL118006", "Award Amount": 7041919.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-22", "CFDA Number": "93.837", "Description": "CENTER FOR HEMOGLOBIN RESEARCH IN MINORITIES (CHARM)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ab2545e4-42db-b0e5-c4ac-2382eeaf8c92-C", "generated_internal_id": "ASST_NON_P50HL118006_7529"}, {"internal_id": 49666369, "Award ID": "P50HL110790", "Award Amount": 9772080.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-07-16", "CFDA Number": "93.839", "Description": "A CONTROLLED CLINICAL TRIAL OF REGADENOSON IN SICKLE CELL ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "be067fa7-a493-7bea-f9cc-e29bd2ccc74a-C", "generated_internal_id": "ASST_NON_P50HL110790_7529"}, {"internal_id": 49666368, "Award ID": "P50HL110789", "Award Amount": 9999361.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-05-26", "CFDA Number": "93.839", "Description": "TRIP-PCI: PAR1 PEPDUCIN-BASED INTERVENTIONS IN ARTERIAL THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "34640ee3-dce1-9923-6e06-25f6c48e1690-C", "generated_internal_id": "ASST_NON_P50HL110789_7529"}, {"internal_id": 49666367, "Award ID": "P50HL110787", "Award Amount": 12417843.33, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-05-16", "CFDA Number": "93.837", "Description": "NOTCH-MEDIATED EXPANSION OF CORD BLOOD PROGENITORS FOR STEM CELL TRANSPLANT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_P50HL110787_7529"}, {"internal_id": 108463911, "Award ID": "P01HL151433", "Award Amount": 9394706.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-05", "CFDA Number": "93.837", "Description": "CELLULAR MECHANISMS OF INFLAMMATION, HEMOSTASIS, AND THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_P01HL151433_7529"}, {"internal_id": 109278466, "Award ID": "P01HL149633", "Award Amount": 6852689.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-19", "CFDA Number": "93.837", "Description": "HOST AND MICROBIAL METABOLISM IN GRAFT VERSUS HOST DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_P01HL149633_7529"}, {"internal_id": 103894137, "Award ID": "P01HL149626", "Award Amount": 12471319.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-20", "CFDA Number": "93.837", "Description": "COMPLICATIONS OF HEMOLYSIS AND TRANSFUSION THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "644797d6-c94c-9e2c-b40a-a4cda190c447-C", "generated_internal_id": "ASST_NON_P01HL149626_7529"}, {"internal_id": 97469698, "Award ID": "P01HL146373", "Award Amount": 9784786.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-08", "CFDA Number": "93.837", "Description": "STUDIES OF PHYSIOLOGIC AND PATHOLOGIC PLATELET PLUG FORMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_P01HL146373_7529"}, {"internal_id": 82471038, "Award ID": "P01HL146372", "Award Amount": 10906515.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-31", "CFDA Number": "93.837", "Description": "TARGETING ENZYMATIC REGULATION OF FETAL HEMOGLOBIN REPRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_P01HL146372_7529"}, {"internal_id": 78991114, "Award ID": "P01HL144457", "Award Amount": 13295147.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-11", "CFDA Number": "93.837", "Description": "ZIMMERMAN PROGRAM ON THE BIOLOGY OF VWD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_P01HL144457_7529"}, {"internal_id": 68167420, "Award ID": "P01HL139420", "Award Amount": 10490373.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-24", "CFDA Number": "93.837", "Description": "HEMOSTASIS AND THROMBOSIS: CHEMISTRY, BIOLOGY AND PHYSIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_P01HL139420_7529"}, {"internal_id": 49359420, "Award ID": "P01HL132819", "Award Amount": 12222380.5, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-21", "CFDA Number": "93.837", "Description": "IMMUNOBIOLOGY OF TRANSFUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "474a19eb-1491-c065-a3ca-a49b264b0d4b-C", "generated_internal_id": "ASST_NON_P01HL132819_7529"}, {"internal_id": 49359417, "Award ID": "P01HL131477", "Award Amount": 14806956.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-05", "CFDA Number": "93.837", "Description": "FUNCTIONAL CONSEQUENCES OF STEM AND PROGENITOR CELL HETEROGENEITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_P01HL131477_7529"}, {"internal_id": 49359416, "Award ID": "P01HL131474", "Award Amount": 20899426.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-13", "CFDA Number": "93.837", "Description": "PROTEIN GLYCOSYLATION IN THE COAGULOPATHY AND INFLAMMATION OF SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e83c70bf-5580-4458-00fc-fb4f3d77119d-C", "generated_internal_id": "ASST_NON_P01HL131474_7529"}, {"internal_id": 49359409, "Award ID": "P01HL122173", "Award Amount": 12926413.23, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-03", "CFDA Number": "93.837", "Description": "CELL AND GENE THERAPY FOR NONMALIGNANT BLOOD DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "569197a4-81d0-b264-5640-e9db4cf71fd0-C", "generated_internal_id": "ASST_NON_P01HL122173_7529"}, {"internal_id": 49359408, "Award ID": "P01HL120846", "Award Amount": 11368068.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-08", "CFDA Number": "93.839", "Description": "PLATELET SIGNALS AND THEIR INTERFACE WITH THE EXTERNAL ENVIRONMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_P01HL120846_7529"}, {"internal_id": 49359397, "Award ID": "P01HL112761", "Award Amount": 11298956.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-02-08", "CFDA Number": "93.839", "Description": "NEUTRALIZING ANTIBODY & AAV FIX GENE THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_P01HL112761_7529"}, {"internal_id": 49359395, "Award ID": "P01HL110900", "Award Amount": 10629639.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-07-27", "CFDA Number": "93.839", "Description": "MECHANISMS AND MODULATION OF ACCELLULAR HBA TOXICITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75e3c1a2-1272-1d1c-d51b-c7a0d1cbe653-C", "generated_internal_id": "ASST_NON_P01HL110900_7529"}, {"internal_id": 49359392, "Award ID": "P01HL110860", "Award Amount": 11218977.0, "Award Type": null, "Base Obligation Date": "2012-08-20", "CFDA Number": "93.839", "Description": "PATHOGENESIS AND MANAGEMENT OF HEPARIN-INDUCED THROMBOCYTOPENEIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_P01HL110860_7529"}, {"internal_id": 49359380, "Award ID": "P01HL107152", "Award Amount": 15670950.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-09-22", "CFDA Number": "93.839", "Description": "CHEMISTRY AND BIOLOGY OF HEPARAN SULFATE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c6121f36-8222-1039-c78e-e1f5ef0bfaf6-C", "generated_internal_id": "ASST_NON_P01HL107152_7529"}, {"internal_id": 49359378, "Award ID": "P01HL107150", "Award Amount": 17954016.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-06-23", "CFDA Number": "93.839", "Description": "GLYCAN MODULATION OF INFLAMMATORY RESPONSES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_P01HL107150_7529"}, {"internal_id": 49359376, "Award ID": "P01HL107146", "Award Amount": 17641049.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-06-28", "CFDA Number": "93.837", "Description": "BIOSYNTHESIS AND FUNCTION OF LACTOSAMINYL GLYCANS IN HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_P01HL107146_7529"}, {"internal_id": 49359360, "Award ID": "P01HL095489", "Award Amount": 20113230.85, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2010-06-11", "CFDA Number": "93.837", "Description": "MOLECULAR MECHANISMS OF BLOOD CELL TRANSFUSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_P01HL095489_7529"}, {"internal_id": 49359332, "Award ID": "P01HL086773", "Award Amount": 17879937.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-12", "CFDA Number": "93.837", "Description": "SERIOUS HAZARDS OF TRANSFUSION & CELLULAR THERAPIES:  MECHANISMS AND INTERVENTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_P01HL086773_7529"}, {"internal_id": 49359329, "Award ID": "P01HL085607", "Award Amount": 13595320.0, "Award Type": null, "Base Obligation Date": "2007-06-28", "CFDA Number": "93.839", "Description": "PROTEIN-GLYCAN INTERACTIONS IN THE VASCULAR SYSTEM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OK", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "36c41119-2158-d09a-55ce-00590b81ab14-C", "generated_internal_id": "ASST_NON_P01HL085607_7529"}, {"internal_id": 49359321, "Award ID": "P01HL081588", "Award Amount": 13821344.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-07", "CFDA Number": "93.839", "Description": "MOLECULAR AND CLINICAL BIOLOGY OF VWD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_P01HL081588_7529"}, {"internal_id": 49359305, "Award ID": "P01HL078784", "Award Amount": 22107886.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-12-10", "CFDA Number": "93.837", "Description": "CELL ADHESION MECHANISMS IN VASCULAR DISEASE&THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_P01HL078784_7529"}, {"internal_id": 49359296, "Award ID": "P01HL075462", "Award Amount": 20163910.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-21", "CFDA Number": "93.837", "Description": "BLOOD STEM CELL TRANSPLANTATION AS IMMUNOTHERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_P01HL075462_7529"}, {"internal_id": 49359290, "Award ID": "P01HL073311", "Award Amount": 19792451.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-04-11", "CFDA Number": "93.839", "Description": "STRUCTURE AND FUNCTION OF BETA3 INTEGRINS ON BLOOD CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_P01HL073311_7529"}, {"internal_id": 49359273, "Award ID": "P01HL064190", "Award Amount": 13831455.0, "Award Type": null, "Base Obligation Date": "2007-05-04", "CFDA Number": "93.839", "Description": "GENE THERAPY FOR HEMOPHILIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_P01HL064190_7529"}, {"internal_id": 49359246, "Award ID": "P01HL053749", "Award Amount": 28221244.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-11", "CFDA Number": "93.837", "Description": "GENE THERAPY FOR SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bccd984e-68ff-4e70-2020-f0129e4b9ecc-C", "generated_internal_id": "ASST_NON_P01HL053749_7529"}, {"internal_id": 49359236, "Award ID": "P01HL048546", "Award Amount": 21813584.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-02", "CFDA Number": "93.837", "Description": "MOLECULAR GENETICS OF FANCONI ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_P01HL048546_7529"}, {"internal_id": 49359233, "Award ID": "P01HL046925", "Award Amount": 24923982.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-07-25", "CFDA Number": "93.837", "Description": "NEONATAL ANEMIA:PATHOPHYSIOLOGY AND TREATMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_P01HL046925_7529"}, {"internal_id": 49359225, "Award ID": "P01HL040387", "Award Amount": 20524572.07, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-05-30", "CFDA Number": "93.837", "Description": "REGULATION OF PLATELET AND ENDOTHELIAL CELL FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_P01HL040387_7529"}, {"internal_id": 49359212, "Award ID": "P01HL032262", "Award Amount": 25759770.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-07-04", "CFDA Number": "93.837", "Description": "DEVELOPMENTAL BIOLOGY OF HUMAN ERYTHROPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_P01HL032262_7529"}, {"internal_id": 49359210, "Award ID": "P01HL031950", "Award Amount": 12387056.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-05", "CFDA Number": "93.839", "Description": "THROMBUS FORMATION AND ANTITHROMBOTIC INTERVENTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_P01HL031950_7529"}, {"internal_id": 110863321, "Award ID": "K99HL153678", "Award Amount": 121793.7, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-21", "CFDA Number": "93.837", "Description": "INHIBITING BIOMECHANICAL PLATELET AGGREGATION TO PREVENT ARTERIAL THROMBOSIS WITHOUT COMPROMISING HEMOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9c6e5599-9f3d-3f33-5740-2c1ed46512c4-C", "generated_internal_id": "ASST_NON_K99HL153678_7529"}, {"internal_id": 107114756, "Award ID": "K99HL153673", "Award Amount": 246794.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-23", "CFDA Number": "93.837", "Description": "BONE MARROW FUNCTIONS OF NOVEL PRO-RESOLVING MEDIATORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K99HL153673_7529"}, {"internal_id": 97852559, "Award ID": "K99HL151887", "Award Amount": 140197.57, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-05-29", "CFDA Number": "93.837", "Description": "PERSISTENT MICROVASCULATURE THROMBOSIS CAUSED BY FIBRINOLYSIS SHUTDOWN DRIVING DELAYED GRAFT FUNCTION IN LIVER TRANSPLANT RECIPIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_K99HL151887_7529"}, {"internal_id": 97015698, "Award ID": "K99HL151750", "Award Amount": 150045.12, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-29", "CFDA Number": "93.837", "Description": "INFLUENCE OF SLEEP ON HEMATOPOIETIC STEM CELL DIVERSITY AND CLONALITY IN CARDIOVASCULAR DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_K99HL151750_7529"}, {"internal_id": 95484284, "Award ID": "K99HL150628", "Award Amount": 949665.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-28", "CFDA Number": "93.837", "Description": "NOVEL SOURCES OF ENDOGENOUS DNA DAMAGE IN HEMATOPOIETIC STEM PROGENITOR CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K99HL150628_7529"}, {"internal_id": 95181078, "Award ID": "K99HL150626", "Award Amount": 876960.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-14", "CFDA Number": "93.837", "Description": "CD8 T CELL-MEDIATED ALLOGENEIC PLATELET CLEARANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_K99HL150626_7529"}, {"internal_id": 95484255, "Award ID": "K99HL150595", "Award Amount": 810000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-21", "CFDA Number": "93.837", "Description": "UTILIZING DENDRITIC CELL BIOLOGY TO CHARACTERIZE THE INNATE IMMUNE RESPONSE TO BLOOD COAGULATION PROTEINS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_K99HL150595_7529"}, {"internal_id": 96558781, "Award ID": "K99HL150594", "Award Amount": 907200.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-17", "CFDA Number": "93.837", "Description": "ADAMTS13 AND LATE NEUROLOGIC MORBIDITY AFTER THROMBOTIC THROMBOCYTOPENIC PURPURA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K99HL150594_7529"}, {"internal_id": 95484640, "Award ID": "K99HL150281", "Award Amount": 129263.8, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-28", "CFDA Number": "93.837", "Description": "ROLE OF REGULATORY T CELLS IN ADVERSE PREGNANCY OUTCOMES AFTER ISCHEMIA REPERFUSION INJURY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aca87389-2cb6-91e2-17a4-df7e81a7314d-C", "generated_internal_id": "ASST_NON_K99HL150281_7529"}, {"internal_id": 96203848, "Award ID": "K99HL150218", "Award Amount": 166469.17, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-31", "CFDA Number": "93.837", "Description": "A SYNTHETIC HEMATOPOIETIC STEM CELL NICHE TO INVESTIGATE STEMNESS AND HEMATOPATHOLOGIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_K99HL150218_7529"}, {"internal_id": 110233553, "Award ID": "K99HL150166", "Award Amount": 216008.32, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-10", "CFDA Number": "93.837", "Description": "AGE-RELATED DECREASE IN MITOFUSIN 1 RESULTS IN PLATELET DYSFUNCTION AND THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K99HL150166_7529"}, {"internal_id": 83797404, "Award ID": "K99HL148646", "Award Amount": 91746.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-27", "CFDA Number": "93.837", "Description": "SYSTEMATIC MULTIDISCIPLINARY APPROACH TO STUDY TRAUMATIC BLEEDING AS A COMPLEX STRUCTURAL AND BIOMECHANICAL PROBLEM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K99HL148646_7529"}, {"internal_id": 81072146, "Award ID": "K99HL146983", "Award Amount": 283757.57, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-27", "CFDA Number": "93.837", "Description": "MECHANISMS OF IN SITU FUNCTIONAL STEM CELL HETEROGENEITY IN NATIVE AND TRANSPLANTATION HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_K99HL146983_7529"}, {"internal_id": 82054022, "Award ID": "K99HL144817", "Award Amount": 300658.75, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-12", "CFDA Number": "93.837", "Description": "THE ROLE OF ENDOTHELIN-1 IN TUBULAR INJURY IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_K99HL144817_7529"}, {"internal_id": 82470356, "Award ID": "K99HL143198", "Award Amount": 192606.11, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-01", "CFDA Number": "93.837", "Description": "THE REGULATION OF LYMPHATIC MUSCLE CELL PACEMAKING BY INTRACELLULAR CALCIUM SIGNALS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f261384c-3ac1-b344-de46-81708f87aa6a-C", "generated_internal_id": "ASST_NON_K99HL143198_7529"}, {"internal_id": 67832801, "Award ID": "K99HL143165", "Award Amount": 159641.99, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-09", "CFDA Number": "93.837", "Description": "VASCULAR PANNEXIN 1 IN ISCHEMIC STROKE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_K99HL143165_7529"}, {"internal_id": 65280436, "Award ID": "K99HL141687", "Award Amount": 205432.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-03-30", "CFDA Number": "93.837", "Description": "DEFINING MIR-223-DEPENDENT MECHANISMS REGULATING HEMATOPOIETIC STEM CELL PRODUCTION FROM ENDOTHELIUM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_K99HL141687_7529"}, {"internal_id": 76738069, "Award ID": "K99HL141638", "Award Amount": 209886.48, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-31", "CFDA Number": "93.837", "Description": "MALADAPTIVE INFLAMMATION IMPAIRS COLLATERAL VESSEL FORMATION IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_K99HL141638_7529"}, {"internal_id": 48920205, "Award ID": "K99HL136924", "Award Amount": 134309.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-22", "CFDA Number": "93.839", "Description": "MECHANISTIC AND FUNCTIONAL DISSECTION OF MYELOID BLOOD CANCERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K99HL136924_7529"}, {"internal_id": 48920202, "Award ID": "K99HL136870", "Award Amount": 248634.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-01", "CFDA Number": "93.839", "Description": "THE MULTIFACETED ROLE OF THE FANCONI ANEMIA TUMOR SUPPRESSOR PATHWAY IN FACILITATING DNA REPLICATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75e3c1a2-1272-1d1c-d51b-c7a0d1cbe653-C", "generated_internal_id": "ASST_NON_K99HL136870_7529"}, {"internal_id": 48920200, "Award ID": "K99HL136784", "Award Amount": 200469.52, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-08", "CFDA Number": "93.837", "Description": "THE RACIAL DISPARITY IN PLATELET PAR4 SIGNALING ENHANCES THROMBUS FORMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K99HL136784_7529"}, {"internal_id": 48920196, "Award ID": "K99HL135740", "Award Amount": 259740.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-04", "CFDA Number": "93.839", "Description": "TOWARDS IMPROVING BONE MARROW TRANSPLANTATION VIA INHIBITION OF 15-PGDH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_K99HL135740_7529"}, {"internal_id": 48920191, "Award ID": "K99HL135265", "Award Amount": 280468.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-21", "CFDA Number": "93.839", "Description": "PLATELET-HYALURONAN INTERACTIONS AS REGULATORS OF INFLAMMATION AND THROMBOSIS.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_K99HL135265_7529"}, {"internal_id": 48920187, "Award ID": "K99HL133590", "Award Amount": 252868.26, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-21", "CFDA Number": "93.837", "Description": "MICRORNA AS A TARGET FOR FETAL HEMOGLOBIN INDUCING AGENTS IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_K99HL133590_7529"}, {"internal_id": 48920183, "Award ID": "K99HL133458", "Award Amount": 238296.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-15", "CFDA Number": "93.839", "Description": "THE ROLE OF WNT SIGNALING IN NORMAL AND ABNORMAL HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_K99HL133458_7529"}, {"internal_id": 48920182, "Award ID": "K99HL133453", "Award Amount": 113999.0, "Award Type": null, "Base Obligation Date": "2016-08-15", "CFDA Number": "93.839", "Description": "ERYTHROCYTE SUBVERSION BY MALARIA PARASITE EXPORTED EFFECTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_K99HL133453_7529"}, {"internal_id": 48920159, "Award ID": "K99HL129193", "Award Amount": 190703.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-14", "CFDA Number": "93.839", "Description": "PROTEIN S ANTICOAGULANT ACTIVITY: BIOCHEMICAL MECHANISMS AND STRUCTURAL STUDIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_K99HL129193_7529"}, {"internal_id": 48920111, "Award ID": "K99HL122503", "Award Amount": 257096.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-26", "CFDA Number": "93.839", "Description": "ROLE OF ABERRANT CYTOKINE SIGNALING IN MYELOPROLIFERATIVE DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b514fc3a-d769-87e9-75ea-7a6766afb5ee-C", "generated_internal_id": "ASST_NON_K99HL122503_7529"}, {"internal_id": 79434359, "Award ID": "K25HL146949", "Award Amount": 334517.37, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-21", "CFDA Number": "93.837", "Description": "MECHANICAL AND BIOCHEMICAL REGULATION OF VON WILLEBRAND FACTOR ADHESION IN FLOW", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_K25HL146949_7529"}, {"internal_id": 76738183, "Award ID": "K25HL145129", "Award Amount": 456592.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-12-31", "CFDA Number": "93.837", "Description": "MRI-BASED QUANTITATIVE BRAIN OXIMETRY FOR SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8245755e-5e2c-a7dc-44d4-4e7b18b8be51-C", "generated_internal_id": "ASST_NON_K25HL145129_7529"}, {"internal_id": 82470193, "Award ID": "K25HL145092", "Award Amount": 744525.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-01", "CFDA Number": "93.837", "Description": "MEMBRANE ANCHORED-PROBES FOR SENSING ANALYTES AT THE CELL SURFACE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K25HL145092_7529"}, {"internal_id": 78599680, "Award ID": "K25HL141636", "Award Amount": 787745.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-22", "CFDA Number": "93.837", "Description": "WEARABLE MICROCHIP FOR ASSESSING GLOBAL HEMOSTATSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_K25HL141636_7529"}, {"internal_id": 48918338, "Award ID": "K25HL135432", "Award Amount": 890460.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-16", "CFDA Number": "93.837", "Description": "MECHANOREGULATORY MECHANISMS OF VON WILLEBRAND DISEASE AND THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_K25HL135432_7529"}, {"internal_id": 48918323, "Award ID": "K25HL121192", "Award Amount": 822464.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-20", "CFDA Number": "93.839", "Description": "MRI-BASED QUANTITATIVE BRAIN PERFUSION MAPPING FOR SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8245755e-5e2c-a7dc-44d4-4e7b18b8be51-C", "generated_internal_id": "ASST_NON_K25HL121192_7529"}, {"internal_id": 48918319, "Award ID": "K25HL118137", "Award Amount": 695236.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-02", "CFDA Number": "93.839", "Description": "STRUCTURAL ANALYSIS OF OXIDATION EFFECTS ON THE HEMOSTATIC PROCESS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_K25HL118137_7529"}, {"internal_id": 48918317, "Award ID": "K25HL111213", "Award Amount": 738983.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-03", "CFDA Number": "93.839", "Description": "PREVENTION OF THROMBOSIS BY NO SECRETING POLYMERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5d50a1e7-6c45-607b-669d-580246737467-C", "generated_internal_id": "ASST_NON_K25HL111213_7529"}, {"internal_id": 86317691, "Award ID": "K24HL148305", "Award Amount": 561321.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-20", "CFDA Number": "93.837", "Description": "(SCANS) SICKLE CELL ANEMIA NEURODEVELOPMENTAL SCREENING - MENTORING AND RESEARCH IN PATIENT ORIENTED RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_K24HL148305_7529"}, {"internal_id": 83103230, "Award ID": "K24HL147017", "Award Amount": 547252.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-14", "CFDA Number": "93.837", "Description": "MENTORING IN PATIENT-ORIENTED RESEARCH FOCUSED ON NEUROLOGICAL COMPLICATIONS OF SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K24HL147017_7529"}, {"internal_id": 66800013, "Award ID": "K24HL141354", "Award Amount": 731004.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-19", "CFDA Number": "93.866", "Description": "USE AND OUTCOMES OF ANTICOAGULANTS FOR THE TREATMENT AND PREVENTION OF THROMBOSIS AMONG HOSPITALIZED PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K24HL141354_7529"}, {"internal_id": 48918022, "Award ID": "K24HL133373", "Award Amount": 953192.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-15", "CFDA Number": "93.837", "Description": "PATIENT ORIENTED RESEARCH IN PERSONALIZED ANTITHROMBOTIC THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_K24HL133373_7529"}, {"internal_id": 48917985, "Award ID": "K24HL093294", "Award Amount": 1501719.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2009-08-31", "CFDA Number": "93.839", "Description": "INFECTIONS IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_K24HL093294_7529"}, {"internal_id": 103897410, "Award ID": "K23HL153763", "Award Amount": 678240.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-21", "CFDA Number": "93.837", "Description": "SICKLE CELL ANEMIA, SPLENIC PATHOLOGY, AND HYDROXYUREA IN SUB-SAHARAN AFRICA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_K23HL153763_7529"}, {"internal_id": 96988885, "Award ID": "K23HL151826", "Award Amount": 529323.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-30", "CFDA Number": "93.837", "Description": "THE MALARIA TRANSFUSION RISK (MATRIX) STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K23HL151826_7529"}, {"internal_id": 107114204, "Award ID": "K23HL150300", "Award Amount": 837432.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-23", "CFDA Number": "93.837", "Description": "ENTERAL IRON SUPPLEMENTATION AND INTESTINAL HEALTH IN PRETERM INFANTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ceec5ef7-d6a5-28f0-e23f-ec61155b7078-C", "generated_internal_id": "ASST_NON_K23HL150300_7529"}, {"internal_id": 95484539, "Award ID": "K23HL150232", "Award Amount": 673920.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-20", "CFDA Number": "93.837", "Description": "AN MHEALTH STRATEGY TO IMPROVE MEDICATION ADHERENCE IN ADOLESCENTS WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "db0f99e3-8b04-ae0e-7470-8dc3317c23d2-C", "generated_internal_id": "ASST_NON_K23HL150232_7529"}, {"internal_id": 100874231, "Award ID": "K23HL148762", "Award Amount": 677750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-13", "CFDA Number": "93.837", "Description": "THE VON WILLEBRAND DISEASE AGING AND BLEEDING CORRELATION (VWD ABC) STUDY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K23HL148762_7529"}, {"internal_id": 98486968, "Award ID": "K23HL148548", "Award Amount": 652688.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-20", "CFDA Number": "93.837", "Description": "CHARACTERIZATION OF B LYMPHOCYTE DEFICIENCY IN PEDIATRIC SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_K23HL148548_7529"}, {"internal_id": 97014606, "Award ID": "K23HL146904", "Award Amount": 682094.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-30", "CFDA Number": "93.837", "Description": "KINETICS OF RED BLOOD CELL CLEARANCE IN CHRONICALLY TRANSFUSED CHILDREN WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_K23HL146904_7529"}, {"internal_id": 108463168, "Award ID": "K23HL146841", "Award Amount": 996246.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-07", "CFDA Number": "93.837", "Description": "OVARIAN RESERVE IN POST-MENARCHAL FEMALES WITH SICKLE CELL ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K23HL146841_7529"}, {"internal_id": 67578997, "Award ID": "K23HL143164", "Award Amount": 837263.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-27", "CFDA Number": "93.837", "Description": "LONG-TERM HEALTH-RELATED QUALITY OF LIFE AND COST OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_K23HL143164_7529"}, {"internal_id": 78600057, "Award ID": "K23HL141666", "Award Amount": 697955.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-11", "CFDA Number": "93.837", "Description": "TRAJECTORY OF COGNITIVE FUNCTIONING IN YOUTH WITH SICKLE CELL DISEASE WITHOUT CEREBRAL INFARCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cf018231-59a5-d301-ae96-b0817a8ee227-C", "generated_internal_id": "ASST_NON_K23HL141666_7529"}, {"internal_id": 80727229, "Award ID": "K23HL141640", "Award Amount": 620696.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-07", "CFDA Number": "93.837", "Description": "PREVENTION OF POSTPARTUM HEMORRHAGE: IDENTIFYING PREGNANT WOMEN AT RISK AND DETERMINING THE SAFE AND EFFECTIVE USE OF TRANEXAMIC ACID USING STATE-OF-THE-ART PHARMACOKINETIC/PHARMACODYNAMICS MODELING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ee8636d0-3f78-fbb3-4346-eb49aabbb2b3-C", "generated_internal_id": "ASST_NON_K23HL141640_7529"}, {"internal_id": 66486842, "Award ID": "K23HL141447", "Award Amount": 920841.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-28", "CFDA Number": "93.837", "Description": "USING PATIENT-CENTERED GUIDELINES IN A TECHNOLOGY PLATFORM TO IMPROVE HEALTH CARE IN ADULTS WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_K23HL141447_7529"}, {"internal_id": 80400817, "Award ID": "K23HL141445", "Award Amount": 597384.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-19", "CFDA Number": "93.837", "Description": "DEVELOPMENT AND VALIDATION OF A DISEASE-RELEVANT PATIENT-REPORTED OUTCOME TOOL IN LIGHT CHAIN AMYLOIDOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_K23HL141445_7529"}, {"internal_id": 67580018, "Award ID": "K23HL140142", "Award Amount": 899413.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-03", "CFDA Number": "93.837", "Description": "STUDYING INTRA-INDIVIDUAL PAIN VARIABILITY IN SICKLE CELL DISEASE AND RESOLUTION OF PAIN AFTER HEMATOPOIETIC CELL TRANSPLANT: A NOVEL MODEL SYSTEM TO ELUCIDATE MECHANISMS OF TRANSITION TO CHRONIC PAIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_K23HL140142_7529"}, {"internal_id": 67579996, "Award ID": "K23HL140134", "Award Amount": 631908.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-31", "CFDA Number": "93.837", "Description": "OPTIMIZING NK EDUCATION AND ALLOREACTIVITY AFTER HLA-HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b514fc3a-d769-87e9-75ea-7a6766afb5ee-C", "generated_internal_id": "ASST_NON_K23HL140134_7529"}, {"internal_id": 48916928, "Award ID": "K23HL140132", "Award Amount": 735716.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-22", "CFDA Number": "93.837", "Description": "THE EFFECT OF RED BLOOD CELL TRANSFUSION ON FATIGUE, ACTIVITY AND FATIGABILITY IN HOSPITALIZED PATIENTS WITH ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_K23HL140132_7529"}, {"internal_id": 48916924, "Award ID": "K23HL138291", "Award Amount": 816676.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-14", "CFDA Number": "93.837", "Description": "INVESTIGATING THE ROLE OF THE JAK/STAT3 PATHWAY IN CLONAL PROLIFERATION AND IMMUNE DYSFUNCTION IN MYELODYSPLASTIC SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K23HL138291_7529"}, {"internal_id": 66199232, "Award ID": "K23HL138261", "Award Amount": 843015.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-07", "CFDA Number": "93.837", "Description": "TESTING AND IMPLEMENTATION OF THE PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM MEASURES OF PAIN INTENSITY, INTERFERENCE, AND BEHAVIOR IN ROUTINE CLINICAL CARE OF PERSONS WITH HEMOPHILIA.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_K23HL138261_7529"}, {"internal_id": 66486983, "Award ID": "K23HL138227", "Award Amount": 798140.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-28", "CFDA Number": "93.837", "Description": "INDOOR ENVIRONMENTAL EXPOSURES AND PULMONARY INFLAMMATION AND MORBIDITY IN SICKLE CELL ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K23HL138227_7529"}, {"internal_id": 48916909, "Award ID": "K23HL136904", "Award Amount": 637578.71, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-16", "CFDA Number": "93.837", "Description": "CEREBRAL OXYGEN METABOLISM AND FUNCTIONAL NETWORK ARCHITECTURE IN PEDIATRIC SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_K23HL136904_7529"}, {"internal_id": 48916908, "Award ID": "K23HL136900", "Award Amount": 618947.91, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-25", "CFDA Number": "93.837", "Description": "CHARACTERIZING THE MOLECULAR SIGNATURE OF CHRONIC GRAFT-VERSUS-HOST DISEASE FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_K23HL136900_7529"}, {"internal_id": 48916903, "Award ID": "K23HL136787", "Award Amount": 891000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-11", "CFDA Number": "93.837", "Description": "THE EFFECTS OF OLDER RED CELL UNITS IN ADULTS WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_K23HL136787_7529"}, {"internal_id": 48916901, "Award ID": "K23HL136783", "Award Amount": 614280.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-11", "CFDA Number": "93.837", "Description": "ADOPTIVE IMMUNOTHERAPY FOR THE TREATMENT OF VIRAL INFECTIONS IN PRIMARY IMMUNODEFICIENCY DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "DC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "cf018231-59a5-d301-ae96-b0817a8ee227-C", "generated_internal_id": "ASST_NON_K23HL136783_7529"}, {"internal_id": 48916895, "Award ID": "K23HL135436", "Award Amount": 642211.87, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-23", "CFDA Number": "93.837", "Description": "DEVELOPMENT OF A PROBLEM SOLVING INTERVENTION TO IMPROVE SELF-MANAGEMENT AND TRANSITION READINESS FOR ADOLESCENTS WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "54768301-b245-c1c5-66ec-e0c90b049cc4-C", "generated_internal_id": "ASST_NON_K23HL135436_7529"}, {"internal_id": 48916893, "Award ID": "K23HL135396", "Award Amount": 596631.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-31", "CFDA Number": "93.837", "Description": "USING TECHNOLOGY TO DELIVER EVIDENCE-BASED INTERVENTIONS FOR PAIN TO PATIENTS WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K23HL135396_7529"}, {"internal_id": 48916876, "Award ID": "K23HL133457", "Award Amount": 747555.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-26", "CFDA Number": "93.837", "Description": "EVIDENCE-BASED APPROACHES TO CHRONIC PAIN MANAGEMENT IN YOUTH WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_K23HL133457_7529"}, {"internal_id": 48916875, "Award ID": "K23HL133455", "Award Amount": 711728.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-04", "CFDA Number": "93.839", "Description": "CLINICAL AND NEUROIMAGING PHENOTYPES OF NEURODEVELOPMENTAL DISORDERS INPEDIATRIC SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8245755e-5e2c-a7dc-44d4-4e7b18b8be51-C", "generated_internal_id": "ASST_NON_K23HL133455_7529"}, {"internal_id": 48916872, "Award ID": "K23HL133446", "Award Amount": 701293.6, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-16", "CFDA Number": "93.837", "Description": "IMPROVING HAPLOIDENTICAL STEM CELL ENGRAFTMENT IN SICKLE CELL DISEASE USING AUTOLOGOUS MESENCHYMAL STROMAL CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K23HL133446_7529"}, {"internal_id": 48916865, "Award ID": "K23HL132054", "Award Amount": 799239.07, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-22", "CFDA Number": "93.837", "Description": "PREDICTING AND PREVENTING POOR OUTCOMES OF VENOUS THROMBOEMBOLISM IN CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_K23HL132054_7529"}, {"internal_id": 48916861, "Award ID": "K23HL132001", "Award Amount": 709684.07, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-29", "CFDA Number": "93.837", "Description": "OVERCOMING ADHERENCE PROBLEMS IN CHILDREN WITH IRON DEFICIENCY ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_K23HL132001_7529"}, {"internal_id": 48916847, "Award ID": "K23HL128942", "Award Amount": 664847.76, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-22", "CFDA Number": "93.837", "Description": "RED CELL TRANSFUSION, SEVERE ANEMIA AND NECROTIZING ENTEROCOLITIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_K23HL128942_7529"}, {"internal_id": 48916842, "Award ID": "K23HL128885", "Award Amount": 909343.71, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-20", "CFDA Number": "93.837", "Description": "THERAPEUTIC RESPONSE EVALUATION AND ADHERENCE TRIAL: A PROSPECTIVE STUDY OF HYDROXYUREA FOR CHILDREN WITH SICKLE CELL ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_K23HL128885_7529"}, {"internal_id": 48916841, "Award ID": "K23HL128882", "Award Amount": 1004400.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-26", "CFDA Number": "93.837", "Description": "HEMOLYSIS AND NITRIC OXIDE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1b850e96-1988-60df-d05c-e0d42a91fc63-C", "generated_internal_id": "ASST_NON_K23HL128882_7529"}, {"internal_id": 48916832, "Award ID": "K23HL127303", "Award Amount": 753130.9, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-20", "CFDA Number": "93.837", "Description": "A MULTIDIMENSIONAL STRATEGY TO IMPROVE HYDROXYUREA ADHERENCE IN CHILDREN WITH SICKLE CELL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "24042a1a-03ec-326e-b5c2-89242d7c209d-C", "generated_internal_id": "ASST_NON_K23HL127303_7529"}, {"internal_id": 48916827, "Award ID": "K23HL127227", "Award Amount": 763965.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-29", "CFDA Number": "93.837", "Description": "A PATIENT CENTERED APPROACH TO RESTARTING ORAL ANTICOAGULANT THERAPY AFTER MAJOR HEMORRHAGE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e7e88775-bcb5-07f2-9311-ab05017c1a34-C", "generated_internal_id": "ASST_NON_K23HL127227_7529"}, {"internal_id": 48916825, "Award ID": "K23HL127223", "Award Amount": 740011.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-25", "CFDA Number": "93.837", "Description": "PATHOGENESIS AND SYMPTOMATOLOGY OF PEDIATRIC MYELOPROLIFERATIVE NEOPLASMS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_K23HL127223_7529"}, {"internal_id": 48916819, "Award ID": "K23HL127100", "Award Amount": 916446.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-24", "CFDA Number": "93.837", "Description": "CHRONOBIOLOGY AND CHRONOPHARMACOLOGY TO PREVENT SICKLE CELL NEPHROPATHY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_K23HL127100_7529"}, {"internal_id": 48916812, "Award ID": "K23HL125984", "Award Amount": 700327.38, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-19", "CFDA Number": "93.837", "Description": "GENETICS AND GENOMICS OF SICKLE CELL NEPHROPATHY.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_K23HL125984_7529"}, {"internal_id": 48916793, "Award ID": "K23HL123601", "Award Amount": 612248.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-28", "CFDA Number": "93.839", "Description": "ADVANCING DIAGNOSTICS AND THERAPEUTICS IN BONE MARROW FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K23HL123601_7529"}, {"internal_id": 48916785, "Award ID": "K23HL122143", "Award Amount": 402330.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-18", "CFDA Number": "93.839", "Description": "METABOLIC AND CD4+ T CELL DYSREGULATION IN POST-TRANSPLANT DIABETES MELLITUS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K23HL122143_7529"}, {"internal_id": 48916777, "Award ID": "K23HL119627", "Award Amount": 497486.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-13", "CFDA Number": "93.839", "Description": "ERYTHROCYTE NITRIC OXIDE LINKS RHEOLOGY AND VASCULOPATHY IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6c10cf51-1fb6-c52e-c48f-8fcef0f37eff-C", "generated_internal_id": "ASST_NON_K23HL119627_7529"}, {"internal_id": 48916768, "Award ID": "K23HL119351", "Award Amount": 856933.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-19", "CFDA Number": "93.839", "Description": "INHALED MOMETASONE TO PROMOTE REDUCTION IN VASO-OCCLUSIVE EVENTS (IMPROVE)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_K23HL119351_7529"}, {"internal_id": 48916732, "Award ID": "K23HL114636", "Award Amount": 751172.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-13", "CFDA Number": "93.839", "Description": "PERIPHERAL SENSITIZATION AS A NOVEL MECHANISM FOR PAIN IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_K23HL114636_7529"}, {"internal_id": 48916723, "Award ID": "K23HL112848", "Award Amount": 728784.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-01", "CFDA Number": "93.839", "Description": "PLATELET TSP1 MEDIATES VASCULAR DISEASE AND PULMONARY HYPERTENSION IN SICKLE CELL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K23HL112848_7529"}, {"internal_id": 98486600, "Award ID": "K22HL142846", "Award Amount": 747000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-06-28", "CFDA Number": "93.837", "Description": "SINGLE MOLECULE STUDIES OF THE DUAL-HELICASE ACTIVITY OF TRANSCRIPTION FACTOR TFIIH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f261384c-3ac1-b344-de46-81708f87aa6a-C", "generated_internal_id": "ASST_NON_K22HL142846_7529"}, {"internal_id": 48914854, "Award ID": "K22HL125593", "Award Amount": 747000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-31", "CFDA Number": "93.837", "Description": "EXPRESSION, REGULATION, AND ROLE OF ENHANCER RNAS IN T HELPER CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3d0e924f-2881-5f66-8511-7122b17340d9-C", "generated_internal_id": "ASST_NON_K22HL125593_7529"}, {"internal_id": 66800634, "Award ID": "K12HL141956", "Award Amount": 5317873.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-10", "CFDA Number": "93.837", "Description": "UCSD BIOMEDICAL SCIENTIST CAREER DEVELOPMENT PROGRAM IN GLYCOSCIENCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_K12HL141956_7529"}, {"internal_id": 66800519, "Award ID": "K12HL141954", "Award Amount": 4866000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-10", "CFDA Number": "93.837", "Description": "GLYCANS IN BLOOD HOMEOSTASIS AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_K12HL141954_7529"}, {"internal_id": 66800813, "Award ID": "K12HL141953", "Award Amount": 4804055.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-08", "CFDA Number": "93.837", "Description": "FORGING TRANSLATIONAL GLYCOBIOLOGISTS: INTERMESHING GLYCOSCIENCE TRAINING AND CLINICAL EDUCATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K12HL141953_7529"}, {"internal_id": 66800843, "Award ID": "K12HL141952", "Award Amount": 4819790.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-11", "CFDA Number": "93.837", "Description": "IMMERSIVE TRAINING IN GLYCOSCIENCES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K12HL141952_7529"}, {"internal_id": 48914332, "Award ID": "K12HL087169", "Award Amount": 2932413.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-02", "CFDA Number": "93.837", "Description": "CLINICAL HEMATOLOGY RESEARCH DEVELOPMENT PROGRAM (K12) AT JOHNS HOPKINS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K12HL087169_7529"}, {"internal_id": 48914331, "Award ID": "K12HL087165", "Award Amount": 3196318.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-02", "CFDA Number": "93.837", "Description": "CAREER DEVELOPMENT IN CLINICAL HEMATOLOGY RESEARCH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_K12HL087165_7529"}, {"internal_id": 48914330, "Award ID": "K12HL087164", "Award Amount": 3139441.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-02", "CFDA Number": "93.839", "Description": "CLINICAL HEMATOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM (K12)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_K12HL087164_7529"}, {"internal_id": 48914329, "Award ID": "K12HL087107", "Award Amount": 2983558.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-08", "CFDA Number": "93.837", "Description": "CLINICAL HEMATOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM AT WASHINGTON UNIVERSITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_K12HL087107_7529"}, {"internal_id": 48914328, "Award ID": "K12HL087097", "Award Amount": 2863663.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-02", "CFDA Number": "93.839", "Description": "DUKE-UNC CLINICAL HEMATOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_K12HL087097_7529"}, {"internal_id": 48914327, "Award ID": "K12HL087064", "Award Amount": 2915271.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-09-02", "CFDA Number": "93.839", "Description": "MENTORED CAREER DEVELOPMENT IN CLINICAL RESEARCH IN NON-MALIGNANT HEMATOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K12HL087064_7529"}, {"internal_id": 110862504, "Award ID": "K08HL153953", "Award Amount": 666100.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-09-21", "CFDA Number": "93.837", "Description": "THE REGULATION AND FUNCTION OF PLATELET FCARIIA IN SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_K08HL153953_7529"}, {"internal_id": 109278432, "Award ID": "K08HL153784", "Award Amount": 627243.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-20", "CFDA Number": "93.837", "Description": "ROLE OF MIRNA-TLR7 SIGNALING IN PLATELET ACTIVATION AND DYSFUNCTION IN SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_K08HL153784_7529"}, {"internal_id": 96204655, "Award ID": "K08HL151960", "Award Amount": 69692.01, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-03-27", "CFDA Number": "93.837", "Description": "INTEGRATING GENETIC, EPIGENETIC, AND MICROENVIRONMENTAL DETERMINANTS OF MYELOPROLIFERATIVE NEOPLASMS VIA SINGLE-CELL MULTI-OMICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2aebf6db-d015-0e5d-4b7c-d63b5d36ebce-C", "generated_internal_id": "ASST_NON_K08HL151960_7529"}, {"internal_id": 96204229, "Award ID": "K08HL151814", "Award Amount": 0.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-05", "CFDA Number": "93.839", "Description": "THERAPEUTIC GENE EDITING OF THE BETA-HEMOGLOBIN LOCUS BY HOMOLOGY DIRECTED REPAIR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e050350a-3939-bf65-9585-238517e3ab1f-C", "generated_internal_id": "ASST_NON_K08HL151814_7529"}, {"internal_id": 111328704, "Award ID": "K08HL151809", "Award Amount": 666144.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-10", "CFDA Number": "93.837", "Description": "IMMUNOSUPPRESSIVE HUMAN INVARIANT NATURAL KILLER T CELLS FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_K08HL151809_7529"}, {"internal_id": 94237098, "Award ID": "K08HL150282", "Award Amount": 611466.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-13", "CFDA Number": "93.837", "Description": "HEMATOPOIETIC CONSEQUENCES OF GAIN-OF-FUNCTION SAMD9 AND SAMD9L MUTATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "af8e08af-9f61-5dc4-b13f-32b17f32dc92-C", "generated_internal_id": "ASST_NON_K08HL150282_7529"}, {"internal_id": 110024181, "Award ID": "K08HL148543", "Award Amount": 0.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-31", "CFDA Number": "93.837", "Description": "SAFETY NETS:NEUTROPHIL EXTRACELLULAR TRAP (NET) STABILIZATION IN THE TREATMENT OF SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_K08HL148543_7529"}, {"internal_id": 79639125, "Award ID": "K08HL146991", "Award Amount": 697620.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-10", "CFDA Number": "93.837", "Description": "THERAPEUTIC APPLICATIONS OF FACTOR VIIIA INACTIVATION IN HEMOPHILIA A", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_K08HL146991_7529"}, {"internal_id": 94235040, "Award ID": "K08HL146941", "Award Amount": 648172.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-07", "CFDA Number": "93.837", "Description": "THE ROLE IN INFLAMMATION IN PLATELET ACTIVATION AND THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c3b44559-c484-d6ca-f0ba-0a3f42e931ae-C", "generated_internal_id": "ASST_NON_K08HL146941_7529"}, {"internal_id": 95181583, "Award ID": "K08HL146840", "Award Amount": 631006.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-10", "CFDA Number": "93.837", "Description": "DYSREGULATION OF PLATELET-VON WILLEBRAND FACTOR INTERACTION IN TRAUMA-INDUCED COAGULOPATHY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_K08HL146840_7529"}, {"internal_id": 78990935, "Award ID": "K08HL146797", "Award Amount": 89317.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-12", "CFDA Number": "93.839", "Description": "MODIFIERS OF TISSUE FACTOR PROCOAGULANT ACTIVITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_K08HL146797_7529"}, {"internal_id": 77189447, "Award ID": "K08HL145139", "Award Amount": 799813.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-01-30", "CFDA Number": "93.837", "Description": "TAILORED ADAPTATION OF THE AHRQ VTE QI GUIDE TO LOCAL HOSPITAL CONTEXT.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_K08HL145139_7529"}, {"internal_id": 83104140, "Award ID": "K08HL145116", "Award Amount": 332703.57, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-09", "CFDA Number": "93.837", "Description": "PROBING NOTCH REGULATION OF ALLOIMMUNITY TO UNCOVER NOVEL STRATEGIES FOR GRAFT-VERSUS-HOST DISEASE CONTROL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_K08HL145116_7529"}, {"internal_id": 82054515, "Award ID": "K08HL144911", "Award Amount": 812700.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-16", "CFDA Number": "93.837", "Description": "A MOLECULAR IMAGING APPROACH TO IMMUNO-METABOLIC CHARACTERIZATION OF VESSEL WALL MACROPHAGES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K08HL144911_7529"}, {"internal_id": 79433193, "Award ID": "K08HL143189", "Award Amount": 858060.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-30", "CFDA Number": "93.837", "Description": "MICROBIOTA MECHANISMS AND BIOMARKERS IN GVHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b514fc3a-d769-87e9-75ea-7a6766afb5ee-C", "generated_internal_id": "ASST_NON_K08HL143189_7529"}, {"internal_id": 83795866, "Award ID": "K08HL141635", "Award Amount": 815400.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-01", "CFDA Number": "93.837", "Description": "TARGETED NON-GENOTOXIC HEMATOPOIETIC STEM CELL TRANSPLANT CONDITIONING APPROACH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_K08HL141635_7529"}, {"internal_id": 66995527, "Award ID": "K08HL141446", "Award Amount": 820260.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-29", "CFDA Number": "93.837", "Description": "THE ROLE OF TYPE 1 INTERFERON IN REGULATING ALLOIMMUNE RESPONSES TO TRANSFUSED RED BLOOD CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6d5b538d-d375-ef95-ce46-71eca3808691-C", "generated_internal_id": "ASST_NON_K08HL141446_7529"}, {"internal_id": 61610342, "Award ID": "K08HL140164", "Award Amount": 54092.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-29", "CFDA Number": "93.839", "Description": "LIGAND MEDIATED CONTROL OF ERYTHROCYTE DEFORMABILITY FOR OPTIMIZED DELIVERY OF HEMOSTATIC AND ANTITHROMBOTIC BIOTHERAPEUTICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K08HL140164_7529"}, {"internal_id": 48913672, "Award ID": "K08HL140143", "Award Amount": 583447.52, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-01-08", "CFDA Number": "93.837", "Description": "FUNCTIONAL AND TRANSCRIPTIONAL ANALYSIS OF EMBRYONIC HEMATOPOIETIC STEM CELL DEVELOPMENT AT THE SINGLE CELL LEVEL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "87713bfa-b929-e721-8173-41e59771b342-C", "generated_internal_id": "ASST_NON_K08HL140143_7529"}, {"internal_id": 61615258, "Award ID": "K08HL140138", "Award Amount": 437609.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-01", "CFDA Number": "93.837", "Description": "INVESTIGATING THE MECHANISMS OF COHESINOPATHY IN MYELODYSPLASTIC SYNDROMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "be067fa7-a493-7bea-f9cc-e29bd2ccc74a-C", "generated_internal_id": "ASST_NON_K08HL140138_7529"}, {"internal_id": 61613985, "Award ID": "K08HL140078", "Award Amount": 637632.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-01", "CFDA Number": "93.837", "Description": "RATIONAL DEVELOPMENT OF BIOENGINEERED FACTOR IX VARIANTS FOR HEMOPHILIA B THERAPY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_K08HL140078_7529"}, {"internal_id": 48913666, "Award ID": "K08HL138305", "Award Amount": 891000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-21", "CFDA Number": "93.837", "Description": "REGULATION OF STEM CELL AGING AND CANCER BY THE VASCULAR NICHE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_K08HL138305_7529"}, {"internal_id": 66994675, "Award ID": "K08HL138142", "Award Amount": 678984.33, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-20", "CFDA Number": "93.837", "Description": "INVESTIGATION OF ERBB2 AND ERBB3 IN HEMATOPOIESIS AND PREDISPOSITION TO HEMATOLOGIC DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K08HL138142_7529"}, {"internal_id": 48913656, "Award ID": "K08HL136894", "Award Amount": 858600.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-05", "CFDA Number": "93.837", "Description": "HEDGEHOG SIGNALING IN THE PROGRESSION OF MYELODYSPLASTIC SYNDROMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K08HL136894_7529"}, {"internal_id": 48913649, "Award ID": "K08HL136840", "Award Amount": 817020.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-06-01", "CFDA Number": "93.837", "Description": "THE ROLE OF COAGULATION FACTOR XII IN HEMOSTASIS AND THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2a11a6dc-948e-2337-13cf-40ff24b2768a-C", "generated_internal_id": "ASST_NON_K08HL136840_7529"}, {"internal_id": 48913645, "Award ID": "K08HL135434", "Award Amount": 899640.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-14", "CFDA Number": "93.837", "Description": "TARGETING SETBP1 IN MYELOPROLIFERATIVE DISORDERS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bb8d1cd4-e0ae-6348-a07c-04df6a112768-C", "generated_internal_id": "ASST_NON_K08HL135434_7529"}, {"internal_id": 48913635, "Award ID": "K08HL134579", "Award Amount": 527472.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-22", "CFDA Number": "93.839", "Description": "MECHANISTIC INSIGHTS INTO HYPOXIC PRECONDITIONING USING GENETIC AND GENOMIC APPROACHES IN ZEBRAFISH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_K08HL134579_7529"}, {"internal_id": 48913633, "Award ID": "K08HL133493", "Award Amount": 872100.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-16", "CFDA Number": "93.837", "Description": "OXIDATIVE STRESS IN VASO-OCCLUSION PATHOPHYSIOLOGY OF SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_K08HL133493_7529"}, {"internal_id": 48913629, "Award ID": "K08HL133479", "Award Amount": 835920.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-15", "CFDA Number": "93.837", "Description": "NEW APPROACHES TO PATHOGENESIS AND DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_K08HL133479_7529"}, {"internal_id": 48913615, "Award ID": "K08HL132109", "Award Amount": 563366.58, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-06-14", "CFDA Number": "93.837", "Description": "TYPE 2 IMMUNE RESPONSES PROTECT AGAINST THE MORBIDITY AND MORTALITY OF SEPSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_K08HL132109_7529"}, {"internal_id": 48913613, "Award ID": "K08HL132101", "Award Amount": 991656.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-05-19", "CFDA Number": "93.837", "Description": "EARLY CLONAL EVOLUTION IN ACQUIRED APLASTIC ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_K08HL132101_7529"}, {"internal_id": 48913579, "Award ID": "K08HL129088", "Award Amount": 621378.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-07", "CFDA Number": "93.839", "Description": "DEFINING THE ROLE OF BRCA1 IN HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_K08HL129088_7529"}, {"internal_id": 48913563, "Award ID": "K08HL128794", "Award Amount": 812160.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-29", "CFDA Number": "93.837", "Description": "THE EVOLUTION OF THE MAMMALIAN SEC23 PARALOGS AND THE MOLECULAR PATHOGENESIS OF CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE II", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K08HL128794_7529"}, {"internal_id": 48913560, "Award ID": "K08HL127293", "Award Amount": 824310.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-06", "CFDA Number": "93.837", "Description": "ACUTE ANEMIA OF INFLAMMATION: MECHANISMS AND NOVEL THERAPIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_K08HL127293_7529"}, {"internal_id": 48913558, "Award ID": "K08HL127269", "Award Amount": 822825.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-10", "CFDA Number": "93.839", "Description": "BONE MARROW MICROENVIRONMENTAL EXPRESSION OF CYTOCHROME P450 ENZYMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K08HL127269_7529"}, {"internal_id": 48913557, "Award ID": "K08HL127187", "Award Amount": 766494.13, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-06", "CFDA Number": "93.837", "Description": "BONE MARROW FAILURE IN MICE DEFICIENT FOR THE EXTRACELLULAR MATRIX COMPONENT, LAMININ-GAMMA1", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_K08HL127187_7529"}, {"internal_id": 48913556, "Award ID": "K08HL127183", "Award Amount": 636935.47, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-09-03", "CFDA Number": "93.837", "Description": "BIOLOGICAL SIGNIFICANCE OF PROTAMINE/HEPARIN ANTIBODIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_K08HL127183_7529"}, {"internal_id": 48913540, "Award ID": "K08HL125100", "Award Amount": 572756.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-02-26", "CFDA Number": "93.839", "Description": "SICKLE CELL TRAIT: AN OVERLOOKED GENETIC MODIFIER OF DISEASE IN AFRICAN-AMERICANS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K08HL125100_7529"}, {"internal_id": 48913532, "Award ID": "K08HL123925", "Award Amount": 725835.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-23", "CFDA Number": "93.839", "Description": "ROLE OF MICRORNA IN STORED RBC INDUCED INNATE IMMUNE SUPPRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "24042a1a-03ec-326e-b5c2-89242d7c209d-C", "generated_internal_id": "ASST_NON_K08HL123925_7529"}, {"internal_id": 48913530, "Award ID": "K08HL123631", "Award Amount": 628719.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-01", "CFDA Number": "93.837", "Description": "CHANGES IN T CELL METABOLISM DURING GRAFT-VERSUS-HOST DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K08HL123631_7529"}, {"internal_id": 48913521, "Award ID": "K08HL122306", "Award Amount": 578718.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-04-10", "CFDA Number": "93.839", "Description": "STUDIES OF HSC ENGRAFTMENT AT THE OSTEOBLASTIC NICHE FOR INHERITED BM FAILURE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_K08HL122306_7529"}, {"internal_id": 48913509, "Award ID": "K08HL121131", "Award Amount": 754246.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-09-02", "CFDA Number": "93.837", "Description": "ROLE OF MYELOID KRUPPEL-LIKE FACTOR 2 IN VASCULAR THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "59649428-1ebf-ef93-ea43-2491b55b3188-C", "generated_internal_id": "ASST_NON_K08HL121131_7529"}, {"internal_id": 48913505, "Award ID": "K08HL119597", "Award Amount": 803452.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-06-23", "CFDA Number": "93.839", "Description": "ROLE OF PIKFYVE IN PLATELET-MEDIATED INFLAMMATION AND THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K08HL119597_7529"}, {"internal_id": 48913503, "Award ID": "K08HL119590", "Award Amount": 767397.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-04-25", "CFDA Number": "93.839", "Description": "T-CELL MONITORING AND IMMUNOTHERAPY FOR TREATING GRAFT-VERSUS-HOST DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_K08HL119590_7529"}, {"internal_id": 48913493, "Award ID": "K08HL118117", "Award Amount": 777964.56, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-28", "CFDA Number": "93.837", "Description": "RE-EVALULATING THE HEMATOPOETIC STEM CELL POOL TO ENHANCE THE TRANSPLANTABLE POPULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_K08HL118117_7529"}, {"internal_id": 48913481, "Award ID": "K08HL116605", "Award Amount": 714032.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-07-15", "CFDA Number": "93.839", "Description": "NOTCH SIGNALING IN MYELOID DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bccd984e-68ff-4e70-2020-f0129e4b9ecc-C", "generated_internal_id": "ASST_NON_K08HL116605_7529"}, {"internal_id": 48913479, "Award ID": "K08HL116547", "Award Amount": 664527.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-08-08", "CFDA Number": "93.839", "Description": "JAK2_STAT3 AS A THERAPEUTIC TARGET AND MARKER OF GRAFT-VERSUS-HOST DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dda62fdb-6501-1ff0-613d-ceb8e9bb2d48-C", "generated_internal_id": "ASST_NON_K08HL116547_7529"}, {"internal_id": 48913476, "Award ID": "K08HL115355", "Award Amount": 718956.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2012-08-24", "CFDA Number": "93.839", "Description": "IL-22 IN EPITHELIAL REGENERATION AFTER ALLOGENEIC TRANSPLANT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b514fc3a-d769-87e9-75ea-7a6766afb5ee-C", "generated_internal_id": "ASST_NON_K08HL115355_7529"}, {"internal_id": 48913472, "Award ID": "K08HL114871", "Award Amount": 488487.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-10", "CFDA Number": "93.839", "Description": "MEMBRANE-CYTOSKELETAL REMODELING IN PLATELET BIOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_K08HL114871_7529"}, {"internal_id": 48913458, "Award ID": "K08HL111280", "Award Amount": 670680.0, "Award Type": null, "Base Obligation Date": "2012-09-26", "CFDA Number": "93.839", "Description": "BETA-CATENIN IS A MOLECULAR TARGET OF THE FANCONI ANEMIA CORE COMPLEX", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_K08HL111280_7529"}, {"internal_id": 48913435, "Award ID": "K08HL106576", "Award Amount": 624326.0, "Award Type": null, "Base Obligation Date": "2012-03-22", "CFDA Number": "93.839", "Description": "ABERRANT JAK-STAT SIGNALING DUE TO LNK MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_K08HL106576_7529"}, {"internal_id": 100874018, "Award ID": "K01HL153210", "Award Amount": 537367.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-15", "CFDA Number": "93.837", "Description": "CONTRIBUTIONS OF BIOPSYCHOSOCIAL FACTORS IN SICKLE CELL DISEASE PAIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7bb49047-7166-d4e3-8873-4218d87cf06c-C", "generated_internal_id": "ASST_NON_K01HL153210_7529"}, {"internal_id": 83796355, "Award ID": "K01HL145580", "Award Amount": 860468.2, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-24", "CFDA Number": "93.837", "Description": "LEVERAGING A VIRTUAL ENVIRONMENT (LEARN) TO ENHANCE PREVENTION OF HIV-RELATED COMORBIDITIES, SUPPLEMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_K01HL145580_7529"}, {"internal_id": 79434081, "Award ID": "K01HL143137", "Award Amount": 508505.5, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-22", "CFDA Number": "93.837", "Description": "GENOMIC AND TRANSCRIPTOMIC INFLUENCES ON HEPARIN-INDUCED THROMBOCYTOPENIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AZ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4f121097-1173-861e-ba01-a877858acd3d-C", "generated_internal_id": "ASST_NON_K01HL143137_7529"}, {"internal_id": 68170460, "Award ID": "K01HL143112", "Award Amount": 745189.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-20", "CFDA Number": "93.837", "Description": "A SYSTEMS BIOLOGY INVESTIGATION OF THE INTERPLAY BETWEEN GUT MICROBES AND BLOOD METABOLITES IN THE DEVELOPMENT OF MALARIAL ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6bb62c37-6b74-a9af-577c-895771e3de6f-C", "generated_internal_id": "ASST_NON_K01HL143112_7529"}, {"internal_id": 67834171, "Award ID": "K01HL143111", "Award Amount": 855677.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-16", "CFDA Number": "93.837", "Description": "MECHANOREGULATION OF THE LEUKOCYTE SPECIFIC INTEGRIN LFA-1 BY THE ACTIN CYTOSKELETON", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9adce466-3b6d-ecdb-7412-8082d6529b1f-C", "generated_internal_id": "ASST_NON_K01HL143111_7529"}, {"internal_id": 82469948, "Award ID": "K01HL140285", "Award Amount": 712181.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-01", "CFDA Number": "93.837", "Description": "DESIGNING A DIVERSITY-COVERING MULTIANTIGEN MULTI-STRAIN MALARIA VACCINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_K01HL140285_7529"}, {"internal_id": 48910257, "Award ID": "K01HL136893", "Award Amount": 483762.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-03", "CFDA Number": "93.837", "Description": "PREDICTION AND PREVENTION OF VENOUS THROMBOEMBOLISM IN MULTIPLE MYELOMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e0af38c9-92a8-f2cb-a5b8-4b4f14f99689-C", "generated_internal_id": "ASST_NON_K01HL136893_7529"}, {"internal_id": 48910253, "Award ID": "K01HL135466", "Award Amount": 687342.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-18", "CFDA Number": "93.837", "Description": "LIFE AFTER RECOVERY IN ADULT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP): LET'S HEAR IT FROM THE SURVIVORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OK", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "35c9af52-79d6-b585-258b-ae9342223de1-C", "generated_internal_id": "ASST_NON_K01HL135466_7529"}, {"internal_id": 48910246, "Award ID": "K01HL135392", "Award Amount": 842372.59, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-28", "CFDA Number": "93.837", "Description": "DEVELOPING AN IMPLEMENTATION STRATEGY TO IMPROVE PERI-PROCEDURAL ANTICOAGULATION MANAGEMENT FOR PATIENTS WITH ATRIAL FIBRILLATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K01HL135392_7529"}, {"internal_id": 48910237, "Award ID": "K01HL133518", "Award Amount": 561547.69, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-24", "CFDA Number": "93.837", "Description": "MECHANISMS OF HYDROXYUREA EFFICACY IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_K01HL133518_7529"}, {"internal_id": 48910230, "Award ID": "K01HL133370", "Award Amount": 736595.86, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-15", "CFDA Number": "93.837", "Description": "ACTION INTERVENTION: PHYSICAL ACTIVITY IN MINORITY WOMEN WITH ASTHMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_K01HL133370_7529"}, {"internal_id": 48910227, "Award ID": "K01HL133331", "Award Amount": 847966.51, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-21", "CFDA Number": "93.837", "Description": "PROTECTION AGAINST SICKLE CELL DISEASE NEPHROPATHY BY NITRATED FATTY ACIDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_K01HL133331_7529"}, {"internal_id": 48910226, "Award ID": "K01HL132057", "Award Amount": 626444.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-19", "CFDA Number": "93.837", "Description": "IDENTIFYING OPPORTUNITIES TO IMPROVE HYDROXYUREA THERAPY INITIATION AND ADHERENCE AMONG CHILDREN WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_K01HL132057_7529"}, {"internal_id": 48910224, "Award ID": "K01HL131333", "Award Amount": 554804.11, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-12", "CFDA Number": "93.837", "Description": "REVERSING HIV-INDUCED B CELL DYSFUNCTION WITH BISPHOSPHONATES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_K01HL131333_7529"}, {"internal_id": 48910223, "Award ID": "K01HL130753", "Award Amount": 889649.64, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-15", "CFDA Number": "93.837", "Description": "CONTRIBUTION OF A NOVEL, DEVELOPMENTALLY-RESTRICTED HEMATOPOIETIC STEM CELL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "UT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "105d3de4-6fbf-6e42-7259-4c62267aa84f-C", "generated_internal_id": "ASST_NON_K01HL130753_7529"}, {"internal_id": 48910193, "Award ID": "K01HL125495", "Award Amount": 749472.2, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-18", "CFDA Number": "93.837", "Description": "IDENTIFICATION OF PREDICTORS AND OUTCOMES OF SICKLE CELL HEALTH CARE TRANSITION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bccd984e-68ff-4e70-2020-f0129e4b9ecc-C", "generated_internal_id": "ASST_NON_K01HL125495_7529"}, {"internal_id": 48910152, "Award ID": "K01HL108832", "Award Amount": 511120.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-08-05", "CFDA Number": "93.839", "Description": "TRAJECTORIES OF TRUST AMONG PATIENTS WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_K01HL108832_7529"}, {"internal_id": 100873964, "Award ID": "F32HL154700", "Award Amount": 205606.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-16", "CFDA Number": "93.837", "Description": "INFLAMMATION-ASSOCIATED ANEMIA AND THE ROLE OF MONOCYTE-DERIVED INFLAMMATORY HEMOPHAGOCYTES IN A MODEL OF BLOOD-STAGE MALARIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6c187478-165a-1db6-d6e6-2be34431a2b3-C", "generated_internal_id": "ASST_NON_F32HL154700_7529"}, {"internal_id": 108463373, "Award ID": "F32HL154667", "Award Amount": 201118.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-12", "CFDA Number": "93.837", "Description": "INNATE CELLULAR RESPONSES AGAINST ADENO-ASSOCIATED VIRUS IN HEMATOPOIETIC STEM AND PROGENTITOR CELLS INFLUENCE CELL SURVIVAL AND REPOPULATION CAPACITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_F32HL154667_7529"}, {"internal_id": 100875176, "Award ID": "F32HL154636", "Award Amount": 127756.87, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-15", "CFDA Number": "93.837", "Description": "FUNCTIONAL EVALUATION OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bccd984e-68ff-4e70-2020-f0129e4b9ecc-C", "generated_internal_id": "ASST_NON_F32HL154636_7529"}, {"internal_id": 109190139, "Award ID": "F32HL154519", "Award Amount": 73534.26, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-14", "CFDA Number": "93.837", "Description": "MAJOR BLEEDING WITH IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F32HL154519_7529"}, {"internal_id": 110024527, "Award ID": "F32HL154320", "Award Amount": 117096.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-26", "CFDA Number": "93.837", "Description": "SKELETAL MUSCLE PERFORMANCE AND CELLULAR ADAPTATIONS TO HIGH HEMOGLOBIN-OXYGEN AFFINITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "30ebe932-79d5-1659-51b4-a59d9be01dee-C", "generated_internal_id": "ASST_NON_F32HL154320_7529"}, {"internal_id": 96559323, "Award ID": "F32HL152524", "Award Amount": 101327.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-16", "CFDA Number": "93.837", "Description": "CUX1 PIONEER FACTOR ACTIVITY IS REQUIRED TO PREVENT MYELOID LEUKEMOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_F32HL152524_7529"}, {"internal_id": 96201500, "Award ID": "F32HL152486", "Award Amount": 16328.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-04", "CFDA Number": "93.837", "Description": "INVESTIGATING A ROLE FOR KIFC1-MEDIATED CENTROSOME CLUSTERING IN TRIGGERING PROPLATELET PRODUCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_F32HL152486_7529"}, {"internal_id": 96560181, "Award ID": "F32HL152484", "Award Amount": 149541.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-09", "CFDA Number": "93.837", "Description": "THE MOLECULAR AND BIOCHEMICAL FUNCTION OF SAMD9 AND SAMD9L IN PEDIATRIC MDS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bccd984e-68ff-4e70-2020-f0129e4b9ecc-C", "generated_internal_id": "ASST_NON_F32HL152484_7529"}, {"internal_id": 95181592, "Award ID": "F32HL151176", "Award Amount": 61610.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-10", "CFDA Number": "93.839", "Description": "DECIPHERING INFLAMMATION IN MYELOPROLIFERATIVE NEOPLASIA PROGRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e71a3a2e-7355-cc73-4dd7-2c5fef917d86-C", "generated_internal_id": "ASST_NON_F32HL151176_7529"}, {"internal_id": 79433316, "Award ID": "F32HL149605", "Award Amount": 123075.33, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-01", "CFDA Number": "93.837", "Description": "FUNCTIONAL T CELLS FROM IPSCS USING CHIMERIC ANTIGEN RECEPTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_F32HL149605_7529"}, {"internal_id": 82469284, "Award ID": "F32HL149341", "Award Amount": 124782.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-29", "CFDA Number": "93.837", "Description": "CMP-NEU5AC: A CENTRAL MOLECULE IN BLEEDING DISEASES AND MEDIATOR OF A NOVEL PLATELET EFFECTOR FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_F32HL149341_7529"}, {"internal_id": 82054570, "Award ID": "F32HL149280", "Award Amount": 128588.26, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-11", "CFDA Number": "93.837", "Description": "THE ROLE OF GPR56 IN PLATELET FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_F32HL149280_7529"}, {"internal_id": 83103991, "Award ID": "F32HL149207", "Award Amount": 126641.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-12", "CFDA Number": "93.837", "Description": "THE ROLE OF PLATELET-SPECIFIC NLRP3 INFLAMMASOME IN VENOUS THROMBOSIS AFTER TRAUMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_F32HL149207_7529"}, {"internal_id": 82470942, "Award ID": "F32HL149155", "Award Amount": 124277.19, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-31", "CFDA Number": "93.837", "Description": "CONTRIBUTION OF ASC DYNAMICS TO SURVIVAL WITHIN THE BONE MARROW", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_F32HL149155_7529"}, {"internal_id": 82470568, "Award ID": "F32HL146119", "Award Amount": 213146.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-31", "CFDA Number": "93.837", "Description": "ROLE OF THE CLASS IA PI3K IN HEMATOPOIETIC STEM CELL SELF-RENEWAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_F32HL146119_7529"}, {"internal_id": 78990251, "Award ID": "F32HL145997", "Award Amount": 176194.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-06", "CFDA Number": "93.837", "Description": "KINETIC CHARACTERIZATION OF HEMATOPOIETIC STEM CELL DIFFERENTIATION DURING HOMEOSTASIS AND PATHOLOGICAL CONDITIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "c07787b9-15d4-d1eb-4f0c-2e0b30320bfb-C", "generated_internal_id": "ASST_NON_F32HL145997_7529"}, {"internal_id": 67832356, "Award ID": "F32HL143941", "Award Amount": 122410.33, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-08", "CFDA Number": "93.837", "Description": "NEURAL MECHANISMS OF TREATMENT MOTIVATION AND ADHERENCE IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "e895f676-c226-223f-b5ed-dda80c2ec73a-C", "generated_internal_id": "ASST_NON_F32HL143941_7529"}, {"internal_id": 69724886, "Award ID": "F32HL143915", "Award Amount": 167176.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-24", "CFDA Number": "93.837", "Description": "WHITE MATTER STRUCTURAL INTEGRITY AND COGNITION IN CHILDREN WITH SICKLE CELL DISEASE", "Place of Performance Country Code": "GBR", "Place of Performance State Code": null, "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "accc2eab-f191-fd71-b1bd-37c6a1557140-C", "generated_internal_id": "ASST_NON_F32HL143915_7529"}, {"internal_id": 67833210, "Award ID": "F32HL143861", "Award Amount": 121160.97, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-17", "CFDA Number": "93.837", "Description": "EXOSOME-MEDIATED ENHANCEMENT OF IN UTERO HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR THE TREATMENT OF HEMOGLOBINOPATHIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_F32HL143861_7529"}, {"internal_id": 81071423, "Award ID": "F32HL143832", "Award Amount": 131662.64, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-28", "CFDA Number": "93.837", "Description": "CONTRIBUTION OF T LYMPHOCYTES IN THE DEVELOPMENT OF MATERNAL SYNDROME IN DAHL SS RATS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "aca87389-2cb6-91e2-17a4-df7e81a7314d-C", "generated_internal_id": "ASST_NON_F32HL143832_7529"}, {"internal_id": 78990500, "Award ID": "F32HL142243", "Award Amount": 208920.93, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-03-06", "CFDA Number": "93.837", "Description": "MICROBIOTA DEPLETION AMELIORATES SICKLE CELL INDUCED VASO-OCCLUSIVE CRISIS AND ORGAN DAMAGE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_F32HL142243_7529"}, {"internal_id": 78599000, "Award ID": "F32HL142222", "Award Amount": 188337.58, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-02-22", "CFDA Number": "93.837", "Description": "SKELETAL STEM CELL PDGFR-BETA SIGNALING AS A NEW REGULATOR OF THE HSC NICHE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OK", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "36c41119-2158-d09a-55ce-00590b81ab14-C", "generated_internal_id": "ASST_NON_F32HL142222_7529"}, {"internal_id": 66199037, "Award ID": "F32HL142175", "Award Amount": 152209.56, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-16", "CFDA Number": "93.837", "Description": "NOVEL ROLE OF PRO-RESOLVING LIPID MEDIATORS IN SIGNALING LEUKOCYTES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "9bfcd9fa-8c45-c6a1-1dd3-d2f18b527530-C", "generated_internal_id": "ASST_NON_F32HL142175_7529"}, {"internal_id": 65894195, "Award ID": "F32HL142144", "Award Amount": 122784.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-20", "CFDA Number": "93.839", "Description": "DEVELOPING POLY(AMINE-CO-ESTER) POLYMERIC DELIVERY VEHICLES AND 3D CULTURE SCREENING PLATFORMS FOR THE TREATMENT OF HEREDITARY BETA-THALASSEMIA WITH PEPTIDE NUCLEIC ACID GENOME EDITING TECHNOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_F32HL142144_7529"}, {"internal_id": 66487135, "Award ID": "F32HL140869", "Award Amount": 46528.4, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-24", "CFDA Number": "93.837", "Description": "INVESTIGATING THE ROLE OF SPLICING FACTOR MUTATIONS IN MDS USING HUMAN IPSCS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_F32HL140869_7529"}, {"internal_id": 48621575, "Award ID": "F32HL139114", "Award Amount": 185750.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-11", "CFDA Number": "93.837", "Description": "A LABORATORY-BASED HYPNOSIS INTERVENTION ON PSYCHOPHYSIOLOGICAL MARKERS OF PAIN RESPONSIVITY IN ADOLESCENTS WITH AND WITHOUT SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_F32HL139114_7529"}, {"internal_id": 48621567, "Award ID": "F32HL139016", "Award Amount": 177048.07, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-26", "CFDA Number": "93.837", "Description": "CHARACTERIZATION OF A NEW GROWTH FACTOR FROM A BONE MARROW VASCULAR NICHE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_F32HL139016_7529"}, {"internal_id": 48621544, "Award ID": "F32HL136202", "Award Amount": 83916.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-23", "CFDA Number": "93.839", "Description": "IDENTIFYING PROTECTIVE ROLES OF THE HEME OXYGENASE/CARBON MONOXIDE PATHWAY IN HYPOXIA-TOLERANT MODEL SYSTEMS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_F32HL136202_7529"}, {"internal_id": 48621538, "Award ID": "F32HL136173", "Award Amount": 182075.54, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-08", "CFDA Number": "93.837", "Description": "RED CELL DETERMINANTS OF PREMATURE HEMOLYSIS OF PLASMODIUM INFECTED RED CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f5f39b56-5a70-1fe5-798f-b53ffca1e353-C", "generated_internal_id": "ASST_NON_F32HL136173_7529"}, {"internal_id": 48621521, "Award ID": "F32HL135975", "Award Amount": 179478.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-23", "CFDA Number": "93.839", "Description": "ROLE OF HSF1 IN HEMATOPOIETIC STEM CELL MAINTENANCE AND FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_F32HL135975_7529"}, {"internal_id": 48621512, "Award ID": "F32HL134244", "Award Amount": 123046.36, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-09", "CFDA Number": "93.837", "Description": "THE COAGULOPATHY-INFLAMMATION INTERFACE: INTEGRATION OF COAGULOPATHY AND COMPLEMENT ACTIVATION AS A MECHANISM FOR NEUTROPHIL PRIMING AND TISSUE DAMAG", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "959819d4-fcbb-189c-44a9-a2fc0644251a-C", "generated_internal_id": "ASST_NON_F32HL134244_7529"}, {"internal_id": 48621492, "Award ID": "F32HL132475", "Award Amount": 127554.96, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-19", "CFDA Number": "93.837", "Description": "INVESTIGATING THE ROLE FOR MIR-223 IN HEMATOPOIETIC STEM CELL EMERGENCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_F32HL132475_7529"}, {"internal_id": 48621486, "Award ID": "F32HL132418", "Award Amount": 95701.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-01", "CFDA Number": "93.839", "Description": "CARBON MONOXIDE INHIBITION OF MITOCHONDRIAL FUNCTION AND EFFICACY OF A NOVEL ANTIDOTAL THERAPEUTIC FOR CARBON MONOXIDE POISONING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_F32HL132418_7529"}, {"internal_id": 48621460, "Award ID": "F32HL129819", "Award Amount": 173111.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-12", "CFDA Number": "93.837", "Description": "INVESTIGATING THE ROLE OF THE WNT16 PATHWAY DURING HSC NICHE SPECIFICATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bccd984e-68ff-4e70-2020-f0129e4b9ecc-C", "generated_internal_id": "ASST_NON_F32HL129819_7529"}, {"internal_id": 48621435, "Award ID": "F32HL129491", "Award Amount": 136029.0, "Award Type": null, "Base Obligation Date": "2015-07-31", "CFDA Number": "93.839", "Description": "PHARMACOGENOMICS STUDIES OF PAR4 REGULATION IN HUMAN PLATELETS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_F32HL129491_7529"}, {"internal_id": 48621421, "Award ID": "F32HL127981", "Award Amount": 101426.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-15", "CFDA Number": "93.837", "Description": "THROMBORESISTANT/BACTERICIDAL INTRAVASCULAR CATHETERS BASED ON ELECTROCHEMICAL NITRIC OXIDE GENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_F32HL127981_7529"}, {"internal_id": 48621411, "Award ID": "F32HL126386", "Award Amount": 54362.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-08-24", "CFDA Number": "93.839", "Description": "VWF-GPIBA BINDING AND VON WILLEBRAND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_F32HL126386_7529"}, {"internal_id": 48621388, "Award ID": "F32HL124947", "Award Amount": 155947.76, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-07-18", "CFDA Number": "93.837", "Description": "NEURAL REGULATION OF THE HEMATOPOIETIC STEM CELL NICHE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_F32HL124947_7529"}, {"internal_id": 48621351, "Award ID": "F32HL123224", "Award Amount": 96878.0, "Award Type": null, "Base Obligation Date": "2014-09-01", "CFDA Number": "93.839", "Description": "BIOMIMETIC ARTIFICIAL NICHE FOR HEMATOPOIETIC STEM CELL EXPANSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75e3c1a2-1272-1d1c-d51b-c7a0d1cbe653-C", "generated_internal_id": "ASST_NON_F32HL123224_7529"}, {"internal_id": 48621345, "Award ID": "F32HL122095", "Award Amount": 143249.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-31", "CFDA Number": "93.839", "Description": "THE ROLE OF PROLINE DEHYDROGENASE IN HEMATOPOIETIC STEM CELL FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3533688b-b8fb-c3f8-76e6-68ad9ad84b99-C", "generated_internal_id": "ASST_NON_F32HL122095_7529"}, {"internal_id": 48621338, "Award ID": "F32HL122007", "Award Amount": 130408.12, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-12-13", "CFDA Number": "93.837", "Description": "A SYNTHETIC BIOLOGY APPROACH TO TARGETING ERYTHROPOIETIN-BASED THERAPEUTICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81e3f12d-5809-de22-dbd3-10b61910a90c-C", "generated_internal_id": "ASST_NON_F32HL122007_7529"}, {"internal_id": 100874494, "Award ID": "F31HL154661", "Award Amount": 138308.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-16", "CFDA Number": "93.837", "Description": "THE MECHANISM OF BATF2-MEDIATED HSC DIFFERENTIATION DURING CHRONIC INFECTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_F31HL154661_7529"}, {"internal_id": 108463082, "Award ID": "F31HL154656", "Award Amount": 78634.92, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-05", "CFDA Number": "93.837", "Description": "TARGETING THE FORCE-REGULATED VON WILLEBRAND FACTOR AUTOINHIBITORY MODULE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_F31HL154656_7529"}, {"internal_id": 107677340, "Award ID": "F31HL154645", "Award Amount": 74748.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-04", "CFDA Number": "93.837", "Description": "ROLE OF THE ETV6 TRANSCRIPTION FACTOR IN HEMATOPOIETIC STEM CELL FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "70f3fb0f-3d78-de82-dcd4-d26a0f1235e4-R", "generated_internal_id": "ASST_NON_F31HL154645_7529"}, {"internal_id": 109190008, "Award ID": "F31HL154562", "Award Amount": 66018.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-05", "CFDA Number": "93.837", "Description": "DETERMINING THE PLATELET SIGNALING PATHWAY(S) CRITICAL IN VENOUS THROMBOSIS PATHOGENESIS\" IT MIGHT CHANGE IN THE PROCESS OF EDITING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_F31HL154562_7529"}, {"internal_id": 96558739, "Award ID": "F31HL154510", "Award Amount": 64793.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-09", "CFDA Number": "93.837", "Description": "INVESTIGATING HOST KINASE MODULATION OF ERYTHROCYTE DEFORMABILITY DURING PLASMODIUM FALCIPARUM INVASION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f5f39b56-5a70-1fe5-798f-b53ffca1e353-C", "generated_internal_id": "ASST_NON_F31HL154510_7529"}, {"internal_id": 100873860, "Award ID": "F31HL154509", "Award Amount": 40862.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-16", "CFDA Number": "93.837", "Description": "USING BIG DATA TO UNDERSTAND SEPSIS IN AN IMMUNOCOMPROMISED POPULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_F31HL154509_7529"}, {"internal_id": 96557045, "Award ID": "F31HL152652", "Award Amount": 116951.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-17", "CFDA Number": "93.837", "Description": "RUNX1 TRANSCRIPTION AND R-LOOP FORMATION IN HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_F31HL152652_7529"}, {"internal_id": 96558392, "Award ID": "F31HL152563", "Award Amount": 106308.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-16", "CFDA Number": "93.837", "Description": "NEW PHARMACOLOGICAL TOOLS TO EXPLORE PLATELET GPR56 FUNCTION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_F31HL152563_7529"}, {"internal_id": 96559452, "Award ID": "F31HL152562", "Award Amount": 206002.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-17", "CFDA Number": "93.837", "Description": "DECIPHERING THE DEVELOPMENT OF HEMATOPOIETIC STEM AND PROGENITOR CELL SELF-RENEWAL AND DIFFERENTIATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_F31HL152562_7529"}, {"internal_id": 96558356, "Award ID": "F31HL152529", "Award Amount": 89897.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-16", "CFDA Number": "93.837", "Description": "CONNECTING TCA CYCLE FLUX AND EPIGENETIC REGULATION OF HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4a536007-27e4-2194-a125-f4b8c55294db-C", "generated_internal_id": "ASST_NON_F31HL152529_7529"}, {"internal_id": 83103571, "Award ID": "F31HL151264", "Award Amount": 124149.35, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-12", "CFDA Number": "93.837", "Description": "NOVEL ENDOTHELIAL AND IMMUNOLOGIC MECHANISMS OF PATHOPHYSIOLOGY IN SICKLE CELL DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_F31HL151264_7529"}, {"internal_id": 94235108, "Award ID": "F31HL151199", "Award Amount": 115163.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-08", "CFDA Number": "93.837", "Description": "DEFINING REGULATORS OF HEMATOPOIETIC STEM CELL SELF-RENEWAL AND LINEAGE POTENTIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "427ea0fd-a29e-756b-4973-911cb119bc8d-C", "generated_internal_id": "ASST_NON_F31HL151199_7529"}, {"internal_id": 93242691, "Award ID": "F31HL151140", "Award Amount": 136925.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-16", "CFDA Number": "93.837", "Description": "AUTOPHAGY ENGAGEMENT AND HEMATOPOIETIC STEM CELL MAINTENANCE DURING AGING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_F31HL151140_7529"}, {"internal_id": 109189786, "Award ID": "F31HL151097", "Award Amount": 89322.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-14", "CFDA Number": "93.837", "Description": "DNA PROCESSING ROLES IN DNA DOUBLE-STRAND BREAK REPAIR BY FANCONI ANEMIA SUB-COMPLEX AG20", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "dbae4064-c48c-5002-9fca-21d077e0f96b-C", "generated_internal_id": "ASST_NON_F31HL151097_7529"}, {"internal_id": 100875066, "Award ID": "F31HL151090", "Award Amount": 37596.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-16", "CFDA Number": "93.837", "Description": "REGULATION OF HEMATOPOIESIS BY EPIGENETIC TIMING CONTROL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_F31HL151090_7529"}, {"internal_id": 95181491, "Award ID": "F31HL150952", "Award Amount": 67158.31, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-12-20", "CFDA Number": "93.837", "Description": "IDENTIFYING NECESSARY CHROMATIN STATES AND TARGETS FOR HEMOGENIC SPECIFICATION AND REPROGRAMMING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F31HL150952_7529"}, {"internal_id": 83797322, "Award ID": "F31HL149357", "Award Amount": 167324.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-22", "CFDA Number": "93.837", "Description": "VON WILLEBRAND FACTOR AND THROMBOCYTOPENIA IN INFECTIVE ENDOCARDITIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_F31HL149357_7529"}, {"internal_id": 83103242, "Award ID": "F31HL149356", "Award Amount": 67039.46, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-16", "CFDA Number": "93.837", "Description": "SITE-SPECIFIC CORRECTION OF SICKLE CELL DISEASE USING ACOUSTOFLUDIC GENE DELIVERY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_F31HL149356_7529"}, {"internal_id": 83103273, "Award ID": "F31HL149340", "Award Amount": 54789.93, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-12", "CFDA Number": "93.837", "Description": "THE ROLE OF PATHOLOGIC PLASMIN ACTIVITY IN TRAUMA-INDUCED SYSTEMIC INFLAMMATORY RESPONSE SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4a536007-27e4-2194-a125-f4b8c55294db-C", "generated_internal_id": "ASST_NON_F31HL149340_7529"}, {"internal_id": 82054271, "Award ID": "F31HL149241", "Award Amount": 68556.28, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-10", "CFDA Number": "93.837", "Description": "INVESTIGATING THE ROLE OF XANTHINE OXIDASE IN HEMOLYTIC DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6ad8c5c3-8085-49bb-9227-fc5bc4a1f938-C", "generated_internal_id": "ASST_NON_F31HL149241_7529"}, {"internal_id": 107115380, "Award ID": "F31HL149219", "Award Amount": 67276.1, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-07-28", "CFDA Number": "93.837", "Description": "A HAND-HELD, PORTABLE ROBOTIC DEVICE FOR AUTOMATED VENIPUNCTURE.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NJ", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "83d0dcf4-2a9e-ab83-7a4e-b740e9121600-C", "generated_internal_id": "ASST_NON_F31HL149219_7529"}, {"internal_id": 82470102, "Award ID": "F31HL149154", "Award Amount": 101804.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-07-29", "CFDA Number": "93.837", "Description": "STEM CELL-NICHE INTERACTIONS IN THE ESTABLISHMENT OF HEMATOPOIETIC STEM CELL HETEROGENEITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81e3f12d-5809-de22-dbd3-10b61910a90c-C", "generated_internal_id": "ASST_NON_F31HL149154_7529"}, {"internal_id": 95181235, "Award ID": "F31HL147514", "Award Amount": 138308.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-10", "CFDA Number": "93.837", "Description": "THE MECHANISMS OF BACTERIAL MICROBIOME REGULATION OF HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_F31HL147514_7529"}, {"internal_id": 80724928, "Award ID": "F31HL147482", "Award Amount": 59578.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-08", "CFDA Number": "93.837", "Description": "AMELIORATION OF BETA-HEMOGLOBINOPATHIES BY EFFICIENT PRECISE DELETION OF THE +58 BCL11A ENHANCER USING ORTHOGONAL CAS9-CAS9 CHIMERAS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68a12c06-0ac5-9595-eda2-d8647ffda5d0-C", "generated_internal_id": "ASST_NON_F31HL147482_7529"}, {"internal_id": 81396020, "Award ID": "F31HL147471", "Award Amount": 74500.41, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-07", "CFDA Number": "93.837", "Description": "IDENTIFICATION OF PARASITE ERYTHROCYTE MEMBRANE ANTIGENS SPECIFIC TO CEREBRAL MALARIA AND SEVERE MALARIAL ANEMIA PATHOGENESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_F31HL147471_7529"}, {"internal_id": 80726472, "Award ID": "F31HL147470", "Award Amount": 49935.44, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-09", "CFDA Number": "93.837", "Description": "UNRAVELING MECHANISMS OF PLASMACYTOID DENDRITIC CELL PRIMING BY CD169+ MACROPHAGES IN SEVERE MURINE MALARIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_F31HL147470_7529"}, {"internal_id": 95180811, "Award ID": "F31HL147468", "Award Amount": 21330.09, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-02-10", "CFDA Number": "93.837", "Description": "UNCOVERING THE ROLE OF PLATELETS IN ANTI-ASPERGILLUS IMMUNE DEFENSE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b514fc3a-d769-87e9-75ea-7a6766afb5ee-C", "generated_internal_id": "ASST_NON_F31HL147468_7529"}, {"internal_id": 80736675, "Award ID": "F31HL147462", "Award Amount": 118269.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-07", "CFDA Number": "93.837", "Description": "CONNECTING SEX TO PLATELET FUNCTION AFTER MECHANICAL ACTIVATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_F31HL147462_7529"}, {"internal_id": 80731356, "Award ID": "F31HL147459", "Award Amount": 96981.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-06", "CFDA Number": "93.837", "Description": "THE MOLECULAR MECHANISM OF THE CD19-CD81 B CELL CO-RECEPTOR COMPLEX", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3c727a6e-aeb7-b7bb-b622-36f566d604a5-C", "generated_internal_id": "ASST_NON_F31HL147459_7529"}, {"internal_id": 80734494, "Award ID": "F31HL147458", "Award Amount": 61255.22, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-10", "CFDA Number": "93.837", "Description": "LUNG MEGAKARYOCYTES ARE A NOVEL PROFESSIONAL ANTIGEN PRESENTING CELL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_F31HL147458_7529"}, {"internal_id": 80736631, "Award ID": "F31HL144115", "Award Amount": 73937.59, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-05-17", "CFDA Number": "93.837", "Description": "CHROMATIN ACCESSIBILITY AND NUCLEAR LOCALIZATION EFFECTS ON HEMATOPOIETIC LINEAGE FATE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "427ea0fd-a29e-756b-4973-911cb119bc8d-C", "generated_internal_id": "ASST_NON_F31HL144115_7529"}, {"internal_id": 67313817, "Award ID": "F31HL143994", "Award Amount": 47145.17, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-19", "CFDA Number": "93.837", "Description": "THERAPEUTIC STRATEGIES FOR ANEMIA IN 3Q26 REARRANGED LEUKEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_F31HL143994_7529"}, {"internal_id": 67314550, "Award ID": "F31HL143844", "Award Amount": 54315.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-06", "CFDA Number": "93.837", "Description": "INVESTIGATING THE ROLE OF ZBTB33 LOSS IN CLONAL HEMATOPOIESIS AND HEMATOLOGIC MALIGNANCIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81e3f12d-5809-de22-dbd3-10b61910a90c-C", "generated_internal_id": "ASST_NON_F31HL143844_7529"}, {"internal_id": 66996807, "Award ID": "F31HL142208", "Award Amount": 131860.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-27", "CFDA Number": "93.837", "Description": "FUNCTIONAL ANALYSIS OF MYC DYSREGULATION BY DIVERSE GENETIC MECHANISMS DURING HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_F31HL142208_7529"}, {"internal_id": 66994988, "Award ID": "F31HL142185", "Award Amount": 92890.48, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-27", "CFDA Number": "93.837", "Description": "TIN2L PHOSPHORYLATION AND DYSKERATOSIS CONGENITA PATHOGENIC VARIANTS IN TELOMERE MAINTENANCE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_F31HL142185_7529"}, {"internal_id": 66487188, "Award ID": "F31HL142150", "Award Amount": 73894.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-30", "CFDA Number": "93.839", "Description": "INVESTIGATING THE REGULATION OF CHEMOATTRACTANT PRIORITIZATION IN HUMAN NEUTROPHILS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1e2f11d9-030b-5288-d89f-1f6fd7f111f3-C", "generated_internal_id": "ASST_NON_F31HL142150_7529"}, {"internal_id": 66487241, "Award ID": "F31HL142146", "Award Amount": 111052.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-05-21", "CFDA Number": "93.839", "Description": "FUNCTIONAL ANALYSES OF EPAS1 ALLELES FROM POPULATIONS ADAPTED TO HIGH ALTITUDE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d4bd68be-2bd0-4a42-0d20-0ad92720d93c-C", "generated_internal_id": "ASST_NON_F31HL142146_7529"}, {"internal_id": 67833144, "Award ID": "F31HL142132", "Award Amount": 173212.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-06", "CFDA Number": "93.837", "Description": "EPIGENETIC PROFILING OF SINGLE CELLS BY IN SITU LABELING FOR STUDYING HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_F31HL142132_7529"}, {"internal_id": 62420920, "Award ID": "F31HL140774", "Award Amount": 80722.14, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-02-07", "CFDA Number": "93.837", "Description": "INVESTIGATING THE MECHANISM OF THROMBOCYTOPENIA DUE TO ETV6 OR RUNX1 MUTATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F31HL140774_7529"}, {"internal_id": 48613819, "Award ID": "F31HL139100", "Award Amount": 58794.11, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-24", "CFDA Number": "93.837", "Description": "CONTRIBUTION OF PLASMA AND PLATELET FACTOR XIII TO VENOUS THROMBOSIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_F31HL139100_7529"}, {"internal_id": 48613816, "Award ID": "F31HL139091", "Award Amount": 120205.69, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-28", "CFDA Number": "93.837", "Description": "INVESTIGATING THE ROLE OF SH2B3 IN HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELL EXPANSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F31HL139091_7529"}, {"internal_id": 48613810, "Award ID": "F31HL138934", "Award Amount": 148030.17, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-31", "CFDA Number": "93.837", "Description": "CHARACTERIZATION OF NATURALLY OCCURRING ANTI-BLOOD GROUP ANTIBODY FORMATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_F31HL138934_7529"}, {"internal_id": 48613808, "Award ID": "F31HL138754", "Award Amount": 59569.35, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-11", "CFDA Number": "93.837", "Description": "ROLE OF RNA SPLICING FACTOR U2AF1 IN REGULATING HEMATOPOIETIC STEM CELL INFLAMMATION RESPONSES.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "7f8eb9f7-3ee7-fb7d-c649-ee912e019c18-C", "generated_internal_id": "ASST_NON_F31HL138754_7529"}, {"internal_id": 48613789, "Award ID": "F31HL136230", "Award Amount": 161420.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-03", "CFDA Number": "93.837", "Description": "ROLE OF FXI IN THROMBOHEMORRHAGIC COMPLICATIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_F31HL136230_7529"}, {"internal_id": 48613788, "Award ID": "F31HL136229", "Award Amount": 105342.59, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-02-02", "CFDA Number": "93.837", "Description": "IMPACT OF AN ABNORMAL BONE MARROW ENDOTHELIAL NICHE ON HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_F31HL136229_7529"}, {"internal_id": 48613781, "Award ID": "F31HL136155", "Award Amount": 199104.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-15", "CFDA Number": "93.837", "Description": "MOLECULAR BASIS OF MEMBRANE BINDING AND ACTIVATION OF COAGULATION FACTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2c3d8c8a-27ef-b1e9-7164-bbfa490faa27-C", "generated_internal_id": "ASST_NON_F31HL136155_7529"}, {"internal_id": 48613780, "Award ID": "F31HL136148", "Award Amount": 43884.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-24", "CFDA Number": "93.839", "Description": "ZERO FOOTPRINT INDUCTION OF HUMAN HEMOGENESIS TO STUDY FANCONI ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_F31HL136148_7529"}, {"internal_id": 48613775, "Award ID": "F31HL136107", "Award Amount": 50423.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-02-03", "CFDA Number": "93.839", "Description": "FUNCTION OF THE UBIQUITIN-SPECIFIC PEPTIDASE 22 (USP22) IN ACUTE MYELOID LEUKEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_F31HL136107_7529"}, {"internal_id": 48613765, "Award ID": "F31HL135986", "Award Amount": 21240.0, "Award Type": null, "Base Obligation Date": "2017-08-15", "CFDA Number": "93.839", "Description": "IDENTIFICATION OF A NOVEL POPULATION OF HEMATOPOIETIC PRECURSOR CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_F31HL135986_7529"}, {"internal_id": 48613764, "Award ID": "F31HL134359", "Award Amount": 68893.92, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-28", "CFDA Number": "93.837", "Description": "CLONAL COMPENSATION BETWEEN HEMATOPOIETIC STEM CELLS UPON DIFFERENTIATION DEFICIENCY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "56e7333e-38ec-5402-80b8-4d50309afb4c-C", "generated_internal_id": "ASST_NON_F31HL134359_7529"}, {"internal_id": 48613762, "Award ID": "F31HL134331", "Award Amount": 74611.7, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-05", "CFDA Number": "93.837", "Description": "INTEGRATIVE EPIGENETIC ANALYSIS AND EX VIVO GENERATION OF MEGAKARYOCYTES FROM UMBILICAL CORD BLOOD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b0be845a-babe-8a5d-2f4b-002e5eff7fcd-C", "generated_internal_id": "ASST_NON_F31HL134331_7529"}, {"internal_id": 48613760, "Award ID": "F31HL134325", "Award Amount": 121910.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-20", "CFDA Number": "93.837", "Description": "THE ROLE OF CAR-EXPRESSING TREGS ON ANTIGEN-SPECIFIC IMMUNE SUPPRESSION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F31HL134325_7529"}, {"internal_id": 48613755, "Award ID": "F31HL134313", "Award Amount": 210933.24, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-28", "CFDA Number": "93.837", "Description": "IMPROVED GLOBIN EXPRESSION VECTORS FOR GENE THERAPY OF HUMAN HEMOGLOBINOPATHIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_F31HL134313_7529"}, {"internal_id": 48613751, "Award ID": "F31HL134284", "Award Amount": 65007.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-03", "CFDA Number": "93.839", "Description": "MECHANISMS UNDERLYING IMPAIRED BACTERIAL CLEARANCE FOLLOWING TRANSFUSION OF STORAGE-DAMAGED RED BLOOD CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_F31HL134284_7529"}, {"internal_id": 48613743, "Award ID": "F31HL134241", "Award Amount": 131417.58, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-01", "CFDA Number": "93.837", "Description": "A MULTIDISCIPLINARY APPROACH TO ELUCIDATE THE PATHOPHYSIOLOGY OF THROMBOCYTOPENIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_F31HL134241_7529"}, {"internal_id": 48613738, "Award ID": "F31HL134208", "Award Amount": 73673.2, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-28", "CFDA Number": "93.837", "Description": "IMPROVING TARGETED NUCLEASE-MEDIATED GENE CORRECTION IN HUMAN HEMATOPOIETIC STEM CELLS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3231cda5-201a-6da0-de9e-e9810a848983-C", "generated_internal_id": "ASST_NON_F31HL134208_7529"}, {"internal_id": 48613719, "Award ID": "F31HL132468", "Award Amount": 144935.74, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-01", "CFDA Number": "93.837", "Description": "SCRIBBLE IN HEMATOPOIETIC STEM CELL ACTIVITY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_F31HL132468_7529"}, {"internal_id": 48613718, "Award ID": "F31HL132463", "Award Amount": 75428.45, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-01", "CFDA Number": "93.837", "Description": "DEVELOPING AN INSTRUMENT TO MEASURE INTERACTIVE EHEALTH LITERACY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "FL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "369ac1e4-8d93-3063-b933-3586dffba549-C", "generated_internal_id": "ASST_NON_F31HL132463_7529"}, {"internal_id": 48613712, "Award ID": "F31HL132420", "Award Amount": 105223.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-19", "CFDA Number": "93.839", "Description": "ABERRANT UBIQUITIN-EDITING IN THE PATHOGENESIS OF MYELOID MALIGNANCIES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a8ad38bc-2827-1399-cd46-c5204062852b-C", "generated_internal_id": "ASST_NON_F31HL132420_7529"}, {"internal_id": 48613710, "Award ID": "F31HL132410", "Award Amount": 36565.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-01-20", "CFDA Number": "93.837", "Description": "THE ROLE OF INFLAMMATION AND INFLAMMATORY MEDIATORS IN HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81e3f12d-5809-de22-dbd3-10b61910a90c-C", "generated_internal_id": "ASST_NON_F31HL132410_7529"}, {"internal_id": 48613705, "Award ID": "F31HL131428", "Award Amount": 97317.12, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-01", "CFDA Number": "93.837", "Description": "THE ROLE OF COMPLEMENT COMPONENT 3 IN RED BLOOD CELL ALLOIMMUNIZATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_F31HL131428_7529"}, {"internal_id": 48613700, "Award ID": "F31HL131355", "Award Amount": 176893.03, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-03-01", "CFDA Number": "93.837", "Description": "THE ROLE OF CD99L2 IN LEUKOCYTE TRANSENDOTHELIAL MIGRATION IN VITRO AND IN VIVO", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_F31HL131355_7529"}, {"internal_id": 48613696, "Award ID": "F31HL131290", "Award Amount": 40312.94, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-01", "CFDA Number": "93.837", "Description": "UNDERSTANDING HOW PROLIFERATION AFFECTS HEMATOPOIETIC STEM CELL REGENERATIVE POTENTIAL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_F31HL131290_7529"}, {"internal_id": 48613688, "Award ID": "F31HL131184", "Award Amount": 61232.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-09", "CFDA Number": "93.837", "Description": "MODULATION OF FUNCTIONALLY DISTINCT HEMATOPOIETIC STEM CELL NICHES BY PTH", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f8e3456f-8dec-1441-72b9-fa2b342bdb94-C", "generated_internal_id": "ASST_NON_F31HL131184_7529"}, {"internal_id": 48613687, "Award ID": "F31HL131155", "Award Amount": 107582.97, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-02-09", "CFDA Number": "93.837", "Description": "RUNX1 ALTERNATIVE POLYADENYLATION IN HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_F31HL131155_7529"}, {"internal_id": 48613686, "Award ID": "F31HL131140", "Award Amount": 97721.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-17", "CFDA Number": "93.837", "Description": "THE EFFECTS OF LUC7L2 ON ALTERNATIVE SPLICING IN MYELODYSPLASTIC SYNDROMES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "513dbccc-53a8-be65-9d72-68c77a4f8608-C", "generated_internal_id": "ASST_NON_F31HL131140_7529"}, {"internal_id": 48613663, "Award ID": "F31HL129517", "Award Amount": 56111.42, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-22", "CFDA Number": "93.837", "Description": "11,12-EPOXYEICOSATRIENOIC ACID REGULATION OF HEMATOPOIETIC STEM CELL ENGRAFTMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81e3f12d-5809-de22-dbd3-10b61910a90c-C", "generated_internal_id": "ASST_NON_F31HL129517_7529"}, {"internal_id": 48613661, "Award ID": "F31HL129481", "Award Amount": 106437.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-07-31", "CFDA Number": "93.839", "Description": "12-LIPOXYGENASE REGULATION OF FCGRIIA-MEDIATED PLATELET ACTIVATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1567efcf-bcdb-61b9-72f2-70cbed5fa626-C", "generated_internal_id": "ASST_NON_F31HL129481_7529"}, {"internal_id": 48613654, "Award ID": "F31HL128088", "Award Amount": 137484.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-05-08", "CFDA Number": "93.837", "Description": "SICKLE CELL DISEASE ASSOCIATED WITH PULMONARY HYPERTENSION: MECHANICAL AND HEMODYNAMIC CONSEQUENCES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f044e52c-101e-349e-69e4-aaa93e72f7ab-C", "generated_internal_id": "ASST_NON_F31HL128088_7529"}, {"internal_id": 48613646, "Award ID": "F31HL128029", "Award Amount": 92995.92, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-15", "CFDA Number": "93.837", "Description": "G PROTEIN-COUPLED RECEPTOR KINASE 3 (GRK3) REGULATION OF RECEPTOR SIGNALING IN STEM CELL FUNCTION AND TRANSPLANTATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f371179b-9f27-8013-f81c-4fd314b1f981-C", "generated_internal_id": "ASST_NON_F31HL128029_7529"}, {"internal_id": 48613632, "Award ID": "F31HL126484", "Award Amount": 75053.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-01", "CFDA Number": "93.839", "Description": "DECIPHERING THE MECHANISMS OF HOW THE RAF/MEK/ERK PATHWAY CONTROLS DENDRITIC CELL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "bace221f-a1f9-fa20-66e4-55984406cf48-C", "generated_internal_id": "ASST_NON_F31HL126484_7529"}, {"internal_id": 48613631, "Award ID": "F31HL126462", "Award Amount": 55501.0, "Award Type": null, "Base Obligation Date": "2015-08-17", "CFDA Number": "93.839", "Description": "THE ROLE OF LONG NONCODING RNAS IN HBF VARIANCE IN INDUCED PLURIPOTENT STEM CELL-DERIVED ERYTHROID CELLS FROM PATIENTS WITH SICKLE CELL ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0f62abfa-f880-18c2-5e58-a64739477e1e-C", "generated_internal_id": "ASST_NON_F31HL126462_7529"}, {"internal_id": 48613620, "Award ID": "F31HL126338", "Award Amount": 92581.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-01", "CFDA Number": "93.837", "Description": "IDENTIFYING FACTORS THAT PROMOTE CLONAL DOMINANCE IN ZEBRAFISH HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81e3f12d-5809-de22-dbd3-10b61910a90c-C", "generated_internal_id": "ASST_NON_F31HL126338_7529"}, {"internal_id": 48613617, "Award ID": "F31HL124977", "Award Amount": 73358.8, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-12-15", "CFDA Number": "93.837", "Description": "SPATIOTEMPORAL ANALYSIS OF CD82-MEDIATED INTEGRIN ADHESION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NM", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "a5b5888e-f4b5-655c-bd88-d970f969d7c9-C", "generated_internal_id": "ASST_NON_F31HL124977_7529"}, {"internal_id": 48613598, "Award ID": "F31HL120614", "Award Amount": 115910.77, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-04-03", "CFDA Number": "93.837", "Description": "BONE MARROW TRANSPLANT WITHOUT CYTOREDUCTIVE CONDITIONING TO CURE COOLEYS ANEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "AL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "385a79b6-b810-9612-774a-ef5d04895c34-C", "generated_internal_id": "ASST_NON_F31HL120614_7529"}, {"internal_id": 108463361, "Award ID": "F30HL154749", "Award Amount": 206002.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-12", "CFDA Number": "93.837", "Description": "DEVELOPING A NOVEL EX VIVO PLATFORM TO SUPPORT HEMATOPOIETIC CELLS AND CHARACTERIZE THE STEM CELL NICHE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_F30HL154749_7529"}, {"internal_id": 96558282, "Award ID": "F30HL152628", "Award Amount": 192194.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-09", "CFDA Number": "93.837", "Description": "SINGLE-CELL PROFILING AND LINEAGE TRACING OF ZEBRAFISH HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81e3f12d-5809-de22-dbd3-10b61910a90c-C", "generated_internal_id": "ASST_NON_F30HL152628_7529"}, {"internal_id": 110024625, "Award ID": "F30HL151075", "Award Amount": 177609.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-27", "CFDA Number": "93.837", "Description": "COMPREHENSIVE CHARACTERIZATION OF MISSENSE VARIANTS IN FACTOR IX", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_F30HL151075_7529"}, {"internal_id": 96558950, "Award ID": "F30HL151074", "Award Amount": 143966.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-04-16", "CFDA Number": "93.837", "Description": "COAI: COST-AWARE ARTIFICIAL INTELLIGENCE FOR EFFICIENT PREHOSPITAL DIAGNOSIS OF TRAUMA PATIENTS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8a022699-f7be-356a-f01a-3aa6f76016ef-C", "generated_internal_id": "ASST_NON_F30HL151074_7529"}, {"internal_id": 83797501, "Award ID": "F30HL149185", "Award Amount": 60037.53, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-21", "CFDA Number": "93.837", "Description": "MECHANISMS OF PNA-MEDIATED GENE THERAPY FOR HEMATOLOGIC DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_F30HL149185_7529"}, {"internal_id": 81728488, "Award ID": "F30HL147460", "Award Amount": 88933.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-06-19", "CFDA Number": "93.837", "Description": "INVESTIGATING THE ROLE OF THE NEOGENIN-1/NETRIN-1 AXIS IN AGING AND LINEAGE BIAS OF HEMATOPOIETIC STEM CELLS (HSCS)", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_F30HL147460_7529"}, {"internal_id": 83104034, "Award ID": "F30HL146095", "Award Amount": 125152.01, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-16", "CFDA Number": "93.837", "Description": "THE ROLE OF RIFINS AND THEIR INTERACTION WITH BLOOD TYPE IN VULNERABILITY TO SEVERE MALARIA IN MALIAN CHILDREN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MD", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "23b1535c-77e8-dafd-4ece-46b518206e5d-C", "generated_internal_id": "ASST_NON_F30HL146095_7529"}, {"internal_id": 67833733, "Award ID": "F30HL143870", "Award Amount": 182545.58, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-06", "CFDA Number": "93.837", "Description": "THE ROLE OF DONOR T CELL-DERIVED GM-CSF IN THE PATHOGENESIS OF GASTROINTESTINAL ACUTE GVHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_F30HL143870_7529"}, {"internal_id": 67832498, "Award ID": "F30HL143826", "Award Amount": 100107.85, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-10", "CFDA Number": "93.837", "Description": "ALTERATIONS IN THE SULFUR ASSIMILATION PATHWAY MEDIATES IRON METABOLISM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4a536007-27e4-2194-a125-f4b8c55294db-C", "generated_internal_id": "ASST_NON_F30HL143826_7529"}, {"internal_id": 66995125, "Award ID": "F30HL142196", "Award Amount": 122690.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-06-27", "CFDA Number": "93.837", "Description": "N6-METHYLADENOSINE RNA MODIFICATION REGULATES HEMATOPOIETIC STEM CELL FUNCTION.", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_F30HL142196_7529"}, {"internal_id": 67313906, "Award ID": "F30HL142161", "Award Amount": 200595.88, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-07-16", "CFDA Number": "93.837", "Description": "UNCOVERING THE ROLE OF THE DEAD BOX HELICASE DDX41 IN HEMATOPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_F30HL142161_7529"}, {"internal_id": 48609243, "Award ID": "F30HL138739", "Award Amount": 37657.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-03-17", "CFDA Number": "93.837", "Description": "LONG NON-CODING RNA REGULATION OF SHORT-LIVED MYELOID HOMEOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F30HL138739_7529"}, {"internal_id": 48609242, "Award ID": "F30HL137563", "Award Amount": 113088.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-10", "CFDA Number": "93.837", "Description": "IN VIVO GENE EDITING OF CCR5 IN BONE MARROW USING IMPROVED LENTIVIRAL VECTORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_F30HL137563_7529"}, {"internal_id": 48609238, "Award ID": "F30HL137323", "Award Amount": 142224.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-04-30", "CFDA Number": "93.837", "Description": "LOCAL AND SYSTEMIC REGULATION OF HEMATOPOIETIC STEM CELLS BY THROMBOPOIETIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "5f6a3877-304a-f4ec-9bd4-082c57aa1297-C", "generated_internal_id": "ASST_NON_F30HL137323_7529"}, {"internal_id": 48609231, "Award ID": "F30HL137235", "Award Amount": 155909.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-12-11", "CFDA Number": "93.837", "Description": "CHARACTERIZING THE CLONAL DYNAMICS AND ORIGINS OF THE DEVELOPING HEMATOPOIETIC SYSTEM", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "81e3f12d-5809-de22-dbd3-10b61910a90c-C", "generated_internal_id": "ASST_NON_F30HL137235_7529"}, {"internal_id": 48609224, "Award ID": "F30HL136127", "Award Amount": 38243.1, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-07-18", "CFDA Number": "93.837", "Description": "THE ROLE OF TRIB1 IN GRANULOCYTE IDENTITY AND ACTIVATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75401b4c-967a-1918-9977-217d3ef9ce68-C", "generated_internal_id": "ASST_NON_F30HL136127_7529"}, {"internal_id": 48609223, "Award ID": "F30HL136080", "Award Amount": 226053.76, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-12-23", "CFDA Number": "93.837", "Description": "LONG NON-CODING RNA-MEDIATED DIFFERENTIAL REGULATION OF NOTCH PATHWAY TARGETS IN EARLY T-CELL DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "74bac010-0a24-8f82-8021-0fa16ab4bc6d-C", "generated_internal_id": "ASST_NON_F30HL136080_7529"}, {"internal_id": 48609218, "Award ID": "F30HL134296", "Award Amount": 170716.14, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-17", "CFDA Number": "93.837", "Description": "PLATELET ERO1ALPHA IN THROMBOSIS AND HEMOSTASIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "98f86457-cdff-6b3c-9ff8-3a4415183bf6-C", "generated_internal_id": "ASST_NON_F30HL134296_7529"}, {"internal_id": 48609213, "Award ID": "F30HL134252", "Award Amount": 106524.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-08-23", "CFDA Number": "93.837", "Description": "NANOPARTICLES FOR SITE-SPECIFIC GENOME EDITING IN UTERO", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_F30HL134252_7529"}, {"internal_id": 48609210, "Award ID": "F30HL134202", "Award Amount": 219188.5, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-15", "CFDA Number": "93.837", "Description": "DEFINING THE ROLE OF IQGAP1 IN LEUKOCYTE TRANSMIGRATION IN VITRO AND IN VIVO", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IL", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "89c1b286-4842-cf79-9563-7ec2e987f771-C", "generated_internal_id": "ASST_NON_F30HL134202_7529"}, {"internal_id": 48609209, "Award ID": "F30HL132613", "Award Amount": 168709.71, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-04-05", "CFDA Number": "93.837", "Description": "CHARACTERIZING THE NOVEL PROTEIN C15ORF65", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b390b1e7-2bd3-be04-2015-3916c222ebaf-C", "generated_internal_id": "ASST_NON_F30HL132613_7529"}, {"internal_id": 48609179, "Award ID": "F30HL128011", "Award Amount": 55995.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-05-05", "CFDA Number": "93.839", "Description": "HSC-INDEPENDENT PROGENITORS CONTRIBUTE TO JUVENILE MYELOMONOCYTIC LEUKEMIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "adf5ba97-e9a1-374f-72a1-40502b70df1a-C", "generated_internal_id": "ASST_NON_F30HL128011_7529"}, {"internal_id": 48609174, "Award ID": "F30HL127977", "Award Amount": 120777.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2015-03-06", "CFDA Number": "93.837", "Description": "STUDYING ANTICOAGULANT SYNERGY OF FACTOR XA APTAMER AND CATALYTIC SITE INHIBITORS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NC", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "6f191f83-6024-f2be-3012-4b740b10ac7a-C", "generated_internal_id": "ASST_NON_F30HL127977_7529"}, {"internal_id": 48609155, "Award ID": "F30HL123205", "Award Amount": 188682.52, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-28", "CFDA Number": "93.837", "Description": "MECHANISMS OF ENDOTHELIAL-DEPENDENT HEMATOPOIETIC STEM CELL REGENERATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OR", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "27f21ab2-7b66-cad9-be60-5f435f28b02f-C", "generated_internal_id": "ASST_NON_F30HL123205_7529"}, {"internal_id": 48609153, "Award ID": "F30HL122096", "Award Amount": 91762.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-01-15", "CFDA Number": "93.839", "Description": "CLONAL EVOLUTION AND PROSPECTIVE ISOLATION OF MYELODYSPLASTIC SYNDROME INITIATING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_F30HL122096_7529"}, {"internal_id": 48609147, "Award ID": "F30HL121873", "Award Amount": 137119.5, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-27", "CFDA Number": "93.837", "Description": "MODIFYING REGULATORY T-CELL SIGNALING TO ENHANCE PREVENTION OF GVHD", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "75c0ae0f-6a5f-aead-72df-d28c71c0d348-C", "generated_internal_id": "ASST_NON_F30HL121873_7529"}, {"internal_id": 83103965, "Award ID": "F30HD100126", "Award Amount": 166731.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-08-02", "CFDA Number": "93.865", "Description": "MECHANISMS LINKING GLOBAL TRANSCRIPTIONAL SILENCING AND ZYGOTIC GENE ACTIVATION DURING THE OOCYTE-TO-EMBRYO TRANSITION IN MAMMALS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_F30HD100126_7529"}, {"internal_id": 109278331, "Award ID": "DP2HL157540", "Award Amount": 2365500.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-08-20", "CFDA Number": "93.839", "Description": "CLONAL HEMATOPOIESIS IN HUMAN AGING AND DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_DP2HL157540_7529"}, {"internal_id": 48539821, "Award ID": "DP2HL141007", "Award Amount": 2609467.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-11", "CFDA Number": "93.837", "Description": "SYSTEMS-LEVEL PERSPECTIVES OF HORIZONTAL GENE TRANSFER WITHIN THE HUMAN MICROBIOME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "NY", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "8c3617e9-a213-5748-732e-c98dc05d3232-C", "generated_internal_id": "ASST_NON_DP2HL141007_7529"}, {"internal_id": 48539820, "Award ID": "DP2HL141006", "Award Amount": 692092.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-11", "CFDA Number": "93.839", "Description": "DISCOVERING MECHANISMS THAT REGULATE ORGANELLE AUTOPHAGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "2f14ac11-bc8d-d1e9-d103-1585414b0792-C", "generated_internal_id": "ASST_NON_DP2HL141006_7529"}, {"internal_id": 48539819, "Award ID": "DP2HL141005", "Award Amount": 2745000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-23", "CFDA Number": "93.310", "Description": "LIVE CELL TRANSCRIPTOMICS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "eb1c4bd6-22a0-1796-63d6-bdf7123782cd-C", "generated_internal_id": "ASST_NON_DP2HL141005_7529"}, {"internal_id": 48539818, "Award ID": "DP2HL137300", "Award Amount": 2650247.47, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-20", "CFDA Number": "93.310", "Description": "HIGH-THROUGHPUT DISCOVERY OF ESSENTIAL NONCODING SEQUENCES FOR ERYTHROPOIESIS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18397352-674d-5e14-840f-49a4315ed3ca-C", "generated_internal_id": "ASST_NON_DP2HL137300_7529"}, {"internal_id": 48539815, "Award ID": "DP2HL137186", "Award Amount": 2355000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-20", "CFDA Number": "93.310", "Description": "IDENTIFYING CRITICAL ERYTHROCYTE HOST FACTORS FOR PLASMODIUM FALCIPARUM MALARIA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "0c13d643-4334-38ed-1952-0db7e2ac5e56-C", "generated_internal_id": "ASST_NON_DP2HL137186_7529"}, {"internal_id": 48539814, "Award ID": "DP2HL137167", "Award Amount": 2486888.07, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-09-20", "CFDA Number": "93.310", "Description": "CRISPR-BASED MODULAR THERAPY FOR PRECISION MEDICINE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "68a12c06-0ac5-9595-eda2-d8647ffda5d0-C", "generated_internal_id": "ASST_NON_DP2HL137167_7529"}, {"internal_id": 48539421, "Award ID": "DP1HL141201", "Award Amount": 6230000.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-18", "CFDA Number": "93.310", "Description": "EXPLORATION OF DIVERSE MOBILE GENETIC ELEMENTS FOR PRECISION GENOME MANIPULATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "eb1c4bd6-22a0-1796-63d6-bdf7123782cd-C", "generated_internal_id": "ASST_NON_DP1HL141201_7529"}, {"internal_id": 69725291, "Award ID": "OT3HL147741", "Award Amount": 5340191.0, "Award Type": "DIRECT PAYMENT FOR SPECIFIED USE, AS A SUBSIDY OR OTHER NON-REIMBURSABLE DIRECT FINANCIAL AID (C)", "Base Obligation Date": "2018-09-24", "CFDA Number": "93.837", "Description": "CURE SICKLE CELL", "Place of Performance Country Code": "USA", "Place of Performance State Code": "WI", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fb8099df-df9c-1d96-f19c-f3a00b918c86-C", "generated_internal_id": "ASST_NON_OT3HL147741_7529"}]